Gene expression markers for colorectal cancer prognosis

ABSTRACT

A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.

CROSS-REFERENCE TO RELATED APPLICATIONS

This is a non-provisional application filed under 37 C.F.R. 1.53(b)claiming priority under 35 U.S.C. §119(e) to provisional ApplicationSer. No. 60/758,392 filed Jan. 11, 2006 and to provisional ApplicationSer. No. 60/800,277 filed May 12, 2006 and to provisional ApplicationSer. No. 60/810,077 filed May 31, 2006 all of which are incorporatedherein by reference in their entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention provides genes and gene sets, the expressionlevels of which are useful for predicting outcome of colorectal cancer.

2. Description of Related Art

Colorectal cancer is the number two cause of cancer-related death in theUnited States and the European Union, accounting for 10% of allcancer-related deaths. Although colon cancer and rectal cancer mayrepresent identical or similar disease at the molecular level, surgeryfor rectal cancer is complicated by anatomical issues. Possibly for thisreason, the rate of local recurrence for rectal cancer is significantlyhigher than for colon cancer, and so the treatment approach issignificantly different. Approximately 100,000 colon cancers are newlydiagnosed each year in the United States, with about 65% of these beingdiagnosed as stage II/III colorectal cancer as discussed below.

Refining a diagnosis of colorectal cancer involves evaluating theprogression status of the cancer using standard classification criteria.Two classification systems have been widely used in colorectal cancer,the modified Duke's or Astler-Coller staging system (Stages A-D) (AstlerV B, Coller F A., Ann Surg 1954; 139:846-52), and more recently TNMstaging (Stages I-IV) as developed by the American Joint Committee onCancer (AJCC Cancer Staging Manual, 6th Edition, Springer-Verlag, NewYork, 2002). Both systems apply measures of the spread of the primarytumor through layers of colon or rectal wall to the adjacent organs,lymph nodes and distant sites to evaluate tumor progression. Estimatesof recurrence risk and treatment decisions in colon cancer are currentlybased primarily on tumor stage.

There are approximately 33,000 newly diagnosed Stage II colorectalcancers each year in the United States. Nearly all of these patients aretreated by surgical resection of the tumor and, in addition, about 40%are currently treated with chemotherapy based on 5-fluorouracil (5-FU).The decision whether to administer adjuvant chemotherapy is notstraightforward. The five-year survival rate for Stage II colon cancerpatients treated with surgery alone is approximately 80%. Standardadjuvant treatment with 5-FU+leucovorin (folinic acid) demonstrates anabsolute benefit of only 2-4% in this population and shows significanttoxicity, including a rate of toxic death from chemotherapy as high as1%. Thus, a large number of patients receive toxic therapy from whichonly a few benefit.

A test capable of prognosis after surgery in Stage II colorectal cancerpatients would be of great benefit for guiding treatment decisions forthese patients.

The benefit of chemotherapy in Stage III colon cancer is more evidentthan it is in Stage II. A large proportion of the 31,000 patientsannually diagnosed with Stage III colon cancer receive 5-FU-basedadjuvant chemotherapy, and the absolute benefit of 5-FU+leucovorin inthis setting is around 18-24%, depending on the particular regimenemployed. Current standard-of-care chemotherapy treatment for Stage IIIcolon cancer patients (5-FU+leucovorin or 5-FU+leucovorin+oxaliplatin)is moderately effective, achieving an improvement in 5-yr survival ratefrom about 50% (surgery alone) to about 65% (5-FU+leucovorin) or 70%(5-FU+leucovorin+oxaliplatin). Treatment with 5-FU+leucovorin alone orin combination with oxaliplatin is accompanied by a range of adverseside-effects, including toxic death in approximately 1% of patientstreated. Furthermore, the three-year survival rate for Stage III coloncancer patients treated with surgery alone is about 47% and it has notbeen established whether a subset of Stage III patients exists for whichrecurrence risk resembles that observed for Stage II patients.

A test that would quantify recurrence risk based on molecular markersrather than tumor stage alone would be useful for identifying a subsetof Stage III patients that may not require adjuvant therapy to achieveacceptable outcomes.

Staging of rectal tumors is carried out based on similar criteria as forcolon tumor staging, although there are some differences resulting forexample from differences in the arrangement of the draining lymph nodes.As a result, Stage II/III rectal tumors bear a reasonable correlation toStage II/III colon tumors as to their state of progression. As notedabove, the rate of local recurrence and other aspects of prognosisdiffer between rectal cancer and colon cancer, and these differences mayarise from difficulties in accomplishing total resection of rectaltumors. Nevertheless, there is no compelling evidence that there is adifference between colon cancer and rectal cancer as to the molecularcharacteristics of the respective tumors. Prognostic tests for rectalcancer would have utility similar in nature as described for coloncancer prognostic tests and the same prognostic markers might well applyto both cancer types.

In addition, there is a clear need for safer and more efficacious drugsfor the treatment of colon cancer. Current chemotherapy for colon canceris based on the relatively crude approach of administering drugs thatgenerally interfere with the proliferation of dividing cells. Recentclinical studies have demonstrated the feasibility of developingimproved drugs based on detailed molecular understanding of particularcancer types and subtypes. For example, the HER2 (ERBB2) gene isamplified and the HER2 protein is overexpressed in a subset of breastcancers; HERCEPTIN® (Genentech, Inc.) a drug developed to target HER2,is indicated only for those patients who have an higher than normal copynumber of HER2 as demonstrated by fluorescent in situ hybridization(FISH) or a high level of HER2 expression as demonstrated byimmunohistochemistry. Genes, whose expression is associated withclinical outcome in human cancer patients, are a valuable resource forselection of targets for drug compound screening and further drugdevelopment activities.

Molecularly targeted drugs, such as HERCEPTIN® (Genentech, Inc.) can bedeveloped and commercialized in conjunction with a diagnostic test thatcan identify patients who are likely to benefit from the drug; oneaspect of such a test is the identification of those patients likely tohave a positive outcome without any treatment other than surgery. Forexample, 80% of Stage II colon cancer patients survive five years ormore when treated with surgery alone. Gene markers that identifypatients more likely to be among the 20% whose cancer will recur withoutadditional treatment are useful in drug development, for example inscreening patients for inclusion in a clinical trial.

SUMMARY OF THE INVENTION

In one aspect, the present invention concerns a method for predictingthe clinical outcome in a subject diagnosed with colorectal cancerfollowing surgical resection of said cancer, comprising determining theexpression level of one or more predictive RNA transcripts listed inTables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expressionproducts, in a biological sample comprising cancer cells obtained fromsaid subject wherein: (a) evidence of increased expression of one ormore of the genes listed in Table 1A, 2A, 3A, 4A, and/or 5A, or thecorresponding expression product, indicates a decreased likelihood of apositive clinical outcome; and (b) evidence of increased expression ofone or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, orthe corresponding expression product, indicates an increased likelihoodof a positive clinical outcome. It is contemplated that if thelikelihood of positive clinical outcome is predicted to be decreasedsaid patient is subjected to further therapy following said surgicalremoval. It is further contemplated that the therapy is chemotherapyand/or radiation therapy.

The clinical outcome of the method of the invention may be expressed,for example, in terms of Recurrence-Free Interval (RFI), OverallSurvival (OS), Disease-Free Survival (DFS), or Distant Recurrence-FreeInterval (DRFI).

In one embodiment, the cancer is Dukes B (stage II) or Dukes C (stageIII) colorectal cancer.

In another aspect, the invention concerns a method of predicting theduration of Recurrence-Free Interval (RFI) in a subject diagnosed withDukes B (stage II) or Dukes C (stage III) colorectal cancer followingsurgical resection of said cancer, comprising determining the expressionlevel of one or more predictive RNA transcripts listed in Tables 1A, 5A,1B, and/or 5B, or their expression products, in a biological samplecomprising cancer cells obtained from said subject, wherein: (a)evidence of increased expression of one or more of the genes listed inTable 1A or 5A, or the corresponding expression product, indicates thatsaid RFI is predicted to be shorter; and (b) evidence of increasedexpression of one or more of the genes listed in Table 1B, or 5B, or thecorresponding expression product, indicates that said RFI is predictedto be longer.

In another aspect, the invention concerns a method of predicting OverallSurvival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C(stage III) colon cancer following surgical resection of said cancer,comprising determining the expression level of one or more predictiveRNA transcripts listed in Tables 2A and/or 2B, or their expressionproducts, in a biological sample comprising cancer cells obtained fromsaid subject, wherein: (a) evidence of increased expression of one ormore of the genes listed in Table 2A, or the corresponding expressionproduct, indicates that said OS is predicted to be shorter; and (b)evidence of increased expression of one or more of the genes listed inTable 2B, or the corresponding expression product, indicates that saidOS is predicted to be longer.

In another aspect, the invention concerns a method of predictingDisease-Free Survival (DFS) in a subject diagnosed with Dukes B (stageII) or Dukes C (stage III) colon cancer following surgical resection ofsaid cancer, comprising determining the expression level of one or morepredictive RNA transcripts listed in Tables 3A, and/or 3B, or theirexpression products, in a biological sample comprising cancer cellsobtained from said subject, wherein: (a) evidence of increasedexpression of one or more of the genes listed in Table 3A, or thecorresponding expression product, indicates that said DFS is predictedto be shorter; and (b) evidence of increased expression of one or moreof the genes listed in Table 3B, or the corresponding expressionproduct, indicates that said DFS is predicted to be longer.

In another aspect, the invention concerns a method of predicting theduration of Distant Recurrence-Free Interval (DRFI) in a subjectdiagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancerfollowing surgical resection of said cancer, comprising determining theexpression level of one or more predictive RNA transcripts listed inTables 4A and/or 4B, or their expression products, in a biologicalsample comprising cancer cells obtained from said subject, wherein: (a)evidence of increased expression of one or more of the genes listed inTable 4A, or the corresponding expression product, indicates that saidDRFI is predicted to be shorter; and (b) evidence of increasedexpression of one or more of the genes listed in Table 4B, or thecorresponding expression product, indicates that said DRFI is predictedto be longer.

In another aspect, the invention concerns a method of predictingclinical outcome for a subject diagnosed with colorectal cancerfollowing surgical resection of said cancer, comprising determiningevidence of the expression level of one or more predictive RNAtranscripts listed in Tables 1.2A-B, 2.2A-B, 3.2A-B, 4.2A-B, 5.2A-B, 6.2and/or 7.2, or their expression products, in a biological samplecomprising cancer cells obtained from said subject, wherein (a) evidenceof increased expression of one or more of the genes listed in Table1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the corresponding expressionproduct, indicates a decreased likelihood of a positive clinicaloutcome; and (b) evidence of increased expression of one or more of thegenes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, or thecorresponding expression product, indicates an increased likelihood of apositive clinical outcome.

In another aspect, the invention concerns a method of predicting theduration of Recurrence-Free Interval (RFI) in a subject diagnosed withDukes B (stage II) or Dukes C (stage III) colorectal cancer followingsurgical resection of said cancer, comprising determining the expressionlevel of one or more predictive RNA transcripts listed in Tables 1.2A,1.2B, 5.2A and/or 5.2B, or their expression products, in a biologicalsample comprising cancer cells obtained from said subject, wherein (a)evidence of increased expression of one or more of the genes listed inTable 1.2A or 5.2A, or the corresponding expression product, indicatesthat said RFI is predicted to be shorter; and (b) evidence of increasedexpression of one or more of the genes listed in Table 1.2B or 5.2B, orthe corresponding expression product, indicates that said RFI ispredicted to be longer.

In another aspect, the invention concerns a method of predicting OverallSurvival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C(stage III) colon cancer following surgical resection of said cancer,comprising determining the expression level of one or more predictiveRNA transcripts listed in Tables 2.2A and/or 2.2B, or their expressionproducts, in a biological sample comprising cancer cells obtained fromsaid subject, wherein (a) evidence of increased expression of one ormore of the genes listed in Table 2.2A, or the corresponding expressionproduct, indicates that said OS is predicted to be shorter; and (b)evidence of increased expression of one or more of the genes listed inTable 2.2B, or the corresponding expression product, indicates that saidOS is predicted to be longer.

In another aspect, the invention concerns a method of predictingDisease-Free Survival (DFS) in a subject diagnosed with Dukes B (stageII) or Dukes C (stage III) colon cancer following surgical resection ofsaid cancer, comprising determining the expression level of one or morepredictive RNA transcripts listed in Tables 3.2A and/or 3.2B, or theirexpression products, in a biological sample comprising cancer cellsobtained from said subject, wherein (a) evidence of increased expressionof one or more of the genes listed in Table 3.2A, or the correspondingexpression product, indicates that said DFS is predicted to be shorter;and (b) evidence of increased expression of one or more of the geneslisted in Table 3.2B, or the corresponding expression product, indicatesthat said DFS is predicted to be longer.

In another aspect, the invention concerns a method of predicting theduration of Distant Recurrence-Free Interval (DRFI) in a subjectdiagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancerfollowing surgical resection of said cancer, comprising determining theexpression level of one or more predictive RNA transcripts listed inTables 4.2A and/or 4.2B, or their expression products, in a biologicalsample comprising cancer cells obtained from said subject, wherein (a)evidence of increased expression of one or more of the genes listed inTable 4.2A, or the corresponding expression product, indicates that saidDRFI is predicted to be shorter; and (b) evidence of increasedexpression of one or more of the genes listed in Table 4.2B, or thecorresponding expression product, indicates that said DRFI is predictedto be longer.

In another aspect, the invention concerns a method of predictingclinical outcome for a subject diagnosed with colorectal cancerfollowing surgical resection of said cancer, comprising determiningevidence of the expression level of one or more predictive RNAtranscripts listed in Tables 1A-B, 1.2A-B, 2A-B, 2.2A-B, 3A-B, 3.2A-B,4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2, or their expressionproducts, in a biological sample comprising cancer cells obtained fromsaid subject, wherein (a) evidence of increased expression of one ormore of the genes listed in Table 1A, 1.2A, 2A, 2.2A, 3A, 3.2A, 4A,4.2A, 5A and/or 5.2A, or the corresponding expression product, indicatesa decreased likelihood of a positive clinical outcome; and (b) evidenceof increased expression of one or more of the genes listed in Table 1B,1.2B, 2B, 2.2B, 3B, 3.2B, 4B, 4.2B, 5B and/or 5.2B, or the correspondingexpression product, indicates an increased likelihood of a positiveclinical outcome.

In another aspect, the invention concerns a method of predicting theduration of Recurrence-Free Interval (RFI) in a subject diagnosed withDukes B (stage II) or Dukes C (stage III) colorectal cancer followingsurgical resection of said cancer, comprising determining the expressionlevel of one or more predictive RNA transcripts listed in Tables 1A,1.2A, 1B, 1.2B, 5A, 5.2A, 5B and/or 5.2B, or their expression products,in a biological sample comprising cancer cells obtained from saidsubject, wherein (a) evidence of increased expression of one or more ofthe genes listed in Table 1A, 1.2A, 5A and/or 5.2A, or the correspondingexpression product, indicates that said RFI is predicted to be shorter;and (b) evidence of increased expression of one or more of the geneslisted in Table 1B, 1.2B, 5B and/or 5.2B, or the correspondingexpression product, indicates that said RFI is predicted to be longer.

In another aspect, the invention concerns a method of predicting OverallSurvival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C(stage III) colon cancer following surgical resection of said cancer,comprising determining the expression level of one or more predictiveRNA transcripts listed in Tables 2A, 2.2A, 2B and/or 2.2B, or theirexpression products, in a biological sample comprising cancer cellsobtained from said subject, wherein (a) evidence of increased expressionof one or more of the genes listed in Table 2A and/or 2.2A, or thecorresponding expression product, indicates that said OS is predicted tobe shorter; and (b) evidence of increased expression of one or more ofthe genes listed in Table 2B and/or 2.2B, or the correspondingexpression product, indicates that said OS is predicted to be longer.

In another aspect, the invention concerns a method of predictingDisease-Free Survival (DFS) in a subject diagnosed with Dukes B (stageII) or Dukes C (stage III) colon cancer following surgical resection ofsaid cancer, comprising determining the expression level of one or morepredictive RNA transcripts listed in Tables 3A, 3.2A, 3B and/or 3.2B, ortheir expression products, in a biological sample comprising cancercells obtained from said subject, wherein (a) evidence of increasedexpression of one or more of the genes listed in Table 3A and/or 3.2A,or the corresponding expression product, indicates that said DFS ispredicted to be shorter; and (b) evidence of increased expression of oneor more of the genes listed in Table 3B and/or 3.2B, or thecorresponding expression product, indicates that said DFS is predictedto be longer.

In another aspect, the invention concerns a method of predicting theduration of Distant Recurrence-Free Interval (DRFI) in a subjectdiagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancerfollowing surgical resection of said cancer, comprising determining theexpression level of one or more predictive RNA transcripts listed inTables 4A, 4.2A, 4B and/or 4.2B, or their expression products, in abiological sample comprising cancer cells obtained from said subject,wherein (a) evidence of increased expression of one or more of the geneslisted in Table 4A and/or 4.2A, or the corresponding expression product,indicates that said DRFI is predicted to be shorter; and (b) evidence ofincreased expression of one or more of the genes listed in Table 4Band/or 4.2B, or the corresponding expression product, indicates thatsaid DRFI is predicted to be longer.

In another aspect, the invention concerns a method of predictingclinical outcome in a subject diagnosed with Dukes B (stage II)colorectal cancer following surgical resection of said cancer,comprising determining the expression level of one or more predictiveRNA transcripts selected from the group consisting of ALCAM, CD24,CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1,PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28,CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, ina biological sample comprising cancer cells obtained from said subject,wherein: (a) evidence of increased expression of one or more of thegenes selected from the group consisting of ALCAM, CD24, CDH11, CENPE,CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2,SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the correspondingexpression product, indicates a decreased likelihood of positiveclinical outcome; and (b) evidence of increased expression of one ormore of the genes selected from the group consisting of CAPG, CD28,CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expressionproduct, indicates an increased likelihood of positive clinical outcome.

In another aspect, the invention concerns a method of predictingclinical outcome in a subject diagnosed with Dukes C (stage III)colorectal cancer following surgical resection of said cancer,comprising determining the expression level of one or more predictiveRNA transcripts selected from the group consisting of CAPG, CD28, CKS1B,CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE,CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3,TMSB4X, TP53BP1, and WIF, or their expression products, in a biologicalsample comprising cancer cells obtained from said subject, wherein: (a)evidence of increased expression of one or more of the genes selectedfrom the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2,LOX, MMP7, and SIR2, or the corresponding expression product, indicatesa decreased likelihood of positive clinical outcome; and (b) evidence ofincreased expression of one or more of the genes selected from the groupconsisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2,MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1,and WIF, or the corresponding expression product, indicates an increasedlikelihood of positive clinical outcome.

For all aspects of the method of the invention, determining theexpression level of one or more genes may be obtained, for example, by amethod of gene expression profiling. The method of gene expressionprofiling may be, for example, a PCR-based method.

For all aspects of the invention, the expression levels of the genes maybe normalized relative to the expression levels of one or more referencegenes, or their expression products.

For all aspects of the invention, the subject preferably is a humanpatient.

For all aspects of the invention, the method may further comprisedetermining evidence of the expression levels of at least two of saidgenes, or their expression products. It is further contemplated that themethod of the invention may further comprise determining evidence of theexpression levels of at least three of said genes, or their expressionproducts. It is also contemplated that the method of the invention mayfurther comprise determining evidence of the expression levels of atleast four of said genes, or their expression products. It is alsocontemplated that the method of the invention may further comprisedetermining evidence of the expression levels of at least five of saidgenes, or their expression products.

For all aspects of the invention, the method may further comprise thestep of creating a report summarizing said prediction.

For all aspects of the invention, it is contemplated that for everyincrement of an increase in the level of one or more predictive RNAtranscripts or their expression products, the patient is identified toshow an incremental increase in clinical outcome.

For all aspects of the invention, the determination of expression levelsmay occur more than one time. For all aspects of the invention, thedetermination of expression levels may occur before the patient issubjected to any therapy following surgical resection.

In a different aspect the invention is directed to a report comprisingthe predicted clinical outcome in a subject diagnosed with colorectalcancer following surgical resection of said cancer, comprising aprediction of clinical outcome based on information comprising theexpression level of one or more predictive RNA transcripts listed inTables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expressionproducts, in a biological sample comprising cancer cells obtained fromsaid subject wherein: (a) evidence of increased expression of one ormore of the genes listed in Table 1A, 2A, 3A, 4A, and/or 5A, or thecorresponding expression product, indicates a decreased likelihood of apositive clinical outcome; and (b) evidence of increased expression ofone or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, orthe corresponding expression product, indicates an increased likelihoodof a positive clinical outcome. The clinical outcome of the report ofthe invention may be expressed, for example, in terms of Recurrence-FreeInterval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), orDistant Recurrence-Free Interval (DRFI). In one embodiment that canceris Dukes B (stage II) or Dukes C (stage III) colorectal cancer. Theprediction of clinical outcome may comprise an estimate of thelikelihood of a particular clinical outcome for a subject or maycomprise the classification of a subject into a risk group based on saidestimate.

In another aspect the invention is directed to a report predictingclinical outcome for a subject diagnosed with colorectal cancerfollowing surgical resection of said cancer, comprising a prediction ofclinical outcome based on information comprising the expression level ofone or more predictive RNA transcripts listed in Tables 1.2A-B, 2.2A-B,3.2A-B, 4.2A-B, 5.2A-B, 6.2 and/or 7.2, or their expression products, ina biological sample comprising cancer cells obtained from said subject,wherein (a) evidence of increased expression of one or more of the geneslisted in Table 1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the correspondingexpression product, indicates a decreased likelihood of a positiveclinical outcome; and (b) evidence of increased expression of one ormore of the genes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, orthe corresponding expression product, indicates an increased likelihoodof a positive clinical outcome. The clinical outcome of the report ofthe invention may be expressed, for example, in terms of Recurrence-FreeInterval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), orDistant Recurrence-Free Interval (DRFI). In one embodiment that canceris Dukes B (stage II) or Dukes C (stage III) colorectal cancer. Theprediction of clinical outcome may comprise an estimate of thelikelihood of a particular clinical outcome for a subject or maycomprise the classification of a subject into a risk group based on saidestimate.

In another aspect, the invention concerns a report predicting clinicaloutcome for a subject diagnosed with colorectal cancer followingsurgical resection of said cancer, comprising a prediction of clinicaloutcome based on information comprising the expression level of one ormore predictive RNA transcripts listed in Tables A-B, 1.2A-B, 2A-B,2.2A-B, 3A-B, 3.2A-B, 4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2,or their expression products, in a biological sample comprising cancercells obtained from said subject, wherein (a) evidence of increasedexpression of one or more of the genes listed in Table 1A, 1.2A, 2A,2.2A, 3A, 3.2A, 4A, 4.2A, 5A and/or 5.2A, or the correspondingexpression product, indicates a decreased likelihood of a positiveclinical outcome; and (b) evidence of increased expression of one ormore of the genes listed in Table 1B, 1.2B, 2B, 2.2B, 3B, 3.2B, 4B,4.2B, 5B and/or 5.2B, or the corresponding expression product, indicatesan increased likelihood of a positive clinical outcome. The predictionof clinical outcome may comprise an estimate of the likelihood of aparticular clinical outcome for a subject or may comprise theclassification of a subject into a risk group based on said estimate.

In another aspect the invention is directed to a report predictingclinical outcome in a subject diagnosed with Dukes B (stage II)colorectal cancer following surgical resection of said cancer,comprising a prediction of clinical outcome based on informationcomprising the expression level of one or more predictive RNAtranscripts selected from the group consisting of ALCAM, CD24, CDH11,CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6,SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28, CDC20,CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, in abiological sample comprising cancer cells obtained from said subject,wherein: (a) evidence of increased expression of one or more of thegenes selected from the group consisting of ALCAM, CD24, CDH11, CENPE,CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2,SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the correspondingexpression product, indicates a decreased likelihood of positiveclinical outcome; and (b) evidence of increased expression of one ormore of the genes selected from the group consisting of CAPG, CD28,CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expressionproduct, indicates an increased likelihood of positive clinical outcome.The prediction of clinical outcome may comprise an estimate of thelikelihood of a particular clinical outcome for a subject or maycomprise the classification of a subject into a risk group based on saidestimate.

In another aspect the invention is directed to a report predictingclinical outcome in a subject diagnosed with Dukes C (stage III)colorectal cancer following surgical resection of said cancer,comprising a prediction of clinical outcome based on informationcomprising the expression level of one or more predictive RNAtranscripts selected from the group consisting of CAPG, CD28, CKS1B,CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE,CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3,TMSB4X, TP53BP1, and WIF, or their expression products, in a biologicalsample comprising cancer cells obtained from said subject, wherein: (a)evidence of increased expression of one or more of the genes selectedfrom the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2,LOX, MMP7, and SIR2, or the corresponding expression product, indicatesa decreased likelihood of positive clinical outcome; and (b) evidence ofincreased expression of one or more of the genes selected from the groupconsisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2,MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1,and WIF, or the corresponding expression product, indicates an increasedlikelihood of positive clinical outcome. The prediction of clinicaloutcome may comprise an estimate of the likelihood of a particularclinical outcome for a subject or may comprise the classification of asubject into a risk group based on said estimate.

In a different aspect the invention concerns a kit comprising one ormore of (1) extraction buffer/reagents and protocol; (2) reversetranscription buffer/reagents and protocol; and (3) qPCR buffer/reagentsand protocol suitable for performing the methods of this invention. Thekit may comprise data retrieval and analysis software.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows a dendrogram representing the expression clustering of 142genes that were statistically significantly related to recurrence-freeinterval (Tables 1.2A and 1.2B) in the univariate Cox proportionalhazards analysis. The cluster analysis used the unweighted pair-groupaverage amalgamation method and 1-Pearson r as the distance measure. Theidentities of particular genes in clusters of interest are indicatedalong the x-axis.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT A. Definitions

Unless defined otherwise, technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Singleton et al., Dictionary ofMicrobiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York,N.Y. 1994), and March, Advanced Organic Chemistry Reactions, Mechanismsand Structure 4th ed., John Wiley & Sons (New York, N.Y. 1992), provideone skilled in the art with a general guide to many of the terms used inthe present application.

One skilled in the art will recognize many methods and materials similaror equivalent to those described herein, which could be used in thepractice of the present invention. Indeed, the present invention is inno way limited to the methods and materials described. For purposes ofthe present invention, the following terms are defined below.

The term “tumor,” as used herein, refers to all neoplastic cell growthand proliferation, whether malignant or benign, and all pre-cancerousand cancerous cells and tissues.

The terms “cancer” and “cancerous” refer to or describe thephysiological condition in mammals that is typically characterized byunregulated cell growth. Examples of cancer include, but are not limitedto, breast cancer, ovarian cancer, colon cancer, lung cancer, prostatecancer, hepatocellular cancer, gastric cancer, pancreatic cancer,cervical cancer, liver cancer, bladder cancer, cancer of the urinarytract, thyroid cancer, renal cancer, carcinoma, melanoma, and braincancer.

The “pathology” of cancer includes all phenomena that compromise thewell-being of the patient. This includes, without limitation, abnormalor uncontrollable cell growth, metastasis, interference with the normalfunctioning of neighboring cells, release of cytokines or othersecretory products at abnormal levels, suppression or aggravation ofinflammatory or immunological response, neoplasia, premalignancy,malignancy, invasion of surrounding or distant tissues or organs, suchas lymph nodes, etc.

The term “colorectal cancer” is used in the broadest sense and refers to(1) all stages and all forms of cancer arising from epithelial cells ofthe large intestine and/or rectum and/or (2) all stages and all forms ofcancer affecting the lining of the large intestine and/or rectum. In thestaging systems used for classification of colorectal cancer, the colonand rectum are treated as one organ.

According to the tumor, node, metastatis (TNM) staging system of theAmerican Joint Committee on Cancer (AJCC) (Greene et al. (eds.), AJCCCancer Staging Manual. 6th Ed. New York, N.Y.: Springer; 2002), thevarious stages of colorectal cancer are defined as follows:

Tumor: T1: tumor invades submucosa; T2: tumor invades muscularispropria; T3: tumor invades through the muscularis propria into thesubserose, or into the pericolic or perirectal tissues; T4: tumordirectly invades other organs or structures, and/or perforates.

Node: N0: no regional lymph node metastasis; N1: metastasis in 1 to 3regional lymph nodes; N2: metastasis in 4 or more regional lymph nodes.

Metastasis: M0: mp distant metastasis; M1: distant metastasis present.

Stage groupings: Stage I: T1 N0 M0; T2 N0 M0; Stage II: T3 N0 M0; T4 N0M0; Stage III: any T, N1-2; M0; Stage IV: any T, any N, M1.

According to the Modified Duke Staging System, the various stages ofcolorectal cancer are defined as follows:

Stage A: the tumor penetrates into the mucosa of the bowel wall but notfurther. Stage B: tumor penetrates into and through the muscularispropria of the bowel wall; Stage C: tumor penetrates into but notthrough muscularis propria of the bowel wall, there is pathologicevidence of colorectal cancer in the lymph nodes; or tumor penetratesinto and through the muscularis propria of the bowel wall, there ispathologic evidence of cancer in the lymph nodes; Stage D: tumor hasspread beyond the confines of the lymph nodes, into other organs, suchas the liver, lung or bone.

Prognostic factors are those variables related to the natural history ofcolorectal cancer, which influence the recurrence rates and outcome ofpatients once they have developed colorectal cancer. Clinical parametersthat have been associated with a worse prognosis include, for example,lymph node involvement, and high grade tumors. Prognostic factors arefrequently used to categorize patients into subgroups with differentbaseline relapse risks.

The term “prognosis” is used herein to refer to the prediction of thelikelihood of cancer-attributable death or progression, includingrecurrence, metastatic spread, and drug resistance, of a neoplasticdisease, such as colon cancer.

The term “prediction” is used herein to refer to the likelihood that apatient will have a particular clinical outcome, whether positive ornegative, following surgical removal of the primary tumor. Thepredictive methods of the present invention can be used clinically tomake treatment decisions by choosing the most appropriate treatmentmodalities for any particular patient. The predictive methods of thepresent invention are valuable tools in predicting if a patient islikely to respond favorably to a treatment regimen, such as surgicalintervention. The prediction may include prognostic factors.

The term “positive clinical outcome” means an improvement in any measureof patient status, including those measures ordinarily used in the art,such as an increase in the duration of Recurrence-Free interval (RFI),an increase in the time of Overall Survival (OS), an increase in thetime of Disease-Free Survival (DFS), an increase in the duration ofDistant Recurrence-Free Interval (DRFI), and the like. An increase inthe likelihood of positive clinical outcome corresponds to a decrease inthe likelihood of cancer recurrence.

The term “risk classification” means the level of risk or the predictionthat a subject will experience a particular clinical outcome. A subjectmay be classified into a risk group or classified at a level of riskbased on the predictive methods of the present invention. A “risk group”is a group of subjects or individuals with a similar level of risk for aparticular clinical outcome.

The term “long-term” survival is used herein to refer to survival for atleast 3 years, more preferably for at least 5 years.

The term “Recurrence-Free Interval (RFI)” is used herein to refer totime in years to first colon cancer recurrence censoring for secondprimary cancer as a first event or death without evidence of recurrence.

The term “Overall Survival (OS)” is used herein to refer to time inyears from surgery to death from any cause.

The term “Disease-Free Survival (DFS)” is used herein to refer to timein years to colon cancer recurrence or death from any cause.

The term “Distant Recurrence-Free Interval (DRFI)” is used herein torefer to the time (in years) from surgery to the first anatomicallydistant cancer recurrence.

The calculation of the measures listed above in practice may vary fromstudy to study depending on the definition of events to be eithercensored or not considered.

The term “microarray” refers to an ordered arrangement of hybridizablearray elements, preferably polynucleotide probes, on a substrate.

The term “polynucleotide,” when used in singular or plural, generallyrefers to any polyribonucleotide or polydeoxyribonucleotide, which maybe unmodified RNA or DNA or modified RNA or DNA. Thus, for instance,polynucleotides as defined herein include, without limitation, single-and double-stranded DNA, DNA including single- and double-strandedregions, single- and double-stranded RNA, and RNA including single- anddouble-stranded regions, hybrid molecules comprising DNA and RNA thatmay be single-stranded or, more typically, double-stranded or includesingle- and double-stranded regions. In addition, the term“polynucleotide” as used herein refers to triple-stranded regionscomprising RNA or DNA or both RNA and DNA. The strands in such regionsmay be from the same molecule or from different molecules. The regionsmay include all of one or more of the molecules, but more typicallyinvolve only a region of some of the molecules. One of the molecules ofa triple-helical region often is an oligonucleotide. The term“polynucleotide” specifically includes cDNAs. The term includes DNAs(including cDNAs) and RNAs that contain one or more modified bases.Thus, DNAs or RNAs with backbones modified for stability or for otherreasons are “polynucleotides” as that term is intended herein. Moreover,DNAs or RNAs comprising unusual bases, such as inosine, or modifiedbases, such as tritiated bases, are included within the term“polynucleotides” as defined herein. In general, the term“polynucleotide” embraces all chemically, enzymatically and/ormetabolically modified forms of unmodified polynucleotides, as well asthe chemical forms of DNA and RNA characteristic of viruses and cells,including simple and complex cells.

The term “oligonucleotide” refers to a relatively short polynucleotide,including, without limitation, single-stranded deoxyribonucleotides,single- or double-stranded ribonucleotides, RNA:DNA hybrids anddouble-stranded DNAs. Oligonucleotides, such as single-stranded DNAprobe oligonucleotides, are often synthesized by chemical methods, forexample using automated oligonucleotide synthesizers that arecommercially available. However, oligonucleotides can be made by avariety of other methods, including in vitro recombinant DNA-mediatedtechniques and by expression of DNAs in cells and organisms.

The terms “differentially expressed gene,” “differential geneexpression” and their synonyms, which are used interchangeably, refer toa gene whose expression is activated to a higher or lower level in asubject suffering from a disease, specifically cancer, such as coloncancer, relative to its expression in a normal or control subject. Theterms also include genes whose expression is activated to a higher orlower level at different stages of the same disease. It is alsounderstood that a differentially expressed gene may be either activatedor inhibited at the nucleic acid level or protein level, or may besubject to alternative splicing to result in a different polypeptideproduct. Such differences may be evidenced by a change in mRNA levels,surface expression, secretion or other partitioning of a polypeptide,for example. Differential gene expression may include a comparison ofexpression between two or more genes or their gene products, or acomparison of the ratios of the expression between two or more genes ortheir gene products, or even a comparison of two differently processedproducts of the same gene, which differ between normal subjects andsubjects suffering from a disease, specifically cancer, or betweenvarious stages of the same disease. Differential expression includesboth quantitative, as well as qualitative, differences in the temporalor cellular expression pattern in a gene or its expression productsamong, for example, normal and diseased cells, or among cells which haveundergone different disease events or disease stages. For the purpose ofthis invention, “differential gene expression” is considered to bepresent when there is at least an about two-fold, preferably at leastabout four-fold, more preferably at least about six-fold, mostpreferably at least about ten-fold difference between the expression ofa given gene in normal and diseased subjects, or in various stages ofdisease development in a diseased subject.

The term “over-expression” with regard to an RNA transcript is used torefer to the level of the transcript determined by normalization to thelevel of reference mRNAs, which might be all measured transcripts in thespecimen or a particular reference set of mRNAs.

The phrase “gene amplification” refers to a process by which multiplecopies of a gene or gene fragment are formed in a particular cell orcell line. The duplicated region (a stretch of amplified DNA) is oftenreferred to as “amplicon.” Usually, the amount of the messenger RNA(mRNA) produced, i.e., the level of gene expression, also increases inthe proportion of the number of copies made of the particular geneexpressed.

“Stringency” of hybridization reactions is readily determinable by oneof ordinary skill in the art, and generally is an empirical calculationdependent upon probe length, washing temperature, and saltconcentration. In general, longer probes require higher temperatures forproper annealing, while shorter probes need lower temperatures.Hybridization generally depends on the ability of denatured DNA toreanneal when complementary strands are present in an environment belowtheir melting temperature. The higher the degree of desired homologybetween the probe and hybridizable sequence, the higher the relativetemperature which can be used. As a result, it follows that higherrelative temperatures would tend to make the reaction conditions morestringent, while lower temperatures less so. For additional details andexplanation of stringency of hybridization reactions, see Ausubel etal., Current Protocols in Molecular Biology, Wiley IntersciencePublishers, (1995).

“Stringent conditions” or “high stringency conditions”, as definedherein, typically: (1) employ low ionic strength and high temperaturefor washing, for example 0.015 M sodium chloride/0.0015 M sodiumcitrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ duringhybridization a denaturing agent, such as formamide, for example, 50%(v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mMsodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50%formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodiumphosphate (pH 6.8), 0.1% sodium pyrophosphate, 5× Denhardt's solution,sonicated salmon sperm DNA (50 μg/ml), 0.1% SDS, and 10% dextran sulfateat 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodiumcitrate) and 50% formamide, followed by a high-stringency washconsisting of 0.1×SSC containing EDTA at 55° C.

“Moderately stringent conditions” may be identified as described bySambrook et al., Molecular Cloning: A Laboratory Manual, New York: ColdSpring Harbor Press, 1989, and include the use of washing solution andhybridization conditions (e.g., temperature, ionic strength and % SDS)less stringent that those described above. An example of moderatelystringent conditions is overnight incubation at 37° C. in a solutioncomprising: 20% formamide, 5×SSC (150 mM NaCl, 15 mM trisodium citrate),50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextransulfate, and 20 mg/ml denatured sheared salmon sperm DNA, followed bywashing the filters in 1×SSC at about 37-50° C. The skilled artisan willrecognize how to adjust the temperature, ionic strength, etc. asnecessary to accommodate factors such as probe length and the like.

In the context of the present invention, reference to “at least one,”“at least two,” “at least five,” etc. of the genes listed in anyparticular gene set means any one or any and all combinations of thegenes listed.

The term “node negative” cancer, such as “node negative” colon cancer,is used herein to refer to cancer that has not spread to the lymphnodes.

The terms “splicing” and “RNA splicing” are used interchangeably andrefer to RNA processing that removes introns and joins exons to producemature mRNA with continuous coding sequence that moves into thecytoplasm of an eukaryotic cell.

In theory, the term “exon” refers to any segment of an interrupted genethat is represented in the mature RNA product (B. Lewin. Genes IV CellPress, Cambridge Mass. 1990). In theory the term “intron” refers to anysegment of DNA that is transcribed but removed from within thetranscript by splicing together the exons on either side of it.Operationally, exon sequences occur in the mRNA sequence of a gene asdefined by Ref. SEQ ID numbers. Operationally, intron sequences are theintervening sequences within the genomic DNA of a gene, bracketed byexon sequences and having GT and AG splice consensus sequences at their5′ and 3′ boundaries.

The term “expression cluster” is used herein to refer to a group ofgenes which demonstrate similar expression patterns when studied withinsamples from a defined set of patients. As used herein, the genes withinan expression cluster show similar expression patterns when studiedwithin samples from patients with Stage II and/or Stage III cancers ofthe colon and/or rectum.

B.1 General Description of the Invention

The practice of the present invention will employ, unless otherwiseindicated, conventional techniques of molecular biology (includingrecombinant techniques), microbiology, cell biology, and biochemistry,which are within the skill of the art. Such techniques are explainedfully in the literature, such as, “Molecular Cloning: A LaboratoryManual”, 2^(nd) edition (Sambrook et al., 1989); “OligonucleotideSynthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I.Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.);“Handbook of Experimental Immunology”, 4^(th) edition (D. M. Weir & C.C. Blackwell, eds., Blackwell Science Inc., 1987); “Gene TransferVectors for Mammalian Cells” (J. M. Miller & M. P. Calos, eds., 1987);“Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds.,1987); and “PCR: The Polymerase Chain Reaction”, (Mullis et al., eds.,1994).

Based on evidence of differential expression of RNA transcripts innormal and cancer cells, the present invention provides prognostic genemarkers for colorectal cancer. Thus, in a particular aspect, theinvention provides prognostic gene markers of Stage II and/or Stage IIIcolorectal cancer, including markers that are specifically prognostic tothe outcome of either Stage II or Stage III disease and those that haveprognostic value at both stages, reflecting underlying differences intumor cells in the two stages and/or in the extent of tumor progression.The prognostic markers and associated information provided by thepresent invention allow physicians to make more intelligent treatmentdecisions, and to customize the treatment of colorectal cancer to theneeds of individual patients, thereby maximizing the benefit oftreatment and minimizing the exposure of patients to unnecessarytreatments, which do not provide any significant benefits and oftencarry serious risks due to toxic side-effects.

Disruptions in the normal functioning of various physiologicalprocesses, including proliferation, apoptosis, angiogenesis andinvasion, have been implicated in the pathology in cancer. The relativecontribution of dysfunctions in particular physiological processes tothe pathology of particular cancer types is not well characterized. Anyphysiological process integrates the contributions of numerous geneproducts expressed by the various cells involved in the process. Forexample, tumor cell invasion of adjacent normal tissue and intravasationof the tumor cell into the circulatory system are effected by an arrayof proteins that mediate various cellular characteristics, includingcohesion among tumor cells, adhesion of tumor cells to normal cells andconnective tissue, ability of the tumor cell first to alter itsmorphology and then to migrate through surrounding tissues, and abilityof the tumor cell to degrade surrounding connective tissue structures.

Multi-analyte gene expression tests can measure the expression level ofone or more genes involved in each of several relevant physiologicprocesses or component cellular characteristics. In some instances thepredictive power of the test, and therefore its utility, can be improvedby using the expression values obtained for individual genes tocalculate a score which is more highly correlated with outcome than isthe expression value of the individual genes. For example, thecalculation of a quantitative score (recurrence score) that predicts thelikelihood of recurrence in estrogen receptor-positive, node-negativebreast cancer is describe in a co-pending U.S. patent application(Publication Number 20050048542). The equation used to calculate such arecurrence score may group genes in order to maximize the predictivevalue of the recurrence score. The grouping of genes may be performed atleast in part based on knowledge of their contribution to physiologicfunctions or component cellular characteristics such as discussed above.The formation of groups, in addition, can facilitate the mathematicalweighting of the contribution of various expression values to therecurrence score. The weighting of a gene group representing aphysiological process or component cellular characteristic can reflectthe contribution of that process or characteristic to the pathology ofthe cancer and clinical outcome. Accordingly, in an important aspect,the present invention also provides specific groups of the prognosticgenes identified herein, that together are more reliable and powerfulpredictors of outcome than the individual genes or random combinationsof the genes identified.

In addition, based on the determination of a recurrence score, one canchoose to partition patients into subgroups at any particular value(s)of the recurrence score, where all patients with values in a given rangecan be classified as belonging to a particular risk group. Thus, thevalues chosen will define subgroups of patients with respectivelygreater or lesser risk.

The utility of a gene marker in predicting colon cancer outcome may notbe unique to that marker. An alternative marker having a expressionpattern that is closely similar to a particular test marker may besubstituted for or used in addition to a test marker and have littleimpact on the overall predictive utility of the test. The closelysimilar expression patterns of two genes may result from involvement ofboth genes in a particular process and/or being under common regulatorycontrol in colon tumor cells. The present invention specificallyincludes and contemplates the use of such substitute genes or gene setsin the methods of the present invention.

The prognostic markers and associated information provided by thepresent invention predicting the clinical outcome in Stage II and/orStage III cancers of the colon and/or rectum has utility in thedevelopment of drugs to treat Stage II and/or Stage III cancers of thecolon and/or rectum.

The prognostic markers and associated information provided by thepresent invention predicting the clinical outcome in Stage II and/orStage III cancers of the colon and/or rectum also have utility inscreening patients for inclusion in clinical trials that test theefficacy of drug compounds for the treatment of patients with Stage IIand/or Stage III cancers of the colon and/or rectum. In particular theprognostic markers may be used on samples collected from patients in aclinical trial and the results of the test used in conjunction withpatient outcomes in order to determine whether subgroups of patients aremore or less likely to show a response to the drug than the whole groupor other subgroups.

The prognostic markers and associated information provided by thepresent invention predicting the clinical outcome in Stage II and/orStage III cancers of the colon and/or rectum are useful as inclusioncriterion for a clinical trial. For example, a patient is more likely tobe included in a clinical trial if the results of the test indicate ahigher likelihood that the patient will have a poor clinical outcome iftreated with surgery alone and a patient is less likely to be includedin a clinical trial if the results of the test indicate a lowerlikelihood that the patient will have a poor clinical outcome if treatedwith surgery alone.

In a particular embodiment, prognostic markers and associatedinformation are used to design or produce a reagent that modulates thelevel or activity of the gene's transcript or its expression product.Said reagents may include but are not limited to an antisense RNA, asmall inhibitory RNA, a ribozyme, a monoclonal or polyclonal antibody.

In a further embodiment, said gene or its transcript, or moreparticularly, an expression product of said transcript is used in an(screening) assay to identify a drug compound, wherein said drugcompounds is used in the development of a drug to treat Stage II and/orStage III cancers of the colon and/or rectum.

In various embodiments of the inventions, various technologicalapproaches are available for determination of expression levels of thedisclosed genes, including, without limitation, RT-PCR, microarrays,serial analysis of gene expression (SAGE) and Gene Expression Analysisby Massively Parallel Signature Sequencing (MPSS), which will bediscussed in detail below. In particular embodiments, the expressionlevel of each gene may be determined in relation to various features ofthe expression products of the gene including exons, introns, proteinepitopes and protein activity. In other embodiments, the expressionlevel of a gene may be inferred from analysis of the structure of thegene, for example from the analysis of the methylation pattern of gene'spromoter(s).

B.2 Gene Expression Profiling

Methods of gene expression profiling include methods based onhybridization analysis of polynucleotides, methods based on sequencingof polynucleotides, and proteomics-based methods. The most commonly usedmethods known in the art for the quantification of mRNA expression in asample include northern blotting and in situ hybridization (Parker &Barnes, Methods in Molecular Biology 106:247-283 (1999)); RNAseprotection assays (Hod, Biotechniques 13:852-854 (1992)); and PCR-basedmethods, such as reverse transcription polymerase chain reaction(RT-PCR) (Weis et al., Trends in Genetics 8:263-264 (1992)).Alternatively, antibodies may be employed that can recognizesequence-specific duplexes, including DNA duplexes, RNA duplexes, andDNA-RNA hybrid duplexes or DNA-protein duplexes. Representative methodsfor sequencing-based gene expression analysis include Serial Analysis ofGene Expression (SAGE), and gene expression analysis by massivelyparallel signature sequencing (MPSS).

a. Reverse Transcriptase PCR (RT-PCR)

Of the techniques listed above, the most sensitive and most flexiblequantitative method is RT-PCR, which can be used to determine mRNAlevels in various samples. The results can be used to compare geneexpression patterns between sample sets, for example in normal and tumortissues and in patients with or without drug treatment.

The first step is the isolation of mRNA from a target sample. Thestarting material is typically total RNA isolated from human tumors ortumor cell lines, and corresponding normal tissues or cell lines,respectively. Thus RNA can be isolated from a variety of primary tumors,including breast, lung, colon, prostate, brain, liver, kidney, pancreas,spleen, thymus, testis, ovary, uterus, etc., tumor, or tumor cell lines,with pooled DNA from healthy donors. If the source of mRNA is a primarytumor, mRNA can be extracted, for example, from frozen or archivedparaffin-embedded and fixed (e.g. formalin-fixed) tissue samples.

General methods for mRNA extraction are well known in the art and aredisclosed in standard textbooks of molecular biology, including Ausubelet al., Current Protocols of Molecular Biology, John Wiley and Sons(1997). Methods for RNA extraction from paraffin embedded tissues aredisclosed, for example, in Rupp and Locker, Lab Invest. 56:A67 (1987),and De Andrés et al., BioTechniques 18:42044 (1995). In particular, RNAisolation can be performed using purification kit, buffer set andprotease from commercial manufacturers, such as Qiagen, according to themanufacturer's instructions. For example, total RNA from cells inculture can be isolated using Qiagen RNeasy mini-columns. Othercommercially available RNA isolation kits include MasterPure™ CompleteDNA and RNA Purification Kit (EPICENTRE®, Madison, Wis.), and ParaffinBlock RNA Isolation Kit (Ambion, Inc.). Total RNA from tissue samplescan be isolated using RNA Stat-60 (Tel-Test). RNA prepared from tumorcan be isolated, for example, by cesium chloride density gradientcentrifugation.

As RNA cannot serve as a template for PCR, the first step in geneexpression profiling by RT-PCR is the reverse transcription of the RNAtemplate into cDNA, followed by its exponential amplification in a PCRreaction. The two most commonly used reverse transcriptases are avilomyeloblastosis virus reverse transcriptase (AMV-RT) and Moloney murineleukemia virus reverse transcriptase (MMLV-RT). The reversetranscription step is typically primed using specific primers, randomhexamers, or oligo-dT primers, depending on the circumstances and thegoal of expression profiling. For example, extracted RNA can bereverse-transcribed using a GeneAmp RNA PCR kit (Perkin Elmer, CA, USA),following the manufacturer's instructions. The derived cDNA can then beused as a template in the subsequent PCR reaction.

Although the PCR step can use a variety of thermostable DNA-dependentDNA polymerases, it typically employs the Taq DNA polymerase, which hasa 5′-3′ nuclease activity but lacks a 3′-5′ proofreading endonucleaseactivity. Thus, TaqMan® PCR typically utilizes the 5′-nuclease activityof Taq or Tth polymerase to hydrolyze a hybridization probe bound to itstarget amplicon, but any enzyme with equivalent 5′ nuclease activity canbe used. Two oligonucleotide primers are used to generate an amplicontypical of a PCR reaction. A third oligonucleotide, or probe, isdesigned to detect nucleotide sequence located between the two PCRprimers. The probe is non-extendible by Taq DNA polymerase enzyme, andis labeled with a reporter fluorescent dye and a quencher fluorescentdye. Any laser-induced emission from the reporter dye is quenched by thequenching dye when the two dyes are located close together as they areon the probe. During the amplification reaction, the Taq DNA polymeraseenzyme cleaves the probe in a template-dependent manner. The resultantprobe fragments disassociate in solution, and signal from the releasedreporter dye is free from the quenching effect of the secondfluorophore. One molecule of reporter dye is liberated for each newmolecule synthesized, and detection of the unquenched reporter dyeprovides the basis for quantitative interpretation of the data.

TaqMan® RT-PCR can be performed using commercially available equipment,such as, for example, ABI PRISM 7700™ Sequence Detection System™(Perkin-Elmer-Applied Biosystems, Foster City, Calif., USA), orLightcycler (Roche Molecular Biochemicals, Mannheim, Germany). In apreferred embodiment, the 5′ nuclease procedure is run on a real-timequantitative PCR device such as the ABI PRISM 7700™ Sequence DetectionSystem™. The system consists of a thermocycler, laser, charge-coupleddevice (CCD), camera and computer. The system amplifies samples in a96-well format on a thermocycler. During amplification, laser-inducedfluorescent signal is collected in real-time through fiber optics cablesfor all 96 wells, and detected at the CCD. The system includes softwarefor running the instrument and for analyzing the data.

5′-Nuclease assay data are initially expressed as Ct, or the thresholdcycle. As discussed above, fluorescence values are recorded during everycycle and represent the amount of product amplified to that point in theamplification reaction. The point when the fluorescent signal is firstrecorded as statistically significant is the threshold cycle (C_(t)).

To minimize errors and the effect of sample-to-sample variation, RT-PCRis usually performed using an internal standard. The ideal internalstandard is expressed at a constant level among different tissues, andis unaffected by the experimental treatment. RNAs most frequently usedto normalize patterns of gene expression are mRNAs for the housekeepinggenes glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) and β-actin.

A more recent variation of the RT-PCR technique is the real timequantitative PCR, which measures PCR product accumulation through adual-labeled fluorigenic probe (i.e., TaqMan® probe). Real time PCR iscompatible both with quantitative competitive PCR, where internalcompetitor for each target sequence is used for normalization, and withquantitative comparative PCR using a normalization gene contained withinthe sample, or a housekeeping gene for RT-PCR. For further details see,e.g. Held et al., Genome Research 6:986-994 (1996).

The steps of a representative protocol for profiling gene expressionusing fixed, paraffin-embedded tissues as the RNA source, including mRNAisolation, purification, primer extension and amplification are given invarious published journal articles (for example: T. E. Godfrey et al. J.Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J. Pathol.158: 419-29 (2001)). Briefly, a representative process starts withcutting about 10 μm thick sections of paraffin-embedded tumor tissuesamples. The RNA is then extracted, and protein and DNA are removed.After analysis of the RNA concentration, RNA repair and/or amplificationsteps may be included, if necessary, and RNA is reverse transcribedusing gene specific promoters followed by RT-PCR.

b. MassARRAY System

In the MassARRAY-based gene expression profiling method, developed bySequenom, Inc. (San Diego, Calif.) following the isolation of RNA andreverse transcription, the obtained cDNA is spiked with a synthetic DNAmolecule (competitor), which matches the targeted cDNA region in allpositions, except a single base, and serves as an internal standard. ThecDNA/competitor mixture is PCR amplified and is subjected to a post-PCRshrimp alkaline phosphatase (SAP) enzyme treatment, which results in thedephosphorylation of the remaining nucleotides. After inactivation ofthe alkaline phosphatase, the PCR products from the competitor and cDNAare subjected to primer extension, which generates distinct mass signalsfor the competitor- and cDNA-derives PCR products. After purification,these products are dispensed on a chip array, which is pre-loaded withcomponents needed for analysis with matrix-assisted laser desorptionionization time-of-flight mass spectrometry (MALDI-TOF MS) analysis. ThecDNA present in the reaction is then quantified by analyzing the ratiosof the peak areas in the mass spectrum generated. For further detailssee, e.g. Ding and Cantor, Proc. Natl. Acad. Sci. USA 100:3059-3064(2003).

c. Other PCR-Based Methods

Further PCR-based techniques include, for example, differential display(Liang and Pardee, Science 257:967-971 (1992)); amplified fragmentlength polymorphism (iAFLP) (Kawamoto et al., Genome Res. 12:1305-1312(1999)); BeadArray™ technology (Illumina, San Diego, Calif.; Oliphant etal., Discovery of Markers for Disease (Supplement to Biotechniques),June 2002; Ferguson et al., Analytical Chemistry 72:5618 (2000));BeadsArray for Detection of Gene Expression (BADGE), using thecommercially available Luminex100 LabMAP system and multiple color-codedmicrospheres (Luminex Corp., Austin, Tex.) in a rapid assay for geneexpression (Yang et al., Genome Res. 11:1888-1898 (2001)); and highcoverage expression profiling (HiCEP) analysis (Fukumura et al., Nucl.Acids. Res. 31(16) e94 (2003)).

d. Microarrays

Differential gene expression can also be identified, or confirmed usingthe microarray technique. Thus, the expression profile of coloncancer-associated genes can be measured in either fresh orparaffin-embedded tumor tissue, using microarray technology. In thismethod, polynucleotide sequences of interest (including cDNAs andoligonucleotides) are plated, or arrayed, on a microchip substrate. Thearrayed sequences are then hybridized with specific DNA probes fromcells or tissues of interest. Just as in the RT-PCR method, the sourceof mRNA typically is total RNA isolated from human tumors or tumor celllines, and corresponding normal tissues or cell lines. Thus RNA can beisolated from a variety of primary tumors or tumor cell lines. If thesource of mRNA is a primary tumor, mRNA can be extracted, for example,from frozen or archived paraffin-embedded and fixed (e.g.formalin-fixed) tissue samples, which are routinely prepared andpreserved in everyday clinical practice.

In a specific embodiment of the microarray technique, PCR amplifiedinserts of cDNA clones are applied to a substrate in a dense array.Preferably at least 10,000 nucleotide sequences are applied to thesubstrate. The microarrayed genes, immobilized on the microchip at10,000 elements each, are suitable for hybridization under stringentconditions. Fluorescently labeled cDNA probes may be generated throughincorporation of fluorescent nucleotides by reverse transcription of RNAextracted from tissues of interest. Labeled cDNA probes applied to thechip hybridize with specificity to each spot of DNA on the array. Afterstringent washing to remove non-specifically bound probes, the chip isscanned by confocal laser microscopy or by another detection method,such as a CCD camera. Quantitation of hybridization of each arrayedelement allows for assessment of corresponding mRNA abundance. With dualcolor fluorescence, separately labeled cDNA probes generated from twosources of RNA are hybridized pair wise to the array. The relativeabundance of the transcripts from the two sources corresponding to eachspecified gene is thus determined simultaneously. The miniaturized scaleof the hybridization affords a convenient and rapid evaluation of theexpression pattern for large numbers of genes. Such methods have beenshown to have the sensitivity required to detect rare transcripts, whichare expressed at a few copies per cell, and to reproducibly detect atleast approximately two-fold differences in the expression levels(Schena et al., Proc. Natl. Acad. Sci. USA 93(2):106-149 (1996)).Microarray analysis can be performed by commercially availableequipment, following manufacturer's protocols, such as by using theAffymetrix GenChip technology, or Incyte's microarray technology.

The development of microarray methods for large-scale analysis of geneexpression makes it possible to search systematically for molecularmarkers of cancer classification and outcome prediction in a variety oftumor types.

e. Serial Analysis of Gene Expression (SAGE)

Serial analysis of gene expression (SAGE) is a method that allows thesimultaneous and quantitative analysis of a large number of genetranscripts, without the need of providing an individual hybridizationprobe for each transcript. First, a short sequence tag (about 10-14 bp)is generated that contains sufficient information to uniquely identify atranscript, provided that the tag is obtained from a unique positionwithin each transcript. Then, many transcripts are linked together toform long serial molecules, that can be sequenced, revealing theidentity of the multiple tags simultaneously. The expression pattern ofany population of transcripts can be quantitatively evaluated bydetermining the abundance of individual tags, and identifying the genecorresponding to each tag. For more details see, e.g. Velculescu et al.,Science 270:484-487 (1995); and Velculescu et al., Cell 88:243-51(1997).

f. Gene Expression Analysis by Massively Parallel Signature Sequencing(MPSS)

This method, described by Brenner et al., Nature Biotechnology18:630-634 (2000), is a sequencing approach that combines non-gel-basedsignature sequencing with in vitro cloning of millions of templates onseparate 5 μm diameter microbeads. First, a microbead library of DNAtemplates is constructed by in vitro cloning. This is followed by theassembly of a planar array of the template-containing microbeads in aflow cell at a high density (typically greater than 3×10⁶microbeads/cm²). The free ends of the cloned templates on each microbeadare analyzed simultaneously, using a fluorescence-based signaturesequencing method that does not require DNA fragment separation. Thismethod has been shown to simultaneously and accurately provide, in asingle operation, hundreds of thousands of gene signature sequences froma yeast cDNA library.

g. Immunohistochemistry

Immunohistochemistry methods are also suitable for detecting theexpression levels of the prognostic markers of the present invention.Thus, antibodies or antisera, preferably polyclonal antisera, and mostpreferably monoclonal antibodies specific for each marker are used todetect expression. The antibodies can be detected by direct labeling ofthe antibodies themselves, for example, with radioactive labels,fluorescent labels, hapten labels such as, biotin, or an enzyme such ashorse radish peroxidase or alkaline phosphatase. Alternatively,unlabeled primary antibody is used in conjunction with a labeledsecondary antibody, comprising antisera, polyclonal antisera or amonoclonal antibody specific for the primary antibody.Immunohistochemistry protocols and kits are well known in the art andare commercially available.

h. Proteomics

The term “proteome” is defined as the totality of the proteins presentin a sample (e.g. tissue, organism, or cell culture) at a certain pointof time. Proteomics includes, among other things, study of the globalchanges of protein expression in a sample (also referred to as“expression proteomics”). Proteomics typically includes the followingsteps: (1) separation of individual proteins in a sample by 2-D gelelectrophoresis (2-D PAGE); (2) identification of the individualproteins recovered from the gel, e.g. my mass spectrometry or N-terminalsequencing, and (3) analysis of the data using bioinformatics.Proteomics methods are valuable supplements to other methods of geneexpression profiling, and can be used, alone or in combination withother methods, to detect the products of the prognostic markers of thepresent invention.

i. Promoter Methylation Analysis

A number of methods for quantization of RNA transcripts (gene expressionanalysis) or their protein translation products are discussed herein.The expression level of genes may also be inferred from informationregarding chromatin structure, such as for example the methylationstatus of gene promoters and other regulatory elements and theacetylation status of histones.

In particular, the methylation status of a promoter influences the levelof expression of the gene regulated by that promoter. Aberrantmethylation of particular gene promoters has been implicated inexpression regulation, such as for example silencing of tumor suppressorgenes. Thus, examination of the methylation status of a gene's promotercan be utilized as a surrogate for direct quantization of RNA levels.

Several approaches for measuring the methylation status of particularDNA elements have been devised, including methylation-specific PCR(Herman J. G. et al. (1996) Methylation-specific PCR: a novel PCR assayfor methylation status of CpG islands. Proc. Natl Acad. Sci. USA. 93,9821-9826.) and bisulfite DNA sequencing (Frommer M. et al. (1992) Agenomic sequencing protocol that yields a positive display of5-methylcytosine residues in individual DNA strands. Proc. Natl Acad.Sci. USA. 89, 1827-1831.). More recently, microarray-based technologieshave been used to characterize promoter methylation status (Chen C. M.(2003) Methylation target array for rapid analysis of CpG islandhypermethylation in multiple tissue genomes. Am. J. Pathol. 163, 3745.).

j. Coexpression of Genes

A further aspect of the invention is the identification of geneexpression clusters. Gene expression clusters can be identified byanalysis of expression data using statistical analyses known in the art,including pairwise analysis of correlation based on Pearson correlationcoefficients (Pearson K. and Lee A. (1902) Biometrika 2, 357).

In one embodiment, an expression cluster identified herein includes BGN,CALD1, COL1A1, COL1A2, SPARC, VIM and other genes which are known to besynthesized predominantly by stromal cells and to be involved inremodeling extracellular matrix. This expression cluster is referred toherein as the Extracellular Matrix Remodeling/Stromal cluster.

In another embodiment, an expression cluster identified herein includesANXA2, KLK6, KLK10, LAMA3, LAMC2, MASPIN, SLPI, and other genes encodingepithelial cell secreted products, most of which are secretedpredominantly by epithelial cells but which may be secreted by othercell types. This expression cluster is referred to herein as theEpithelial/Secreted cluster.

In still another embodiment, an expression cluster identified hereinincludes DUSP1, EGR1, EGR3, FOS, NR4A1, RHOB, and other genes whosetranscription is upregulated early after exposure of cells to certainstimuli. A variety of stimuli trigger transcription of early responsegenes, e.g. exposure to growth factor s, which enables cells to quicklyincrease their motility and their ability to transport nutrients such asglucose. This expression cluster is referred to herein as the EarlyResponse cluster.

In yet another embodiment, an expression cluster identified hereinincludes MCP1, CD68, CTSB, OPN, and other genes encoding proteinsusually associated with cells of the immune system. This expressioncluster is referred to herein as the Immune cluster.

In a further embodiment, an expression cluster identified hereinincludes CCNE2, CDC20, SKP2, CHK1, BRCA1, CSEL1 and other genesimplicated in cell proliferation and regulation of the cell cycle. Thisexpression cluster is referred to herein as the Proliferation/Cell Cyclecluster.

k. General Description of the mRNA Isolation, Purification andAmplification

The steps of a representative protocol for profiling gene expressionusing fixed, paraffin-embedded tissues as the RNA source, including mRNAisolation, purification, primer extension and amplification are providedin various published journal articles (for example: T. E. Godfrey etal., J. Molec. Diagnostics 2: 84-91 (2000); K. Specht et al., Am. J.Pathol. 158: 419-29 (2001)). Briefly, a representative process startswith cutting about 10 μm thick sections of paraffin-embedded tumortissue samples. The RNA is then extracted, and protein and DNA areremoved. After analysis of the RNA concentration, RNA repair and/oramplification steps may be included, if necessary, and RNA is reversetranscribed using gene specific promoters followed by RT-PCR. Finally,the data are analyzed to identify the best treatment option(s) availableto the patient on the basis of the characteristic gene expressionpattern identified in the tumor sample examined, dependent on thepredicted likelihood of cancer recurrence.

l. Colon Cancer Gene Set, Assayed Gene Subsequences, and ClinicalApplication of Gene Expression Data

An important aspect of the present invention is to use the measuredexpression of certain genes by colon cancer tissue to provide prognosticinformation. For this purpose it is necessary to correct for (normalizeaway) both differences in the amount of RNA assayed and variability inthe quality of the RNA used. Therefore, the assay typically measures andincorporates the expression of certain normalizing genes, including wellknown housekeeping genes, such as GAPDH and Cyp1. Alternatively,normalization can be based on the mean or median signal (Ct) of all ofthe assayed genes or a large subset thereof (global normalizationapproach). On a gene-by-gene basis, measured normalized amount of apatient tumor mRNA is compared to the amount found in a colon cancertissue reference set. The number (N) of colon cancer tissues in thisreference set should be sufficiently high to ensure that differentreference sets (as a whole) behave essentially the same way. If thiscondition is met, the identity of the individual colon cancer tissuespresent in a particular set will have no significant impact on therelative amounts of the genes assayed. Usually, the colon cancer tissuereference set consists of at least about 30, preferably at least about40 different FPE colon cancer tissue specimens. Unless noted otherwise,normalized expression levels for each mRNA/tested tumor/patient will beexpressed as a percentage of the expression level measured in thereference set. More specifically, the reference set of a sufficientlyhigh number (e.g. 40) of tumors yields a distribution of normalizedlevels of each mRNA species. The level measured in a particular tumorsample to be analyzed falls at some percentile within this range, whichcan be determined by methods well known in the art. Below, unless notedotherwise, reference to expression levels of a gene assume normalizedexpression relative to the reference set although this is not alwaysexplicitly stated.

m. Design of Intron-Based PCR Primers and Probes

According to one aspect of the present invention, PCR primers and probesare designed based upon intron sequences present in the gene to beamplified. Accordingly, the first step in the primer/probe design is thedelineation of intron sequences within the genes. This can be done bypublicly available software, such as the DNA BLAT software developed byKent, W. J., Genome Res. 12(4):656-64 (2002), or by the BLAST softwareincluding its variations. Subsequent steps follow well establishedmethods of PCR primer and probe design.

In order to avoid non-specific signals, it is important to maskrepetitive sequences within the introns when designing the primers andprobes. This can be easily accomplished by using the Repeat Maskerprogram available on-line through the Baylor College of Medicine, whichscreens DNA sequences against a library of repetitive elements andreturns a query sequence in which the repetitive elements are masked.The masked intron sequences can then be used to design primer and probesequences using any commercially or otherwise publicly availableprimer/probe design packages, such as Primer Express (AppliedBiosystems); MGB assay-by-design (Applied Biosystems); Primer3 (SteveRozen and Helen J. Skaletsky (2000) Primer3 on the WWW for general usersand for biologist programmers. In: Krawetz S, Misener S (eds)Bioinformatics Methods and Protocols: Methods in Molecular Biology.Humana Press, Totowa, N.J., pp 365-386).

The most important factors considered in PCR primer design includeprimer length, melting temperature (Tm), and G/C content, specificity,complementary primer sequences, and 3′-end sequence. In general, optimalPCR primers are generally 17-30 bases in length, and contain about20-80%, such as, for example, about 50-60% G+C bases. Tm's between 50and 80° C., e.g. about 50 to 70° C. are typically preferred.

For further guidelines for PCR primer and probe design see, e.g.Dieffenbach, C. W. et al., “General Concepts for PCR Primer Design” in:PCR Primer, A Laboratory Manual, Cold Spring Harbor Laboratory Press,New York, 1995, pp. 133-155; Innis and Gelfand, “Optimization of PCRs”in: PCR Protocols, A Guide to Methods and Applications, CRC Press,London, 1994, pp. 5-11; and Plasterer, T. N. Primerselect: Primer andprobe design. Methods Mol. Biol. 70:520-527 (1997), the entiredisclosures of which are hereby expressly incorporated by reference.

n. Kits of the Invention

The materials for use in the methods of the present invention are suitedfor preparation of kits produced in accordance with well knownprocedures. The invention thus provides kits comprising agents, whichmay include gene-specific or gene-selective probes and/or primers, forquantitating the expression of the disclosed genes for predictingprognostic outcome or response to treatment. Such kits may optionallycontain reagents for the extraction of RNA from tumor samples, inparticular fixed paraffin-embedded tissue samples and/or reagents forRNA amplification. In addition, the kits may optionally comprise thereagent(s) with an identifying description or label or instructionsrelating to their use in the methods of the present invention. The kitsmay comprise containers (including microtiter plates suitable for use inan automated implementation of the method), each with one or more of thevarious reagents (typically in concentrated form) utilized in themethods, including, for example, pre-fabricated microarrays, buffers,the appropriate nucleotide triphosphates (e.g., dATP, dCTP, dGTP anddTTP; or rATP, rCTP, rGTP and UTP), reverse transcriptase, DNApolymerase, RNA polymerase, and one or more probes and primers of thepresent invention (e.g., appropriate length poly(T) or random primerslinked to a promoter reactive with the RNA polymerase). Mathematicalalgorithms used to estimate or quantify prognostic or predictiveinformation are also properly potential components of kits.

o. Reports of the Invention

The methods of this invention, when practiced for commercial diagnosticpurposes generally produce a report or summary of the normalizedexpression levels of one or more of the selected genes. The methods ofthis invention will produce a report comprising a prediction of theclinical outcome of a subject diagnosed with colorectal cancer followingsurgical resection of said cancer. The methods and reports of thisinvention can further include storing the report in a database.Alternatively, the method can further create a record in a database forthe subject and populate the record with data. In one embodiment thereport is a paper report, in another embodiment the report is anauditory report, in another embodiment the report is an electronicrecord. It is contemplated that the report is provided to a physicianand/of the patient. The receiving of the report can further includeestablishing a network connection to a server computer that includes thedata and report and requesting the data and report from the servercomputer.

The methods provided by the present invention may also be automated inwhole or in part.

All aspects of the present invention may also be practiced such that alimited number of additional genes that are co-expressed with thedisclosed genes, for example as evidenced by high Pearson correlationcoefficients, are included in a prognostic or predictive test inaddition to and/or in place of disclosed genes.

Having described the invention, the same will be more readily understoodthrough reference to the following Example, which is provided by way ofillustration, and is not intended to limit the invention in any way.

EXAMPLES A Study to Explore Relationships Between Genomic TumorExpression Profiles and the Likelihood of Recurrence in Dukes' B andDuke's C Patients Treated with Resection of the Colon

The primary objective of this study was to determine whether there is asignificant relationship between the expression of each of 757 ampliconsidentified in Table B and clinical outcome in stage II and stage IIIcolon cancer patients who receive colon resection (surgery) withoutchemotherapy.

Study Design

This was an exploratory study using tissue and outcome data fromNational Surgical Adjuvant Breast and Bowel Project (NSABP) Studies C-01and C-02 in up to 400 Dukes B (stage II) and Dukes C (stage III)patients who received colon resection (surgery) only or surgery andpostoperative Bacillus Calmette-Guerin (BCG).

Inclusion Criteria

Patients enrolled in either NSABP Study C-01: “A Clinical Trial ToEvaluate Postoperative Immunotherapy And Postoperative SystemicChemotherapy In The Management Of Resectable Colon Cancer” or NSABPStudy C-02: “A Protocol To Evaluate The Postoperative Portal VeinInfusion Of 5-Flourouracil And Heparin In Adenocarcinoma Of The Colon”Details of C-01 and C-02 can be found on the NSABP Website at thefollowing URL:

http://www.nsabp.pitt.edu/NSABP_Protocols.htm#treatment%20closed

Tissue samples from the surgery only and surgery+postoperative BCG armsof NSABP C01 and from the surgery only arm of NSABP C02 surgery werecombined into one sample set.

Exclusion Criteria

Patients enrolled in NSABP Study C-01 or NSABP Study C-02 were excludedfrom the present study if one or more of the following applied:

No tumor block available from initial diagnosis in the NSABP archive.

-   -   Insufficient tumor in block as assessed by examination of        hematoxylin and eosin (H&E) slide    -   Insufficient RNA (<700 ng) recovered from tissue sections for        RT-PCR analysis.

Of 1943 patients enrolled in NSABP Study C-01 or NSABP Study C-02, 270patient samples were available after application of exclusion criteriaand used in the gene expression study disclosed herein. The overalldemographic and clinical characteristics of the 270 included sampleswere similar to the original NSABP combined cohorts.

Gene Panel

Seven hundred sixty-one genes, including seven reference genes, werechosen for expression analysis. These genes are listed in Table Atogether with the sequences of primers and probes used in qRT-PCR todetermine expression level.

Experimental Materials and Methods

The expression of 750 cancer-related genes and 7 genes designated foruse as reference genes was quantitatively assessed for each patientusing TaqMan® RT-PCR, which was performed in singlet with RNA input at 1nanogram per reaction.

Data Analysis Methods Reference Normalization

For normalization of extraneous effects, cycle threshold (C_(T))measurements obtained by RT-PCR were normalized relative to the meanexpression of a set of six reference genes. The resultingreference-normalized expression measurements typically range from 0 to15, where a one unit increase generally reflects a 2-fold increase inRNA quantity.

Comparison of Study Cohort to Original NSABP Study Populations

We compared the distribution of clinical and demographic variables forthe current study cohort of evaluable tissue blocks versus the originalNSABP C-01 and C-02 study populations. There were no clinicallymeaningful differences in the distributions.

Univariate Analysis

For each of the 757 amplicons under study, we used the Cox proportionalhazard model to examine the relationship between gene expression andrecurrence free interval (RFI). The likelihood ratio was used as thetest of statistical significance. The method of Benjamini and Hochberg(Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discoveryrate: a practical and powerful approach to multiple testing. J.R.Statist. Soc. B 57, 289-300.), as well as resampling and permutationbased methods (Tusher V G, Tibshirani R, Chu G (2001) Significanceanalysis of microarrays applied to the ionizing radiation response. ProcNatl Acad Sci USA, 98:5116-5121.; Storey J D, Tibshirani R (2001)Estimating false discovery rates under dependence, with applications toDNA microarrays. Stanford: Stanford University, Department ofStatistics; Report No.: Technical Report 2001-28.; Korn E L, Troendle J,McShane L, Simon R (2001) Controlling the number of false discoveries:Application to high-dimensional genomic data. Technical Report 003.2001. National Cancer Institute.) were applied to the resulting set ofp-values to estimate false discovery rates. All analyses were repeatedfor each of the alternative endpoints: distant recurrence free interval(DRFI), overall survival (OS), and disease free survival (DFS).

Multivariate Analysis

For each of the 757 amplicons under study, we used the Cox proportionalhazard model to examine the relationship between gene expression andRFI, while controlling for the effects of other standard clinicalcovariates (including tumor location, surgery type, tumor grade, numberof lymph nodes examined, and number of positive lymph nodes. Thedifference in the log likelihoods of the (reduced) model including onlythe standard clinical covariates and the (full) model including thestandard clinical covariates plus gene expression was used as the testof statistical significance.

Non-Linear Analysis

For each of the 757 amplicons under study, we explored alternativefunctional relationships between gene expression and recurrence usingseveral different methods. For each amplicon, we fit a Cox proportionalhazards model of RFI as a function of gene expression using a 2degree-of-freedom (DF) natural spline (Stone C, Koo C. (1985) InProceedings of the Statistical Computing Section ASA. Washington, D.C.,45-48). Statistical significance was assessed by the 2 DF likelihoodratio test for the model. Functional relationships were also explored byexamining the pattern of (smoothed) Martingale residuals derived fromunivariate Cox proportional hazards models of RFI as a strictly linearfunction of gene expression (Gray R J (1992) Flexible methods foranalyzing survival data using splines, with applications to breastcancer prognosis. Journal of the American Statistical Association,87:942-951.; Gray R J (1994) Spline-based tests in survival analysis.Biometrics, 50:640-652.; Gray R J (1990) Some diagnostic methods for Coxregression models through hazard smoothing. Biometrics, 46:93-102.).Additionally, cumulative sums of Martingale residuals from each the sameCox proportional hazards models were used to detect departures fromlinearity (Lin D, Wei L, Ying Z. (1993) Checking the Cox Model withCumulative Sums of Martingale-Based Residuals. Vol. 80, No. 3, 557-572).

Interaction with Stage

We determined whether there is a significantly different relationshipbetween gene expression and RFI in stage II and stage III patients. Foreach of the 757 amplicons, we tested the hypothesis that there is asignificant difference between the (reduced) proportional hazards modelfor gene expression and tumor stage versus the (full) proportionalhazards model based on gene expression, tumor stage, and theirinteraction. The difference in the log likelihoods of the reduced andfull models was used as the test of statistical significance.

Table A shows qRT-PCR probe and primer sequences for all genes includedin the study described in the Example.

Table B shows target amplicons for all genes included in the studydescribed in the Example.

First Analysis Study Results

Reference Gene set for the first analysis was CLTC, FZD6, NEDD8, RPLPO,RPS13, UBB, UBC.

Table 1A shows associations for those genes whose increased expressionis predictive of shorter Recurrence-Free Interval (RFI) based onunivariate proportional hazards analysis.

Table 1B shows associations for those genes whose increased expressionis predictive of longer Recurrence-Free Interval (RFI) based onunivariate proportional hazards analysis.

Table 2A shows associations for those genes whose increased expressionis predictive of decreased rate of Overall Survival (OS) based onunivariate proportional hazards analysis.

Table 2B shows associations for those genes whose increased expressionis predictive of increased rate of Overall Survival (OS) based onunivariate proportional hazards analysis.

Table 3A shows associations for those genes whose increased expressionis predictive of decreased rate of Disease Free Survival (DFS) based onunivariate proportional hazards analysis.

Table 3B shows associations for those genes whose increased expressionis predictive of increased rate of Disease Free Survival (DFS) based onunivariate proportional hazards analysis.

Table 4A shows associations for those genes whose increased expressionis predictive of shorter Distant Recurrence-Free Interval (DRFI) basedon univariate proportional hazards analysis.

Table 4B shows associations for those genes whose increased expressionis predictive of longer Distant Recurrence-Free Interval (DRFI) based onunivariate proportional hazards analysis.

Table 5A shows associations between gene expression and RFI for thosegenes whose increased expression is predictive of shorterRecurrence-Free Interval (RFI), based on a multivariate analysiscontrolling for particular demographic and clinical characteristics ofpatients included in the analysis.

Table 5B shows associations between gene expression and RFI for thosegenes whose increased expression is predictive of longer Recurrence-FreeInterval (RFI), based on a multivariate analysis controlling forparticular demographic and clinical characteristics of patients includedin the analysis.

Table 6 shows genes for which an association between gene expression andclinical outcome was identified based on a nonlinear proportionalhazards analysis, using a 2 degree-of-freedom natural spline.

Table 7 shows all genes exhibiting an interaction (p-value<0.05) withtumor stage.

Table 1A shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio>1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using RFI as the metric for clinical outcome.

TABLE 1A Hazard Accession Gene Ratio P Value OfficialSymbol Number RARB2.13 0.0252 RARB NM_016152 ITGB1 1.94 0.0002 ITGB1 NM_002211 ALDOA 1.920.0853 ALDOA NM_000034 ANXA2 1.90 <.0001 ANXA2 NM_004039 CYP3A4 1.810.0038 CYP3A4 NM_017460 KRAS2 1.64 0.0043 KRAS NM_004985 COX2 1.620.0521 PTGS2 NM_000963 RhoC 1.61 0.0034 RHOC NM_175744 TJP1 1.60 0.0554TJP1 NM_003257 RhoB 1.57 0.0001 RHOB NM_004040 KIAA0125 1.56 0.0940KIAA0125 NM_014792 TIMP1 1.52 <.0001 TIMP1 NM_003254 UBC 1.49 0.0031 UBCNM_021009 ANXA5 1.49 0.0084 ANXA5 NM_001154 NTN1 1.49 0.0386 NTN1NM_004822 AKT3 1.47 <.0001 AKT3 NM_005465 CALD1 1.46 0.0007 CALD1NM_004342 IGFBP7 1.46 0.0019 IGFBP7 NM_001553 VEGFC 1.45 0.0092 VEGFCNM_005429 BGN 1.44 0.0002 BGN NM_001711 CYP1B1 1.44 0.0180 CYP1B1NM_000104 DLC1 1.43 0.0012 DLC1 NM_006094 SI 1.43 0.0063 SI NM_001041CCNE2 variant 1 1.43 0.0506 CCNE2 NM_057749 LAMC2 1.42 0.0003 LAMC2NM_005562 TIMP2 1.42 0.0018 TIMP2 NM_003255 CDC42BPA 1.42 0.0029CDC42BPA NM_003607 p21 1.41 0.0062 CDKN1A NM_000389 HB-EGF 1.40 0.0105HBEGF NM_001945 TLN1 1.40 0.0260 TLN1 NM_006289 DUSP1 1.39 <.0001 DUSP1NM_004417 ROCK1 1.39 0.0121 ROCK1 NM_005406 CTSB 1.39 0.0307 CTSBNM_001908 ITGAV 1.38 0.0020 ITGAV NM_002210 HSPG2 1.38 0.0215 HSPG2NM_005529 GADD45B 1.37 0.0002 GADD45B NM_015675 VCL 1.37 0.0201 VCLNM_003373 SBA2 1.37 0.0250 WSB2 NM_018639 Maspin 1.36 <.0001 SERPINB5NM_002639 CGB 1.36 0.0018 CGB NM_000737 TIMP3 1.36 0.0024 TIMP3NM_000362 VIM 1.36 0.0073 VIM NM_003380 S100A1 1.36 0.0247 S100A1NM_006271 INHBA 1.35 0.0008 INHBA NM_002192 SIR2 1.35 0.0039 SIRT1NM_012238 TMSB10 1.35 0.0469 TMSB10 NM_021103 CD68 1.34 0.0036 CD68NM_001251 RBX1 1.34 0.0469 RBX1 NM_014248 INHBB 1.34 0.0514 INHBBNM_002193 PKR2 1.34 0.0628 PKM2 NM_002654 FOS 1.33 0.0006 FOS NM_005252FYN 1.33 0.0036 FYN NM_002037 LOXL2 1.33 0.0064 LOXL2 NM_002318 STC11.33 0.0101 STC1 NM_003155 DKK1 1.33 0.0208 DKK1 NM_012242 IGFBP5 1.320.0064 IGFBP5 NM_000599 EPAS1 1.32 0.0270 EPAS1 NM_001430 UNC5C 1.320.0641 UNC5C NM_003728 FAP 1.31 0.0017 FAP NM_004460 IGFBP3 1.31 0.0041IGFBP3 NM_000598 SNAI2 1.31 0.0055 SNAI2 NM_003068 PRKCA 1.31 0.0065PRKCA NM_002737 FST 1.31 0.0399 FST NM_006350 KCNH2 iso a/b 1.31 0.0950KCNH2 NM_000238 CTHRC1 1.30 0.0017 CTHRC1 NM_138455 PDGFC 1.30 0.0034PDGFC NM_016205 EGR1 1.30 0.0048 EGR1 NM_001964 TAGLN 1.30 0.0058 TAGLNNM_003186 SPARC 1.30 0.0104 SPARC NM_003118 KLF6 1.30 0.0514 KLF6NM_001300 GRIK1 1.30 0.0753 GRIK1 NM_000830 CYR61 1.29 0.0018 CYR61NM_001554 SLPI 1.29 0.0026 SLPI NM_003064 COL1A2 1.29 0.0076 COL1A2NM_000089 MAPK14 1.29 0.0916 MAPK14 NM_139012 LAMA3 1.28 0.0020 LAMA3NM_000227 THBS1 1.28 0.0053 THBS1 NM_003246 NRP2 1.28 0.0120 NRP2NM_003872 LOX 1.27 0.0028 LOX NM_002317 S100A4 1.27 0.0067 S100A4NM_002961 CXCR4 1.27 0.0083 CXCR4 NM_003467 CEBPB 1.27 0.0943 CEBPBNM_005194 AKAP12 1.26 0.0044 AKAP12 NM_005100 ADAMTS12 1.26 0.0100ADAMTS12 NM_030955 CRYAB 1.25 0.0038 CRYAB NM_001885 Grb10 1.25 0.0108GRB10 NM_005311 MCP1 1.25 0.0118 CCL2 NM_002982 COL1A1 1.25 0.0167COL1A1 NM_000088 EFNB2 1.25 0.0241 EFNB2 NM_004093 ANXA1 1.25 0.0292ANXA1 NM_000700 ANGPT2 1.25 0.0485 ANGPT2 NM_001147 EphB6 1.25 0.0825EPHB6 NM_004445 HSPA1A 1.24 0.0018 HSPA1A NM_005345 TGFB3 1.24 0.0081TGFB3 NM_003239 PTGER3 1.24 0.0306 PTGER3 NM_000957 FXYD5 1.24 0.0367FXYD5 NM_014164 CAPG 1.24 0.0604 CAPG NM_001747 PDGFB 1.23 0.0157 PDGFBNM_002608 ANTXR1 1.23 0.0164 ANTXR1 NM_032208 TGFBI 1.23 0.0191 TGFBINM_000358 CTGF 1.23 0.0233 CTGF NM_001901 PDGFA 1.23 0.0274 NM_002607P14ARF 1.23 0.0362 S78535 KLK10 1.22 0.0005 KLK10 NM_002776 ITGA5 1.220.0178 ITGA5 NM_002205 GBP2 1.22 0.0201 GBP2 NM_004120 SIAT4A 1.220.0231 ST3GAL1 NM_003033 GJB2 1.22 0.0271 GJB2 NM_004004 LAT 1.22 0.0306LAT NM_014387 CTSL 1.22 0.0331 CTSL NM_001912 DAPK1 1.22 0.0384 DAPK1NM_004938 SKP1A 1.22 0.0542 SKP1A NM_006930 NDRG1 1.22 0.0712 NDRG1NM_006096 ITGB5 1.22 0.0991 ITGB5 NM_002213 KLK6 1.21 0.0034 KLK6NM_002774 SFRP2 1.21 0.0037 SFRP2 NM_003013 TMEPAI 1.21 0.0173 TMEPAINM_020182 ID4 1.21 0.0530 ID4 NM_001546 SFRP4 1.20 0.0077 SFRP4NM_003014 HOXB7 1.20 0.0274 HOXB7 NM_004502 GJA1 1.20 0.0311 GJA1NM_000165 CDH11 1.20 0.0662 CDH11 NM_001797 PAI1 1.19 0.0060 SERPINE1NM_000602 S100P 1.19 0.0119 S100P NM_005980 EGR3 1.19 0.0164 EGR3NM_004430 EMP1 1.19 0.0460 EMP1 NM_001423 ABCC5 1.19 0.0536 ABCC5NM_005688 FZD1 1.19 0.0701 FZD1 NM_003505 MAD 1.19 0.0811 MXD1 NM_002357EFNA1 1.19 0.0920 EFNA1 NM_004428 OPN_osteopontin 1.18 0.0028 SPP1NM_000582 ALDH1A1 1.18 0.0246 ALDH1A1 NM_000689 NR4A1 1.18 0.0277 NR4A1NM_002135 SIAT7B 1.18 0.0301 ST6GALNAC2 NM_006456 p16-INK4 1.18 0.0439L27211 TUBB 1.18 0.0761 TUBB2 NM_001069 IL6 1.18 0.0939 IL6 NM_000600RAB32 1.18 0.0948 RAB32 NM_006834 TULP3 1.18 0.0953 TULP3 NM_003324 F31.17 0.0561 F3 NM_001993 PLK3 1.16 0.0792 PLK3 NM_004073 EPHA2 1.160.0962 EPHA2 NM_004431 SLC2A1 1.15 0.0745 SLC2A1 NM_006516 CXCL12 1.140.0911 CXCL12 NM_000609 S100A2 1.13 0.0287 S100A2 NM_005978 FABP4 1.130.0340 FABP4 NM_001442 STMY3 1.13 0.0517 MMP11 NM_005940 BCAS1 1.130.0939 BCAS1 NM_003657 REG4 1.11 0.0026 REG4 NM_032044 pS2 1.09 0.0605TFF1 NM_003225 MUC2 1.06 0.0626 MUC2 NM_002457

Table 1B shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio<1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using RFI as the metric for clinical outcome.

TABLE 1B Hazard Accession Gene Ratio P Value OfficialSymbol Number ORC1L0.42 0.0728 ORC1L NM_004153 HSPA8 0.62 0.0430 HSPA8 NM_006597 E2F1 0.640.0009 E2F1 NM_005225 RAD54L 0.65 0.0026 RAD54L NM_003579 RPLPO 0.670.0150 RPLP0 NM_001002 BRCA1 0.68 0.0001 BRCA1 NM_007295 DHFR 0.690.0096 DHFR NM_000791 SLC25A3 0.69 0.0110 SLC25A3 NM_213611 PPM1D 0.710.0033 PPM1D NM_003620 SKP2 0.71 0.0098 SKP2 NM_005983 FASN 0.72 0.0071FASN NM_004104 HNRPD 0.72 0.0686 HNRPD NM_031370 ENO1 0.73 0.0418 ENO1NM_001428 RPS13 0.75 0.0786 RPS13 NM_001017 DDB1 0.75 0.0804 DDB1NM_001923 C20 orf1 0.76 0.0122 TPX2 NM_012112 KIF22 0.76 0.0137 KIF22NM_007317 Chk1 0.76 0.0174 CHEK1 NM_001274 TCF-1 0.77 0.0021 TCF1NM_000545 ST14 0.77 0.0446 ST14 NM_021978 RRM1 0.77 0.0740 RRM1NM_001033 BRCA2 0.77 0.0800 BRCA2 NM_000059 LMNB1 0.78 0.0513 LMNB1NM_005573 CMYC 0.79 0.0086 MYC NM_002467 CDC20 0.79 0.0290 CDC20NM_001255 CSEL1 0.79 0.0344 CSE1L NM_001316 Bax 0.79 0.0662 BAXNM_004324 NME1 0.79 0.0742 NME1 NM_000269 c-myb (MYB official) 0.800.0077 MYB NM_005375 CDCA7 v2 0.80 0.0159 CDCA7 NM_145810 EFP 0.800.0405 TRIM25 NM_005082 UBE2M 0.80 0.0437 UBE2M NM_003969 RRM2 0.810.0168 RRM2 NM_001034 ABCC6 0.81 0.0373 ABCC6 NM_001171 SURV 0.81 0.0584BIRC5 NM_001168 CKS2 0.81 0.0753 CKS2 NM_001827 RAF1 0.81 0.0899 RAF1NM_002880 EPHB2 0.82 0.0190 EPHB2 NM_004442 NOTCH1 0.82 0.0232 NOTCH1NM_017617 UMPS 0.82 0.0456 UMPS NM_000373 CCNE2 0.82 0.0544 CCNE2NM_057749 PI3KC2A 0.82 0.0916 PIK3C2A NM_002645 CD80 0.82 0.0954 CD80NM_005191 AREG 0.83 0.0014 AREG NM_001657 EREG 0.83 0.0062 EREGNM_001432 MYBL2 0.83 0.0259 MYBL2 NM_002466 ABCB1 0.83 0.0322 ABCB1NM_000927 HRAS 0.83 0.0760 HRAS NM_005343 SLC7A5 0.84 0.0585 SLC7A5NM_003486 MAD2L1 0.84 0.0590 MAD2L1 NM_002358 Ki-67 0.85 0.0620 MKI67NM_002417 MCM2 0.85 0.0700 MCM2 NM_004526 ING5 0.85 0.0947 ING5NM_032329 Cdx2 0.88 0.0476 CDX2 NM_001265 PTPRO 0.89 0.0642 PTPRONM_030667 cripto (TDGF1 0.90 0.0803 TDGF1 NM_003212 official)

Table 2A shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio>1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using OS as the metric for clinical outcome.

TABLE 2A Hazard Accession Gene Ratio P Value OfficialSymbol Number RARB1.75 0.0820 RARB NM_016152 RhoC 1.70 0.0001 RHOC NM_175744 ANXA2 1.640.0002 ANXA2 NM_004039 CYP3A4 1.58 0.0064 CYP3A4 NM_017460 p21 1.54<.0001 CDKN1A NM_000389 ITGB1 1.54 0.0058 ITGB1 NM_002211 UBC 1.500.0003 UBC NM_021009 TNF 1.46 0.0859 TNF NM_000594 VEGFC 1.44 0.0049VEGFC NM_005429 HMLH 1.44 0.0435 MLH1 NM_000249 RhoB 1.37 0.0015 RHOBNM_004040 TGFBR1 1.37 0.0127 TGFBR1 NM_004612 SPINT2 1.37 0.0235 SPINT2NM_021102 PFN1 1.37 0.0842 PFN1 NM_005022 HSPG2 1.36 0.0115 HSPG2NM_005529 TIMP1 1.35 0.0008 TIMP1 NM_003254 INHBB 1.35 0.0190 INHBBNM_002193 VCL 1.34 0.0099 VCL NM_003373 KCNH2 iso a/b 1.33 0.0362 KCNH2NM_000238 LAMC2 1.32 0.0005 LAMC2 NM_005562 FXYD5 1.31 0.0021 FXYD5NM_014164 HLA-G 1.31 0.0458 HLA-G NM_002127 GADD45B 1.30 0.0002 GADD45BNM_015675 CDC42 1.30 0.0120 CDC42 NM_001791 LAMB3 1.30 0.0163 LAMB3NM_000228 DKK1 1.30 0.0209 DKK1 NM_012242 UNC5C 1.30 0.0452 UNC5CNM_003728 UBL1 1.29 0.0171 SUMO1 NM_003352 HB-EGF 1.29 0.0262 HBEGFNM_001945 KRAS2 1.29 0.0726 KRAS NM_004985 ID3 1.28 0.0023 ID3 NM_002167LOXL2 1.28 0.0039 LOXL2 NM_002318 EphB6 1.28 0.0322 EPHB6 NM_004445DUSP1 1.27 0.0003 DUSP1 NM_004417 BGN 1.27 0.0040 BGN NM_001711 CALD11.27 0.0119 CALD1 NM_004342 CDC42BPA 1.27 0.0151 CDC42BPA NM_003607 SBA21.27 0.0373 WSB2 NM_018639 INHBA 1.26 0.0018 INHBA NM_002192 NRP1 1.260.0113 NRP1 NM_003873 TIMP2 1.26 0.0123 TIMP2 NM_003255 KLF6 1.26 0.0444KLF6 NM_001300 KLK10 1.25 <.0001 KLK10 NM_002776 TIMP3 1.25 0.0083 TIMP3NM_000362 CAPG 1.25 0.0170 CAPG NM_001747 IGFBP7 1.25 0.0249 IGFBP7NM_001553 S100A1 1.25 0.0529 S100A1 NM_006271 SHC1 1.25 0.0605 SHC1NM_003029 CTSB 1.25 0.0766 CTSB NM_001908 ANXA5 1.25 0.0787 ANXA5NM_001154 PKR2 1.25 0.0800 PKM2 NM_002654 HSPA1A 1.24 0.0003 HSPA1ANM_005345 CGB 1.24 0.0148 CGB NM_000737 DLC1 1.24 0.0231 DLC1 NM_006094TMSB10 1.24 0.0890 TMSB10 NM_021103 LAMA3 1.23 0.0017 LAMA3 NM_000227FOS 1.23 0.0028 FOS NM_005252 SNAI2 1.23 0.0123 SNAI2 NM_003068 SPARC1.23 0.0134 SPARC NM_003118 SIR2 1.23 0.0173 SIRT1 NM_012238 KRT19 1.230.0217 KRT19 NM_002276 CTSD 1.23 0.0395 CTSD NM_001909 EPAS1 1.23 0.0409EPAS1 NM_001430 GAGE4 1.23 0.0468 GAGE4 NM_001474 BMP4 1.22 0.0024 BMP4NM_001202 PLK3 1.22 0.0056 PLK3 NM_004073 Grb10 1.22 0.0059 GRB10NM_005311 FYN 1.22 0.0120 FYN NM_002037 STC1 1.22 0.0409 STC1 NM_003155G-Catenin 1.22 0.0661 JUP NM_002230 HK1 1.22 0.0872 HK1 NM_000188 MADH41.22 0.0956 SMAD4 NM_005359 KLK6 1.21 0.0011 KLK6 NM_002774 CTHRC1 1.210.0065 CTHRC1 NM_138455 LAT 1.21 0.0146 LAT NM_014387 IGFBP3 1.21 0.0149IGFBP3 NM_000598 AKT3 1.21 0.0212 AKT3 NM_005465 HSPA1B 1.21 0.0262HSPA1B NM_005346 THY1 1.21 0.0278 THY1 NM_006288 ANXA1 1.21 0.0322 ANXA1NM_000700 LOX 1.20 0.0067 LOX NM_002317 CD68 1.20 0.0223 CD68 NM_001251EFNB2 1.20 0.0268 EFNB2 NM_004093 DYRK1B 1.20 0.0473 DYRK1B NM_004714PTK2 1.20 0.0889 PTK2 NM_005607 THBS1 1.19 0.0203 THBS1 NM_003246 TAGLN1.19 0.0263 TAGLN NM_003186 TULP3 1.19 0.0334 TULP3 NM_003324 SR-A1 1.190.0387 SR-A1 NM_021228 APC 1.19 0.0433 APC NM_000038 ERK1 1.19 0.0488Z11696 VIM 1.19 0.0661 VIM NM_003380 CREBBP 1.19 0.0802 CREBBP NM_004380ANGPT2 1.19 0.0860 ANGPT2 NM_001147 Maspin 1.18 0.0029 SERPINB5NM_002639 PDGFB 1.18 0.0252 PDGFB NM_002608 S100A4 1.18 0.0270 S100A4NM_002961 EGR1 1.18 0.0334 EGR1 NM_001964 IGFBP5 1.18 0.0526 IGFBP5NM_000599 NOTCH2 1.18 0.0527 NOTCH2 NM_024408 PAI1 1.17 0.0036 SERPINE1NM_000602 NR4A1 1.17 0.0110 NR4A1 NM_002135 BCAS1 1.17 0.0137 BCAS1NM_003657 BRK 1.17 0.0137 PTK6 NM_005975 AKAP12 1.17 0.0195 AKAP12NM_005100 EMP1 1.17 0.0291 EMP1 NM_001423 SIAT4A 1.17 0.0304 ST3GAL1NM_003033 MRP3 1.17 0.0334 ABCC3 NM_003786 COL1A1 1.17 0.0399 COL1A1NM_000088 Upa 1.17 0.0588 PLAU NM_002658 UNC5B 1.17 0.0986 UNC5BNM_170744 PDGFC 1.16 0.0355 PDGFC NM_016205 MCP1 1.16 0.0449 CCL2NM_002982 CTGF 1.16 0.0576 CTGF NM_001901 COL1A2 1.16 0.0612 COL1A2NM_000089 RAB32 1.16 0.0645 RAB32 NM_006834 SIN3A 1.16 0.0787 SIN3ANM_015477 SKP1A 1.16 0.0837 SKP1A NM_006930 EFNA1 1.16 0.0957 EFNA1NM_004428 S100A2 1.15 0.0040 S100A2 NM_005978 MMP7 1.15 0.0374 MMP7NM_002423 HOXB7 1.15 0.0405 HOXB7 NM_004502 FAP 1.15 0.0455 FAPNM_004460 ANTXR1 1.15 0.0482 ANTXR1 NM_032208 TGFBI 1.15 0.0553 TGFBINM_000358 TMEPAI 1.14 0.0435 TMEPAI NM_020182 CYR61 1.14 0.0490 CYR61NM_001554 SLPI 1.14 0.0724 SLPI NM_003064 TP53I3 1.14 0.0831 TP53I3NM_004881 PDGFA 1.14 0.0845 NM_002607 SFRP2 1.13 0.0255 SFRP2 NM_003013S100A8 1.13 0.0693 S100A8 NM_002964 F3 1.13 0.0708 F3 NM_001993 Bcl21.13 0.0962 BCL2 NM_000633 OPN_osteopontin 1.12 0.0097 SPP1 NM_000582FZD6 1.12 0.0692 FZD6 NM_003506 OSM 1.11 0.0744 OSM NM_020530 EGLN3 1.110.0884 EGLN3 NM_022073 SIAT7B 1.11 0.0938 ST6GALNAC2 NM_006456 FABP41.10 0.0454 FABP4 NM_001442 EFNA3 1.10 0.0958 EFNA3 NM_004952 MMP2 1.100.0969 MMP2 NM_004530 GSTT1 1.09 0.0737 GSTT1 NM_000853 REG4 1.07 0.0286REG4 NM_032044

Table 2B shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio<1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using OS as the metric for clinical outcome.

TABLE 2B Hazard Accession Gene Ratio P Value Official Symbol NumberHSPA8 0.62 0.0145 HSPA8 NM_006597 SKP2 0.70 0.0010 SKP2 NM_005983 DHFR0.74 0.0085 DHFR NM_000791 PRDX4 0.74 0.0197 PRDX4 NM_006406 RRM1 0.750.0162 RRM1 NM_001033 SLC25A3 0.75 0.0342 SLC25A3 NM_213611 RPLPO 0.750.0416 RPLP0 NM_001002 E2F1 0.78 0.0190 E2F1 NM_005225 SURV 0.79 0.0086BIRC5 NM_001168 c-myb (MYB 0.80 0.0020 MYB NM_005375 official) BRCA10.80 0.0077 BRCA1 NM_007295 Chk1 0.80 0.0186 CHEK1 NM_001274 ST14 0.800.0407 ST14 NM_021978 TCF-1 0.81 0.0045 TCF1 NM_000545 CCNE2 0.81 0.0112CCNE2 NM_057749 PPM1D 0.81 0.0194 PPM1D NM_003620 CDC20 0.81 0.0213CDC20 NM_001255 EI24 0.81 0.0585 EI24 NM_004879 C20 orf1 0.82 0.0348TPX2 NM_012112 DUT 0.83 0.0396 DUT NM_001948 CD44E 0.83 0.0439 X55150KIF22 0.83 0.0506 KIF22 NM_007317 PPID 0.83 0.0615 PPID NM_005038 UBE2M0.83 0.0805 UBE2M NM_003969 LMNB1 0.83 0.0868 LMNB1 NM_005573 MCM2 0.840.0207 MCM2 NM_004526 CDC6 0.84 0.0218 CDC6 NM_001254 MRPL40 0.84 0.0769MRPL40 NM_003776 EPHB2 0.85 0.0253 EPHB2 NM_004442 CMYC 0.85 0.0371 MYCNM_002467 AURKB 0.85 0.0375 AURKB NM_004217 CDCA7 v2 0.85 0.0421 CDCA7NM_145810 ABCB1 0.86 0.0390 ABCB1 NM_000927 SMARCA3 0.86 0.0601 SMARCA3NM_003071 Cdx2 0.88 0.0166 CDX2 NM_001265 PPARG 0.88 0.0645 PPARGNM_005037 MYBL2 0.88 0.0647 MYBL2 NM_002466 EREG 0.89 0.0411 EREGNM_001432 AREG 0.90 0.0235 AREG NM_001657

Table 3A shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio>1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DFS as the metric for clinical outcome.

TABLE 3A Hazard Accession Gene Ratio P Value OfficialSymbol Number ANXA21.74 <.0001 ANXA2 NM_004039 CYP3A4 1.69 0.0020 CYP3A4 NM_017460 RhoC1.53 0.0009 RHOC NM_175744 TJP1 1.45 0.0787 TJP1 NM_003257 UBC 1.430.0007 UBC NM_021009 p21 1.42 0.0004 CDKN1A NM_000389 HB-EGF 1.39 0.0032HBEGF NM_001945 SPINT2 1.37 0.0154 SPINT2 NM_021102 HMLH 1.36 0.0711MLH1 NM_000249 VEGFC 1.35 0.0157 VEGFC NM_005429 PKR2 1.34 0.0187 PKM2NM_002654 LAMC2 1.33 0.0002 LAMC2 NM_005562 ITGB1 1.33 0.0499 ITGB1NM_002211 TIMP1 1.32 0.0007 TIMP1 NM_003254 VCL 1.31 0.0114 VCLNM_003373 INHBB 1.31 0.0302 INHBB NM_002193 GADD45B 1.30 <.0001 GADD45BNM_015675 RhoB 1.30 0.0053 RHOB NM_004040 DUSP1 1.28 <.0001 DUSP1NM_004417 HK1 1.28 0.0297 HK1 NM_000188 GRIK1 1.28 0.0364 GRIK1NM_000830 FOS 1.27 0.0002 FOS NM_005252 CGB 1.27 0.0126 CGB NM_000737KLF6 1.27 0.0288 KLF6 NM_001300 ANXA5 1.27 0.0504 ANXA5 NM_001154 KRAS21.27 0.0724 KRAS NM_004985 INHBA 1.26 0.0009 INHBA NM_002192 DLC1 1.260.0096 DLC1 NM_006094 IGFBP7 1.26 0.0116 IGFBP7 NM_001553 BGN 1.250.0039 BGN NM_001711 LOXL2 1.25 0.0076 LOXL2 NM_002318 STC1 1.25 0.0135STC1 NM_003155 CTSD 1.25 0.0208 CTSD NM_001909 HSPG2 1.25 0.0485 HSPG2NM_005529 KCNH2 iso a/b 1.25 0.0832 KCNH2 NM_000238 TIMP3 1.24 0.0057TIMP3 NM_000362 FXYD5 1.24 0.0070 FXYD5 NM_014164 A-Catenin 1.24 0.0447CTNNA1 NM_001903 LOX 1.23 0.0013 LOX NM_002317 EGR1 1.23 0.0037 EGR1NM_001964 CAPG 1.23 0.0191 CAPG NM_001747 LAMB3 1.23 0.0377 LAMB3NM_000228 GAGE4 1.23 0.0402 GAGE4 NM_001474 SHC1 1.23 0.0640 SHC1NM_003029 MVP 1.23 0.0726 MVP NM_017458 VEGF 1.22 0.0250 VEGF NM_003376UNC5B 1.22 0.0256 UNC5B NM_170744 CDC42BPA 1.22 0.0297 CDC42BPANM_003607 SBA2 1.22 0.0614 WSB2 NM_018639 DKK1 1.22 0.0689 DKK1NM_012242 EphB6 1.22 0.0763 EPHB6 NM_004445 IGFBP3 1.21 0.0078 IGFBP3NM_000598 HSPA1B 1.21 0.0167 HSPA1B NM_005346 CALD1 1.21 0.0277 CALD1NM_004342 TIMP2 1.21 0.0309 TIMP2 NM_003255 NR4A1 1.20 0.0023 NR4A1NM_002135 LAMA3 1.20 0.0028 LAMA3 NM_000227 SIAT4A 1.20 0.0082 ST3GAL1NM_003033 PDGFB 1.20 0.0084 PDGFB NM_002608 EMP1 1.20 0.0107 EMP1NM_001423 THBS1 1.20 0.0126 THBS1 NM_003246 CD68 1.20 0.0143 CD68NM_001251 FYN 1.20 0.0151 FYN NM_002037 TULP3 1.20 0.0213 TULP3NM_003324 EFNA1 1.20 0.0254 EFNA1 NM_004428 SIR2 1.20 0.0255 SIRT1NM_012238 G-Catenin 1.20 0.0689 JUP NM_002230 S100A1 1.20 0.0998 S100A1NM_006271 Maspin 1.19 0.0013 SERPINB5 NM_002639 HSPA1A 1.19 0.0013HSPA1A NM_005345 SPARC 1.19 0.0359 SPARC NM_003118 PTHR1 1.19 0.0801PTHR1 NM_000316 SNAI2 1.18 0.0353 SNAI2 NM_003068 KRT19 1.18 0.0419KRT19 NM_002276 ERK1 1.18 0.0459 Z11696 KLK10 1.17 0.0007 KLK10NM_002776 BMP4 1.17 0.0121 BMP4 NM_001202 CYR61 1.17 0.0127 CYR61NM_001554 Grb10 1.17 0.0216 GRB10 NM_005311 PLK3 1.17 0.0242 PLK3NM_004073 EFNB2 1.17 0.0403 EFNB2 NM_004093 P14ARF 1.17 0.0439 S78535ID3 1.17 0.0446 ID3 NM_002167 IGFBP5 1.17 0.0503 IGFBP5 NM_000599 THY11.17 0.0574 THY1 NM_006288 VIM 1.17 0.0858 VIM NM_003380 EPAS1 1.170.0897 EPAS1 NM_001430 PAI1 1.16 0.0039 SERPINE1 NM_000602 F3 1.160.0172 F3 NM_001993 CTHRC1 1.16 0.0181 CTHRC1 NM_138455 ANTXR1 1.160.0237 ANTXR1 NM_032208 FAP 1.16 0.0289 FAP NM_004460 ADAMTS12 1.160.0350 ADAMTS12 NM_030955 CTGF 1.16 0.0424 CTGF NM_001901 PTGER3 1.160.0569 PTGER3 NM_000957 ANXA1 1.16 0.0699 ANXA1 NM_000700 NRP1 1.160.0797 NRP1 NM_003873 NDRG1 1.16 0.0856 NDRG1 NM_006096 KLK6 1.15 0.0092KLK6 NM_002774 EGR3 1.15 0.0153 EGR3 NM_004430 HOXB7 1.15 0.0345 HOXB7NM_004502 PDGFC 1.15 0.0363 PDGFC NM_016205 Herstatin 1.15 0.0403AF177761 MCP1 1.15 0.0409 CCL2 NM_002982 TGFBI 1.15 0.0437 TGFBINM_000358 TP53I3 1.15 0.0438 TP53I3 NM_004881 SLPI 1.15 0.0457 SLPINM_003064 PLAUR 1.15 0.0471 PLAUR NM_002659 GJB2 1.15 0.0610 GJB2NM_004004 COL1A1 1.15 0.0647 COL1A1 NM_000088 IL6 1.15 0.0790 IL6NM_000600 APC 1.15 0.0821 APC NM_000038 S100A2 1.14 0.0048 S100A2NM_005978 TMEPAI 1.14 0.0300 TMEPAI NM_020182 PDGFA 1.14 0.0644NM_002607 S100A4 1.14 0.0680 S100A4 NM_002961 TAGLN 1.14 0.0820 TAGLNNM_003186 Upa 1.14 0.0823 PLAU NM_002658 COL1A2 1.14 0.0856 COL1A2NM_000089 OSM 1.13 0.0299 OSM NM_020530 BRK 1.13 0.0479 PTK6 NM_005975SEMA3B 1.13 0.0525 SEMA3B NM_004636 OPN_osteopontin 1.12 0.0084 SPP1NM_000582 S100P 1.12 0.0283 S100P NM_005980 SFRP2 1.12 0.0291 SFRP2NM_003013 EGLN3 1.12 0.0465 EGLN3 NM_022073 SIAT7B 1.12 0.0570ST6GALNAC2 NM_006456 MMP7 1.12 0.0743 MMP7 NM_002423 FABP4 1.11 0.0195FABP4 NM_001442 AKAP12 1.11 0.0899 AKAP12 NM_005100 EFNA3 1.10 0.0684EFNA3 NM_004952 SFRP4 1.10 0.0684 SFRP4 NM_003014 CRYAB 1.10 0.0987CRYAB NM_001885 GSTT1 1.09 0.0457 GSTT1 NM_000853 REG4 1.08 0.0074 REG4NM_032044 pS2 1.08 0.0302 TFF1 NM_003225 MUC5B 1.08 0.0401 MUC5BXM_039877 IGFBP2 1.08 0.0873 IGFBP2 NM_000597

Table 3B shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio<1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DFS as the metric for clinical outcome.

TABLE 3B Hazard Accession Gene Ratio P Value Official Symbol NumberHSPA8 0.70 0.0487 HSPA8 NM_006597 SLC25A3 0.71 0.0084 SLC25A3 NM_213611E2F1 0.73 0.0019 E2F1 NM_005225 SKP2 0.73 0.0038 SKP2 NM_005983 PPM1D0.75 0.0008 PPM1D NM_003620 RRM1 0.76 0.0161 RRM1 NM_001033 RPLPO 0.760.0388 RPLP0 NM_001002 NPM1 0.78 0.0223 NPM1 NM_002520 DDB1 0.78 0.0673DDB1 NM_001923 PRDX4 0.79 0.0526 PRDX4 NM_006406 BRCA1 0.80 0.0051 BRCA1NM_007295 Chk1 0.80 0.0114 CHEK1 NM_001274 SURV 0.81 0.0155 BIRC5NM_001168 C20 orf1 0.81 0.0195 TPX2 NM_012112 EI24 0.81 0.0382 EI24NM_004879 RAD54L 0.81 0.0501 RAD54L NM_003579 DHFR 0.81 0.0530 DHFRNM_000791 c-myb (MYB 0.82 0.0029 MYB NM_005375 official) CCNE2 0.820.0109 CCNE2 NM_057749 KIF22 0.82 0.0235 KIF22 NM_007317 HMGB1 0.820.0849 HMGB1 NM_002128 LMNB1 0.83 0.0665 LMNB1 NM_005573 CDCA7 v2 0.840.0224 CDCA7 NM_145810 CDC20 0.84 0.0461 CDC20 NM_001255 FASN 0.840.0797 FASN NM_004104 ABCB1 0.85 0.0157 ABCB1 NM_000927 MCM2 0.85 0.0183MCM2 NM_004526 DUT 0.85 0.0469 DUT NM_001948 KIF2C 0.85 0.0786 KIF2CNM_006845 MCM6 0.85 0.0791 MCM6 NM_005915 EIF4E 0.85 0.0863 EIF4ENM_001968 EPHB2 0.86 0.0271 EPHB2 NM_004442 RCC1 0.86 0.0444 RCC1NM_001269 EFP 0.86 0.0760 TRIM25 NM_005082 AREG 0.87 0.0029 AREGNM_001657 CMYC 0.87 0.0483 MYC NM_002467 GCLC 0.87 0.0824 GCLC NM_001498TCF-1 0.88 0.0520 TCF1 NM_000545 MYBL2 0.88 0.0527 MYBL2 NM_002466 EREG0.89 0.0237 EREG NM_001432 Cdx2 0.90 0.0353 CDX2 NM_001265 PTPRO 0.920.0896 PTPRO NM_030667 cripto (TDGF1 0.92 0.0913 TDGF1 NM_003212official) HLA-DRB1 0.93 0.0536 HLA-DRB1 NM_002124

Table 4A shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio>1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DRFI as the metric for clinical outcome.

TABLE 4A Hazard Accession Gene Ratio P Value Official Symbol NumberALDOA 3.37 0.0106 ALDOA NM_000034 DCK 2.74 0.0130 DCK NM_000788 ITGB12.50 <.0001 ITGB1 NM_002211 COX2 2.15 0.0128 PTGS2 NM_000963 TJP1 2.120.0072 TJP1 NM_003257 STAT3 1.98 0.0062 STAT3 NM_003150 HMLH 1.93 0.0087MLH1 NM_000249 CYP3A4 1.90 0.0092 CYP3A4 NM_017460 RhoC 1.89 0.0033 RHOCNM_175744 ANXA2 1.87 0.0025 ANXA2 NM_004039 TIMP1 1.83 <.0001 TIMP1NM_003254 WWOX 1.81 0.0288 WWOX NM_016373 ANXA5 1.80 0.0029 ANXA5NM_001154 FUS 1.79 0.0179 FUS NM_004960 PADI4 1.78 0.0168 PADI4NM_012387 RBX1 1.71 0.0082 RBX1 NM_014248 CRIP2 1.71 0.0343 CRIP2NM_001312 HB-EGF 1.69 0.0013 HBEGF NM_001945 KCNH2 iso a/b 1.69 0.0070KCNH2 NM_000238 SBA2 1.68 0.0066 WSB2 NM_018639 RhoB 1.67 0.0010 RHOBNM_004040 VIM 1.66 0.0010 VIM NM_003380 LILRB3 1.66 0.0227 LILRB3NM_006864 UBC 1.64 0.0051 UBC NM_021009 p21 1.63 0.0032 CDKN1A NM_000389CCNE2 variant 1 1.62 0.0363 CCNE2 NM_057749 RAB6C 1.61 0.0107 RAB6CNM_032144 MSH3 1.61 0.0213 MSH3 NM_002439 AKT3 1.59 0.0003 AKT3NM_005465 PI3K 1.58 0.0552 PIK3C2B NM_002646 RAP1GDS1 1.57 0.0154RAP1GDS1 NM_021159 CTSB 1.57 0.0250 CTSB NM_001908 PRDX6 1.57 0.0770PRDX6 NM_004905 NRP2 1.56 0.0005 NRP2 NM_003872 DLC1 1.56 0.0026 DLC1NM_006094 BGN 1.55 0.0006 BGN NM_001711 SIR2 1.55 0.0016 SIRT1 NM_012238CALD1 1.53 0.0046 CALD1 NM_004342 YWHAH 1.53 0.0429 YWHAH NM_003405CDC42 1.52 0.0207 CDC42 NM_001791 ITGA5 1.51 0.0004 ITGA5 NM_002205 KLF61.51 0.0197 KLF6 NM_001300 TLN1 1.51 0.0414 TLN1 NM_006289 LAMC2 1.490.0017 LAMC2 NM_005562 STC1 1.49 0.0040 STC1 NM_003155 CDC42BPA 1.490.0109 CDC42BPA NM_003607 RBM5 1.49 0.0184 RBM5 NM_005778 INHBB 1.490.0310 INHBB NM_002193 TGFBR1 1.49 0.0502 TGFBR1 NM_004612 ADAM10 1.490.0819 ADAM10 NM_001110 CEBPB 1.48 0.0399 CEBPB NM_005194 AKT1 1.480.0846 AKT1 NM_005163 FYN 1.47 0.0036 FYN NM_002037 ARG 1.47 0.0067 ABL2NM_005158 HIF1A 1.47 0.0221 HIF1A NM_001530 S100A1 1.47 0.0293 S100A1NM_006271 KRAS2 1.47 0.0958 KRAS NM_004985 CTHRC1 1.46 0.0008 CTHRC1NM_138455 IGFBP7 1.46 0.0173 IGFBP7 NM_001553 ROCK1 1.46 0.0326 ROCK1NM_005406 VEGFC 1.46 0.0516 VEGFC NM_005429 EPAS1 1.45 0.0316 EPAS1NM_001430 DUSP1 1.44 0.0008 DUSP1 NM_004417 FST 1.44 0.0340 FSTNM_006350 GADD45B 1.43 0.0013 GADD45B NM_015675 FLT4 1.43 0.0663 FLT4NM_002020 PTEN 1.43 0.0760 PTEN NM_000314 FAP 1.42 0.0017 FAP NM_004460PDGFC 1.42 0.0033 PDGFC NM_016205 LOXL2 1.42 0.0115 LOXL2 NM_002318 Pak11.42 0.0846 PAK1 NM_002576 Grb10 1.41 0.0020 GRB10 NM_005311 INHBA 1.410.0036 INHBA NM_002192 GJA1 1.41 0.0039 GJA1 NM_000165 CTGF 1.41 0.0053CTGF NM_001901 COL1A2 1.41 0.0057 COL1A2 NM_000089 PTK2 1.40 0.0496 PTK2NM_005607 THBS1 1.39 0.0059 THBS1 NM_003246 RANBP9 1.39 0.0333 RANBP9NM_005493 RANBP2 1.39 0.0988 RANBP2 NM_006267 ITGAV 1.38 0.0210 ITGAVNM_002210 TIMP2 1.38 0.0285 TIMP2 NM_003255 PTHR1 1.38 0.0297 PTHR1NM_000316 GADD45 1.38 0.0340 GADD45A NM_001924 c-ab1 1.38 0.0526 ABL1NM_005157 EGR1 1.37 0.0097 EGR1 NM_001964 NCAM1 1.37 0.0657 NCAM1NM_000615 VCL 1.37 0.0845 VCL NM_003373 LOX 1.36 0.0026 LOX NM_002317SNAI2 1.36 0.0178 SNAI2 NM_003068 SPARC 1.36 0.0198 SPARC NM_003118CDH11 1.36 0.0233 CDH11 NM_001797 NFKBp50 1.36 0.0767 NFKB1 NM_003998CYR61 1.35 0.0065 CYR61 NM_001554 S100A4 1.35 0.0104 S100A4 NM_002961TAGLN 1.35 0.0168 TAGLN NM_003186 PCAF 1.34 0.0327 PCAF NM_003884 NOTCH21.34 0.0390 NOTCH2 NM_024408 LRP5 1.34 0.0722 LRP5 NM_002335 SI 1.340.0787 SI NM_001041 GBP2 1.33 0.0139 GBP2 NM_004120 Bcl2 1.33 0.0143BCL2 NM_000633 MCP1 1.33 0.0159 CCL2 NM_002982 EPHA2 1.33 0.0184 EPHA2NM_004431 PRKCA 1.33 0.0329 PRKCA NM_002737 TIMP3 1.33 0.0337 TIMP3NM_000362 ANGPT2 1.33 0.0476 ANGPT2 NM_001147 CTSD 1.33 0.0766 CTSDNM_001909 SEMA3F 1.33 0.0931 SEMA3F NM_004186 BCAS1 1.32 0.0044 BCAS1NM_003657 ANXA1 1.32 0.0458 ANXA1 NM_000700 KRT19 1.32 0.0535 KRT19NM_002276 PTPRJ 1.32 0.0618 PTPRJ NM_002843 CAPG 1.32 0.0641 CAPGNM_001747 FOS 1.31 0.0129 FOS NM_005252 COL1A1 1.31 0.0236 COL1A1NM_000088 CXCR4 1.31 0.0251 CXCR4 NM_003467 TUBB 1.31 0.0354 TUBB2NM_001069 PIM1 1.31 0.0373 PIM1 NM_002648 IGFBP5 1.31 0.0477 IGFBP5NM_000599 AP-1 (JUN official) 1.31 0.0519 JUN NM_002228 GCNT1 1.310.0534 GCNT1 NM_001490 MAX 1.31 0.0650 MAX NM_002382 PAI1 1.30 0.0017SERPINE1 NM_000602 SLPI 1.30 0.0176 SLPI NM_003064 IGFBP3 1.30 0.0320IGFBP3 NM_000598 DAPK1 1.30 0.0402 DAPK1 NM_004938 ID3 1.30 0.0442 ID3NM_002167 EFNA1 1.30 0.0623 EFNA1 NM_004428 AKAP12 1.29 0.0162 AKAP12NM_005100 PDGFB 1.29 0.0242 PDGFB NM_002608 CD68 1.29 0.0524 CD68NM_001251 FGFR1 1.29 0.0709 FGFR1 NM_023109 GSK3B 1.29 0.0765 GSK3BNM_002093 CXCL12 1.28 0.0129 CXCL12 NM_000609 DPYD 1.28 0.0186 DPYDNM_000110 LAMA3 1.28 0.0193 LAMA3 NM_000227 MRP3 1.28 0.0384 ABCC3NM_003786 ABCC5 1.28 0.0402 ABCC5 NM_005688 PDGFA 1.28 0.0482 NM_002607XPA 1.28 0.0740 XPA NM_000380 NDRG1 1.28 0.0786 NDRG1 NM_006096 FES 1.270.0458 FES NM_002005 CTSL 1.27 0.0485 CTSL NM_001912 IL6 1.27 0.0606 IL6NM_000600 SFRP2 1.26 0.0085 SFRP2 NM_003013 Maspin 1.26 0.0096 SERPINB5NM_002639 TGFBI 1.26 0.0470 TGFBI NM_000358 NOS3 1.26 0.0978 NOS3NM_000603 HSPA1A 1.25 0.0161 HSPA1A NM_005345 S100A8 1.25 0.0180 S100A8NM_002964 HOXB7 1.25 0.0396 HOXB7 NM_004502 P14ARF 1.25 0.0697 S78535WISP1 1.25 0.0712 WISP1 NM_003882 ID4 1.25 0.0883 ID4 NM_001546 SFRP41.24 0.0200 SFRP4 NM_003014 FZD6 1.24 0.0220 FZD6 NM_003506 EGR3 1.240.0237 EGR3 NM_004430 ALDH1A1 1.24 0.0258 ALDH1A1 NM_000689 CRYAB 1.230.0394 CRYAB NM_001885 TGFB3 1.23 0.0541 TGFB3 NM_003239 ANTXR1 1.230.0661 ANTXR1 NM_032208 KLK6 1.22 0.0211 KLK6 NM_002774 ILT-2 1.220.0676 LILRB1 NM_006669 EMP1 1.22 0.0871 EMP1 NM_001423 PLAUR 1.220.0943 PLAUR NM_002659 S100A2 1.20 0.0100 S100A2 NM_005978 MMP7 1.190.0810 MMP7 NM_002423 OPN_osteopontin 1.17 0.0231 SPP1 NM_000582 FABP41.17 0.0325 FABP4 NM_001442 KLK10 1.17 0.0452 KLK10 NM_002776 PS2 1.160.0140 TFF1 NM_003225 STMY3 1.15 0.0850 MMP11 NM_005940 REG4 1.14 0.0042REG4 NM_032044 MUC2 1.09 0.0370 MUC2 NM_002457

Table 4B shows associations between clinical outcome and gene expressionfor those genes which demonstrated a Hazard Ratio<1.0 and for whichp<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DRFI as the metric for clinical outcome.

Hazard Accession Gene Ratio P Value OfficialSymbol Number HSPA8 0.510.0261 HSPA8 NM_006597 RPS13 0.58 0.0089 RPS13 NM_001017 RPLPO 0.630.0324 RPLP0 NM_001002 NDUFS3 0.66 0.0142 NDUFS3 NM_004551 LMNB1 0.670.0202 LMNB1 NM_005573 ST14 0.67 0.0206 ST14 NM_021978 BRCA1 0.68 0.0032BRCA1 NM_007295 TMSB4X 0.68 0.0075 TMSB4X NM_021109 DHFR 0.68 0.0356DHFR NM_000791 SKP2 0.69 0.0248 SKP2 NM_005983 TCF-1 0.70 0.0015 TCF1NM_000545 CDC20 0.70 0.0067 CDC20 NM_001255 SLC25A3 0.70 0.0418 SLC25A3NM_213611 NME1 0.72 0.0503 NME1 NM_000269 RRM1 0.72 0.0850 RRM1NM_001033 MCM2 0.76 0.0168 MCM2 NM_004526 ABCC6 0.76 0.0445 ABCC6NM_001171 CKS2 0.76 0.0869 CKS2 NM_001827 EPHB2 0.77 0.0174 EPHB2NM_004442 C20 orf1 0.77 0.0716 TPX2 NM_012112 CSEL1 0.77 0.0725 CSE1LNM_001316 NFKBp65 0.78 0.0957 RELA NM_021975 AURKB 0.79 0.0742 AURKBNM_004217 CMYC 0.82 0.0901 MYC NM_002467 Cdx2 0.85 0.0510 CDX2 NM_001265EREG 0.85 0.0730 EREG NM_001432 AREG 0.86 0.0365 AREG NM_001657

Table 5A shows associations between gene expression and RFI, controllingfor particular demographic and clinical characteristics of patientsincluded in the analysis. All genes are listed whose expressioncorrelates with RFI (p<0.1) and which demonstrated a Hazard Ratio>1 in amultivariate analysis including the following variables: tumor location,surgery, tumor grade, nodes examined, and number of positive nodes.

TABLE 5A Gene HR LR Chi-Square DF P-Value RARB 2.06780 4.23265 1 0.03965CYP3A4 1.85387 7.99462 1 0.00469 ANXA2 1.80012 10.84166 1 0.00099 COX21.79051 4.52307 1 0.03344 RhoC 1.73986 9.97133 1 0.00159 MAPK14 1.683828.04253 1 0.00457 UBC 1.67323 11.69444 1 0.00063 RhoB 1.66612 15.92497 10.00007 ITGB1 1.65796 8.18638 1 0.00422 KRAS2 1.63873 6.80447 1 0.00909NTN1 1.61833 5.43469 1 0.01974 ATP5E 1.60990 4.93660 1 0.02629 G-Catenin1.58482 9.24422 1 0.00236 STC1 1.58163 11.10757 1 0.00086 SPINT2 1.526536.17276 1 0.01297 Claudin 4 1.50290 12.29943 1 0.00045 IGFBP7 1.487899.62569 1 0.00192 NCAM1 1.48294 5.11428 1 0.02373 TIMP1 1.46045 9.984921 0.00158 CEBPB 1.46025 5.23659 1 0.02212 KCNH2 iso a/b 1.44616 3.973041 0.04623 TMSB10 1.43107 4.65463 1 0.03097 VEGFC 1.41860 4.66904 10.03071 HB-EGF 1.41757 7.00399 1 0.00813 FST 1.41061 5.59674 1 0.01799LAMC2 1.40860 11.33997 1 0.00076 GADD45B 1.40671 12.26323 1 0.00046 AKT31.40161 10.13028 1 0.00146 EFNA1 1.40048 8.86645 1 0.00290 p21 1.399395.42981 1 0.01980 INHBA 1.38204 11.03909 1 0.00089 CALD1 1.38009 6.934061 0.00846 DUSP1 1.36464 13.04379 1 0.00030 HSPG2 1.36387 4.11749 10.04244 GJB2 1.36358 8.42204 1 0.00371 EPAS1 1.36323 4.74318 1 0.02941BGN 1.35821 7.66947 1 0.00562 TIMP2 1.35571 5.78791 1 0.01614 A-Catenin1.35566 4.35623 1 0.03687 LOXL2 1.35470 7.23663 1 0.00714 DKK1 1.351263.88504 1 0.04872 ITGAV 1.34899 8.03554 1 0.00459 CGB 1.34840 7.06221 10.00787 EGR1 1.33424 8.41855 1 0.00371 TIMP3 1.33197 6.28550 1 0.01217VIM 1.33196 4.92198 1 0.02652 TGFBI 1.32511 8.30278 1 0.00396 FXYD51.32500 6.22751 1 0.01258 VEGF 1.32291 4.93825 1 0.02627 ADAMTS121.31794 7.46749 1 0.00628 SLPI 1.31565 8.38324 1 0.00379 DLC1 1.308625.51638 1 0.01884 HOXB7 1.30822 8.04076 1 0.00457 TMEPAI 1.30395 8.437361 0.00368 IGFBP5 1.30260 5.44022 1 0.01968 CDC42BPA 1.30167 4.20771 10.04024 PDGFA 1.29760 5.54964 1 0.01848 GSTp 1.29594 3.96268 1 0.04652FOS 1.29427 8.42847 1 0.00369 PDGFC 1.28813 6.81737 1 0.00903 IGFBP31.28701 6.33625 1 0.01183 LOX 1.28433 8.15598 1 0.00429 SPARC 1.282604.75876 1 0.02915 EFNB2 1.27720 4.71247 1 0.02994 Maspin 1.2764510.57657 1 0.00115 THBS1 1.27619 6.61087 1 0.01014 TAGLN 1.26904 5.151231 0.02323 VEGF_altsplice1 1.26734 5.29282 1 0.02141 S100P 1.265869.88713 1 0.00166 HSPA1A 1.26209 8.59704 1 0.00337 MAD 1.26112 3.96163 10.04655 ANGPT2 1.25701 3.91148 1 0.04796 PRKCA 1.24853 4.69452 1 0.03026F3 1.24848 5.06788 1 0.02437 FAP 1.24657 5.19589 1 0.02264 BRK 1.245075.44048 1 0.01968 CD68 1.23943 4.02530 1 0.04482 NR4A1 1.23772 7.09548 10.00773 CTHRC1 1.23465 5.21100 1 0.02244 SLC2A1 1.22967 5.22364 10.02228 Grb10 1.22209 4.12811 1 0.04218 p16-INK4 1.21325 4.44296 10.03505 MDK 1.21116 5.25025 1 0.02194 CYR61 1.19995 4.14452 1 0.04177LAMA3 1.19794 4.33073 1 0.03743 FOXO3A 1.19557 4.20079 1 0.04041 EFNA31.19439 5.51728 1 0.01883 CRYAB 1.17514 3.90435 1 0.04816 CEACAM61.16804 3.96486 1 0.04646 OPN_osteopontin 1.16112 5.50891 1 0.01892KLK10 1.15851 5.65625 1 0.01739 SFRP2 1.15773 4.02893 1 0.04473 KLK61.15163 4.65953 1 0.03088 S100A2 1.14185 3.94284 1 0.04707 REG4 1.090374.16995 1 0.04115

Table 5B shows associations between gene expression and RFI, controllingfor particular demographic and clinical characteristics of patientsincluded in the analysis. All genes are listed whose expressioncorrelates with RFI (p<0.1) and which demonstrated a Hazard Ratio<1 in amultivariate analysis including the following variables: tumor location,surgery, tumor grade, nodes examined, and number of positive nodes.

TABLE 5B Gene HR LR Chi-Square DF P-Value BFGF 0.46674 6.95233 1 0.00837Fasl 0.47324 4.08714 1 0.04321 KLRK1 0.63331 10.28820 1 0.00134 DHFR0.64947 7.64434 1 0.00570 BRCA1 0.65247 15.21566 1 0.00010 SLC25A30.67480 5.72977 1 0.01668 RAD54L 0.68215 5.38684 1 0.02029 PPM1D 0.6877710.02879 1 0.00154 CD80 0.69347 8.70087 1 0.00318 ATP5A1 0.70467 4.067181 0.04372 PRKCB1 0.73152 5.21950 1 0.02234 KIF22 0.73945 5.13202 10.02349 Chk1 0.75865 4.38139 1 0.03633 TRAIL 0.76430 4.12533 1 0.04225CDC20 0.77071 5.04557 1 0.02469 DUT 0.78196 4.13381 1 0.04203 ABCB10.79434 5.33783 1 0.02087 UMPS 0.80011 4.65425 1 0.03098 ING5 0.802304.04085 1 0.04441 CMYC 0.80757 4.26709 1 0.03886 CBP1 0.83015 3.98302 10.04596 AREG 0.86091 4.94239 1 0.02621

Table 6 shows associations between gene expression and clinical outcomebased on a nonlinear proportional hazards analysis, using a 2degree-of-freedom natural spline. All genes are listed whichdemonstrated a departure from a strictly linear relationship (p<0.05)with RFI in combined Stage II (Duke's B) and Stage III (Duke's C)patients. The relationship between gene expression and RFI was notconstant throughout the observed range of expression values in thestudy, e.g. increases in gene expression may have been related toincreases in duration of RFI in one portion of the observed range andwith decreases in duration of RFI in a different portion of the range.

TABLE 6 Accession Gene P-Value Official Symbol Number PTHLH 0.001 PTHLHNM_002820 CDCA7 v2 0.002 CDCA7 NM_145810 CREBBP 0.002 CREBBP NM_004380KLF5 0.002 KLF5 NM_001730 LAMB3 0.004 LAMB3 NM_000228 TGFBR1 0.005TGFBR1 NM_004612 NR4A1 0.005 NR4A1 NM_002135 Upa 0.005 PLAU NM_002658Cad17 0.007 CDH17 NM_004063 S100A4 0.008 S100A4 NM_002961 A-Catenin0.008 CTNNA1 NM_001903 EPHB2 0.009 EPHB2 NM_004442 Axin 2 0.011 AXIN2NM_004655 PTPRJ 0.011 PTPRJ NM_002843 CAPN1 0.012 CAPN1 NM_005186 CEGP10.013 SCUBE2 NM_020974 APOC1 0.013 APOC1 NM_001645 GBP1 0.015 GBP1NM_002053 SKP2 0.016 SKP2 NM_005983 ATP5E 0.016 ATP5E NM_006886 GRIK10.017 GRIK1 NM_000830 PRKR 0.018 EIF2AK2 NM_002759 FUT6 0.020 FUT6NM_000150 PFN2 0.020 PFN2 NM_053024 ITGB4 0.021 ITGB4 NM_000213 MADH70.021 SMAD7 NM_005904 RALBP1 0.021 RALBP1 NM_006788 AKT1 0.022 AKT1NM_005163 KLK6 0.022 KLK6 NM_002774 PLK 0.023 PLK1 NM_005030 CYP2C80.025 CYP2C8 NM_000770 BTF3 0.026 BTF3 NM_001207 CCNE2 variant 1 0.026CCNE2 NM_057749 STMY3 0.030 MMP11 NM_005940 NRP1 0.030 NRP1 NM_003873SIAT4A 0.031 ST3GAL1 NM_003033 SEMA3B 0.033 SEMA3B NM_004636 TRAG3 0.033CSAG2 NM_004909 HSPE1 0.035 HSPE1 NM_002157 SBA2 0.036 WSB2 NM_018639TK1 0.036 TK1 NM_003258 CCNB2 0.037 CCNB2 NM_004701 TMEPAI 0.037 TMEPAINM_020182 SPRY2 0.037 SPRY2 NM_005842 AGXT 0.038 AGXT NM_000030 ALCAM0.038 ALCAM NM_001627 HSPCA 0.038 HSPCA NM_005348 TIMP3 0.038 TIMP3NM_000362 DET1 0.039 DET1 NM_017996 tusc4 0.040 TUSC4 NM_006545 SNAI20.040 SNAI2 NM_003068 CD28 0.040 CD28 NM_006139 RNF11 0.041 RNF11NM_014372 PAI1 0.042 SERPINE1 NM_000602 XRCC1 0.042 XRCC1 NM_006297EGLN1 0.044 EGLN1 NM_022051 EGFR 0.044 EGFR NM_005228 HES6 0.044 HES6NM_018645 KCNK4 0.045 KCNK4 NM_016611 CXCR4 0.047 CXCR4 NM_003467 PTP4A30.048 PTP4A3 NM_007079 p27 0.048 CDKN1B NM_004064 MADH4 0.049 SMAD4NM_005359 ICAM1 0.049 ICAM1 NM_000201

Table 7 shows all genes exhibiting an interaction (p-value<0.05) withtumor stage. The data were modeled using a proportional hazards model ofRFI with gene expression, tumor stage, and their interaction aspredictors.

TABLE 7 P-value for Gene HR Stage II HR Stage III Interaction ICAM2 1.490.68 0.0019 CD24 1.26 0.84 0.0054 PRDX6 2.29 0.73 0.0058 HSD17B2 0.621.29 0.0072 ALCAM 1.61 0.94 0.0088 SIR2 2.02 1.09 0.0089 NUFIP1 1.320.79 0.0093 EMR3 2.14 0.57 0.0127 CDC20 0.56 0.98 0.0130 MT3 1.37 0.790.0134 CLTC 1.80 0.71 0.0144 CYR61 1.73 1.10 0.0145 WIF 1.34 0.78 0.0195TFF3 1.23 0.90 0.0209 SOS1 1.46 0.79 0.0287 TMSB4X 1.34 0.74 0.0293CENPE 3.05 0.85 0.0330 CDH11 1.49 0.96 0.0339 CAPG 0.90 1.50 0.0348TP53BP1 1.54 0.93 0.0357 MGAT5 1.25 0.73 0.0362 MADH2 1.36 0.70 0.0393LOX 1.58 1.11 0.0396 DKK1 0.87 1.55 0.0415 CKS1B 0.31 1.75 0.0467 MMP70.92 1.28 0.0471 STAT5B 1.28 0.86 0.0471 CD28 0.69 1.25 0.0472

Second Analysis Study Results

Reference Gene Set for the second analysis was ATP5E, CLTC, GPX1, NEDD8,PGK1, UBB.

Table 1.2A shows associations for those genes whose increased expressionis predictive of shorter Recurrence-Free Interval (RFI) based onunivariate proportional hazards analysis.

Table 1.2B shows associations for those genes whose increased expressionis predictive of longer Recurrence-Free Interval (RFI) based onunivariate proportional hazards analysis.

Table 2.2A shows associations for those genes whose increased expressionis predictive of decreased rate of Overall Survival (OS) based onunivariate proportional hazards analysis.

Table 2.2B shows associations for those genes whose increased expressionis predictive of increased rate of Overall Survival (OS) based onunivariate proportional hazards analysis.

Table 3.2A shows associations for those genes whose increased expressionis predictive of decreased rate of Disease Free Survival (DFS) based onunivariate proportional hazards analysis.

Table 3.2B shows associations for those genes whose increased expressionis predictive of increased rate of Disease Free Survival (DFS) based onunivariate proportional hazards analysis.

Table 4.2A shows associations for those genes whose increased expressionis predictive of shorter Distant Recurrence-Free Interval (DRFI) basedon univariate proportional hazards analysis.

Table 4.2B shows associations for those genes whose increased expressionis predictive of longer Distant Recurrence-Free Interval (DRFI) based onunivariate proportional hazards analysis.

Table 5.2A shows associations between gene expression and RFI for thosegenes whose increased expression is predictive of shorterRecurrence-Free Interval (RFI), based on a multivariate analysiscontrolling for particular demographic and clinical characteristics ofpatients included in the analysis.

Table 5.2B shows associations between gene expression and RFI for thosegenes whose increased expression is predictive of longer Recurrence-FreeInterval (RFI), based on a multivariate analysis controlling forparticular demographic and clinical characteristics of patients includedin the analysis.

Table 6.2 shows genes for which an association between gene expressionand clinical outcome was identified based on a nonlinear proportionalhazards analysis, using a 2 degree-of-freedom natural spline.

Table 7.2 shows all genes exhibiting an interaction (p-value<0.05) withtumor stage.

Table 1.2A shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio>1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using RFI as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number RARB 2.220.0294 RARB NM_016152 ITGB1 2.04 0.0002 ITGB1 NM_002211 ANXA2 1.780.0003 ANXA2 NM_004039 CYP3A4 1.68 0.0075 CYP3A4 NM_017460 COX2 1.640.0604 PTGS2 NM_000963 KRAS2 1.62 0.0064 KRAS NM_004985 TJP1 1.58 0.0751TJP1 NM_003257 KIAA0125 1.58 0.0889 KIAA0125 NM_014792 RhoB 1.57 0.0002RHOB NM_004040 RhoC 1.56 0.0059 RHOC NM_175744 NTN1 1.54 0.0336 NTN1NM_004822 ANXA5 1.52 0.0086 ANXA5 NM_001154 TIMP1 1.52 <.0001 TIMP1NM_003254 AKT3 1.50 <.0001 AKT3 NM_005465 CALD1 1.48 0.0007 CALD1NM_004342 IGFBP7 1.46 0.0023 IGFBP7 NM_001553 CYP1B1 1.45 0.0222 CYP1B1NM_000104 BGN 1.44 0.0002 BGN NM_001711 VEGFC 1.44 0.0151 VEGFCNM_005429 DLC1 1.44 0.0014 DLC1 NM_006094 SI 1.42 0.0086 SI NM_001041TIMP2 1.42 0.0022 TIMP2 NM_003255 CDC42BPA 1.41 0.0038 CDC42BPANM_003607 LAMC2 1.40 0.0004 LAMC2 NM_005562 ITGAV 1.40 0.0019 ITGAVNM_002210 CTSB 1.40 0.0357 CTSB NM_001908 DUSP1 1.39 <.0001 DUSP1NM_004417 TLN1 1.39 0.0335 TLN1 NM_006289 CCNE2 1.39 0.0708 CCNE2NM_057749 variant 1 TIMP3 1.38 0.0023 TIMP3 NM_000362 GHI BRAF 1.380.0537 GHI_BRAF_mut4 mut4 HB-EGF 1.38 0.0109 HBEGF NM_001945 HSPG2 1.380.0258 HSPG2 NM_005529 VIM 1.37 0.0077 VIM NM_003380 ROCK1 1.37 0.0168ROCK1 NM_005406 S100A1 1.36 0.0233 S100A1 NM_006271 p21 1.36 0.0113CDKN1A NM_000389 CGB 1.36 0.0023 CGB NM_000737 UBC 1.36 0.0137 UBCNM_021009 GADD45B 1.36 0.0003 GADD45B NM_015675 INHBA 1.35 0.0010 INHBANM_002192 VCL 1.34 0.0286 VCL NM_003373 SIR2 1.34 0.0049 SIRT1 NM_012238CD68 1.34 0.0042 CD68 NM_001251 Maspin 1.34 <.0001 SERPINB5 NM_002639FST 1.33 0.0326 FST NM_006350 EPAS1 1.33 0.0306 EPAS1 NM_001430 LOXL21.33 0.0076 LOXL2 NM_002318 STC1 1.33 0.0119 STC1 NM_003155 UNC5C 1.320.0642 UNC5C NM_003728 IGFBP5 1.32 0.0080 IGFBP5 NM_000599 INHBB 1.320.0643 INHBB NM_002193 FAP 1.32 0.0017 FAP NM_004460 DKK1 1.31 0.0298DKK1 NM_012242 FYN 1.31 0.0053 FYN NM_002037 CTHRC1 1.31 0.0017 CTHRC1NM_138455 FOS 1.31 0.0010 FOS NM_005252 RBX1 1.31 0.0633 RBX1 NM_014248TAGLN 1.31 0.0058 TAGLN NM_003186 SBA2 1.31 0.0439 WSB2 NM_018639 CYR611.30 0.0018 CYR61 NM_001554 SPARC 1.30 0.0117 SPARC NM_003118 SNAI2 1.300.0076 SNAI2 NM_003068 TMSB10 1.30 0.0757 TMSB10 NM_021103 IGFBP3 1.300.0056 IGFBP3 NM_000598 PDGFC 1.29 0.0040 PDGFC NM_016205 SLPI 1.290.0026 SLPI NM_003064 COL1A2 1.29 0.0087 COL1A2 NM_000089 NRP2 1.290.0112 NRP2 NM_003872 PRKCA 1.29 0.0093 PRKCA NM_002737 KLF6 1.29 0.0661KLF6 NM_001300 THBS1 1.28 0.0062 THBS1 NM_003246 EGR1 1.28 0.0067 EGR1NM_001964 S100A4 1.28 0.0070 S100A4 NM_002961 CXCR4 1.28 0.0089 CXCR4NM_003467 LAMA3 1.27 0.0024 LAMA3 NM_000227 LOX 1.26 0.0036 LOXNM_002317 AKAP12 1.26 0.0046 AKAP12 NM_005100 ADAMTS12 1.26 0.0109ADAMTS12 NM_030955 MCP1 1.25 0.0122 CCL2 NM_002982 Grb10 1.25 0.0107GRB10 NM_005311 PTGER3 1.25 0.0240 PTGER3 NM_000957 CRYAB 1.25 0.0035CRYAB NM_001885 ANGPT2 1.25 0.0566 ANGPT2 NM_001147 ANXA1 1.25 0.0353ANXA1 NM_000700 EphB6 1.24 0.0960 EPHB6 NM_004445 PDGFB 1.24 0.0139PDGFB NM_002608 COL1A1 1.24 0.0198 COL1A1 NM_000088 TGFB3 1.23 0.0094TGFB3 NM_003239 CTGF 1.23 0.0265 CTGF NM_001901 PDGFA 1.23 0.0312NM_002607 HSPA1A 1.23 0.0027 HSPA1A NM_005345 EFNB2 1.23 0.0331 EFNB2NM_004093 CAPG 1.23 0.0724 CAPG NM_001747 TGFBI 1.22 0.0231 TGFBINM_000358 SIAT4A 1.22 0.0253 ST3GAL1 NM_003033 LAT 1.22 0.0307 LATNM_014387 ITGA5 1.22 0.0224 ITGA5 NM_002205 GBP2 1.22 0.0225 GBP2NM_004120 ANTXR1 1.22 0.0204 ANTXR1 NM_032208 ID4 1.22 0.0512 ID4NM_001546 SFRP2 1.22 0.0039 SFRP2 NM_003013 TMEPAI 1.21 0.0170 TMEPAINM_020182 CTSL 1.21 0.0388 CTSL NM_001912 KLK10 1.21 0.0007 KLK10NM_002776 FXYD5 1.21 0.0547 FXYD5 NM_014164 GJB2 1.21 0.0356 GJB2NM_004004 P14ARF 1.21 0.0451 S78535 DAPK1 1.21 0.0525 DAPK1 NM_004938SKP1A 1.21 0.0663 SKP1A NM_006930 SFRP4 1.21 0.0078 SFRP4 NM_003014 KLK61.20 0.0048 KLK6 NM_002774 GJA1 1.20 0.0345 GJA1 NM_000165 HOXB7 1.200.0278 HOXB7 NM_004502 NDRG1 1.20 0.0948 NDRG1 NM_006096 PAI1 1.190.0061 SERPINE1 NM_000602 CDH11 1.19 0.0762 CDH11 NM_001797 EGR3 1.190.0149 EGR3 NM_004430 EMP1 1.19 0.0533 EMP1 NM_001423 FZD1 1.19 0.0671FZD1 NM_003505 ABCC5 1.19 0.0631 ABCC5 NM_005688 S100P 1.18 0.0160 S100PNM_005980 OPN, 1.18 0.0030 SPP1 NM_000582 osteopontin p16-INK4 1.170.0503 L27211 NR4A1 1.17 0.0332 NR4A1 NM_002135 TUBB 1.17 0.0950 TUBB2NM_001069 SIAT7B 1.17 0.0352 ST6GALNAC2 NM_006456 ALDH1A1 1.17 0.0299ALDH1A1 NM_000689 F3 1.16 0.0654 F3 NM_001993 SLC2A1 1.15 0.0806 SLC2A1NM_006516 CXCL12 1.13 0.0986 CXCL12 NM_000609 STMY3 1.13 0.0518 MMP11NM_005940 S100A2 1.13 0.0303 S100A2 NM_005978 FABP4 1.13 0.0363 FABP4NM_001442 REG4 1.11 0.0034 REG4 NM_032044 pS2 1.09 0.0690 TFF1 NM_003225MUC2 1.06 0.0674 MUC2 NM_002457

Table 1.2B shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio<1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using RFI as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number ORC1L 0.410.0623 ORC1L NM_004153 E2F1 0.63 0.0006 E2F1 NM_005225 HSPA8 0.63 0.0346HSPA8 NM_006597 RAD54L 0.65 0.0026 RAD54L NM_003579 BRCA1 0.68 0.0001BRCA1 NM_007295 SLC25A3 0.70 0.0100 SLC25A3 NM_213611 PPM1D 0.71 0.0025PPM1D NM_003620 DHFR 0.71 0.0106 DHFR NM_000791 SKP2 0.72 0.0087 SKP2NM_005983 FASN 0.73 0.0070 FASN NM_004104 HNRPD 0.73 0.0611 HNRPDNM_031370 ENO1 0.74 0.0432 ENO1 NM_001428 C20 orf1 0.74 0.0086 TPX2NM_012112 BRCA2 0.75 0.0515 BRCA2 NM_000059 DDB1 0.75 0.0639 DDB1NM_001923 KIF22 0.76 0.0127 KIF22 NM_007317 RPLPO 0.76 0.0330 RPLP0NM_001002 Chk1 0.76 0.0164 CHEK1 NM_001274 ST14 0.77 0.0392 ST14NM_021978 Bax 0.77 0.0502 BAX NM_004324 TCF-1 0.78 0.0023 TCF1 NM_000545LMNB1 0.78 0.0458 LMNB1 NM_005573 RRM1 0.78 0.0693 RRM1 NM_001033 CSEL10.79 0.0261 CSE1L NM_001316 CDC20 0.79 0.0274 CDC20 NM_001255 PRDX2 0.790.0930 PRDX2 NM_005809 RPS13 0.79 0.0906 RPS13 NM_001017 RAF1 0.800.0717 RAF1 NM_002880 CMYC 0.80 0.0095 MYC NM_002467 UBE2M 0.80 0.0390UBE2M NM_003969 CKS2 0.80 0.0596 CKS2 NM_001827 NME1 0.80 0.0694 NME1NM_000269 c-myb (MYB official) 0.80 0.0082 MYB NM_005375 CD80 0.800.0688 CD80 NM_005191 CDCA7 v2 0.81 0.0164 CDCA7 NM_145810 EFP 0.810.0387 TRIM25 NM_005082 CCNE2 0.81 0.0405 CCNE2 NM_057749 SURV 0.810.0573 BIRC5 NM_001168 RRM2 0.82 0.0181 RRM2 NM_001034 ABCC6 0.82 0.0464ABCC6 NM_001171 UMPS 0.82 0.0371 UMPS NM_000373 PI3KC2A 0.82 0.0855PIK3C2A NM_002645 NOTCH1 0.82 0.0222 NOTCH1 NM_017617 EIF4E 0.82 0.0928EIF4E NM_001968 EPHB2 0.82 0.0183 EPHB2 NM_004442 AREG 0.83 0.0012 AREGNM_001657 EREG 0.83 0.0059 EREG NM_001432 MYBL2 0.83 0.0234 MYBL2NM_002466 ABCB1 0.83 0.0342 ABCB1 NM_000927 HRAS 0.83 0.0708 HRASNM_005343 SLC7A5 0.84 0.0547 SLC7A5 NM_003486 MAD2L1 0.84 0.0653 MAD2L1NM_002358 ING5 0.85 0.0920 ING5 NM_032329 Ki-67 0.85 0.0562 MKI67NM_002417 MCM2 0.85 0.0671 MCM2 NM_004526 Cdx2 0.88 0.0430 CDX2NM_001265 HES6 0.89 0.0966 HES6 NM_018645 PTPRO 0.89 0.0664 PTPRONM_030667 cripto (TDGF1 official) 0.90 0.0781 TDGF1 NM_003212

Table 2.2A shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio>1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using OS as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number RhoC 1.660.0002 RHOC NM_175744 ITGB1 1.59 0.0049 ITGB1 NM_002211 ANXA2 1.580.0004 ANXA2 NM_004039 CYP3A4 1.49 0.0114 CYP3A4 NM_017460 p21 1.49<.0001 CDKN1A NM_000389 HMLH 1.42 0.0555 MLH1 NM_000249 VEGFC 1.410.0095 VEGFC NM_005429 TGFBR1 1.40 0.0113 TGFBR1 NM_004612 UBC 1.380.0013 UBC NM_021009 RhoB 1.37 0.0016 RHOB NM_004040 HSPG2 1.37 0.0111HSPG2 NM_005529 PFN1 1.35 0.0987 PFN1 NM_005022 TIMP1 1.35 0.0008 TIMP1NM_003254 VCL 1.33 0.0116 VCL NM_003373 INHBB 1.32 0.0265 INHBBNM_002193 SPINT2 1.32 0.0358 SPINT2 NM_021102 GHI BRAF mut4 1.31 0.0822GHI_BRAF_mut4 LAMC2 1.31 0.0007 LAMC2 NM_005562 KCNH2 iso a/b 1.310.0474 KCNH2 NM_000238 UNC5C 1.30 0.0417 UNC5C NM_003728 CDC42 1.300.0122 CDC42 NM_001791 UBL1 1.29 0.0169 SUMO1 NM_003352 GADD45B 1.290.0003 GADD45B NM_015675 KRAS2 1.29 0.0774 KRAS NM_004985 HB-EGF 1.290.0219 HBEGF NM_001945 DKK1 1.28 0.0304 DKK1 NM_012242 FXYD5 1.28 0.0035FXYD5 NM_014164 CALD1 1.28 0.0107 CALD1 NM_004342 ANXA5 1.27 0.0723ANXA5 NM_001154 HLA-G 1.27 0.0732 HLA-G NM_002127 DUSP1 1.27 0.0004DUSP1 NM_004417 LOXL2 1.27 0.0050 LOXL2 NM_002318 CDC42BPA 1.27 0.0155CDC42BPA NM_003607 BGN 1.27 0.0039 BGN NM_001711 LAMB3 1.27 0.0221 LAMB3NM_000228 EphB6 1.27 0.0373 EPHB6 NM_004445 SHC1 1.27 0.0582 SHC1NM_003029 TIMP2 1.26 0.0126 TIMP2 NM_003255 CTSB 1.26 0.0748 CTSBNM_001908 TIMP3 1.26 0.0072 TIMP3 NM_000362 ID3 1.26 0.0033 ID3NM_002167 CAPG 1.26 0.0162 CAPG NM_001747 NRP1 1.26 0.0135 NRP1NM_003873 INHBA 1.26 0.0021 INHBA NM_002192 KLF6 1.25 0.0477 KLF6NM_001300 IGFBP7 1.25 0.0251 IGFBP7 NM_001553 S100A1 1.25 0.0528 S100A1NM_006271 EPAS1 1.24 0.0382 EPAS1 NM_001430 DLC1 1.24 0.0228 DLC1NM_006094 KLK10 1.24 <.0001 KLK10 NM_002776 SBA2 1.24 0.0493 WSB2NM_018639 SPARC 1.24 0.0133 SPARC NM_003118 GAGE4 1.23 0.0475 GAGE4NM_001474 HSPA1A 1.23 0.0004 HSPA1A NM_005345 SIR2 1.23 0.0179 SIRT1NM_012238 CGB 1.23 0.0202 CGB NM_000737 Grb10 1.22 0.0059 GRB10NM_005311 SNAI2 1.22 0.0145 SNAI2 NM_003068 LAMA3 1.22 0.0019 LAMA3NM_000227 AKT3 1.22 0.0169 AKT3 NM_005465 FYN 1.22 0.0138 FYN NM_002037FOS 1.22 0.0035 FOS NM_005252 CTHRC1 1.21 0.0056 CTHRC1 NM_138455 CTSD1.21 0.0506 CTSD NM_001909 THY1 1.21 0.0290 THY1 NM_006288 ANXA1 1.210.0339 ANXA1 NM_000700 CD68 1.21 0.0227 CD68 NM_001251 G-Catenin 1.200.0789 JUP NM_002230 PLK3 1.20 0.0081 PLK3 NM_004073 STC1 1.20 0.0577STC1 NM_003155 TAGLN 1.20 0.0238 TAGLN NM_003186 VIM 1.20 0.0632 VIMNM_003380 HSPA1B 1.20 0.0302 HSPA1B NM_005346 LAT 1.20 0.0184 LATNM_014387 KRT19 1.20 0.0309 KRT19 NM_002276 IGFBP3 1.20 0.0167 IGFBP3NM_000598 BMP4 1.20 0.0035 BMP4 NM_001202 KLK6 1.20 0.0014 KLK6NM_002774 THBS1 1.20 0.0206 THBS1 NM_003246 TULP3 1.19 0.0344 TULP3NM_003324 ERK1 1.19 0.0522 Z11696 CREBBP 1.19 0.0866 CREBBP NM_004380S100A4 1.19 0.0259 S100A4 NM_002961 PDGFB 1.19 0.0205 PDGFB NM_002608EFNB2 1.19 0.0299 EFNB2 NM_004093 LOX 1.19 0.0104 LOX NM_002317 PTK21.18 0.0983 PTK2 NM_005607 IGFBP5 1.18 0.0544 IGFBP5 NM_000599 APC 1.180.0461 APC NM_000038 DYRK1B 1.18 0.0681 DYRK1B NM_004714 NOTCH2 1.180.0533 NOTCH2 NM_024408 Maspin 1.18 0.0033 SERPINB5 NM_002639 AKAP121.18 0.0195 AKAP12 NM_005100 COL1A1 1.17 0.0417 COL1A1 NM_000088 EMP11.17 0.0295 EMP1 NM_001423 SIAT4A 1.17 0.0311 ST3GAL1 NM_003033 PAI11.17 0.0036 SERPINE1 NM_000602 NR4A1 1.17 0.0117 NR4A1 NM_002135 EGR11.17 0.0379 EGR1 NM_001964 BRK 1.17 0.0156 PTK6 NM_005975 UNC5B 1.170.0956 UNC5B NM_170744 SR-A1 1.17 0.0512 SR-A1 NM_021228 MRP3 1.160.0353 ABCC3 NM_003786 hCRA a 1.16 0.0878 U78556 Upa 1.16 0.0630 PLAUNM_002658 BCAS1 1.16 0.0147 BCAS1 NM_003657 PDGFC 1.16 0.0375 PDGFCNM_016205 COL1A2 1.16 0.0620 COL1A2 NM_000089 CTGF 1.16 0.0580 CTGFNM_001901 MCP1 1.16 0.0463 CCL2 NM_002982 RAB32 1.16 0.0686 RAB32NM_006834 SKP1A 1.16 0.0842 SKP1A NM_006930 FAP 1.16 0.0443 FAPNM_004460 EFNA1 1.16 0.0990 EFNA1 NM_004428 HOXB7 1.15 0.0378 HOXB7NM_004502 CYR61 1.15 0.0452 CYR61 NM_001554 TGFBI 1.15 0.0591 TGFBINM_000358 TMEPAI 1.15 0.0419 TMEPAI NM_020182 SIN3A 1.15 0.0853 SIN3ANM_015477 S100A2 1.15 0.0038 S100A2 NM_005978 PDGFA 1.15 0.0840NM_002607 MMP7 1.15 0.0469 MMP7 NM_002423 ANTXR1 1.15 0.0520 ANTXR1NM_032208 SLPI 1.14 0.0755 SLPI NM_003064 SFRP2 1.13 0.0253 SFRP2NM_003013 S100A8 1.13 0.0795 S100A8 NM_002964 TP53I3 1.13 0.0973 TP53I3NM_004881 F3 1.13 0.0735 F3 NM_001993 OPN, osteopontin 1.12 0.0100 SPP1NM_000582 EGLN3 1.11 0.0883 EGLN3 NM_022073 FZD6 1.11 0.0791 FZD6NM_003506 OSM 1.10 0.0913 OSM NM_020530 FABP4 1.10 0.0521 FABP4NM_001442 GSTT1 1.09 0.0837 GSTT1 NM_000853 REG4 1.07 0.0300 REG4NM_032044

Table 2.2B shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio<1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using OS as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number ORC1L 0.520.0895 ORC1L NM_004153 HSPA8 0.64 0.0164 HSPA8 NM_006597 SKP2 0.710.0012 SKP2 NM_005983 PRDX4 0.74 0.0202 PRDX4 NM_006406 DHFR 0.76 0.0111DHFR NM_000791 FGF18 0.76 0.0915 FGF18 NM_003862 SLC25A3 0.76 0.0391SLC25A3 NM_213611 RRM1 0.77 0.0218 RRM1 NM_001033 E2F1 0.78 0.0180 E2F1NM_005225 SURV 0.79 0.0098 BIRC5 NM_001168 PPM1D 0.80 0.0154 PPM1DNM_003620 CCNE2 0.80 0.0090 CCNE2 NM_057749 BRCA1 0.80 0.0093 BRCA1NM_007295 ST14 0.80 0.0436 ST14 NM_021978 c-myb (MYB official) 0.810.0027 MYB NM_005375 Chk1 0.81 0.0220 CHEK1 NM_001274 C20 orf1 0.810.0305 TPX2 NM_012112 EI24 0.81 0.0574 EI24 NM_004879 CDC20 0.82 0.0234CDC20 NM_001255 TCF-1 0.82 0.0061 TCF1 NM_000545 PPID 0.83 0.0584 PPIDNM_005038 KIF22 0.83 0.0466 KIF22 NM_007317 UBE2M 0.83 0.0850 UBE2MNM_003969 MRPL40 0.83 0.0716 MRPL40 NM_003776 RPLPO 0.84 0.0987 RPLP0NM_001002 LMNB1 0.84 0.0910 LMNB1 NM_005573 DUT 0.84 0.0401 DUTNM_001948 CD44E 0.84 0.0483 X55150 MCM2 0.85 0.0214 MCM2 NM_004526 CDC60.85 0.0235 CDC6 NM_001254 AURKB 0.85 0.0373 AURKB NM_004217 SMARCA30.86 0.0562 SMARCA3 NM_003071 CDCA7 v2 0.86 0.0435 CDCA7 NM_145810 EPHB20.86 0.0281 EPHB2 NM_004442 CMYC 0.86 0.0441 MYC NM_002467 ABCB1 0.860.0352 ABCB1 NM_000927 Cdx2 0.87 0.0156 CDX2 NM_001265 PPARG 0.88 0.0655PPARG NM_005037 MYBL2 0.88 0.0667 MYBL2 NM_002466 EREG 0.89 0.0352 EREGNM_001432 AREG 0.90 0.0221 AREG NM_001657

Table 3.2A shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio>1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DFS as the metric for clinical outcome.

Official Accession Gene Hazard Ratio P Value Symbol Number ANXA2 1.67<.0001 ANXA2 NM_004039 CYP3A4 1.59 0.0035 CYP3A4 NM_017460 RhoC 1.520.0010 RHOC NM_175744 TJP1 1.44 0.0951 TJP1 NM_003257 HB-EGF 1.39 0.0023HBEGF NM_001945 p21 1.39 0.0006 CDKN1A NM_000389 HMLH 1.37 0.0678 MLH1NM_000249 ITGB1 1.37 0.0419 ITGB1 NM_002211 UBC 1.34 0.0024 UBCNM_021009 VEGFC 1.33 0.0246 VEGFC NM_005429 TIMP1 1.33 0.0007 TIMP1NM_003254 CCNE2 variant 1 1.32 0.0745 CCNE2 NM_057749 SPINT2 1.32 0.0224SPINT2 NM_021102 LAMC2 1.32 0.0002 LAMC2 NM_005562 VCL 1.31 0.0119 VCLNM_003373 RhoB 1.31 0.0049 RHOB NM_004040 PKR2 1.30 0.0258 PKM2NM_002654 ANXA5 1.30 0.0406 ANXA5 NM_001154 GADD45B 1.30 0.0001 GADD45BNM_015675 INHBB 1.29 0.0368 INHBB NM_002193 DUSP1 1.29 <.0001 DUSP1NM_004417 KRAS2 1.28 0.0686 KRAS NM_004985 KLF6 1.28 0.0284 KLF6NM_001300 IGFBP7 1.27 0.0103 IGFBP7 NM_001553 GRIK1 1.27 0.0421 GRIK1NM_000830 DLC1 1.27 0.0084 DLC1 NM_006094 FOS 1.26 0.0003 FOS NM_005252HSPG2 1.26 0.0443 HSPG2 NM_005529 INHBA 1.26 0.0009 INHBA NM_002192TIMP3 1.26 0.0045 TIMP3 NM_000362 BGN 1.26 0.0035 BGN NM_001711 CGB 1.260.0172 CGB NM_000737 HK1 1.26 0.0352 HK1 NM_000188 SHC1 1.25 0.0562 SHC1NM_003029 STC1 1.25 0.0161 STC1 NM_003155 LOXL2 1.24 0.0078 LOXL2NM_002318 CAPG 1.24 0.0161 CAPG NM_001747 UNC5B 1.23 0.0204 UNC5BNM_170744 MVP 1.23 0.0729 MVP NM_017458 CTSD 1.23 0.0256 CTSD NM_001909EGR1 1.23 0.0041 EGR1 NM_001964 LOX 1.23 0.0017 LOX NM_002317 CDC42BPA1.23 0.0278 CDC42BPA NM_003607 GAGE4 1.23 0.0425 GAGE4 NM_001474 CALD11.22 0.0239 CALD1 NM_004342 FXYD5 1.22 0.0096 FXYD5 NM_014164 EphB6 1.220.0825 EPHB6 NM_004445 LAMB3 1.22 0.0444 LAMB3 NM_000228 VEGF 1.210.0267 VEGF NM_003376 PDGFB 1.21 0.0062 PDGFB NM_002608 TIMP2 1.210.0292 TIMP2 NM_003255 A-Catenin 1.21 0.0598 CTNNA1 NM_001903 IGFBP31.21 0.0081 IGFBP3 NM_000598 CD68 1.21 0.0138 CD68 NM_001251 S100A1 1.210.0886 S100A1 NM_006271 SIAT4A 1.21 0.0076 ST3GAL1 NM_003033 HSPA1B 1.210.0182 HSPA1B NM_005346 DKK1 1.20 0.0900 DKK1 NM_012242 SBA2 1.20 0.0733WSB2 NM_018639 SIR2 1.20 0.0250 SIRT1 NM_012238 THBS1 1.20 0.0119 THBS1NM_003246 FYN 1.20 0.0156 FYN NM_002037 TULP3 1.20 0.0205 TULP3NM_003324 LAMA3 1.20 0.0026 LAMA3 NM_000227 NR4A1 1.20 0.0022 NR4A1NM_002135 EFNA1 1.20 0.0258 EFNA1 NM_004428 EMP1 1.20 0.0102 EMP1NM_001423 SPARC 1.19 0.0333 SPARC NM_003118 G-Catenin 1.19 0.0761 JUPNM_002230 CYR61 1.19 0.0103 CYR61 NM_001554 Maspin 1.19 0.0015 SERPINB5NM_002639 HSPA1A 1.18 0.0018 HSPA1A NM_005345 PTHR1 1.18 0.0856 PTHR1NM_000316 EPAS1 1.18 0.0789 EPAS1 NM_001430 Grb10 1.18 0.0173 GRB10NM_005311 ERK1 1.18 0.0464 Z11696 VIM 1.18 0.0772 VIM NM_003380 SNAI21.18 0.0379 SNAI2 NM_003068 IGFBP5 1.17 0.0492 IGFBP5 NM_000599 CTHRC11.17 0.0155 CTHRC1 NM_138455 THY1 1.17 0.0562 THY1 NM_006288 NRP1 1.170.0747 NRP1 NM_003873 PTGER3 1.17 0.0493 PTGER3 NM_000957 ID3 1.170.0437 ID3 NM_002167 F3 1.17 0.0157 F3 NM_001993 CTGF 1.17 0.0394 CTGFNM_001901 KRT19 1.17 0.0517 KRT19 NM_002276 PAI1 1.17 0.0033 SERPINE1NM_000602 FAP 1.17 0.0260 FAP NM_004460 ANXA1 1.16 0.0688 ANXA1NM_000700 KLK10 1.16 0.0009 KLK10 NM_002776 EFNB2 1.16 0.0447 EFNB2NM_004093 P14ARF 1.16 0.0573 S78535 MCP1 1.16 0.0359 CCL2 NM_002982 PLK31.16 0.0296 PLK3 NM_004073 ANTXR1 1.16 0.0243 ANTXR1 NM_032208 ADAMTS121.16 0.0346 ADAMTS12 NM_030955 EGR3 1.16 0.0109 EGR3 NM_004430 APC 1.160.0733 APC NM_000038 PDGFC 1.16 0.0326 PDGFC NM_016205 BMP4 1.16 0.0151BMP4 NM_001202 HOXB7 1.15 0.0281 HOXB7 NM_004502 NDRG1 1.15 0.0912 NDRG1NM_006096 Herstatin 1.15 0.0380 AF177761 TMEPAI 1.15 0.0268 TMEPAINM_020182 IL6 1.15 0.0914 IL6 NM_000600 PDGFA 1.15 0.0599 NM_002607TGFBI 1.15 0.0439 TGFBI NM_000358 Upa 1.15 0.0740 PLAU NM_002658 S100A41.15 0.0621 S100A4 NM_002961 SLPI 1.15 0.0447 SLPI NM_003064 KLK6 1.150.0112 KLK6 NM_002774 COL1A1 1.15 0.0637 COL1A1 NM_000088 GJB2 1.150.0604 GJB2 NM_004004 PKD1 1.15 0.0939 PKD1 NM_000296 TP53I3 1.15 0.0450TP53I3 NM_004881 PLAUR 1.14 0.0477 PLAUR NM_002659 TAGLN 1.14 0.0739TAGLN NM_003186 COL1A2 1.14 0.0818 COL1A2 NM_000089 S100A2 1.14 0.0045S100A2 NM_005978 AKT3 1.14 0.0949 AKT3 NM_005465 SEMA3B 1.13 0.0467SEMA3B NM_004636 BRK 1.13 0.0476 PTK6 NM_005975 OSM 1.13 0.0344 OSMNM_020530 SFRP2 1.12 0.0279 SFRP2 NM_003013 MRP3 1.12 0.0946 ABCC3NM_003786 EGLN3 1.12 0.0452 EGLN3 NM_022073 SIAT7B 1.12 0.0603ST6GALNAC2 NM_006456 OPN, osteopontin 1.12 0.0082 SPP1 NM_000582 S100P1.12 0.0313 S100P NM_005980 AKAP12 1.12 0.0865 AKAP12 NM_005100 MMP71.11 0.0909 MMP7 NM_002423 FABP4 1.11 0.0214 FABP4 NM_001442 CRYAB 1.110.0960 CRYAB NM_001885 SFRP4 1.10 0.0625 SFRP4 NM_003014 EFNA3 1.100.0707 EFNA3 NM_004952 GSTT1 1.09 0.0516 GSTT1 NM_000853 pS2 1.08 0.0313TFF1 NM_003225 REG4 1.08 0.0080 REG4 NM_032044 IGFBP2 1.08 0.0846 IGFBP2NM_000597 MUC5B 1.08 0.0387 MUC5B XM_039877

Table 3.2B shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio<1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DFS as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number HSPA8 0.720.0604 HSPA8 NM_006597 SLC25A3 0.73 0.0126 SLC25A3 NM_213611 E2F1 0.730.0019 E2F1 NM_005225 IFIT1 0.74 0.0820 IFIT1 NM_001548 PPM1D 0.740.0007 PPM1D NM_003620 SKP2 0.75 0.0049 SKP2 NM_005983 RRM1 0.78 0.0224RRM1 NM_001033 DDB1 0.79 0.0720 DDB1 NM_001923 NPM1 0.79 0.0255 NPM1NM_002520 PRDX4 0.80 0.0570 PRDX4 NM_006406 BRCA1 0.80 0.0064 BRCA1NM_007295 C20 orf1 0.81 0.0180 TPX2 NM_012112 Chk1 0.81 0.0148 CHEK1NM_001274 EI24 0.81 0.0417 EI24 NM_004879 CCNE2 0.81 0.0094 CCNE2NM_057749 HMGB1 0.82 0.0852 HMGB1 NM_002128 SURV 0.82 0.0185 BIRC5NM_001168 KIF22 0.82 0.0264 KIF22 NM_007317 RAD54L 0.82 0.0674 RAD54LNM_003579 c-myb (MYB official) 0.82 0.0038 MYB NM_005375 DHFR 0.820.0669 DHFR NM_000791 TNFRSF5 0.83 0.0855 CD40 NM_001250 LMNB1 0.830.0741 LMNB1 NM_005573 CDC20 0.85 0.0538 CDC20 NM_001255 CDCA7 v2 0.850.0277 CDCA7 NM_145810 FASN 0.85 0.0919 FASN NM_004104 MCM2 0.85 0.0194MCM2 NM_004526 ABCB1 0.85 0.0169 ABCB1 NM_000927 EIF4E 0.85 0.0902 EIF4ENM_001968 DUT 0.86 0.0535 DUT NM_001948 C20ORF126 0.86 0.0932 PDRG1NM_030815 MCM6 0.86 0.0970 MCM6 NM_005915 EFP 0.87 0.0850 TRIM25NM_005082 EPHB2 0.87 0.0314 EPHB2 NM_004442 GCLC 0.87 0.0862 GCLCNM_001498 RCC1 0.87 0.0540 RCC1 NM_001269 AREG 0.87 0.0028 AREGNM_001657 CMYC 0.88 0.0584 MYC NM_002467 MYBL2 0.88 0.0567 MYBL2NM_002466 TCF-1 0.88 0.0644 TCF1 NM_000545 EREG 0.89 0.0232 EREGNM_001432 Cdx2 0.90 0.0354 CDX2 NM_001265 PTPRO 0.92 0.0935 PTPRONM_030667 cripto (TDGF1 official) 0.92 0.0950 TDGF1 NM_003212 HLA-DRB10.93 0.0521 HLA-DRB1 NM_002124

Table 4.2A shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio>1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DRFI as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number ALDOA 3.210.0189 ALDOA NM_000034 DCK 2.60 0.0248 DCK NM_000788 ITGB1 2.58 0.0002ITGB1 NM_002211 COX2 2.16 0.0198 PTGS2 NM_000963 TJP1 2.10 0.0122 TJP1NM_003257 STAT3 1.87 0.0148 STAT3 NM_003150 ANXA5 1.83 0.0043 ANXA5NM_001154 GHI BRAF mut4 1.82 0.0024 GHI_BRAF_mut4 TIMP1 1.80 <.0001TIMP1 NM_003254 hMLH 1.80 0.0242 MLH1 NM_000249 PADI4 1.74 0.0288 PADI4NM_012387 rhoC 1.74 0.0093 RHOC NM_175744 CYP3A4 1.73 0.0219 CYP3A4NM_017460 WWOX 1.72 0.0467 WWOX NM_016373 ANXA2 1.70 0.0081 ANXA2NM_004039 LILRB3 1.70 0.0295 LILRB3 NM_006864 VIM 1.66 0.0015 VIMNM_003380 FUS 1.65 0.0432 FUS NM_004960 KCNH2 iso a/b 1.64 0.0111 KCNH2NM_000238 RhoB 1.63 0.0019 RHOB NM_004040 CRIP2 1.62 0.0455 CRIP2NM_001312 AKT3 1.60 0.0004 AKT3 NM_005465 RBX1 1.60 0.0195 RBX1NM_014248 HB-EGF 1.59 0.0032 HBEGF NM_001945 NRP2 1.55 0.0007 NRP2NM_003872 MSH3 1.55 0.0353 MSH3 NM_002439 PI3K 1.54 0.0651 PIK3C2BNM_002646 BGN 1.54 0.0009 BGN NM_001711 RAB6C 1.54 0.0210 RAB6CNM_032144 CTSB 1.53 0.0415 CTSB NM_001908 DLC1 1.53 0.0047 DLC1NM_006094 p21 1.53 0.0085 CDKN1A NM_000389 CCNE2 variant 1 1.52 0.0647CCNE2 NM_057749 CALD1 1.51 0.0069 CALD1 NM_004342 SBA2 1.51 0.0202 WSB2NM_018639 SIR2 1.51 0.0028 SIRT1 NM_012238 ITGA5 1.50 0.0006 ITGA5NM_002205 RAP1GDS1 1.50 0.0317 RAP1GDS1 NM_021159 CTHRC1 1.46 0.0010CTHRC1 NM_138455 STC1 1.46 0.0083 STC1 NM_003155 KLF6 1.46 0.0362 KLF6NM_001300 CDC42BPA 1.45 0.0187 CDC42BPA NM_003607 CEBPB 1.45 0.0605CEBPB NM_005194 LAMC2 1.45 0.0031 LAMC2 NM_005562 TGFBR1 1.45 0.0824TGFBR1 NM_004612 TLN1 1.45 0.0730 TLN1 NM_006289 CDC42 1.44 0.0387 CDC42NM_001791 FYN 1.43 0.0070 FYN NM_002037 IGFBP7 1.43 0.0283 IGFBP7NM_001553 ARG 1.43 0.0119 ABL2 NM_005158 HIF1A 1.42 0.0397 HIF1ANM_001530 FST 1.42 0.0460 FST NM_006350 S100A1 1.42 0.0473 S100A1NM_006271 FAP 1.42 0.0023 FAP NM_004460 DUSP1 1.42 0.0014 DUSP1NM_004417 EPAS1 1.41 0.0494 EPAS1 NM_001430 Grb10 1.41 0.0027 GRB10NM_005311 VEGFC 1.41 0.0894 VEGFC NM_005429 INHBB 1.41 0.0710 INHBBNM_002193 GADD45B 1.40 0.0023 GADD45B NM_015675 UBC 1.40 0.0368 UBCNM_021009 GJA1 1.40 0.0053 GJA1 NM_000165 COL1A2 1.40 0.0086 COL1A2NM_000089 RBM5 1.40 0.0423 RBM5 NM_005778 ROCK1 1.39 0.0604 ROCK1NM_005406 CTGF 1.39 0.0081 CTGF NM_001901 FLT4 1.39 0.0978 FLT4NM_002020 PDGFC 1.39 0.0052 PDGFC NM_016205 INHBA 1.39 0.0058 INHBANM_002192 LOXL2 1.38 0.0209 LOXL2 NM_002318 THBS1 1.37 0.0090 THBS1NM_003246 ITGAV 1.37 0.0298 ITGAV NM_002210 NCAM1 1.36 0.0714 NCAM1NM_000615 PTHR1 1.35 0.0410 PTHR1 NM_000316 TIMP2 1.35 0.0446 TIMP2NM_003255 LOX 1.35 0.0041 LOX NM_002317 SPARC 1.35 0.0292 SPARCNM_003118 TAGLN 1.34 0.0222 TAGLN NM_003186 CYR61 1.34 0.0086 CYR61NM_001554 RANBP9 1.34 0.0553 RANBP9 NM_005493 GADD45 1.34 0.0604 GADD45ANM_001924 S100A4 1.34 0.0141 S100A4 NM_002961 SNAI2 1.33 0.0263 SNAI2NM_003068 EGR1 1.33 0.0174 EGR1 NM_001964 CDH11 1.33 0.0355 CDH11NM_001797 SI 1.33 0.0967 SI NM_001041 PTK2 1.33 0.0911 PTK2 NM_005607MCP1 1.32 0.0215 CCL2 NM_002982 PCAF 1.32 0.0463 PCAF NM_003884 c-abl1.32 0.0868 ABL1 NM_005157 TIMP3 1.32 0.0455 TIMP3 NM_000362 ANGPT2 1.310.0711 ANGPT2 NM_001147 NOTCH2 1.30 0.0645 NOTCH2 NM_024408 GBP2 1.300.0218 GBP2 NM_004120 PAI1 1.30 0.0022 SERPINE1 NM_000602 CXCR4 1.300.0341 CXCR4 NM_003467 BCAS1 1.30 0.0060 BCAS1 NM_003657 COL1A1 1.290.0349 COL1A1 NM_000088 PIM1 1.29 0.0507 PIM1 NM_002648 PDGFB 1.290.0288 PDGFB NM_002608 Bcl2 1.29 0.0270 BCL2 NM_000633 SLPI 1.29 0.0222SLPI NM_003064 IGFBP5 1.29 0.0676 IGFBP5 NM_000599 ANXA1 1.29 0.0690ANXA1 NM_000700 FGFR1 1.28 0.0790 FGFR1 NM_023109 CAPG 1.28 0.0987 CAPGNM_001747 PRKCA 1.28 0.0548 PRKCA NM_002737 EPHA2 1.28 0.0339 EPHA2NM_004431 AKAP12 1.28 0.0215 AKAP12 NM_005100 FOS 1.28 0.0219 FOSNM_005252 CXCL12 1.27 0.0169 CXCL12 NM_000609 GCNT1 1.27 0.0875 GCNT1NM_001490 IGFBP3 1.27 0.0499 IGFBP3 NM_000598 DPYD 1.27 0.0259 DPYDNM_000110 CD68 1.27 0.0752 CD68 NM_001251 EFNA1 1.27 0.0890 EFNA1NM_004428 ABCC5 1.26 0.0536 ABCC5 NM_005688 TUBB 1.26 0.0635 TUBB2NM_001069 PDGFA 1.26 0.0676 NM_002607 DAPK1 1.26 0.0701 DAPK1 NM_004938SFRP2 1.25 0.0109 SFRP2 NM_003013 ID3 1.25 0.0744 ID3 NM_002167 CTSL1.25 0.0679 CTSL NM_001912 LAMA3 1.25 0.0299 LAMA3 NM_000227 KRT19 1.250.0982 KRT19 NM_002276 S100A8 1.25 0.0228 S100A8 NM_002964 IL6 1.250.0933 IL6 NM_000600 MRP3 1.25 0.0538 ABCC3 NM_003786 FES 1.25 0.0694FES NM_002005 AP-1 (JUN 1.25 0.0974 JUN NM_002228 official) WISP1 1.240.0897 WISP1 NM_003882 SFRP4 1.24 0.0250 SFRP4 NM_003014 TGFBI 1.240.0692 TGFBI NM_000358 Maspin 1.24 0.0152 SERPINB5 NM_002639 HOXB7 1.230.0541 HOXB7 NM_004502 P14ARF 1.23 0.0944 S78535 HSPA1A 1.23 0.0259HSPA1A NM_005345 EGR3 1.22 0.0312 EGR3 NM_004430 CRYAB 1.22 0.0483 CRYABNM_001885 ALDH1A1 1.22 0.0372 ALDH1A1 NM_000689 TGFB3 1.22 0.0673 TGFB3NM_003239 KLK6 1.21 0.0288 KLK6 NM_002774 ANTXR1 1.21 0.0942 ANTXR1NM_032208 FZD6 1.20 0.0479 FZD6 NM_003506 ILT-2 1.20 0.0930 LILRB1NM_006669 S100A2 1.20 0.0116 S100A2 NM_005978 MMP7 1.18 0.0987 MMP7NM_002423 FABP4 1.17 0.0371 FABP4 NM_001442 OPN, osteopontin 1.17 0.0301SPP1 NM_000582 KLK10 1.16 0.0581 KLK10 NM_002776 pS2 1.15 0.0186 TEF1NM_003225 REG4 1.14 0.0053 REG4 NM_032044 MUC2 1.09 0.0429 MUC2NM_002457

Table 4.2B shows associations between clinical outcome and geneexpression for those genes which demonstrated a Hazard Ratio<1.0 and forwhich p<0.1. Univariate Cox Proportional Hazards Regression analysis wasapplied in combined Stage II (Duke's B) and Stage III (Duke's C)patients using DRFI as the metric for clinical outcome.

Hazard Official Accession Gene Ratio P Value Symbol Number HSPA8 0.480.0114 HSPA8 NM_006597 RPS13 0.64 0.0082 RPS13 NM_001017 NDUFS3 0.660.0096 NDUFS3 NM_004551 ST14 0.66 0.0132 ST14 NM_021978 LMNB1 0.660.0135 LMNB1 NM_005573 TMSB4X 0.67 0.0039 TMSB4X NM_021109 DHFR 0.680.0260 DHFR NM_000791 BRCA1 0.68 0.0029 BRCA1 NM_007295 SKP2 0.68 0.0151SKP2 NM_005983 SLC25A3 0.69 0.0265 SLC25A3 NM_213611 CDC20 0.69 0.0048CDC20 NM_001255 RPLPO 0.70 0.0320 RPLP0 NM_001002 TCF-1 0.70 0.0013 TCF1NM_000545 RRM1 0.71 0.0598 RRM1 NM_001033 ATP5A1 0.71 0.0827 ATP5A1NM_004046 NME1 0.73 0.0378 NME1 NM_000269 CKS2 0.74 0.0537 CKS2NM_001827 EI24 0.74 0.0639 EI24 NM_004879 C20 orf1 0.74 0.0435 TPX2NM_012112 SDC1 0.74 0.0930 SDC1 NM_002997 CSEL1 0.75 0.0443 CSE1LNM_001316 ABCC6 0.76 0.0416 ABCC6 NM_001171 MCM2 0.76 0.0136 MCM2NM_004526 NFKBp65 0.77 0.0672 RELA NM_021975 EPHB2 0.77 0.0133 EPHB2NM_004442 FASN 0.78 0.0980 FASN NM_004104 AURKB 0.78 0.0528 AURKBNM_004217 VDR 0.79 0.0832 VDR NM_000376 UMPS 0.80 0.0721 UMPS NM_000373UBE2C 0.81 0.0860 UBE2C NM_007019 CMYC 0.82 0.0742 MYC NM_002467 MYBL20.83 0.0780 MYBL2 NM_002466 Cdx2 0.84 0.0392 CDX2 NM_001265 MX1 0.850.0786 MX1 NM_002462 EREG 0.85 0.0638 EREG NM_001432 AREG 0.85 0.0295AREG NM_001657

Table 5.2A shows associations between gene expression and RFI,controlling for particular demographic and clinical characteristics ofpatients included in the analysis. All genes are listed whose expressioncorrelates with RFI (p<0.1) and which demonstrated a Hazard Ratio>1 in amultivariate analysis including the following variables: tumor location,year of surgery, tumor grade, treatment protocol (C-01 or C-02), BCGtreatment (yes or no), and classification of patients according to lymphnode status as follows: 0 positive nodes and <12 nodes examined, 0positive nodes and ≧12 nodes examined, 1-3 positive nodes, and ≧4positive nodes.

Hazard Official Accession Gene Ratio LR Chi-Square DF P Value SymbolNumber RARB 2.02 3.42 1 0.0644 RARB NM_016152 COX2 1.69 3.13 1 0.0768PTGS2 NM_000963 RhoC 1.60 8.71 1 0.0032 RHOC NM_175744 CYP3A4 1.57 5.151 0.0233 CYP3A4 NM_017460 RhoB 1.54 12.40 1 0.0004 RHOB NM_004040 ANXA21.54 7.01 1 0.0081 ANXA2 NM_004039 ITGB1 1.54 5.54 1 0.0186 ITGB1NM_002211 NTN1 1.53 3.63 1 0.0568 NTN1 NM_004822 KRAS2 1.51 4.83 10.0279 KRAS NM_004985 IGFBP7 1.44 8.53 1 0.0035 IGFBP7 NM_001553 TIMP11.43 9.03 1 0.0027 TIMP1 NM_003254 WWOX 1.43 2.73 1 0.0988 WWOXNM_016373 CYP1B1 1.39 3.69 1 0.0548 CYP1B1 NM_000104 KCNH2 iso a/b 1.383.23 1 0.0723 KCNH2 NM_000238 STC1 1.37 6.55 1 0.0105 STC1 NM_003155ITGAV 1.37 9.37 1 0.0022 ITGAV NM_002210 VEGFC 1.37 3.62 1 0.0571 VEGFCNM_005429 G-Catenin 1.36 4.78 1 0.0287 JUP NM_002230 S100A1 1.34 4.12 10.0423 S100A1 NM_006271 GADD45B 1.34 9.63 1 0.0019 GADD45B NM_015675NCAM1 1.33 3.00 1 0.0832 NCAM1 NM_000615 CALD1 1.33 6.05 1 0.0139 CALD1NM_004342 FST 1.33 4.24 1 0.0396 FST NM_006350 INHBA 1.33 9.68 1 0.0019INHBA NM_002192 BGN 1.33 7.27 1 0.0070 BGN NM_001711 Claudin 4 1.33 7.131 0.0076 CLDN4 NM_001305 CEBPB 1.33 2.96 1 0.0851 CEBPB NM_005194 LAMC21.32 8.62 1 0.0033 LAMC2 NM_005562 SPINT2 1.32 3.14 1 0.0762 SPINT2NM_021102 AKT3 1.32 7.54 1 0.0060 AKT3 NM_005465 TIMP3 1.32 6.33 10.0119 TIMP3 NM_000362 MAPK14 1.31 2.75 1 0.0972 MAPK14 NM_139012 HB-EGF1.31 4.74 1 0.0294 HBEGF NM_001945 DUSP1 1.30 11.34 1 0.0008 DUSP1NM_004417 EFNA1 1.30 5.87 1 0.0154 EFNA1 NM_004428 PTK2 1.29 3.60 10.0576 PTK2 NM_005607 DLC1 1.29 5.19 1 0.0227 DLC1 NM_006094 EPAS1 1.283.30 1 0.0693 EPAS1 NM_001430 THBS1 1.28 7.51 1 0.0061 THBS1 NM_003246TIMP2 1.28 4.20 1 0.0404 TIMP2 NM_003255 TGFBI 1.27 6.68 1 0.0098 TGFBINM_000358 DKK1 1.27 3.05 1 0.0806 DKK1 NM_012242 SPARC 1.26 4.37 10.0366 SPARC NM_003118 PDGFC 1.26 6.74 1 0.0094 PDGFC NM_016205 RAB6C1.26 3.27 1 0.0704 RAB6C NM_032144 LOXL2 1.26 4.48 1 0.0343 LOXL2NM_002318 CD68 1.25 4.68 1 0.0305 CD68 NM_001251 LOX 1.25 7.16 1 0.0075LOX NM_002317 CDC42BPA 1.25 3.35 1 0.0671 CDC42BPA NM_003607 TAGLN 1.254.83 1 0.0279 TAGLN NM_003186 CTHRC1 1.25 5.96 1 0.0146 CTHRC1 NM_138455PDGFA 1.25 4.63 1 0.0314 NM_002607 TMEPAI 1.24 5.63 1 0.0176 TMEPAINM_020182 RAB32 1.24 4.48 1 0.0343 RAB32 NM_006834 HSPA1A 1.24 8.19 10.0042 HSPA1A NM_005345 VIM 1.24 2.97 1 0.0848 VIM NM_003380 IGFBP5 1.233.69 1 0.0549 IGFBP5 NM_000599 EGR1 1.23 5.12 1 0.0236 EGR1 NM_001964ANGPT2 1.23 2.96 1 0.0852 ANGPT2 NM_001147 NDRG1 1.22 2.91 1 0.0879NDRG1 NM_006096 VEGF_altsplice1 1.22 4.08 1 0.0433 AF486837 SLPI 1.224.94 1 0.0262 SLPI NM_003064 FOS 1.22 5.67 1 0.0172 FOS NM_005252 VEGF1.22 2.80 1 0.0942 VEGF NM_003376 ADAMTS12 1.22 4.40 1 0.0359 ADAMTS12NM_030955 Maspin 1.22 7.60 1 0.0058 SERPINB5 NM_002639 CGB 1.22 3.25 10.0713 CGB NM_000737 CYR61 1.21 5.22 1 0.0224 CYR61 NM_001554 GJB2 1.213.77 1 0.0522 GJB2 NM_004004 IGFBP3 1.21 4.24 1 0.0396 IGFBP3 NM_000598PRKCA 1.21 3.81 1 0.0508 PRKCA NM_002737 S100P 1.21 6.98 1 0.0082 S100PNM_005980 NRP2 1.21 3.25 1 0.0714 NRP2 NM_003872 EFNB2 1.21 3.00 10.0834 EFNB2 NM_004093 COL1A2 1.21 3.59 1 0.0581 COL1A2 NM_000089 VEGFB1.20 2.80 1 0.0942 VEGFB NM_003377 HOXB7 1.20 4.37 1 0.0367 HOXB7NM_004502 Grb10 1.20 3.91 1 0.0480 GRB10 NM_005311 FAP 1.20 4.12 10.0425 FAP NM_004460 GJA1 1.20 4.80 1 0.0285 GJA1 NM_000165 CTGF 1.193.38 1 0.0660 CTGF NM_001901 NR4A1 1.18 5.13 1 0.0235 NR4A1 NM_002135COL1A1 1.18 2.77 1 0.0961 COL1A1 NM_000088 ABCC5 1.17 2.80 1 0.0945ABCC5 NM_005688 EMP1 1.17 3.06 1 0.0804 EMP1 NM_001423 SFRP2 1.17 4.89 10.0270 SFRP2 NM_003013 SLC2A1 1.17 3.52 1 0.0606 SLC2A1 NM_006516 F31.17 3.10 1 0.0783 F3 NM_001993 S100A4 1.17 2.87 1 0.0900 S100A4NM_002961 BRK 1.17 2.81 1 0.0935 PTK6 NM_005975 CRYAB 1.17 3.77 1 0.0523CRYAB NM_001885 MDK 1.16 3.84 1 0.0500 MDK NM_002391 OPN, osteopontin1.16 6.07 1 0.0138 SPP1 NM_000582 SFRP4 1.16 4.09 1 0.0432 SFRP4NM_003014 SIAT4A 1.16 2.76 1 0.0969 ST3GAL1 NM_003033 LAMA3 1.16 3.23 10.0725 LAMA3 NM_000227 AKAP12 1.15 2.74 1 0.0976 AKAP12 NM_005100 KLK101.15 5.23 1 0.0221 KLK10 NM_002776 EGR3 1.14 3.16 1 0.0755 EGR3NM_004430 PAI1 1.13 3.39 1 0.0655 SERPINE1 NM_000602 CEACAM6 1.13 2.98 10.0845 CEACAM6 NM_002483 KLK6 1.13 3.74 1 0.0532 KLK6 NM_002774 Nkd-11.11 3.34 1 0.0674 NKD1 NM_033119 IGFBP2 1.11 3.15 1 0.0758 IGFBP2NM_000597 REG4 1.08 3.51 1 0.0610 REG4 NM_032044

Table 5.2B shows associations between gene expression and RFI,controlling for particular demographic and clinical characteristics ofpatients included in the analysis. All genes are listed whose expressioncorrelates with RFI (p<0.1) and which demonstrated a Hazard Ratio<1 in amultivariate analysis including the following variables: tumor location,year of surgery, tumor grade, treatment protocol (C-01 or C-02), BCGtreatment (yes or no), and classification of patients according to lymphnode status as follows: 0 positive nodes and <12 nodes examined, 0positive nodes and ≧12 nodes examined, 1-3 positive nodes, and ≧4positive nodes.

Hazard LR Official Accession Gene Ratio Chi-Square DF P Value SymbolNumber Fasl 0.43 5.57 1 0.0183 FASLG NM_000639 BFGF 0.57 4.68 1 0.0306NUDT6 NM_007083 EstR1 0.57 3.22 1 0.0726 ESR1 NM_000125 IFIT1 0.60 4.301 0.0381 IFIT1 NM_001548 KLRK1 0.64 10.81 1 0.0010 KLRK1 NM_007360 E2F10.65 7.49 1 0.0062 E2F1 NM_005225 BRCA1 0.66 16.33 1 <.0001 BRCA1NM_007295 RAD54L 0.67 6.36 1 0.0117 RAD54L NM_003579 ATP5A1 0.67 5.50 10.0190 ATP5A1 NM_004046 MCM3 0.68 2.84 1 0.0922 MCM3 NM_002388 DHFR 0.687.44 1 0.0064 DHFR NM_000791 HSPA8 0.68 2.96 1 0.0855 HSPA8 NM_006597APG-1 0.71 5.86 1 0.0155 HSPA4L NM_014278 BRCA2 0.71 4.69 1 0.0304 BRCA2NM_000059 TRAIL 0.71 7.27 1 0.0070 TNFSF10 NM_003810 SLC25A3 0.71 5.56 10.0184 SLC25A3 NM_213611 PPM1D 0.72 8.02 1 0.0046 PPM1D NM_003620 Chk10.73 6.61 1 0.0102 CHEK1 NM_001274 CD80 0.73 6.85 1 0.0089 CD80NM_005191 MADH2 0.73 3.93 1 0.0476 SMAD2 NM_005901 KIF22 0.75 5.77 10.0163 KIF22 NM_007317 TNFRSF5 0.76 3.52 1 0.0607 CD40 NM_001250 C20orf1 0.76 4.82 1 0.0281 TPX2 NM_012112 ENO1 0.76 2.88 1 0.0894 ENO1NM_001428 PRKCB1 0.77 4.25 1 0.0393 PRKCB1 NM_002738 RAF1 0.77 4.17 10.0412 RAF1 NM_002880 RRM1 0.78 3.07 1 0.0799 RRM1 NM_001033 UBE2M 0.784.43 1 0.0352 UBE2M NM_003969 SKP2 0.79 3.42 1 0.0644 SKP2 NM_005983 DUT0.79 4.38 1 0.0364 DUT NM_001948 EI24 0.80 2.85 1 0.0912 EI24 NM_004879UMPS 0.80 4.96 1 0.0260 UMPS NM_000373 EFP 0.81 3.83 1 0.0502 TRIM25NM_005082 HRAS 0.81 3.80 1 0.0513 HRAS NM_005343 CDC20 0.81 3.78 10.0519 CDC20 NM_001255 CSF1 0.82 2.86 1 0.0910 CSF1 NM_000757 CKS2 0.822.90 1 0.0886 CKS2 NM_001827 ABCB1 0.82 4.02 1 0.0450 ABCB1 NM_000927CDC6 0.83 4.23 1 0.0397 CDC6 NM_001254 GBP1 0.83 4.34 1 0.0373 GBP1NM_002053 SURV 0.83 2.91 1 0.0878 BIRC5 NM_001168 CCNE2 0.83 2.75 10.0975 CCNE2 NM_057749 RRM2 0.83 4.19 1 0.0407 RRM2 NM_001034 CMYC 0.843.34 1 0.0677 MYC NM_002467 TCF-1 0.84 3.96 1 0.0466 TCF1 NM_000545c-myb (MYB official) 0.84 3.72 1 0.0538 MYB NM_005375 NOTCH1 0.85 3.39 10.0658 NOTCH1 NM_017617 MCM2 0.85 3.30 1 0.0693 MCM2 NM_004526 ING5 0.852.84 1 0.0922 ING5 NM_032329 AREG 0.88 3.72 1 0.0538 AREG NM_001657HLA-DRB1 0.90 3.84 1 0.0500 HLA-DRB1 NM_002124

Table 6.2 shows associations between gene expression and clinicaloutcome based on a nonlinear proportional hazards analysis, using a 2degree-of-freedom natural spline. All genes are listed whichdemonstrated a departure from a strictly linear relationship (p<0.05)with RFI in combined Stage II (Duke's B) and Stage III (Duke's C)patients. The relationship between gene expression and RFI was notconstant throughout the observed range of expression values in thestudy, e.g. increases in gene expression may have been related toincreases in duration of RFI in one portion of the observed range andwith decreases in duration of RFI in a different portion of the range.

Official Accession Gene P Value Symbol Number PTHLH <.0001 PTHLHNM_002820 TGFBR1 0.0011 TGFBR1 NM_004612 CDCA7 v2 0.0020 CDCA7 NM_145810S100A4 0.0034 S100A4 NM_002961 CREBBP 0.0040 CREBBP NM_004380 Upa 0.0040PLAU NM_002658 KLF5 0.0048 KLF5 NM_001730 CYP2C8 0.0070 CYP2C8 NM_000770HES6 0.0090 HES6 NM_018645 Cad17 0.0093 CDH17 NM_004063 CEGP1 0.0100SCUBE2 NM_020974 GHI k-ras mut3 0.0100 GHI_k-ras_mut3 AKT1 0.0104 AKT1NM_005163 LAMB3 0.0111 LAMB3 NM_000228 CAPG 0.0120 CAPG NM_001747 FUT60.0130 FUT6 NM_000150 A-Catenin 0.0141 CTNNA1 NM_001903 CAPN1 0.0167CAPN1 NM_005186 HSPE1 0.0180 HSPE1 NM_002157 MADH4 0.0180 SMAD4NM_005359 STMY3 0.0190 MMP11 NM_005940 TRAG3 0.0200 CSAG2 NM_004909 GBP10.0200 GBP1 NM_002053 EFNA1 0.0210 EFNA1 NM_004428 SEMA3B 0.0210 SEMA3BNM_004636 CLTC 0.0216 CLTC NM_004859 BRK 0.0240 PTK6 NM_005975 Fas0.0240 FAS NM_000043 CCNE2 variant 1 0.0243 CCNE2 NM_057749 TMEPAI0.0246 TMEPAI NM_020182 PTPRJ 0.0260 PTPRJ NM_002843 SKP2 0.0261 SKP2NM_005983 AGXT 0.0273 AGXT NM_000030 MAP2 0.0320 MAP2 NM_031846 PFN20.0330 PFN2 NM_053024 ATP5E 0.0350 ATP5E NM_006886 NRP1 0.0352 NRP1NM_003873 MYH11 0.0360 MYH11 NM_002474 cIAP2 0.0369 BIRC3 NM_001165INHBA 0.0370 INHBA NM_002192 EGLN1 0.0371 EGLN1 NM_022051 GRIK1 0.0380GRIK1 NM_000830 KDR 0.0380 KDR NM_002253 KLK6 0.0388 KLK6 NM_002774APOC1 0.0390 APOC1 NM_001645 EP300 0.0390 EP300 NM_001429 DET1 0.0390DET1 NM_017996 ITGB4 0.0394 ITGB4 NM_000213 CD3z 0.0400 CD3Z NM_000734MAX 0.0400 MAX NM_002382 PAI1 0.0407 SERPINE1 NM_000602 MADH7 0.0430SMAD7 NM_005904 SIR2 0.0440 SIRT1 NM_012238 NEDD8 0.0440 NEDD8 NM_006156EPHB2 0.0445 EPHB2 NM_004442 BTF3 0.0460 BTF3 NM_001207 CD34 0.0470 CD34NM_001773 VEGF_altsplice2 0.0480 AF214570 Wnt-5b 0.0480 WNT5B NM_032642RXRA 0.0482 RXRA NM_002957 tusc4 0.0486 TUSC4 NM_006545

Table 7.2 shows all genes exhibiting an interaction (p-value<0.1) withtumor stage. The data were modeled using a proportional hazards model ofRFI with gene expression, tumor stage, and their interaction aspredictors. Patients who had 0 positive nodes but <12 nodes examinedwere excluded from these analyses.

P-Value HR HR for Stage Stage Inter- Official Accession Gene II IIIaction Symbol Number SOS1 3.35 0.81 0.0009 SOS1 NM_005633 ALCAM 2.360.94 0.0020 ALCAM NM_001627 pS2 1.58 1.04 0.0040 TFF1 NM_003225 TGFB21.83 0.95 0.0064 TGFB2 NM_003238 TFF3 1.57 0.90 0.0066 TFF3 NM_003226KLF6 0.35 1.34 0.0092 KLF6 NM_001300 SNRPF 0.50 1.16 0.0106 SNRPFNM_003095 CENPA 2.41 0.94 0.0106 CENPA NM_001809 HES6 1.69 0.86 0.0119HES6 NM_018645 CLDN1 0.51 0.95 0.0124 CLDN1 NM_021101 FGF2 0.19 0.970.0125 FGF2 NM_002006 LEF 1.94 0.94 0.0141 LEF1 NM_016269 MADH2 2.700.74 0.0145 SMAD2 NM_005901 TP53BP1 2.31 0.91 0.0153 TP53BP1 NM_005657CCR7 1.89 0.98 0.0182 CCR7 NM_001838 MRP3 2.26 1.08 0.0204 ABCC3NM_003786 UPP1 0.16 1.02 0.0208 UPP1 NM_003364 PTEN 3.46 1.00 0.0216PTEN NM_000314 ST14 1.64 0.66 0.0223 ST14 NM_021978 FYN 2.28 1.10 0.0241FYN NM_002037 CD24 1.33 0.84 0.0260 CD24 NM_013230 LMYC 1.80 0.82 0.0275RLF NM_012421 CDC42BPA 2.82 1.12 0.0315 CDC42BPA NM_003607 CAV1 2.110.95 0.0364 CAV1 NM_001753 CHFR 1.81 0.99 0.0382 CHFR NM_018223 MGAT51.59 0.72 0.0383 MGAT5 NM_002410 FPGS 1.93 0.71 0.0402 FPGS NM_004957EMR3 2.63 0.57 0.0488 EMR3 NM_032571 SIR2 2.17 1.07 0.0538 SIRT1NM_012238 PTK2B 1.44 0.93 0.0542 PTK2B NM_004103 Axin 2 1.38 0.90 0.0549AXIN2 NM_004655 TRAG3 0.46 1.12 0.0570 CSAG2 NM_004909 MMP7 0.78 1.280.0608 MMP7 NM_002423 PFN2 1.33 0.84 0.0610 PFN2 NM_053024 PTPRJ 2.051.00 0.0632 PTPRJ NM_002843 CXCR4 1.96 1.08 0.0644 CXCR4 NM_003467 CCNA21.55 0.79 0.0661 CCNA2 NM_001237 MMP12 0.74 1.11 0.0685 MMP12 NM_002426KRT8 0.64 1.27 0.0694 KRT8 NM_002273 ABCC5 2.06 1.14 0.0704 ABCC5NM_005688 PRDX6 2.09 0.74 0.0711 PRDX6 NM_004905 WIF 1.54 0.77 0.0738WIF1 NM_007191 cdc25A 2.48 0.94 0.0769 CDC25A NM_001789 KLF5 1.87 1.030.0772 KLF5 NM_001730 LRP5 1.92 0.98 0.0783 LRP5 NM_002335 PTPD1 0.541.00 0.0789 PTPN21 NM_007039 RALBP1 2.20 0.91 0.0791 RALBP1 NM_006788TP53BP2 1.82 1.05 0.0819 TP53BP2 NM_005426 STAT5B 1.57 0.86 0.0822STAT5B NM_012448 PPARG 1.32 0.79 0.0844 PPARG NM_005037 HB-EGF 0.50 1.380.0845 HBEGF NM_001945 RARA 1.77 0.96 0.0848 RARA NM_000964 GCNT1 1.861.07 0.0883 GCNT1 NM_001490 Ki-67 1.53 0.86 0.0885 MKI67 NM_002417 EFNB21.76 1.05 0.0895 EFNB2 NM_004093 LGMN 0.59 1.37 0.0900 LGMN NM_001008530DKK1 0.68 1.51 0.0922 DKK1 NM_012242 MADH4 2.04 0.98 0.0964 SMAD4NM_005359 BIK 1.53 0.94 0.0966 BIK NM_001197 CD44v3 1.58 0.97 0.0996AJ251595v3

TABLE A Sequence ID Gene Accession Reagent Sequence Number A-CateninNM_001903.1 Forward Primer CGTTCCGATCCTCTATACTGCAT SEQ ID NO: 1 ProbeATGCCTACAGCACCCTGATGTCGCA SEQ ID NO: 2 Reverse PrimerAGGTCCCTGTTGGCCTTATAGG SEQ ID NO: 3 ABCB1 NM_000927.2 Forward PrimerAAACACCACTGGAGCATTGA SEQ ID NO: 4 Probe CTCGCCAATGATGCTGCTCAAGTT SEQ IDNO: 5 Reverse Primer CAAGCCTGGAACCTATAGCC SEQ ID NO: 6 ABCC5 NM_005688.1Forward Primer TGCAGACTGTACCATGCTGA SEQ ID NO: 7 ProbeCTGCACACGGTTCTAGGCTCCG SEQ ID NO: 8 Reverse Primer GGCCAGCACCATAATCCTATSEQ ID NO: 9 ABCC6 NM_001171.2 Forward Primer GGATGAACCTCGACCTGC SEQ IDNO: 10 Probe CCAGATAGCCTCGTCCGAGTGCTC SEQ ID NO: 11 Reverse PrimerGAGCTGCACCGTCTCCAG SEQ ID NO: 12 ACP1 NM_004300.2 Forward PrimerGCTACCAAGTCCGTGCTGT SEQ ID NO: 13 Probe TGATCGACAAATGTTACCCAGACACACA SEQID NO: 14 Reverse Primer GAAAACTGCTTCTGCAATGG SEQ ID NO: 15 ADAM10NM_001110.1 Forward Primer CCCATCAACTTGTGCCAGTA SEQ ID NO: 16 ProbeTGCCTACTCCACTGCACAGACCCT SEQ ID NO: 17 Reverse PrimerGGTGATGGTTCGACCACTG SEQ ID NO: 18 ADAM17 NM_003183.3 Forward PrimerGAAGTGCCAGGAGGCGATTA SEQ ID NO: 19 Probe TGCTACTTGCAAAGGCGTGTCCTACTGCSEQ ID NO: 20 Reverse Primer CGGGCACTCACTGCTATTACC SEQ ID NO: 21ADAMTS12 NM_030955.2 Forward Primer GGAGAAGGGTGGAGTGCAG SEQ ID NO: 22Probe CGCACAGTCAGAATCCATCTGGGT SEQ ID NO: 23 Reverse PrimerCAGGGTCAGGTCTCTGGATG SEQ ID NO: 24 ADPRT NM_001618.2 Forward PrimerTTGACAACCTGCTGGACATC SEQ ID NO: 25 Probe CCCTGAGCAGACTGTAGGCCACCT SEQ IDNO: 26 Reverse Primer ATGGGATCCTTGCTGCTATC SEQ ID NO: 27 AGXTNM_000030.1 Forward Primer CTTTTCCCTCCAGTGGCA SEQ ID NO: 28 ProbeCTCCTGGAAACAGTCCACTTGGGC SEQ ID NO: 29 Reverse PrimerATTTGGAAGGCACTGGGTTT SEQ ID NO: 30 AKAP12 NM_005100.2 Forward PrimerTAGAGAGCCCCTGACAATCC SEQ ID NO: 31 Probe TGGCTCTAGCTCCTGATGAAGCCTC SEQID NO: 32 Reverse Primer GGTTGGTCTTGGAAAGAGGA SEQ ID NO: 33 AKT1NM_005163.1 Forward Primer CGCTTCTATGGCGCTGAGAT SEQ ID NO: 34 ProbeCAGCCCTGGACTACCTGCACTCGG SEQ ID NO: 35 Reverse PrimerTCCCGGTACACCACGTTCTT SEQ ID NO: 36 AKT2 NM_001626.2 Forward PrimerTCCTGCCACCCTTCAAACC SEQ ID NO: 37 Probe CAGGTCACGTCCGAGGTCGACACA SEQ IDNO: 38 Reverse Primer GGCGGTAAATTCATCATCGAA SEQ ID NO: 39 AKT3NM_005465.1 Forward Primer TTGTCTCTGCCTTGGACTATCTACA SEQ ID NO: 40 ProbeTCACGGTACACAATCTTTCCGGA SEQ ID NO: 41 Reverse PrimerCCAGCATTAGATTCTCCAACTTGA SEQ ID NO: 42 AL137428 AL137428.1 ForwardPrimer CAAGAAGAGGCTCTACCCTGG SEQ ID NO: 43 ProbeACTGGGAATTTCCAAGGCCACCTT SEQ ID NO: 44 Reverse PrimerAAATGAGCTCTGCGATCCTC SEQ ID NO: 45 ALCAM NM_001627.1 Forward PrimerGAGGAATATGGAATCCAAGGG SEQ ID NO: 46 Probe CCAGTTCCTGCCGTCTGCTCTTCT SEQID NO: 47 Reverse Primer GTGGCGGAGATCAAGAGG SEQ ID NO: 48 ALDH1A1NM_000689.1 Forward Primer GAAGGAGATAAGGAGGATGTTGACA SEQ ID NO: 49 ProbeAGTGAAGGCCGCAAGACAGGCTTTTC SEQ ID NO: 50 Reverse PrimerCGCCACGGAGATCCAATC SEQ ID NO: 51 ALDOA NM_000034.2 Forward PrimerGCCTGTACGTGCCAGCTC SEQ ID NO: 52 Probe TGCCAGAGCCTCAACTGTCTCTGC SEQ IDNO: 53 Reverse Primer TCATCGGAGCTTGATCTCG SEQ ID NO: 54 AMFR NM_001144.2Forward Primer GATGGTTCAGCTCTGCAAGGA SEQ ID NO: 55 ProbeCGATTTGAATATCTTTCCTTCTCGCCCACC SEQ ID NO: 56 Reverse PrimerTCGACCGTGGCTGCTCAT SEQ ID NO: 57 ANGPT2 NM_001147.1 Forward PrimerCCGTGAAAGCTGCTCTGTAA SEQ ID NO: 58 Probe AAGCTGACACAGCCCTCCCAAGTG SEQ IDNO: 59 Reverse Primer TTGCAGTGGGAAGAACAGTC SEQ ID NO: 60 ANTXR1NM_032208.1 Forward Primer CTCCAGGTGTACCTCCAACC SEQ ID NO: 61 ProbeAGCCTTCTCCCACAGCTGCCTACA SEQ ID NO: 62 Reverse PrimerGAGAAGGCTGGGAGACTCTG SEQ ID NO: 63 ANXA1 NM_000700.1 Forward PrimerGCCCCTATCCTACCTTCAATCC SEQ ID NO: 64 Probe TCCTCGGATGTCGCTGCCT SEQ IDNO: 65 Reverse Primer CCTTTAACCATTATGGCCTTATGC SEQ ID NO: 66 ANXA2NM_004039.1 Forward Primer CAAGACACTAAGGGCGACTACCA SEQ ID NO: 67 ProbeCCACCACACAGGTACAGCAGCGCT SEQ ID NO: 68 Reverse PrimerCGTGTCGGGCTTCAGTCAT SEQ ID NO: 69 ANXA5 NM_001154.2 Forward PrimerGCTCAAGCCTGGAAGATGAC SEQ ID NO: 70 Probe AGTACCCTGAAGTGTCCCCCACCA SEQ IDNO: 71 Reverse Primer AGAACCACCAACATCCGCT SEQ ID NO: 72 AP-1 (JUNNM_002228.2 Forward Primer GACTGCAAAGATGGAAACGA SEQ ID NO: 73 official)Probe CTATGACGATGCCCTCAACGCCTC SEQ ID NO: 74 Reverse PrimerTAGCCATAAGGTCCGCTCTC SEQ ID NO: 75 APC NM_000038.1 Forward PrimerGGACAGCAGGAATGTGTTTC SEQ ID NO: 76 Probe CATTGGCTCCCCGTGACCTGTA SEQ IDNO: 77 Reverse Primer ACCCACTCGATTTGTTTCTG SEQ ID NO: 78 APEX-1NM_001641.2 Forward Primer GATGAAGCCTTTCGCAAGTT SEQ ID NO: 79 ProbeCTTTCGGGAAGCCAGGCCCTT SEQ ID NO: 80 Reverse Primer AGGTCTCCACACAGCACAAGSEQ ID NO: 81 APG-1 NM_014278.2 Forward Primer ACCCCGGCCTGTATATCAT SEQID NO: 82 Probe CCAATGGCTCGAGTTCTTGATCCC SEQ ID NO: 83 Reverse PrimerCTATCTGGCTCTTTGCTGCAT SEQ ID NO: 84 APN (ANPEP NM_001150.1 ForwardPrimer CCACCTTGGACCAAAGTAAAGC SEQ ID NO: 85 official) ProbeCTCCCCAACACGCTGAAACCCG SEQ ID NO: 86 Reverse PrimerTCTCAGCGTCACCTGGTAGGA SEQ ID NO: 87 APOC1 NM_001645.3 Forward PrimerGGAAACACACTGGAGGACAAG SEQ ID NO: 88 Probe TCATCAGCCGCATCAAACAGAGTG SEQID NO: 89 Reverse Primer CGCATCTTGGCAGAAAGTT SEQ ID NO: 90 AREGNM_001657.1 Forward Primer TGTGAGTGAAATGCCTTCTAGTAGTGA SEQ ID NO: 91Probe CCGTCCTCGGGAGCCGACTATGA SEQ ID NO: 92 Reverse PrimerTTGTGGTTCGTTATCATACTCTTCTGA SEQ ID NO: 93 ARG NM_005158.2 Forward PrimerCGCAGTGCAGCTGAGTATCTG SEQ ID NO: 94 Probe TCGCACCAGGAAGCTGCCATTGA SEQ IDNO: 95 Reverse Primer TGCCCAGGGCTACTCTCACTT SEQ ID NO: 96 ARHFNM_019034.2 Forward Primer ACTGGCCCACTTAGTCCTCA SEQ ID NO: 97 ProbeCTCCCAACCTGCTGTCCCTCAAG SEQ ID NO: 98 Reverse PrimerCTGAACTCCACAGGCTGGTA SEQ ID NO: 99 ATOH1 NM_005172.1 Forward PrimerGCAGCCACCTGCAACTTT SEQ ID NO: 100 Probe CAGGCGAGAGAGCATCCCGTCTAC SEQ IDNO: 101 Reverse Primer TCCAGGAGGGACAGCTCA SEQ ID NO: 102 ATP5A1NM_004046.3 Forward Primer GATGCTGCCACTCAACAACT SEQ ID NO: 103 ProbeAGTTAGACGCACGCCACGACTCAA SEQ ID NO: 104 Reverse PrimerTGTCCTTGCTTCAGCAACTC SEQ ID NO: 105 ATP5E NM_006886.2 Forward PrimerCCGCTTTCGCTACAGCAT SEQ ID NO: 106 Probe TCCAGCCTGTCTCCAGTAGGCCAC SEQ IDNO: 107 Reverse Primer TGGGAGTATCGGATGTAGCTG SEQ ID NO: 108 AURKBNM_004217.1 Forward Primer AGCTGCAGAAGAGCTGCACAT SEQ ID NO: 109 ProbeTGACGAGCAGCGAACAGCCACG SEQ ID NO: 110 Reverse PrimerGCATCTGCCAACTCCTCCAT SEQ ID NO: 111 Axin 2 NM_004655.2 Forward PrimerGGCTATGTCTTTGCACCAGC SEQ ID NO: 112 Probe ACCAGCGCCAACGACAGTGAGATA SEQID NO: 113 Reverse Primer ATCCGTCAGCGCATCACT SEQ ID NO: 114 axin1NM_003502.2 Forward Primer CCGTGTGACAGCATCGTT SEQ ID NO: 115 ProbeCGTACTACTTCTGCGGGGAACCCA SEQ ID NO: 116 Reverse PrimerCTCACCAGGGTGCGGTAG SEQ ID NO: 117 B-Catenin NM_001904.1 Forward PrimerGGCTCTTGTGCGTACTGTCCTT SEQ ID NO: 118 ProbeAGGCTCAGTGATGTCTTCCCTGTCACCAG SEQ ID NO: 119 Reverse PrimerTCAGATGACGAAGAGCACAGATG SEQ ID NO: 120 BAD NM_032989.1 Forward PrimerGGGTCAGGTGCCTCGAGAT SEQ ID NO: 121 Probe TGGGCCCAGAGCATGTTCCAGATC SEQ IDNO: 122 Reverse Primer CTGCTCACTCGGCTCAAACTC SEQ ID NO: 123 BAG1NM_004323.2 Forward Primer CGTTGTCAGCACTTGGAATACAA SEQ ID NO: 124 ProbeCCCAATTAACATGACCCGGCAACCAT SEQ ID NO: 125 Reverse PrimerGTTCAACCTCTTCCTGTGGACTGT SEQ ID NO: 126 BAG2 NM_004282.2 Forward PrimerCTAGGGGCAAAAAGCATGA SEQ ID NO: 127 Probe TTCCATGCCAGACAGGAAAAAGCA SEQ IDNO: 128 Reverse Primer CTAAATGCCCAAGGTGACTG SEQ ID NO: 129 BAG3NM_004281.2 Forward Primer GAAAGTAAGCCAGGCCCAGTT SEQ ID NO: 130 ProbeCAGAACTCCCTCCTGGACACATCCCAA SEQ ID NO: 131 Reverse PrimerACCTCTTTGCGGATCACTTGA SEQ ID NO: 132 Bak NM_001188.1 Forward PrimerCCATTCCCACCATTCTACCT SEQ ID NO: 133 Probe ACACCCCAGACGTCCTGGCCT SEQ IDNO: 134 Reverse Primer GGGAACATAGACCCACCAAT SEQ ID NO: 135 BaxNM_004324.1 Forward Primer CCGCCGTGGACACAGACT SEQ ID NO: 136 ProbeTGCCACTCGGAAAAAGACCTCTCGG SEQ ID NO: 137 Reverse PrimerTTGCCGTCAGAAAACATGTCA SEQ ID NO: 138 BBC3 NM_014417.1 Forward PrimerCCTGGAGGGTCCTGTACAAT SEQ ID NO: 139 Probe CATCATGGGACTCCTGCCCTTACC SEQID NO: 140 Reverse Primer CTAATTGGGCTCCATCTCG SEQ ID NO: 141 BCAS1NM_003657.1 Forward Primer CCCCGAGACAACGGAGATAA SEQ ID NO: 142 ProbeCTTTCCGTTGGCATCCGCAACAG SEQ ID NO: 143 Reverse PrimerCTCGGGTTTGGCCTCTTTC SEQ ID NO: 144 Bcl2 NM_000633.1 Forward PrimerCAGATGGACCTAGTACCCACTGAGA SEQ ID NO: 145 Probe TTCCACGCCGAAGGACAGCGATSEQ ID NO: 146 Reverse Primer CCTATGATTTAAGGGCATTTTTCC SEQ ID NO: 147BCL2L10 NM_020396.2 Forward Primer GCTGGGATGGCTTTTGTCA SEQ ID NO: 148Probe TCTTCAGGACCCCCTTTCCACTGGC SEQ ID NO: 149 Reverse PrimerGCCTGGACCAGCTGTTTTCTC SEQ ID NO: 150 BCL2L11 NM_138621.1 Forward PrimerAATTACCAAGCAGCCGAAGA SEQ ID NO: 151 Probe CCACCCACGAATGGTTATCTTACGACTGSEQ ID NO: 152 Reverse Primer CAGGCGGACAATGTAACGTA SEQ ID NO: 153BCL2L12 NM_138639.1 Forward Primer AACCCACCCCTGTCTTGG SEQ ID NO: 154Probe TCCGGGTAGCTCTCAAACTCGAGG SEQ ID NO: 155 Reverse PrimerCTCAGCTGACGGGAAAGG SEQ ID NO: 156 Bclx NM_001191.1 Forward PrimerCTTTTGTGGAACTCTATGGGAACA SEQ ID NO: 157 Probe TTCGGCTCTCGGCTGCTGCA SEQID NO: 158 Reverse Primer CAGCGGTTGAAGCGTTCCT SEQ ID NO: 159 BCRPNM_004827.1 Forward Primer TGTACTGGCGAAGAATATTTGGTAAA SEQ ID NO: 160Probe CAGGGCATCGATCTCTCACCCTGG SEQ ID NO: 161 Reverse PrimerGCCACGTGATTCTTCCACAA SEQ ID NO: 162 BFGF NM_007083.1 Forward PrimerCCAGGAAGAATGCTTAAGATGTGA SEQ ID NO: 163 Probe TTCGCCAGGTCATTGAGATCCATCCASEQ ID NO: 164 Reverse Primer TGGTGATGGGAGTTGTATTTTCAG SEQ ID NO: 165BGN NM_001711.3 Forward Primer GAGCTCCGCAAGGATGAC SEQ ID NO: 166 ProbeCAAGGGTCTCCAGCACCTCTACGC SEQ ID NO: 167 Reverse PrimerCTTGTTGTTCACCAGGACGA SEQ ID NO: 168 BID NM_001196.2 Forward PrimerGGACTGTGAGGTCAACAACG SEQ ID NO: 169 Probe TGTGATGCACTCATCCCTGAGGCT SEQID NO: 170 Reverse Primer GGAAGCCAAACACCAGTAGG SEQ ID NO: 171 BIKNM_001197.3 Forward Primer ATTCCTATGGCTCTGCAATTGTC SEQ ID NO: 172 ProbeCCGGTTAACTGTGGCCTGTGCCC SEQ ID NO: 173 Reverse PrimerGGCAGGAGTGAATGGCTCTTC SEQ ID NO: 174 BIN1 NM_004305.1 Forward PrimerCCTGCAAAAGGGAACAAGAG SEQ ID NO: 175 Probe CTTCGCCTCCAGATGGCTCCC SEQ IDNO: 176 Reverse Primer CGTGGTTGACTCTGATCTCG SEQ ID NO: 177 BLMHNM_000386.2 Forward Primer GGTTGCTGCCTCCATCAAAG SEQ ID NO: 178 ProbeACATCACAGCCAAACCACACAGCCTCT SEQ ID NO: 179 Reverse PrimerCCAGCTTGCTATTGAAGTGTTTTC SEQ ID NO: 180 BMP2 NM_001200.1 Forward PrimerATGTGGACGCTCTTTCAATG SEQ ID NO: 181 Probe ACCGCAGTCCGTCTAAGAAGCACG SEQID NO: 182 Reverse Primer ACCATGGTCGACCTTTAGGA SEQ ID NO: 183 BMP4NM_001202.2 Forward Primer GGGCTAGCCATTGAGGTG SEQ ID NO: 184 ProbeCTCACCTCCATCAGACTCGGACCC SEQ ID NO: 185 Reverse PrimerGCTAATCCTGACATGCTGGC SEQ ID NO: 186 BMP7 NM_001719.1 Forward PrimerTCGTGGAACATGACAAGGAATT SEQ ID NO: 187 Probe TTCCACCCACGCTACCACCATCG SEQID NO: 188 Reverse Primer TGGAAAGATCAAACCGGAACTC SEQ ID NO: 189 BMPR1ANM_004329.2 Forward Primer TTGGTTCAGCGAACTATTGC SEQ ID NO: 190 ProbeCAAACAGATTCAGATGGTCCGGCA SEQ ID NO: 191 Reverse PrimerTCTCCATATCGGCCTTTACC SEQ ID NO: 192 BRAF NM_004333.1 Forward PrimerCCTTCCGACCAGCAGATGAA SEQ ID NO: 193 Probe CAATTTGGGCAACGAGACCGATCCT SEQID NO: 194 Reverse Primer TTTATATGCACATTGGGAGCTGAT SEQ ID NO: 195 BRCA1NM_007295.1 Forward Primer TCAGGGGGCTAGAAATCTGT SEQ ID NO: 196 ProbeCTATGGGCCCTTCACCAACATGC SEQ ID NO: 197 Reverse PrimerCCATTCCAGTTGATCTGTGG SEQ ID NO: 198 BRCA2 NM_000059.1 Forward PrimerAGTTCGTGCTTTGCAAGATG SEQ ID NO: 199 Probe CATTCTTCACTGCTTCATAAAGCTCTGCASEQ ID NO: 200 Reverse Primer AAGGTAAGCTGGGTCTGCTG SEQ ID NO: 201 BRKNM_005975.1 Forward Primer GTGCAGGAAAGGTTCACAAA SEQ ID NO: 202 ProbeAGTGTCTGCGTCCAATACACGCGT SEQ ID NO: 203 Reverse PrimerGCACACACGATGGAGTAAGG SEQ ID NO: 204 BTF3 NM_001207.2 Forward PrimerCAGTGATCCACTTTAACAACCCTAAAG SEQ ID NO: 205 ProbeTCAGGCATCTCTGGCAGCGAACAC SEQ ID NO: 206 Reverse PrimerAGCATGGCCTGTAATGGTGAA SEQ ID NO: 207 BTRC NM_033637.2 Forward PrimerGTTGGGACACAGTTGGTCTG SEQ ID NO: 208 Probe CAGTCGGCCCAGGACGGTCTACT SEQ IDNO: 209 Reverse Primer TGAAGCAGTCAGTTGTGCTG SEQ ID NO: 210 BUB1NM_004336.1 Forward Primer CCGAGGTTAATCCAGCACGTA SEQ ID NO: 211 ProbeTGCTGGGAGCCTACACTTGGCCC SEQ ID NO: 212 Reverse PrimerAAGACATGGCGCTCTCAGTTC SEQ ID NO: 213 BUB1B NM_001211.3 Forward PrimerTCAACAGAAGGCTGAACCACTAGA SEQ ID NO: 214 Probe TACAGTCCCAGCACCGACAATTCCSEQ ID NO: 215 Reverse Primer CAACAGAGTTTGCCGAGACACT SEQ ID NO: 216 BUB3NM_004725.1 Forward Primer CTGAAGCAGATGGTTCATCATT SEQ ID NO: 217 ProbeCCTCGCTTTGTTTAACAGCCCAGG SEQ ID NO: 218 Reverse PrimerGCTGATTCCCAAGAGTCTAACC SEQ ID NO: 219 c-abl NM_005157.2 Forward PrimerCCATCTCGCTGAGATACGAA SEQ ID NO: 220 Probe GGGAGGGTGTACCATTACAGGATCAACASEQ ID NO: 221 Reverse Primer AGACGTAGAGCTTGCCATCA SEQ ID NO: 222 c-kitNM_000222.1 Forward Primer GAGGCAACTGCTTATGGCTTAATTA SEQ ID NO: 223Probe TTACAGCGACAGTCATGGCCGCAT SEQ ID NO: 224 Reverse PrimerGGCACTCGGCTTGAGCAT SEQ ID NO: 225 c-myb (MYB NM_005375.1 Forward PrimerAACTCAGACTTGGAAATGCCTTCT SEQ ID NO: 226 official) ProbeAACTTCCACCCCCCTCATTGGTCACA SEQ ID NO: 227 Reverse PrimerCTGGTCTCTATGAAATGGTGTTGTAAC SEQ ID NO: 228 c-Src NM_005417.3 ForwardPrimer TGAGGAGTGGTATTTTGGCAAGA SEQ ID NO: 229 ProbeAACCGCTCTGACTCCCGTCTGGTG SEQ ID NO: 230 Reverse PrimerCTCTCGGGTTCTCTGCATTGA SEQ ID NO: 231 C20 orf1 NM_012112.2 Forward PrimerTCAGCTGTGAGCTGCGGATA SEQ ID NO: 232 Probe CAGGTCCCATTGCCGGGCG SEQ ID NO:233 Reverse Primer ACGGTCCTAGGTTTGAGGTTAAGA SEQ ID NO: 234 C20ORF126NM_030815.2 Forward Primer CCAGCACTGCTCGTTACTGT SEQ ID NO: 235 ProbeTGGGACCTCAGACCACTGAAGGC SEQ ID NO: 236 Reverse PrimerTTGACTTCACGGCAGTTCATA SEQ ID NO: 237 C8orf4 NM_020130.2 Forward PrimerCTACGAGTCAGCCCATCCAT SEQ ID NO: 238 Probe CATGGCTACCACTTCGACACAGCC SEQID NO: 239 Reverse Primer TGCCCACGGCTTTCTTAC SEQ ID NO: 240 CA9NM_001216.1 Forward Primer ATCCTAGCCCTGGTTTTTGG SEQ ID NO: 241 ProbeTTTGCTGTCACCAGCGTCGC SEQ ID NO: 242 Reverse Primer CTGCCTTCTCATCTGCACAASEQ ID NO: 243 Cad17 NM_004063.2 Forward Primer GAAGGCCAAGAACCGAGTCA SEQID NO: 244 Probe TTATATTCCAGTTTAAGGCCAATCCTC SEQ ID NO: 245 ReversePrimer TCCCCAGTTAGTTCAAAAGTCACA SEQ ID NO: 246 CALD1 NM_004342.4 ForwardPrimer CACTAAGGTTTGAGACAGTTCCAGAA SEQ ID NO: 247 ProbeAACCCAAGCTCAAGACGCAGGACGAG SEQ ID NO: 248 Reverse PrimerGCGAATTAGCCCTCTACAACTGA SEQ ID NO: 249 CAPG NM_001747.1 Forward PrimerGATTGTCACTGATGGGGAGG SEQ ID NO: 250 Probe AGGACCTGGATCATCTCAGCAGGC SEQID NO: 251 Reverse Primer CCTTCAGAGCAGGCTTGG SEQ ID NO: 252 CAPN1NM_005186.2 Forward Primer CAAGAAGCTGTACGAGCTCATCA SEQ ID NO: 253 ProbeCCGCTACTCGGAGCCCGACCTG SEQ ID NO: 254 Reverse PrimerGCAGCAAACGAAATTGTCAAAG SEQ ID NO: 255 CASP8 NM_033357.1 Forward PrimerCCTCGGGGATACTGTCTGAT SEQ ID NO: 256 Probe CAACAATCACAATTTTGCAAAAGCACGSEQ ID NO: 257 Reverse Primer GAAGTTTGGGCACTTTCTCC SEQ ID NO: 258 CASP9NM_001229.2 Forward Primer TGAATGCCGTGGATTGCA SEQ ID NO: 259 ProbeCACTAGCCCTGGACCAGCCACTGCT SEQ ID NO: 260 Reverse PrimerACAGGGATCATGGGACACAAG SEQ ID NO: 261 CAT NM_001752.1 Forward PrimerATCCATTCGATCTCACCAAGGT SEQ ID NO: 262 Probe TGGCCTCACAAGGACTACCCTCTCATCCSEQ ID NO: 263 Reverse Primer TCCGGTTTAAGACCAGTTTACCA SEQ ID NO: 264CAV1 NM_001753.3 Forward Primer GTGGCTCAACATTGTGTTCC SEQ ID NO: 265Probe ATTTCAGCTGATCAGTGGGCCTCC SEQ ID NO: 266 Reverse PrimerCAATGGCCTCCATTTTACAG SEQ ID NO: 267 CBL NM_005188.1 Forward PrimerTCATTCACAAACCTGGCAGT SEQ ID NO: 268 Probe TTCCGGCTGAGCTGTACTCGTCTG SEQID NO: 269 Reverse Primer CATACCCAATAGCCCACTGA SEQ ID NO: 270 CCL20NM_004591.1 Forward Primer CCATGTGCTGTACCAAGAGTTTG SEQ ID NO: 271 ProbeCAGCACTGACATCAAAGCAGCCAGGA SEQ ID NO: 272 Reverse PrimerCGCCGCAGAGGTGGAGTA SEQ ID NO: 273 CCL3 NM_002983.1 Forward PrimerAGCAGACAGTGGTCAGTCCTT SEQ ID NO: 274 Probe CTCTGCTGACACTCGAGCCCACAT SEQID NO: 275 Reverse Primer CTGCATGATTCTGAGCAGGT SEQ ID NO: 276 CCNA2NM_001237.2 Forward Primer CCATACCTCAAGTATTTGCCATCAG SEQ ID NO: 277Probe ATTGCTGGAGCTGCCTTTCATTTAGCACT SEQ ID NO: 278 Reverse PrimerAGCTTTGTCCCGTGACTGTGTA SEQ ID NO: 279 CCNB1 NM_031966.1 Forward PrimerTTCAGGTTGTTGCAGGAGAC SEQ ID NO: 280 Probe TGTCTCCATTATTGATCGGTTCATGCASEQ ID NO: 281 Reverse Primer CATCTTCTTGGGCACACAAT SEQ ID NO: 282 CCNB2NM_004701.2 Forward Primer AGGCTTCTGCAGGAGACTCTGT SEQ ID NO: 283 ProbeTCGATCCATAATGCCAACGCACATG SEQ ID NO: 284 Reverse PrimerGGGAAACTGGCTGAACCTGTAA SEQ ID NO: 285 CCND1 NM_001758.1 Forward PrimerGCATGTTCGTGGCCTCTAAGA SEQ ID NO: 286 Probe AAGGAGACCATCCCCCTGACGGC SEQID NO: 287 Reverse Primer CGGTGTAGATGCACAGCTTCTC SEQ ID NO: 288 CCND3NM_001760.2 Forward Primer CCTCTGTGCTACAGATTATACCTTTGC SEQ ID NO: 289Probe TACCCGCCATCCATGATCGCCA SEQ ID NO: 290 Reverse PrimerCACTGCAGCCCCAATGCT SEQ ID NO: 291 CCNE1 NM_001238.1 Forward PrimerAAAGAAGATGATGACCGGGTTTAC SEQ ID NO: 292 Probe CAAACTCAACGTGCAAGCCTCGGASEQ ID NO: 293 Reverse Primer GAGCCTCTGGATGGTGCAAT SEQ ID NO: 294 CCNE2NM_057749.1 Forward Primer GGTCACCAAGAAACATCAGTATGAA SEQ ID NO: 295Probe CCCAGATAATACAGGTGGCCAACAATTCCT SEQ ID NO: 296 Reverse PrimerTTCAATGATAATGCAAGGACTGATC SEQ ID NO: 297 CCNE2 NM_057749var1 ForwardPrimer ATGCTGTGGCTCCTTCCTAACT SEQ ID NO: 298 variant 1 ProbeTACCAAGCAACCTACATGTCAAGAAAGCCC SEQ ID NO: 299 Reverse PrimerACCCAAATTGTGATATACAAAAAGGTT SEQ ID NO: 300 CCR7 NM_001838.2 ForwardPrimer GGATGACATGCACTCAGCTC SEQ ID NO: 301 Probe CTCCCATCCCAGTGGAGCCAASEQ ID NO: 302 Reverse Primer CCTGACATTTCCCTTGTCCT SEQ ID NO: 303 CD105NM_000118.1 Forward Primer GCAGGTGTCAGCAAGTATGATCAG SEQ ID NO: 304 ProbeCGACAGGATATTGACCACCGCCTCATT SEQ ID NO: 305 Reverse PrimerTTTTTCCGCTGTGGTGATGA SEQ ID NO: 306 CD134 NM_003327.1 Forward PrimerGCCCAGTGCGGAGAACAG SEQ ID NO: 307 (TNFRSF4 ProbeCCAGCTTGATTCTCGTCTCTGCACTTAAGC SEQ ID NO: 308 official) Reverse PrimerAATCACACGCACCTGGAGAAC SEQ ID NO: 309 CD18 NM_000211.1 Forward PrimerCGTCAGGACCCACCATGTCT SEQ ID NO: 310 Probe CGCGGCCGAGACATGGCTTG SEQ IDNO: 311 Reverse Primer GGTTAATTGGTGACATCCTCAAGA SEQ ID NO: 312 CD24NM_013230.1 Forward Primer TCCAACTAATGCCACCACCAA SEQ ID NO: 313 ProbeCTGTTGACTGCAGGGCACCACCA SEQ ID NO: 314 Reverse PrimerGAGAGAGTGAGACCACGAAGAGACT SEQ ID NO: 315 CD28 NM_006139.1 Forward PrimerTGTGAAAGGGAAACACCTTTG SEQ ID NO: 316 Probe CCAAGTCCCCTATTTCCCGGACCT SEQID NO: 317 Reverse Primer AGCACCCAAAAGGGCTTAG SEQ ID NO: 318 CD31NM_000442.1 Forward Primer TGTATTTCAAGACCTCTGTGCACTT SEQ ID NO: 319Probe TTTATGAACCTGCCCTGCTCCCACA SEQ ID NO: 320 Reverse PrimerTTAGCCTGAGGAATTGCTGTGTT SEQ ID NO: 321 CD34 NM_001773.1 Forward PrimerCCACTGCACACACCTCAGA SEQ ID NO: 322 Probe CTGTTCTTGGGGCCCTACACCTTG SEQ IDNO: 323 Reverse Primer CAGGAGTTTACCTGCCCCT SEQ ID NO: 324 CD3zNM_000734.1 Forward Primer AGATGAAGTGGAAGGCGCTT SEQ ID NO: 325 ProbeCACCGCGGCCATCCTGCA SEQ ID NO: 326 Reverse Primer TGCCTCTGTAATCGGCAACTGSEQ ID NO: 327 CD44E X55150 Forward Primer ATCACCGACAGCACAGACA SEQ IDNO: 328 Probe CCCTGCTACCAATATGGACTCCAGTCA SEQ ID NO: 329 Reverse PrimerACCTGTGTTTGGATTTGCAG SEQ ID NO: 330 CD44s M59040.1 Forward PrimerGACGAAGACAGTCCCTGGAT SEQ ID NO: 331 Probe CACCGACAGCACAGACAGAATCCC SEQID NO: 332 Reverse Primer ACTGGGGTGGAATGTGTCTT SEQ ID NO: 333 CD44v3AJ251595v3 Forward Primer CACACAAAACAGAACCAGGACT SEQ ID NO: 334 ProbeACCCAGTGGAACCCAAGCCATTC SEQ ID NO: 335 Reverse PrimerCTGAAGTAGCACTTCCGGATT SEQ ID NO: 336 CD44v6 AJ251595v6 Forward PrimerCTCATACCAGCCATCCAATG SEQ ID NO: 337 Probe CACCAAGCCCAGAGGACAGTTCCT SEQID NO: 338 Reverse Primer TTGGGTTGAAGAAATCAGTCC SEQ ID NO: 339 CD68NM_001251.1 Forward Primer TGGTTCCCAGCCCTGTGT SEQ ID NO: 340 ProbeCTCCAAGCCCAGATTCAGATTCGAGTCA SEQ ID NO: 341 Reverse PrimerCTCCTCCACCCTGGGTTGT SEQ ID NO: 342 CD80 NM_005191.2 Forward PrimerTTCAGTTGCTTTGCAGGAAG SEQ ID NO: 343 Probe TTCTGTGCCCACCATATTCCTCTAGACASEQ ID NO: 344 Reverse Primer TTGATCAAGGTCACCAGAGC SEQ ID NO: 345 CD82NM_002231.2 Forward Primer GTGCAGGCTCAGGTGAAGTG SEQ ID NO: 346 ProbeTCAGCTTCTACAACTGGACAGACAACGCTG SEQ ID NO: 347 Reverse PrimerGACCTCAGGGCGATTCATGA SEQ ID NO: 348 CD8A NM_171827.1 Forward PrimerAGGGTGAGGTGCTTGAGTCT SEQ ID NO: 349 Probe CCAACGGCAAGGGAACAAGTACTTCT SEQID NO: 350 Reverse Primer GGGCACAGTATCCCAGGTA SEQ ID NO: 351 CD9NM_001769.1 Forward Primer GGGCGTGGAACAGTTTATCT SEQ ID NO: 352 ProbeAGACATCTGCCCCAAGAAGGACGT SEQ ID NO: 353 Reverse PrimerCACGGTGAAGGTTTCGAGT SEQ ID NO: 354 CDC2 NM_001786.2 Forward PrimerGAGAGCGACGCGGTTGTT SEQ ID NO: 355 Probe TAGCTGCCGCTGCGGCCG SEQ ID NO:356 Reverse Primer GTATGGTAGATCCCGGCTTATTATTC SEQ ID NO: 357 CDC20NM_001255.1 Forward Primer TGGATTGGAGTTCTGGGAATG SEQ ID NO: 358 ProbeACTGGCCGTGGCACTGGACAACA SEQ ID NO: 359 Reverse PrimerGCTTGCACTCCACAGGTACACA SEQ ID NO: 360 cdc25A NM_001789.1 Forward PrimerTCTTGCTGGCTACGCCTCTT SEQ ID NO: 361 Probe TGTCCCTGTTAGACGTCCTCCGTCCATASEQ ID NO: 362 Reverse Primer CTGCATTGTGGCACAGTTCTG SEQ ID NO: 363CDC25B NM_021874.1 Forward Primer AAACGAGCAGTTTGCCATCAG SEQ ID NO: 364Probe CCTCACCGGCATAGACTGGAAGCG SEQ ID NO: 365 Reverse PrimerGTTGGTGATGTTCCGAAGCA SEQ ID NO: 366 CDC25C NM_001790.2 Forward PrimerGGTGAGCAGAAGTGGCCTAT SEQ ID NO: 367 Probe CTCCCCGTCGATGCCAGAGAACT SEQ IDNO: 368 Reverse Primer CTTCAGTCTTGGCCTGTTCA SEQ ID NO: 369 CDC4NM_018315.2 Forward Primer GCAGTCCGCTGTGTTCAA SEQ ID NO: 370 ProbeTGCTCCACTAACAACCCTCCTGCC SEQ ID NO: 371 Reverse PrimerGGATCCCACACCTTTACCATAA SEQ ID NO: 372 CDC42 NM_001791.2 Forward PrimerTCCAGAGACTGCTGAAAA SEQ ID NO: 373 Probe CCCGTGACCTGAAGGCTGTCAAG SEQ IDNO: 374 Reverse Primer TGTGTAAGTGCAGAACAC SEQ ID NO: 375 CDC42BPANM_003607.2 Forward Primer GAGCTGAAAGACGCACACTG SEQ ID NO: 376 ProbeAATTCCTGCATGGCCAGTTTCCTC SEQ ID NO: 377 Reverse PrimerGCCGCTCATTGATCTCCA SEQ ID NO: 378 CDC6 NM_001254.2 Forward PrimerGCAACACTCCCCATTTACCTC SEQ ID NO: 379 Probe TTGTTCTCCACCAAAGCAAGGCAA SEQID NO: 380 Reverse Primer TGAGGGGGACCATTCTCTTT SEQ ID NO: 381 CDCA7 v2NM_145810.1 Forward Primer AAGACCGTGGATGGCTACAT SEQ ID NO: 382 ProbeATGAAGATGACCTGCCCAGAAGCC SEQ ID NO: 383 Reverse PrimerAGGGTCACGGATGATCTGG SEQ ID NO: 384 CDH1 NM_004360.2 Forward PrimerTGAGTGTCCCCCGGTATCTTC SEQ ID NO: 385 Probe TGCCAATCCCGATGAAATTGGAAATTTSEQ ID NO: 386 Reverse Primer CAGCCGCTTTCAGATTTTCAT SEQ ID NO: 387 CDH11NM_001797.2 Forward Primer GTCGGCAGAAGCAGGACT SEQ ID NO: 388 ProbeCCTTCTGCCCATAGTGATCAGCGA SEQ ID NO: 389 Reverse PrimerCTACTCATGGGCGGGATG SEQ ID NO: 390 CDH3 NM_001793.3 Forward PrimerACCCATGTACCGTCCTCG SEQ ID NO: 391 Probe CCAACCCAGATGAAATCGGCAACT SEQ IDNO: 392 Reverse Primer CCGCCTTCAGGTTCTCAAT SEQ ID NO: 393 CDK2NM_001798.2 Forward Primer AATGCTGCACTACGACCCTA SEQ ID NO: 394 ProbeCCTTGGCCGAAATCCGCTTGT SEQ ID NO: 395 Reverse Primer TTGGTCACATCCTGGAAGAASEQ ID NO: 396 CDX1 NM_001804.1 Forward Primer AGCAACACCAGCCTCCTG SEQ IDNO: 397 Probe CACCTCCTCTCCAATGCCTGTGAA SEQ ID NO: 398 Reverse PrimerGGGCTATGGCAGAAACTCCT SEQ ID NO: 399 Cdx2 NM_001265.2 Forward PrimerGGGCAGGCAAGGTTTACA SEQ ID NO: 400 Probe ATCTTAGCTGCCTTTGGCTTCCGC SEQ IDNO: 401 Reverse Primer GTCTTTGGTCAGTCCAGCTTTC SEQ ID NO: 402 CEACAM1NM_001712.2 Forward Primer ACTTGCCTGTTCAGAGCACTCA SEQ ID NO: 403 ProbeTCCTTCCCACCCCCAGTCCTGTC SEQ ID NO: 404 Reverse PrimerTGGCAAATCCGAATTAGAGTGA SEQ ID NO: 405 CEACAM6 NM_002483.2 Forward PrimerCACAGCCTCACTTCTAACCTTCTG SEQ ID NO: 406 Probe ACCCACCCACCACTGCCAAGCTCSEQ ID NO: 407 Reverse Primer TTGAATGGCGTGGATTCAATAG SEQ ID NO: 408CEBPB NM_005194.2 Forward Primer GCAACCCACGTGTAACTGTC SEQ ID NO: 409Probe CCGGGCCCTGAGTAATCGCTTAA SEQ ID NO: 410 Reverse PrimerACAAGCCCGTAGGAACATCT SEQ ID NO: 411 CEGP1 NM_020974.1 Forward PrimerTGACAATCAGCACACCTGCAT SEQ ID NO: 412 Probe CAGGCCCTCTTCCGAGCGGT SEQ IDNO: 413 Reverse Primer TGTGACTACAGCCGTGATCCTTA SEQ ID NO: 414 CENPANM_001809.2 Forward Primer TAAATTCACTCGTGGTGTGGA SEQ ID NO: 415 ProbeCTTCAATTGGCAAGCCCAGGC SEQ ID NO: 416 Reverse Primer GCCTCTTGTAGGGCCAATAGSEQ ID NO: 417 CENPE NM_001813.1 Forward Primer GGATGCTGGTGACCTCTTCT SEQID NO: 418 Probe TCCCTCACGTTGCAACAGGAATTAA SEQ ID NO: 419 Reverse PrimerGCCAAGGCACCAAGTAACTC SEQ ID NO: 420 CENPF NM_016343.2 Forward PrimerCTCCCGTCAACAGCGTTC SEQ ID NO: 421 Probe ACACTGGACCAGGAGTGCATCCAG SEQ IDNO: 422 Reverse Primer GGGTGAGTCTGGCCTTCA SEQ ID NO: 423 CES2NM_003869.4 Forward Primer ACTTTGCGAGAAATGGGAAC SEQ ID NO: 424 ProbeAGTGTGGCAGACCCTCGCCATT SEQ ID NO: 425 Reverse PrimerCAGGTATTGCTCCTCCTGGT SEQ ID NO: 426 CGA (CHGA NM_001275.2 Forward PrimerCTGAAGGAGCTCCAAGACCT SEQ ID NO: 427 official) ProbeTGCTGATGTGCCCTCTCCTTGG SEQ ID NO: 428 Reverse PrimerCAAAACCGCTGTGTTTCTTC SEQ ID NO: 429 CGB NM_000737.2 Forward PrimerCCACCATAGGCAGAGGCA SEQ ID NO: 430 Probe ACACCCTACTCCCTGTGCCTCCAG SEQ IDNO: 431 Reverse Primer AGTCGTCGAGTGCTAGGGAC SEQ ID NO: 432 CHAF1BNM_005441.1 Forward Primer GAGGCCAGTGGTGGAAACAG SEQ ID NO: 433 ProbeAGCTGATGAGTCTGCCCTACCGCCTG SEQ ID NO: 434 Reverse PrimerTCCGAGGCCACAGCAAAC SEQ ID NO: 435 CHD2 NM_001271.1 Forward PrimerCTCTGTGCGAGGCTGTCA SEQ ID NO: 436 Probe ACCCATCTCGGGATCCCTGATACC SEQ IDNO: 437 Reverse Primer GGTAAGGACTGTGGGCTGG SEQ ID NO: 438 CHFRNM_018223.1 Forward Primer AAGGAAGTGGTCCCTCTGTG SEQ ID NO: 439 ProbeTGAAGTCTCCAGCTTTGCCTCAGC SEQ ID NO: 440 Reverse PrimerGACGCAGTCTTTCTGTCTGG SEQ ID NO: 441 Chk1 NM_001274.1 Forward PrimerGATAAATTGGTACAAGGGATCAGCTT SEQ ID NO: 442 ProbeCCAGCCCACATGTCCTGATCATATGC SEQ ID NO: 443 Reverse PrimerGGGTGCCAAGTAACTGACTATTCA SEQ ID NO: 444 Chk2 NM_007194.1 Forward PrimerATGTGGAACCCCCACCTACTT SEQ ID NO: 445 Probe AGTCCCAACAGAAACAAGAACTTCAGGCGSEQ ID NO: 446 Reverse Primer CAGTCCACAGCACGGTTATACC SEQ ID NO: 447CIAP1 NM_001166.2 Forward Primer TGCCTGTGGTGGGAAGCT SEQ ID NO: 448 ProbeTGACATAGCATCATCCTTTGGTTCCCAGTT SEQ ID NO: 449 Reverse PrimerGGAAAATGCCTCCGGTGTT SEQ ID NO: 450 cIAP2 NM_001165.2 Forward PrimerGGATATTTCCGTGGCTCTTATTCA SEQ ID NO: 451 ProbeTCTCCATCAAATCCTGTAAACTCCAGAGCA SEQ ID NO: 452 Reverse PrimerCTTCTCATCAAGGCAGAAAAATCTT SEQ ID NO: 453 CKS1B NM_001826.1 ForwardPrimer GGTCCCTAAAACCCATCTGA SEQ ID NO: 454 ProbeTGAACGCCAAGATTCCTCCATTCA SEQ ID NO: 455 Reverse PrimerTAATGGACCCATCCCTGACT SEQ ID NO: 456 CKS2 NM_001827.1 Forward PrimerGGCTGGACGTGGTTTTGTCT SEQ ID NO: 457 Probe CTGCGCCCGCTCTTCGCG SEQ ID NO:458 Reverse Primer CGCTGCAGAAAATGAAACGA SEQ ID NO: 459 Claudin 4NM_001305.2 Forward Primer GGCTGCTTTGCTGCAACTG SEQ ID NO: 460 ProbeCGCACAGACAAGCCTTACTCCGCC SEQ ID NO: 461 Reverse PrimerCAGAGCGGGCAGCAGAATA SEQ ID NO: 462 CLDN1 NM_021101.3 Forward PrimerTCTGGGAGGTGCCCTACTT SEQ ID NO: 463 Probe TGTTCCTGTCCCCGAAAAACAACC SEQ IDNO: 464 Reverse Primer TGGATAGGGCCTTGGTGTT SEQ ID NO: 465 CLDN7NM_001307.3 Forward Primer GGTCTGCCCTAGTCATCCTG SEQ ID NO: 466 ProbeTGCACTGCTCTCCTGTTCCTGTCC SEQ ID NO: 467 Reverse PrimerGTACCCAGCCTTGCTCTCAT SEQ ID NO: 468 CLIC1 NM_001288.3 Forward PrimerCGGTACTTGAGCAATGCCTA SEQ ID NO: 469 Probe CGGGAAGAATTCGCTTCCACCTG SEQ IDNO: 470 Reverse Primer TCGATCTCCTCATCATCTGG SEQ ID NO: 471 CLTCNM_004859.1 Forward Primer ACCGTATGGACAGCCACAG SEQ ID NO: 472 ProbeTCTCACATGCTGTACCCAAAGCCA SEQ ID NO: 473 Reverse PrimerTGACTACAGGATCAGCGCTTC SEQ ID NO: 474 CLU NM_001831.1 Forward PrimerCCCCAGGATACCTACCACTACCT SEQ ID NO: 475 Probe CCCTTCAGCCTGCCCCACCG SEQ IDNO: 476 Reverse Primer TGCGGGACTTGGGAAAGA SEQ ID NO: 477 cMetNM_000245.1 Forward Primer GACATTTCCAGTCCTGCAGTCA SEQ ID NO: 478 ProbeTGCCTCTCTGCCCCACCCTTTGT SEQ ID NO: 479 Reverse PrimerCTCCGATCGCACACATTTGT SEQ ID NO: 480 cMYC NM_002467.1 Forward PrimerTCCCTCCACTCGGAAGGACTA SEQ ID NO: 481 Probe TCTGACACTGTCCAACTTGACCCTCTTSEQ ID NO: 482 Reverse Primer CGGTTGTTGCTGATCTGTCTCA SEQ ID NO: 483 CNNNM_001299.2 Forward Primer TCCACCCTCCTGGCTTTG SEQ ID NO: 484 ProbeTCCTTTCGTCTTCGCCATGCTGG SEQ ID NO: 485 Reverse PrimerTCACTCCCACGTTCACCTTGT SEQ ID NO: 486 COL1A1 NM_000088.2 Forward PrimerGTGGCCATCCAGCTGACC SEQ ID NO: 487 Probe TCCTGCGCCTGATGTCCACCG SEQ ID NO:488 Reverse Primer CAGTGGTAGGTGATGTTCTGGGA SEQ ID NO: 489 COL1A2NM_000089.2 Forward Primer CAGCCAAGAACTGGTATAGGAGCT SEQ ID NO: 490 ProbeTCTCCTAGCCAGACGTGTTTCTTGTCCTTG SEQ ID NO: 491 Reverse PrimerAAACTGGCTGCCAGCATTG SEQ ID NO: 492 COPS3 NM_003653.2 Forward PrimerATGCCCAGTGTTCCTGACTT SEQ ID NO: 493 Probe CGAAACGCTATTCTCACAGGTTCAGC SEQID NO: 494 Reverse Primer CTCCCCATTACAAGTGCTGA SEQ ID NO: 495 COX2NM_000963.1 Forward Primer TCTGCAGAGTTGGAAGCACTCTA SEQ ID NO: 496 ProbeCAGGATACAGCTCCACAGCATCGATGTC SEQ ID NO: 497 Reverse PrimerGCCGAGGCTTTTCTACCAGAA SEQ ID NO: 498 COX3 MITO_COX3 Forward PrimerTCGAGTCTCCCTTCACCATT SEQ ID NO: 499 Probe CGACGGCATCTACGGCTCAACAT SEQ IDNO: 500 Reverse Primer GACGTGAAGTCCGTGGAAG SEQ ID NO: 501 CP NM_000096.1Forward Primer CGTGAGTACACAGATGCCTCC SEQ ID NO: 502 ProbeTCTTCAGGGCCTCTCTCCTTTCGA SEQ ID NO: 503 Reverse PrimerCCAGGATGCCAAGATGCT SEQ ID NO: 504 CRBP NM_002899.2 Forward PrimerTGGTCTGCAAGCAAGTATTCAAG SEQ ID NO: 505 Probe TCTGCTTGGGCCTCACTGCACCT SEQID NO: 506 Reverse Primer GCTGATTGGTTGGGACAAGGT SEQ ID NO: 507 CREBBPNM_004380.1 Forward Primer TGGGAAGCAGCTGTGTACCAT SEQ ID NO: 508 ProbeCCTCGCGATGCTGCCTACTACAGCTATC SEQ ID NO: 509 Reverse PrimerGAAACACTTCTCACAGAAATGATACCTATT SEQ ID NO: 510 CRIP2 NM_001312.1 ForwardPrimer GTGCTACGCCACCCTGTT SEQ ID NO: 511 Probe CCGATGTTCACGCCTTTGGGTCSEQ ID NO: 512 Reverse Primer CAGGGGCTTCTCGTAGATGT SEQ ID NO: 513 criptoNM_003212.1 Forward Primer GGGTCTGTGCCCCATGAC SEQ ID NO: 514 (TDGF1Probe CCTGGCTGCCCAAGAAGTGTTCCCT SEQ ID NO: 515 official) Reverse PrimerTGACCGTGCCAGCATTTACA SEQ ID NO: 516 CRK(a) NM_016823.2 Forward PrimerCTCCCTAACCTCCAGAATGG SEQ ID NO: 517 Probe ACTCGCTTCTGGATAACCCTGGCA SEQID NO: 518 Reverse Primer TGTCTTGTCGTAGGCATTGG SEQ ID NO: 519 CRMP1NM_001313.1 Forward Primer AAGGTTTTTGGATTGCAAGG SEQ ID NO: 520 ProbeACCGTCATACATGCCCCTGGAAAC SEQ ID NO: 521 Reverse PrimerGGGTGTAGCTGGTACCTCGT SEQ ID NO: 522 CRYAB NM_001885.1 Forward PrimerGATGTGATTGAGGTGCATGG SEQ ID NO: 523 Probe TGTTCATCCTGGCGCTCTTCATGT SEQID NO: 524 Reverse Primer GAACTCCCTGGAGATGAAACC SEQ ID NO: 525 CSEL1NM_001316.2 Forward Primer TTACGCAGCTCATGCTCTTG SEQ ID NO: 526 ProbeACGGCTCTTTACTATGCGAGGGCC SEQ ID NO: 527 Reverse PrimerGCAGCTGTAAAGAGAGTGGCAT SEQ ID NO: 528 CSF1 NM_000757.3 Forward PrimerTGCAGCGGCTGATTGACA SEQ ID NO: 529 Probe TCAGATGGAGACCTCGTGCCAAATTACA SEQID NO: 530 Reverse Primer CAACTGTTCCTGGTCTACAAACTCA SEQ ID NO: 531 CSK(SRC) NM_004383.1 Forward Primer CCTGAACATGAAGGAGCTGA SEQ ID NO: 532Probe TCCCGATGGTCTGCAGCAGCT SEQ ID NO: 533 Reverse PrimerCATCACGTCTCCGAACTCC SEQ ID NO: 534 CTAG1B NM_001327.1 Forward PrimerGCTCTCCATCAGCTCCTGTC SEQ ID NO: 535 Probe CCACATCAACAGGGAAAGCTGCTG SEQID NO: 536 Reverse Primer AACACGGGCAGAAAGCACT SEQ ID NO: 537 CTGFNM_001901.1 Forward Primer GAGTTCAAGTGCCCTGACG SEQ ID NO: 538 ProbeAACATCATGTTCTTCTTCATGACCTCGC SEQ ID NO: 539 Reverse PrimerAGTTGTAATGGCAGGCACAG SEQ ID NO: 540 CTHRC1 NM_138455.2 Forward PrimerGCTCACTTCGGCTAAAATGC SEQ ID NO: 541 Probe ACCAACGCTGACAGCATGCATTTC SEQID NO: 542 Reverse Primer TCAGCTCCATTGAATGTGAAA SEQ ID NO: 543 CTLA4NM_005214.2 Forward Primer CACTGAGGTCCGGGTGACA SEQ ID NO: 544 ProbeCACCTGGCTGTCAGCCTGCCG SEQ ID NO: 545 Reverse PrimerGTAGGTTGCCGCACAGACTTC SEQ ID NO: 546 CTNNBIP1 NM_020248.2 Forward PrimerGTTTTCCAGGTCGGAGACG SEQ ID NO: 547 Probe CTTTGCAGCTACTGCCTCCGGTCT SEQ IDNO: 548 Reverse Primer AGCATCCAGGGTGTTCCA SEQ ID NO: 549 CTSBNM_001908.1 Forward Primer GGCCGAGATCTACAAAAACG SEQ ID NO: 550 ProbeCCCCGTGGAGGGAGCTTTCTC SEQ ID NO: 551 Reverse Primer GCAGGAAGTCCGAATACACASEQ ID NO: 552 CTSD NM_001909.1 Forward Primer GTACATGATCCCCTGTGAGAAGGTSEQ ID NO: 553 Probe ACCCTGCCCGCGATCACACTGA SEQ ID NO: 554 ReversePrimer GGGACAGCTTGTAGCCTTTGC SEQ ID NO: 555 CTSH NM_004390.1 ForwardPrimer GCAAGTTCCAACCTGGAAAG SEQ ID NO: 556 ProbeTGGCTACATCCTTGACAAAGCCGA SEQ ID NO: 557 Reverse PrimerCATCGCTTCCTCGTCATAGA SEQ ID NO: 558 CTSL NM_001912.1 Forward PrimerGGGAGGCTTATCTCACTGAGTGA SEQ ID NO: 559 ProbeTTGAGGCCCAGAGCAGTCTACCAGATTCT SEQ ID NO: 560 Reverse PrimerCCATTGCAGCCTTCATTGC SEQ ID NO: 561 CTSL2 NM_001333.2 Forward PrimerTGTCTCACTGAGCGAGCAGAA SEQ ID NO: 562 Probe CTTGAGGACGCGAACAGTCCACCA SEQID NO: 563 Reverse Primer ACCATTGCAGCCCTGATTG SEQ ID NO: 564 CUL1NM_003592.2 Forward Primer ATGCCCTGGTAATGTCTGCAT SEQ ID NO: 565 ProbeCAGCCACAAAGCCAGCGTCATTGT SEQ ID NO: 566 Reverse PrimerGCGACCACAAGCCTTATCAAG SEQ ID NO: 567 CUL4A NM_003589.1 Forward PrimerAAGCATCTTCCTGTTCTTGGA SEQ ID NO: 568 Probe TATGTGCTGCAGAACTCCACGCTG SEQID NO: 569 Reverse Primer AATCCCATATCCCAGATGGA SEQ ID NO: 570 CXCL12NM_000609.3 Forward Primer GAGCTACAGATGCCCATGC SEQ ID NO: 571 ProbeTTCTTCGAAAGCCATGTTGCCAGA SEQ ID NO: 572 Reverse PrimerTTTGAGATGCTTGACGTTGG SEQ ID NO: 573 CXCR4 NM_003467.1 Forward PrimerTGACCGCTTCTACCCCAATG SEQ ID NO: 574 Probe CTGAAACTGGAACACAACCACCCACAAGSEQ ID NO: 575 Reverse Primer AGGATAAGGCCAACCATGATGT SEQ ID NO: 576 CYBANM_000101.1 Forward Primer GGTGCCTACTCCATTGTGG SEQ ID NO: 577 ProbeTACTCCAGCAGGCACACAAACACG SEQ ID NO: 578 Reverse PrimerGTGGAGCCCTTCTTCCTCTT SEQ ID NO: 579 CYP1B1 NM_000104.2 Forward PrimerCCAGCTTTGTGCCTGTCACTAT SEQ ID NO: 580 Probe CTCATGCCACCACTGCCAACACCTCSEQ ID NO: 581 Reverse Primer GGGAATGTGGTAGCCCAAGA SEQ ID NO: 582 CYP2C8NM_000770.2 Forward Primer CCGTGTTCAAGAGGAAGCTC SEQ ID NO: 583 ProbeTTTTCTCAACTCCTCCACAAGGCA SEQ ID NO: 584 Reverse PrimerAGTGGGATCACAGGGTGAAG SEQ ID NO: 585 CYP3A4 NM_017460.3 Forward PrimerAGAACAAGGACAACATAGATCCTTACATAT SEQ ID NO: 586 ProbeCACACCCTTTGGAAGTGGACCCAGAA SEQ ID NO: 587 Reverse PrimerGCAAACCTCATGCCAATGC SEQ ID NO: 588 CYR61 NM_001554.3 Forward PrimerTGCTCATTCTTGAGGAGCAT SEQ ID NO: 589 Probe CAGCACCCTTGGCAGTTTCGAAAT SEQID NO: 590 Reverse Primer GTGGCTGCATTAGTGTCCAT SEQ ID NO: 591 DAPK1NM_004938.1 Forward Primer CGCTGACATCATGAATGTTCCT SEQ ID NO: 592 ProbeTCATATCCAAACTCGCCTCCAGCCG SEQ ID NO: 593 Reverse PrimerTCTCTTTCAGCAACGATGTGTCTT SEQ ID NO: 594 DCC NM_005215.1 Forward PrimerAAATGTCCTCCTCGACTGCT SEQ ID NO: 595 Probe ATCACTGGAACTCCTCGGTCGGAC SEQID NO: 596 Reverse Primer TGAATGCCATCTTTCTTCCA SEQ ID NO: 597DCC_exons18-23 X76132_18-23 Forward Primer GGTCACCGTTGGTGTCATCA SEQ IDNO: 598 Probe CAGCCACGATGACCACTACCAGCACT SEQ ID NO: 599 Reverse PrimerGAGCGTCGGGTGCAAATC SEQ ID NO: 600 DCC_exons6-7 X76132_6-7 Forward PrimerATGGAGATGTGGTCATTCCTAGTG SEQ ID NO: 601 Probe TGCTTCCTCCCACTATCTGAAAATAASEQ ID NO: 602 Reverse Primer CACCACCCCAAGTATCCGTAAG SEQ ID NO: 603 DCKNM_000788.1 Forward Primer GCCGCCACAAGACTAAGGAAT SEQ ID NO: 604 ProbeAGCTGCCCGTCTTTCTCAGCCAGC SEQ ID NO: 605 Reverse PrimerCGATGTTCCCTTCGATGGAG SEQ ID NO: 606 DDB1 NM_001923.2 Forward PrimerTGCGGATCATCCGGAATG SEQ ID NO: 607 Probe AATTGGAATCCACGAGCATGCCAGC SEQ IDNO: 608 Reverse Primer TCCTTTGATGCCTGGTAAGTCA SEQ ID NO: 609 DET1NM_017996.2 Forward Primer CTTGTGGAGATCACCCAATCAG SEQ ID NO: 610 ProbeCTATGCCCGGGACTCGGGCCT SEQ ID NO: 611 Reverse Primer CCCGCCTGGATCTCAAACTSEQ ID NO: 612 DHFR NM_000791.2 Forward PrimerTTGCTATAACTAAGTGCTTCTCCAAGA SEQ ID NO: 613 Probe CCCAACTGAGTCCCCAGCACCTSEQ ID NO: 614 Reverse Primer GTGGAATGGCAGCTCACTGTAG SEQ ID NO: 615 DHPSNM_013407.1 Forward Primer GGGAGAACGGGATCAATAGGAT SEQ ID NO: 616 ProbeCTCATTGGGCACCAGCAGGTTTCC SEQ ID NO: 617 Reverse PrimerGCATCAGCCAGTCCTCAAACT SEQ ID NO: 618 DIABLO NM_019887.1 Forward PrimerCACAATGGCGGCTCTGAAG SEQ ID NO: 619 Probe AAGTTACGCTGCGCGACAGCCAA SEQ IDNO: 620 Reverse Primer ACACAAACACTGTCTGTACCTGAAGA SEQ ID NO: 621 DIAPH1NM_005219.2 Forward Primer CAAGCAGTCAAGGAGAACCA SEQ ID NO: 622 ProbeTTCTTCTGTCTCCCGCCGCTTC SEQ ID NO: 623 Reverse PrimerAGTTTTGCTCGCCTCATCTT SEQ ID NO: 624 DICER1 NM_177438.1 Forward PrimerTCCAATTCCAGCATCACTGT SEQ ID NO: 625 Probe AGAAAAGCTGTTTGTCTCCCCAGCA SEQID NO: 626 Reverse Primer GGCAGTGAAGGCGATAAAGT SEQ ID NO: 627 DKK1NM_012242.1 Forward Primer TGACAACTACCAGCCGTACC SEQ ID NO: 628 ProbeAGTGCCGCACTCCTCGTCCTCT SEQ ID NO: 629 Reverse PrimerGGGACTAGCGCAGTACTCATC SEQ ID NO: 630 DLC1 NM_006094.3 Forward PrimerGATTCAGACGAGGATGAGCC SEQ ID NO: 631 Probe AAAGTCCATTTGCCACTGATGGCA SEQID NO: 632 Reverse Primer CACCTCTTGCTGTCCCTTTG SEQ ID NO: 633 DPYDNM_000110.2 Forward Primer AGGACGCAAGGAGGGTTTG SEQ ID NO: 634 ProbeCAGTGCCTACAGTCTCGAGTCTGCCAGTG SEQ ID NO: 635 Reverse PrimerGATGTCCGCCGAGTCCTTACT SEQ ID NO: 636 DR4 NM_003844.1 Forward PrimerTGCACAGAGGGTGTGGGTTAC SEQ ID NO: 637 Probe CAATGCTTCCAACAATTTGTTTGCTTGCCSEQ ID NO: 638 Reverse Primer TCTTCATCTGATTTACAAGCTGTACATG SEQ ID NO:639 DR5 NM_003842.2 Forward Primer CTCTGAGACAGTGCTTCGATGACT SEQ ID NO:640 Probe CAGACTTGGTGCCCTTTGACTCC SEQ ID NO: 641 Reverse PrimerCCATGAGGCCCAACTTCCT SEQ ID NO: 642 DRG1 NM_004147.3 Forward PrimerCCTGGATCTCCCAGGTATCA SEQ ID NO: 643 Probe ACCTTTCCCATCCTTGGCACCTTC SEQID NO: 644 Reverse Primer TGCAATGACTTGACGACCTC SEQ ID NO: 645 DSPNM_004415.1 Forward Primer TGGCACTACTGCATGATTGACA SEQ ID NO: 646 ProbeCAGGGCCATGACAATCGCCAA SEQ ID NO: 647 Reverse Primer CCTGCCGCATTGTTTTCAGSEQ ID NO: 648 DTYMK NM_012145.1 Forward Primer AAATCGCTGGGAACAAGTG SEQID NO: 649 Probe CGCCCTGGCTCAACTTTTCCTTAA SEQ ID NO: 650 Reverse PrimerAATGCGTATCTGTCCACGAC SEQ ID NO: 651 DUSP1 NM_004417.2 Forward PrimerAGACATCAGCTCCTGGTTCA SEQ ID NO: 652 Probe CGAGGCCATTGACTTCATAGACTCCA SEQID NO: 653 Reverse Primer GACAAACACCCTTCCTCCAG SEQ ID NO: 654 DUSP2NM_004418.2 Forward Primer TATCCCTGTGGAGGACAACC SEQ ID NO: 655 ProbeCCTCCTGGAACCAGGCACTGATCT SEQ ID NO: 656 Reverse PrimerCACCCAGTCAATGAAGCCTA SEQ ID NO: 657 DUT NM_001948.2 Forward PrimerACACATGGAGTGCTTCTGGA SEQ ID NO: 658 Probe ATCAGCCCACTTGACCACCCAGTT SEQID NO: 659 Reverse Primer CTCTTGCCTGTGCTTCCAC SEQ ID NO: 660 DYRK1BNM_004714.1 Forward Primer AGCATGACACGGAGATGAAG SEQ ID NO: 661 ProbeCACCTGAAGCGGCACTTCATGTTC SEQ ID NO: 662 Reverse PrimerAATACCAGGCACAGGTGGTT SEQ ID NO: 663 E2F1 NM_005225.1 Forward PrimerACTCCCTCTACCCTTGAGCA SEQ ID NO: 664 Probe CAGAAGAACAGCTCAGGGACCCCT SEQID NO: 665 Reverse Primer CAGGCCTCAGTTCCTTCAGT SEQ ID NO: 666 EDN1NM_001955.1 Forward Primer TGCCACCTGGACATCATTTG SEQ ID NO: 667endothelin Probe CACTCCCGAGCACGTTGTTCCGT SEQ ID NO: 668 Reverse PrimerTGGACCTAGGGCTTCCAAGTC SEQ ID NO: 669 EFNA1 NM_004428.2 Forward PrimerTACATCTCCAAACCCATCCA SEQ ID NO: 670 Probe CAACCTCAAGCAGCGGTCTTCATG SEQID NO: 671 Reverse Primer TTGCCACTGACAGTCACCTT SEQ ID NO: 672 EFNA3NM_004952.3 Forward Primer ACTACATCTCCACGCCCACT SEQ ID NO: 673 ProbeCCTCAGACACTTCCAGTGCAGGTTG SEQ ID NO: 674 Reverse PrimerCAGCAGACGAACACCTTCAT SEQ ID NO: 675 EFNB1 NM_004429.3 Forward PrimerGGAGCCCGTATCCTGGAG SEQ ID NO: 676 Probe CCCTCAACCCCAAGTTCCTGAGTG SEQ IDNO: 677 Reverse Primer GGATAGATCACCAAGCCCTTC SEQ ID NO: 678 EFNB2NM_004093.2 Forward Primer TGACATTATCATCCCGCTAAGGA SEQ ID NO: 679 ProbeCGGACAGCGTCTTCTGCCCTCACT SEQ ID NO: 680 Reverse PrimerGTAGTCCCCGCTGACCTTCTC SEQ ID NO: 681 EFP NM_005082.2 Forward PrimerTTGAACAGAGCCTGACCAAG SEQ ID NO: 682 Probe TGATGCTTTCTCCAGAAACTCGAACTCASEQ ID NO: 683 Reverse Primer TGTTGAGATTCCTCGCAGTT SEQ ID NO: 684 EGFRNM_005228.1 Forward Primer TGTCGATGGACTTCCAGAAC SEQ ID NO: 685 ProbeCACCTGGGCAGCTGCCAA SEQ ID NO: 686 Reverse Primer ATTGGGACAGCTTGGATCA SEQID NO: 687 EGLN1 NM_022051.1 Forward Primer TCAATGGCCGGACGAAAG SEQ IDNO: 688 Probe CATTGCCCGGATAACAAGCAACCATG SEQ ID NO: 689 Reverse PrimerTTTGGATTATCAACATGACGTACATAAC SEQ ID NO: 690 EGLN3 NM_022073.2 ForwardPrimer GCTGGTCCTCTACTGCGG SEQ ID NO: 691 Probe CCGGCTGGGCAAATACTACGTCAASEQ ID NO: 692 Reverse Primer CCACCATTGCCTTAGACCTC SEQ ID NO: 693 EGR1NM_001964.2 Forward Primer GTCCCCGCTGCAGATCTCT SEQ ID NO: 694 ProbeCGGATCCTTTCCTCACTCGCCCA SEQ ID NO: 695 Reverse PrimerCTCCAGCTTAGGGTAGTTGTCCAT SEQ ID NO: 696 EGR3 NM_004430.2 Forward PrimerCCATGTGGATGAATGAGGTG SEQ ID NO: 697 Probe ACCCAGTCTCACCTTCTCCCCACC SEQID NO: 698 Reverse Primer TGCCTGAGAAGAGGTGAGGT SEQ ID NO: 699 EI24NM_004879.2 Forward Primer AAAGTGGTGAATGCCATTTG SEQ ID NO: 700 ProbeCCTCAAATGCCAGGTCAGCTATATCCTG SEQ ID NO: 701 Reverse PrimerGTGAGGCTTCCTCCCTGATA SEQ ID NO: 702 EIF4E NM_001968.1 Forward PrimerGATCTAAGATGGCGACTGTCGAA SEQ ID NO: 703 Probe ACCACCCCTACTCCTAATCCCCCGACTSEQ ID NO: 704 Reverse Primer TTAGATTCCGTTTTCTCCTCTTCTG SEQ ID NO: 705EIF4EL3 NM_004846.1 Forward Primer AAGCCGCGGTTGAATGTG SEQ ID NO: 706Probe TGACCCTCTCCCTCTCTGGATGGCA SEQ ID NO: 707 Reverse PrimerTGACGCCAGCTTCAATGATG SEQ ID NO: 708 ELAVL1 NM_001419.2 Forward PrimerGACAGGAGGCCTCTATCCTG SEQ ID NO: 709 Probe CACCCCACCCTCCACCTCAATC SEQ IDNO: 710 Reverse Primer GTGAGGTAGGTCTGGGGAAG SEQ ID NO: 711 EMP1NM_001423.1 Forward Primer GCTAGTACTTTGATGCTCCCTTGAT SEQ ID NO: 712Probe CCAGAGAGCCTCCCTGCAGCCA SEQ ID NO: 713 Reverse PrimerGAACAGCTGGAGGCCAAGTC SEQ ID NO: 714 EMR3 NM_032571.2 Forward PrimerTGGCCTACCTCTTCACCATC SEQ ID NO: 715 Probe TCAACAGCCTCCAAGGCTTCTTCA SEQID NO: 716 Reverse Primer TGAGGAGGCAGTAGACCAAGA SEQ ID NO: 717 EMS1NM_005231.2 Forward Primer GGCAGTGTCACTGAGTCCTTGA SEQ ID NO: 718 ProbeATCCTCCCCTGCCCCGCG SEQ ID NO: 719 Reverse Primer TGCACTGTGCGTCCCAAT SEQID NO: 720 ENO1 NM_001428.2 Forward Primer CAAGGCCGTGAACGAGAAGT SEQ IDNO: 721 Probe CTGCAACTGCCTCCTGCTCAAAGTCA SEQ ID NO: 722 Reverse PrimerCGGTCACGGAGCCAATCT SEQ ID NO: 723 EP300 NM_001429.1 Forward PrimerAGCCCCAGCAACTACAGTCT SEQ ID NO: 724 Probe CACTGACATCATGGCTGGCCTTG SEQ IDNO: 725 Reverse Primer TGTTCAAAGGTTGACCATGC SEQ ID NO: 726 EPAS1NM_001430.3 Forward Primer AAGCCTTGGAGGGTTTCATTG SEQ ID NO: 727 ProbeTGTCGCCATCTTGGGTCACCACG SEQ ID NO: 728 Reverse PrimerTGCTGATGTTTTCTGACAGAAAGAT SEQ ID NO: 729 EpCAM NM_002354.1 ForwardPrimer GGGCCCTCCAGAACAATGAT SEQ ID NO: 730 ProbeCCGCTCTCATCGCAGTCAGGATCAT SEQ ID NO: 731 Reverse PrimerTGCACTGCTTGGCCTTAAAGA SEQ ID NO: 732 EPHA2 NM_004431.2 Forward PrimerCGCCTGTTCACCAAGATTGAC SEQ ID NO: 733 Probe TGCGCCCGATGAGATCACCG SEQ IDNO: 734 Reverse Primer GTGGCGTGCCTCGAAGTC SEQ ID NO: 735 EPHB2NM_004442.4 Forward Primer CAACCAGGCAGCTCCATC SEQ ID NO: 736 ProbeCACCTGATGCATGATGGACACTGC SEQ ID NO: 737 Reverse PrimerGTAATGCTGTCCACGGTGC SEQ ID NO: 738 EPHB4 NM_004444.3 Forward PrimerTGAACGGGGTATCCTCCTTA SEQ ID NO: 739 Probe CGTCCCATTTGAGCCTGTCAATGT SEQID NO: 740 Reverse Primer AGGTACCTCTCGGTCAGTGG SEQ ID NO: 741 EphB6NM_004445.1 Forward Primer ACTGGTCCTCCATCGGCT SEQ ID NO: 742 ProbeCCTTGCACCTCAAACCAAAGCTCC SEQ ID NO: 743 Reverse PrimerCCAGTGTAGCATGAGTGCTGA SEQ ID NO: 744 EPM2A NM_005670.2 Forward PrimerACTGTGGCACTTAGGGGAGA SEQ ID NO: 745 Probe CTGCCTCTGCCCAAAGCAAATGTC SEQID NO: 746 Reverse Primer AGTGGAAATGTGTCCTGGCT SEQ ID NO: 747 ErbB3NM_001982.1 Forward Primer CGGTTATGTCATGCCAGATACAC SEQ ID NO: 748 ProbeCCTCAAAGGTACTCCCTCCTCCCGG SEQ ID NO: 749 Reverse PrimerGAACTGAGACCCACTGAAGAAAGG SEQ ID NO: 750 ERCC1 NM_001983.1 Forward PrimerGTCCAGGTGGATGTGAAAGA SEQ ID NO: 751 Probe CAGCAGGCCCTCAAGGAGCTG SEQ IDNO: 752 Reverse Primer CGGCCAGGATACACATCTTA SEQ ID NO: 753 ERCC2NM_000400.2 Forward Primer TGGCCTTCTTCACCAGCTA SEQ ID NO: 754 ProbeAGGCCACGGTGCTCTCCATGTACT SEQ ID NO: 755 Reverse PrimerCAAGGATCCCCTGCTCATAC SEQ ID NO: 756 EREG NM_001432.1 Forward PrimerATAACAAAGTGTAGCTCTGACATGAATG SEQ ID NO: 757 ProbeTTGTTTGCATGGACAGTGCATCTATCTGGT SEQ ID NO: 758 Reverse PrimerCACACCTGCAGTAGTTTTGACTCA SEQ ID NO: 759 ERK1 Z11696.1 Forward PrimerACGGATCACAGTGGAGGAAG SEQ ID NO: 760 Probe CGCTGGCTCACCCCTACCTG SEQ IDNO: 761 Reverse Primer CTCATCCGTCGGGTCATAGT SEQ ID NO: 762 ERK2NM_002745.1 Forward Primer AGTTCTTGACCCCTGGTCCT SEQ ID NO: 763 ProbeTCTCCAGCCCGTCTTGGCTT SEQ ID NO: 764 Reverse Primer AAACGGCTCAAAGGAGTCAASEQ ID NO: 765 ESPL1 NM_012291.1 Forward Primer ACCCCCAGACCGGATCAG SEQID NO: 766 Probe CTGGCCCTCATGTCCCCTTCACG SEQ ID NO: 767 Reverse PrimerTGTAGGGCAGACTTCCTCAAACA SEQ ID NO: 768 EstR1 NM_000125.1 Forward PrimerCGTGGTGCCCCTCTATGAC SEQ ID NO: 769 Probe CTGGAGATGCTGGACGCCC SEQ ID NO:770 Reverse Primer GGCTAGTGGGCGCATGTAG SEQ ID NO: 771 ETV4 NM_001986.1Forward Primer TCCAGTGCCTATGACCCC SEQ ID NO: 772 ProbeCAGACAAATCGCCATCAAGTCCCC SEQ ID NO: 773 Reverse PrimerACTGTCCAAGGGCACCAG SEQ ID NO: 774 F3 NM_001993.2 Forward PrimerGTGAAGGATGTGAAGCAGACGTA SEQ ID NO: 775 Probe TGGCACGGGTCTTCTCCTACC SEQID NO: 776 Reverse Primer AACCGGTGCTCTCCACATTC SEQ ID NO: 777 FABP4NM_001442.1 Forward Primer GCTTTGCCACCAGGAAAGT SEQ ID NO: 778 ProbeCTGGCATGGCCAAACCTAACATGA SEQ ID NO: 779 Reverse PrimerCATCCCCATTCACACTGATG SEQ ID NO: 780 FAP NM_004460.2 Forward PrimerCTGACCAGAACCACGGCT SEQ ID NO: 781 Probe CGGCCTGTCCACGAACCACTTATA SEQ IDNO: 782 Reverse Primer GGAAGTGGGTCATGTGGG SEQ ID NO: 783 fas NM_000043.1Forward Primer GGATTGCTCAACAACCATGCT SEQ ID NO: 784 ProbeTCTGGACCCTCCTACCTCTGGTTCTTACGCT SEQ ID NO: 785 Reverse PrimerGGCATTAACACTTTTGGACGATAA SEQ ID NO: 786 fasl NM_000639.1 Forward PrimerGCACTTTGGGATTCTTTCCATTAT SEQ ID NO: 787 ProbeACAACATTCTCGGTGCCTGTAACAAAGAA SEQ ID NO: 788 Reverse PrimerGCATGTAAGAAGACCCTCACTGAA SEQ ID NO: 789 FASN NM_004104.4 Forward PrimerGCCTCTTCCTGTTCGACG SEQ ID NO: 790 Probe TCGCCCACCTACGTACTGGCCTAC SEQ IDNO: 791 Reverse Primer GCTTTGCCCGGTAGCTCT SEQ ID NO: 792 FBXO5NM_012177.2 Forward Primer GGCTATTCCTCATTTTCTCTACAAAGTG SEQ ID NO: 793Probe CCTCCAGGAGGCTACCTTCTTCATGTTCAC SEQ ID NO: 794 Reverse PrimerGGATTGTAGACTGTCACCGAAATTC SEQ ID NO: 795 FBXW7 NM_033632.1 ForwardPrimer CCCCAGTTTCAACGAGACTT SEQ ID NO: 796 ProbeTCATTGCTCCCTAAAGAGTTGGCACTC SEQ ID NO: 797 Reverse PrimerGTTCCAGGAATGAAAGCACA SEQ ID NO: 798 FDXR NM_004110.2 Forward PrimerGAGATGATTCAGTTACCGGGAG SEQ ID NO: 799 Probe AATCCACAGGATCCAAAATGGGCC SEQID NO: 800 Reverse Primer ATCTTGTCCTGGAGACCCAA SEQ ID NO: 801 FESNM_002005.2 Forward Primer CTCTGCAGGCCTAGGTGC SEQ ID NO: 802 ProbeCTCCTCAGCGGCTCCAGCTCATAT SEQ ID NO: 803 Reverse PrimerCCAGGACTGTGAAGAGCTGTC SEQ ID NO: 804 FGF18 NM_003862.1 Forward PrimerCGGTAGTCAAGTCCGGATCAA SEQ ID NO: 805 Probe CAAGGAGACGGAATTCTACCTGTGC SEQID NO: 806 Reverse Primer GCTTGCCTTTGCGGTTCA SEQ ID NO: 807 FGF2NM_002006.2 Forward Primer AGATGCAGGAGAGAGGAAGC SEQ ID NO: 808 ProbeCCTGCAGACTGCTTTTTGCCCAAT SEQ ID NO: 809 Reverse PrimerGTTTTGCAGCCTTACCCAAT SEQ ID NO: 810 FGFR1 NM_023109.1 Forward PrimerCACGGGACATTCACCACATC SEQ ID NO: 811 Probe ATAAAAAGACAACCAACGGCCGACTGCSEQ ID NO: 812 Reverse Primer GGGTGCCATCCACTTCACA SEQ ID NO: 813 FGFR2NM_000141.2 Forward Primer GAGGGACTGTTGGCATGCA SEQ ID NO: 814 isoform 1Probe TCCCAGAGACCAACGTTCAAGCAGTTG SEQ ID NO: 815 Reverse PrimerGAGTGAGAATTCGATCCAAGTCTTC SEQ ID NO: 816 FHIT NM_002012.1 Forward PrimerCCAGTGGAGCGCTTCCAT SEQ ID NO: 817 Probe TCGGCCACTTCATCAGGACGCAG SEQ IDNO: 818 Reverse Primer CTCTCTGGGTCGTCTGAAACAA SEQ ID NO: 819 FIGFNM_004469.2 Forward Primer GGTTCCAGCTTTCTGTAGCTGT SEQ ID NO: 820 ProbeATTGGTGGCCACACCACCTCCTTA SEQ ID NO: 821 Reverse PrimerGCCGCAGGTTCTAGTTGCT SEQ ID NO: 822 FLJ12455 NM_022078.1 Forward PrimerCCACCAGCATGAAGTTTCG SEQ ID NO: 823 Probe ACCCCTCACAAAGGCCATGTCTGT SEQ IDNO: 824 Reverse Primer GGCTGTCTGAAGCACAACTG SEQ ID NO: 825 FLJ20712AK000719.1 Forward Primer GCCACACAAACATGCTCCT SEQ ID NO: 826 ProbeATGTCTTTCCCAGCAGCTCTGCCT SEQ ID NO: 827 Reverse PrimerGCCACAGGAAACTTCCGA SEQ ID NO: 828 FLT1 NM_002019.1 Forward PrimerGGCTCCCGAATCTATCTTTG SEQ ID NO: 829 Probe CTACAGCACCAAGAGCGACGTGTG SEQID NO: 830 Reverse Primer TCCCACAGCAATACTCCGTA SEQ ID NO: 831 FLT4NM_002020.1 Forward Primer ACCAAGAAGCTGAGGACCTG SEQ ID NO: 832 ProbeAGCCCGCTGACCATGGAAGATCT SEQ ID NO: 833 Reverse PrimerCCTGGAAGCTGTAGCAGACA SEQ ID NO: 834 FOS NM_005252.2 Forward PrimerCGAGCCCTTTGATGACTTCCT SEQ ID NO: 835 Probe TCCCAGCATCATCCAGGCCCAG SEQ IDNO: 836 Reverse Primer GGAGCGGGCTGTCTCAGA SEQ ID NO: 837 FOXO3ANM_001455.1 Forward Primer TGAAGTCCAGGACGATGATG SEQ ID NO: 838 ProbeCTCTACAGCAGCTCAGCCAGCCTG SEQ ID NO: 839 Reverse PrimerACGGCTTGCTTACTGAAGGT SEQ ID NO: 840 FPGS NM_004957.3 Forward PrimerCAGCCCTGCCAGTTTGAC SEQ ID NO: 841 Probe ATGCCGTCTTCTGCCCTAACCTGA SEQ IDNO: 842 Reverse Primer GTTGCCTGTGGATGACACC SEQ ID NO: 843 FRP1NM_003012.2 Forward Primer TTGGTACCTGTGGGTTAGCA SEQ ID NO: 844 ProbeTCCCCAGGGTAGAATTCAATCAGAGC SEQ ID NO: 845 Reverse PrimerCACATCCAAATGCAAACTGG SEQ ID NO: 846 FST NM_006350.2 Forward PrimerGTAAGTCGGATGAGCCTGTCTGT SEQ ID NO: 847 Probe CCAGTGACAATGCCACTTATGCCAGCSEQ ID NO: 848 Reverse Primer CAGCTTCCTTCATGGCACACT SEQ ID NO: 849 FurinNM_002569.1 Forward Primer AAGTCCTCGATACGCACTATAGCA SEQ ID NO: 850 ProbeCCCGGATGGTCTCCACGTCAT SEQ ID NO: 851 Reverse Primer CTGGCATGTGGCACATGAGSEQ ID NO: 852 FUS NM_004960.1 Forward Primer GGATAATTCAGACAACAACACCATCTSEQ ID NO: 853 Probe TCAATTGTAACATTCTCACCCAGGCCTTG SEQ ID NO: 854Reverse Primer TGAAGTAATCAGCCACAGACTCAAT SEQ ID NO: 855 FUT1 NM_000148.1Forward Primer CCGTGCTCATTGCTAACCA SEQ ID NO: 856 ProbeTCTGTCCCTGAACTCCCAGAACCA SEQ ID NO: 857 Reverse PrimerCTGCCCAAAGCCAGATGTA SEQ ID NO: 858 FUT3 NM_000149.1 Forward PrimerCAGTTCGGTCCAACAGAGAA SEQ ID NO: 859 Probe AGCAGGCAACCACCATGTCATTTG SEQID NO: 860 Reverse Primer TGCGAATTATATCCCGATGA SEQ ID NO: 861 FUT6NM_000150.1 Forward Primer CGTGTGTCTCAAGACGATCC SEQ ID NO: 862 ProbeTGTGTACCCTAATGGGTCCCGCTT SEQ ID NO: 863 Reverse PrimerGGTCCCTGTGCTGTCTGG SEQ ID NO: 864 FXYD5 NM_014164.4 Forward PrimerAGAGCACCAAAGCAGCTCAT SEQ ID NO: 865 Probe CACTGATGACACCACGACGCTCTC SEQID NO: 866 Reverse Primer GTGCTTGGGGATGGTCTCT SEQ ID NO: 867 FYNNM_002037.3 Forward Primer GAAGCGCAGATCATGAAGAA SEQ ID NO: 868 ProbeCTGAAGCACGACAAGCTGGTCCAG SEQ ID NO: 869 Reverse PrimerCTCCTCAGACACCACTGCAT SEQ ID NO: 870 FZD1 NM_003505.1 Forward PrimerGGTGCACCAGTTCTACCCTC SEQ ID NO: 871 Probe ACTTGAGCTCAGCGGAACACTGCA SEQID NO: 872 Reverse Primer GCGTACATGGAGCACAGGA SEQ ID NO: 873 FZD2NM_001466.2 Forward Primer TGGATCCTCACCTGGTCG SEQ ID NO: 874 ProbeTGCGCTTCCACCTTCTTCACTGTC SEQ ID NO: 875 Reverse PrimerGCGCTGCATGTCTACCAA SEQ ID NO: 876 FZD6 NM_003506.2 Forward PrimerAATGAGAGAGGTGAAAGCGG SEQ ID NO: 877 Probe CGGAGCTAGCACCCCCAGGTTAAG SEQID NO: 878 Reverse Primer AGGTTCACCACAGTCCTGTTC SEQ ID NO: 879 G-CateninNM_002230.1 Forward Primer TCAGCAGCAAGGGCATCAT SEQ ID NO: 880 ProbeCGCCCGCAGGCCTCATCCT SEQ ID NO: 881 Reverse PrimerGGTGGTTTTCTTGAGCGTGTACT SEQ ID NO: 882 G1P2 NM_005101.1 Forward PrimerCAACGAATTCCAGGTGTCC SEQ ID NO: 883 Probe CTGAGCAGCTCCATGTCGGTGTC SEQ IDNO: 884 Reverse Primer GATCTGCGCCTTCAGCTC SEQ ID NO: 885 GADD45NM_001924.2 Forward Primer GTGCTGGTGACGAATCCA SEQ ID NO: 886 ProbeTTCATCTCAATGGAAGGATCCTGCC SEQ ID NO: 887 Reverse PrimerCCCGGCAAAAACAAATAAGT SEQ ID NO: 888 GADD45B NM_015675.1 Forward PrimerACCCTCGACAAGACCACACT SEQ ID NO: 889 Probe AACTTCAGCCCCAGCTCCCAAGTC SEQID NO: 890 Reverse Primer TGGGAGTTCATGGGTACAGA SEQ ID NO: 891 GADD45GNM_006705.2 Forward Primer CGCGCTGCAGATCCATTT SEQ ID NO: 892 ProbeCGCTGATCCAGGCTTTCTGCTGC SEQ ID NO: 893 Reverse PrimerCGCACTATGTCGATGTCGTTCT SEQ ID NO: 894 GAGE4 NM_001474.1 Forward PrimerGGAACAGGGTCACCCACAGA SEQ ID NO: 895 Probe TCAGGACCATCTTCACACTCACACCCASEQ ID NO: 896 Reverse Primer GATTTGGCGGGTCCATCTC SEQ ID NO: 897 GBP1NM_002053.1 Forward Primer TTGGGAAATATTTGGGCATT SEQ ID NO: 898 ProbeTTGGGACATTGTAGACTTGGCCAGAC SEQ ID NO: 899 Reverse PrimerAGAAGCTAGGGTGGTTGTCC SEQ ID NO: 900 GBP2 NM_004120.2 Forward PrimerGCATGGGAACCATCAACCA SEQ ID NO: 901 Probe CCATGGACCAACTTCACTATGTGACAGAGCSEQ ID NO: 902 Reverse Primer TGAGGAGTTTGCCTTGATTCG SEQ ID NO: 903 GCLCNM_001498.1 Forward Primer CTGTTGCAGGAAGGCATTGA SEQ ID NO: 904 ProbeCATCTCCTGGCCCAGCATGTT SEQ ID NO: 905 Reverse PrimerGTCAGTGGGTCTCTAATAAAGAGATGAG SEQ ID NO: 906 GCLM NM_002061.1 ForwardPrimer TGTAGAATCAAACTCTTCATCATCAACTAG SEQ ID NO: 907 ProbeTGCAGTTGACATGGCCTGTTCAGTCC SEQ ID NO: 908 Reverse PrimerCACAGAATCCAGCTGTGCAACT SEQ ID NO: 909 GCNT1 NM_001490.3 Forward PrimerTGGTGCTTGGAGCATAGAAG SEQ ID NO: 910 Probe TGCCCTTCACAAAGGAAATCCCTG SEQID NO: 911 Reverse Primer GCAACGTCCTCAGCATTTC SEQ ID NO: 912 GDF15NM_004864.1 Forward Primer CGCTCCAGACCTATGATGACT SEQ ID NO: 913 ProbeTGTTAGCCAAAGACTGCCACTGCA SEQ ID NO: 914 Reverse PrimerACAGTGGAAGGACCAGGACT SEQ ID NO: 915 GIT1 NM_014030.2 Forward PrimerGTGTATGACGAGGTGGATCG SEQ ID NO: 916 Probe AGCCAGCCACACTGCATCATTTTC SEQID NO: 917 Reverse Primer ACCAGAGTGCTGTGGTTTTG SEQ ID NO: 918 GJA1NM_000165.2 Forward Primer GTTCACTGGGGGTGTATGG SEQ ID NO: 919 ProbeATCCCCTCCCTCTCCACCCATCTA SEQ ID NO: 920 Reverse PrimerAAATACCAACATGCACCTCTCTT SEQ ID NO: 921 GJB2 NM_004004.3 Forward PrimerTGTCATGTACGACGGCTTCT SEQ ID NO: 922 Probe AGGCGTTGCACTTCACCAGCC SEQ IDNO: 923 Reverse Primer AGTCCACAGTGTTGGGACAA SEQ ID NO: 924 GPX1NM_000581.2 Forward Primer GCTTATGACCGACCCCAA SEQ ID NO: 925 ProbeCTCATCACCTGGTCTCCGGTGTGT SEQ ID NO: 926 Reverse PrimerAAAGTTCCAGGCAACATCGT SEQ ID NO: 927 GPX2 NM_002083.1 Forward PrimerCACACAGATCTCCTACTCCATCCA SEQ ID NO: 928 Probe CATGCTGCATCCTAAGGCTCCTCAGGSEQ ID NO: 929 Reverse Primer GGTCCAGCAGTGTCTCCTGAA SEQ ID NO: 930 Grb10NM_005311.2 Forward Primer CTTCGCCTTTGCTGATTGC SEQ ID NO: 931 ProbeCTCCAAACGCCTGCCTGACGACTG SEQ ID NO: 932 Reverse PrimerCCATAACGCACATGCTCCAA SEQ ID NO: 933 GRB14 NM_004490.1 Forward PrimerTCCCACTGAAGCCCTTTCAG SEQ ID NO: 934 Probe CCTCCAAGCGAGTCCTTCTTCAACCG SEQID NO: 935 Reverse Primer AGTGCCCAGGCGTAAACATC SEQ ID NO: 936 GRB2NM_002086.2 Forward Primer GTCCATCAGTGCATGACGTT SEQ ID NO: 937 ProbeAGGCCACGTATAGTCCTAGCTGACGC SEQ ID NO: 938 Reverse PrimerAGCCCACTTGGTTTCTTGTT SEQ ID NO: 939 GRB7 NM_005310.1 Forward PrimerCCATCTGCATCCATCTTGTT SEQ ID NO: 940 Probe CTCCCCACCCTTGAGAAGTGCCT SEQ IDNO: 941 Reverse Primer GGCCACCAGGGTATTATCTG SEQ ID NO: 942 GRIK1NM_000830.2 Forward Primer GTTGGGTGCATCTCTCGG SEQ ID NO: 943 ProbeAATTCATGCCGAGATACAGCCGCT SEQ ID NO: 944 Reverse PrimerCGTGCTCCATCTTCCTAGCTT SEQ ID NO: 945 GRO1 NM_001511.1 Forward PrimerCGAAAAGATGCTGAACAGTGACA SEQ ID NO: 946 ProbeCTTCCTCCTCCCTTCTGGTCAGTTGGAT SEQ ID NO: 947 Reverse PrimerTCAGGAACAGCCACCAGTGA SEQ ID NO: 948 GRP NM_002091.1 Forward PrimerCTGGGTCTCATAGAAGCAAAGGA SEQ ID NO: 949 Probe AGAAACCACCAGCCACCTCAACCCASEQ ID NO: 950 Reverse Primer CCACGAAGGCTGCTGATTG SEQ ID NO: 951 GRPRNM_005314.1 Forward Primer ATGCTGCTGGCCATTCCA SEQ ID NO: 952 ProbeCCGTGTTTTCTGACCTCCATCCCTTCC SEQ ID NO: 953 Reverse PrimerAGGTCTGGTTGGTGCTTTCCT SEQ ID NO: 954 GSK3B NM_002093.2 Forward PrimerGACAAGGACGGCAGCAAG SEQ ID NO: 955 Probe CCAGGAGTTGCCACCACTGTTGTC SEQ IDNO: 956 Reverse Primer TTGTGGCCTGTCTGGACC SEQ ID NO: 957 GSTA3NM_000847.3 Forward Primer TCTCCAACTTCCCTCTGCTG SEQ ID NO: 958 ProbeAGGCCCTGAAAACCAGAATCAGCA SEQ ID NO: 959 Reverse PrimerACTTCTTCACCGTGGGCA SEQ ID NO: 960 GSTM1 NM_000561.1 Forward PrimerAAGCTATGAGGAAAAGAAGTACACGAT SEQ ID NO: 961 ProbeTCAGCCACTGGCTTCTGTCATAATCAGGAG SEQ ID NO: 962 Reverse PrimerGGCCCAGCTTGAATTTTTCA SEQ ID NO: 963 GSTM3 NM_000849.3 Forward PrimerCAATGCCATCTTGCGCTACAT SEQ ID NO: 964 Probe CTCGCAAGCACAACATGTGTGGTGAGASEQ ID NO: 965 Reverse Primer GTCCACTCGAATCTTTTCTTCTTCA SEQ ID NO: 966GSTp NM_000852.2 Forward Primer GAGACCCTGCTGTCCCAGAA SEQ ID NO: 967Probe TCCCACAATGAAGGTCTTGCCTCCCT SEQ ID NO: 968 Reverse PrimerGGTTGTAGTCAGCGAAGGAGATC SEQ ID NO: 969 GSTT1 NM_000853.1 Forward PrimerCACCATCCCCACCCTGTCT SEQ ID NO: 970 Probe CACAGCCGCCTGAAAGCCACAAT SEQ IDNO: 971 Reverse Primer GGCCTCAGTGTGCATCATTCT SEQ ID NO: 972 H2AFZNM_002106.2 Forward Primer CCGGAAAGGCCAAGACAA SEQ ID NO: 973 ProbeCCCGCTCGCAGAGAGCCGG SEQ ID NO: 974 Reverse Primer AATACGGCCCACTGGGAACTSEQ ID NO: 975 HB-EGF NM_001945.1 Forward Primer GACTCCTTCGTCCCCAGTTGSEQ ID NO: 976 Probe TTGGGCCTCCCATAATTGCTTTGCC SEQ ID NO: 977 ReversePrimer TGGCACTTGAAGGCTCTGGTA SEQ ID NO: 978 hCRA a U78556.1 ForwardPrimer TGACACCCTTACCTTCCTGAGAA SEQ ID NO: 979 ProbeTCTGCTTTCCGCGCTCCCAGG SEQ ID NO: 980 Reverse PrimerAAAAACACGAGTCAAAAATAGAAGTCACT SEQ ID NO: 981 HDAC1 NM_004964.2 ForwardPrimer CAAGTACCACAGCGATGACTACATTAA SEQ ID NO: 982 ProbeTTCTTGCGCTCCATCCGTCCAGA SEQ ID NO: 983 Reverse PrimerGCTTGCTGTACTCCGACATGTT SEQ ID NO: 984 HDAC2 NM_001527.1 Forward PrimerGGTGGCTACACAATCCGTAA SEQ ID NO: 985 Probe TGCAGTCTCATATGTCCAACATCGAGCSEQ ID NO: 986 Reverse Primer TGGGAATCTCACAATCAAGG SEQ ID NO: 987 HDGFNM_004494.1 Forward Primer TCCTAGGCATTCTGGACCTC SEQ ID NO: 988 ProbeCATTCCTACCCCTGATCCCAACCC SEQ ID NO: 989 Reverse PrimerGCTGTTGATGCTCCATCCTT SEQ ID NO: 990 hENT1 NM_004955.1 Forward PrimerAGCCGTGACTGTTGAGGTC SEQ ID NO: 991 Probe AAGTCCAGCATCGCAGGCAGC SEQ IDNO: 992 Reverse Primer AAGTAACGTTCCCAGGTGCT SEQ ID NO: 993 HepsinNM_002151.1 Forward Primer AGGCTGCTGGAGGTCATCTC SEQ ID NO: 994 ProbeCCAGAGGCCGTTTCTTGGCCG SEQ ID NO: 995 Reverse Primer CTTCCTGCGGCCACAGTCTSEQ ID NO: 996 HER2 NM_004448.1 Forward Primer CGGTGTGAGAAGTGCAGCAA SEQID NO: 997 Probe CCAGACCATAGCACACTCGGGCAC SEQ ID NO: 998 Reverse PrimerCCTCTCGCAAGTGCTCCAT SEQ ID NO: 999 Herstatin AF177761.2 Forward PrimerCACCCTGTCCTATCCTTCCT SEQ ID NO: 1000 Probe CCCTCTTGGGACCTAGTCTCTGCCT SEQID NO: 1001 Reverse Primer GGCCAGGGGTAGAGAGTAGA SEQ ID NO: 1002 HES6NM_018645.3 Forward Primer TTAGGGACCCTGCAGCTCT SEQ ID NO: 1003 ProbeTAGCTCCCTCCCTCCACCCACTC SEQ ID NO: 1004 Reverse PrimerCTACAAAATTCTTCCTCCTGCC SEQ ID NO: 1005 HGF M29145.1 Forward PrimerCCGAAATCCAGATGATGATG SEQ ID NO: 1006 Probe CTCATGGACCCTGGTGCTACACG SEQID NO: 1007 Reverse Primer CCCAAGGAATGAGTGGATTT SEQ ID NO: 1008 HIF1ANM_001530.1 Forward Primer TGAACATAAAGTCTGCAACATGGA SEQ ID NO: 1009Probe TTGCACTGCACAGGCCACATTCAC SEQ ID NO: 1010 Reverse PrimerTGAGGTTGGTTACTGTTGGTATCATATA SEQ ID NO: 1011 HK1 NM_000188.1 ForwardPrimer TACGCACAGAGGCAAGCA SEQ ID NO: 1012 Probe TAAGAGTCCGGGATCCCCAGCCTASEQ ID NO: 1013 Reverse Primer GAGAGAAGTGCTGGAGAGGC SEQ ID NO: 1014HLA-DPB1 NM_002121.4 Forward Primer TCCATGATGGTTCTGCAGGTT SEQ ID NO:1015 Probe CCCCGGACAGTGGCTCTGACG SEQ ID NO: 1016 Reverse PrimerTGAGCAGCACCATCAGTAACG SEQ ID NO: 1017 HLA-DRA NM_019111.3 Forward PrimerGACGATTTGCCAGCTTTGAG SEQ ID NO: 1018 Probe TCAAGGTGCATTGGCCAACATAGC SEQID NO: 1019 Reverse Primer TCCAGGTTGGCTTTGTCC SEQ ID NO: 1020 HLA-DRB1NM_002124.1 Forward Primer GCTTTCTCAGGACCTGGTTG SEQ ID NO: 1021 ProbeCATTTTCTGCAGTTGCCGAACCAG SEQ ID NO: 1022 Reverse PrimerAGGAAGCCACAAGGGAGG SEQ ID NO: 1023 HLA-G NM_002127.2 Forward PrimerCCTGCGCGGCTACTACAAC SEQ ID NO: 1024 Probe CGAGGCCAGTTCTCACACCCTCCAG SEQID NO: 1025 Reverse Primer CAGGTCGCAGCCAATCATC SEQ ID NO: 1026 HMGB1NM_002128.3 Forward Primer TGGCCTGTCCATTGGTGAT SEQ ID NO: 1027 ProbeTTCCACATCTCTCCCAGTTTCTTCGCAA SEQ ID NO: 1028 Reverse PrimerGCTTGTCATCTGCAGCAGTGTT SEQ ID NO: 1029 hMLH NM_000249.2 Forward PrimerCTACTTCCAGCAACCCCAGA SEQ ID NO: 1030 Probe TCCACATCAGAATCTTCCCG SEQ IDNO: 1031 Reverse Primer CTTTCGGGAATCATCTTCCA SEQ ID NO: 1032 HNRPABNM_004499.2 Forward Primer CAAGGGAGCGACCAACTGA SEQ ID NO: 1033 ProbeCTCCATATCCAAACAAAGCATGTGTGCG SEQ ID NO: 1034 Reverse PrimerGTTTGCCAAGTTAAATTTGGTACATAAT SEQ ID NO: 1035 HNRPD NM_031370.2 ForwardPrimer GCCAGTAAGAACGAGGAGGA SEQ ID NO: 1036 ProbeAAGGCCATTCAAACTCCTCCCCAC SEQ ID NO: 1037 Reverse PrimerCGTCGCTGCTTCAGAGTGT SEQ ID NO: 1038 HoxA1 NM_005522.3 Forward PrimerAGTGACAGATGGACAATGCAAGA SEQ ID NO: 1039 Probe TGAACTCCTTCCTGGAATACCCCASEQ ID NO: 1040 Reverse Primer CCGAGTCGCCACTGCTAAGT SEQ ID NO: 1041HoxA5 NM_019102.2 Forward Primer TCCCTTGTGTTCCTTCTGTGAA SEQ ID NO: 1042Probe AGCCCTGTTCTCGTTGCCCTAATTCATC SEQ ID NO: 1043 Reverse PrimerGGCAATAAACAGGCTCATGATTAA SEQ ID NO: 1044 HOXB13 NM_006361.2 ForwardPrimer CGTGCCTTATGGTTACTTTGG SEQ ID NO: 1045 ProbeACACTCGGCAGGAGTAGTACCCGC SEQ ID NO: 1046 Reverse PrimerCACAGGGTTTCAGCGAGC SEQ ID NO: 1047 HOXB7 NM_004502.2 Forward PrimerCAGCCTCAAGTTCGGTTTTC SEQ ID NO: 1048 Probe ACCGGAGCCTTCCCAGAACAAACT SEQID NO: 1049 Reverse Primer GTTGGAAGCAAACGCACA SEQ ID NO: 1050 HRASNM_005343.2 Forward Primer GGACGAATACGACCCCACT SEQ ID NO: 1051 ProbeACCACCTGCTTCCGGTAGGAATCC SEQ ID NO: 1052 Reverse PrimerGCACGTCTCCCCATCAAT SEQ ID NO: 1053 HSBP1 NM_001537.1 Forward PrimerGGAGATGGCCGAGACTGAC SEQ ID NO: 1054 Probe CAAGACCGTGCAGGACCTCACCT SEQ IDNO: 1055 Reverse Primer CTGCAGGAGTGTCTGCACC SEQ ID NO: 1056 HSD17B1NM_000413.1 Forward Primer CTGGACCGCACGGACATC SEQ ID NO: 1057 ProbeACCGCTTCTACCAATACCTCGCCCA SEQ ID NO: 1058 Reverse PrimerCGCCTCGCGAAAGACTTG SEQ ID NO: 1059 HSD17B2 NM_002153.1 Forward PrimerGCTTTCCAAGTGGGGAATTA SEQ ID NO: 1060 Probe AGTTGCTTCCATCCAACCTGGAGG SEQID NO: 1061 Reverse Primer TGCCTGCGATATTTGTTAGG SEQ ID NO: 1062 HSPA1ANM_005345.4 Forward Primer CTGCTGCGACAGTCCACTA SEQ ID NO: 1063 ProbeAGAGTGACTCCCGTTGTCCCAAGG SEQ ID NO: 1064 Reverse PrimerCAGGTTCGCTCTGGGAAG SEQ ID NO: 1065 HSPA1B NM_005346.3 Forward PrimerGGTCCGCTTCGTCTTTCGA SEQ ID NO: 1066 Probe TGACTCCCGCGGTCCCAAGG SEQ IDNO: 1067 Reverse Primer GCACAGGTTCGCTCTGGAA SEQ ID NO: 1068 HSPA4NM_002154.3 Forward Primer TTCAGTGTGTCCAGTGCATC SEQ ID NO: 1069 ProbeCATTTTCCTCAGACTTGTGAACCTCCACT SEQ ID NO: 1070 Reverse PrimerATCTGTTTCCATTGGCTCCT SEQ ID NO: 1071 HSPA5 NM_005347.2 Forward PrimerGGCTAGTAGAACTGGATCCCAACA SEQ ID NO: 1072 ProbeTAATTAGACCTAGGCCTCAGCTGCACTGCC SEQ ID NO: 1073 Reverse PrimerGGTCTGCCCAAATGCTTTTC SEQ ID NO: 1074 HSPA8 NM_006597.3 Forward PrimerCCTCCCTCTGGTGGTGCTT SEQ ID NO: 1075 Probe CTCAGGGCCCACCATTGAAGAGGTTG SEQID NO: 1076 Reverse Primer GCTACATCTACACTTGGTTGGCTTAA SEQ ID NO: 1077HSPB1 NM_001540.2 Forward Primer CCGACTGGAGGAGCATAAA SEQ ID NO: 1078Probe CGCACTTTTCTGAGCAGACGTCCA SEQ ID NO: 1079 Reverse PrimerATGCTGGCTGACTCTGCTC SEQ ID NO: 1080 HSPCA NM_005348.2 Forward PrimerCAAAAGGCAGAGGCTGATAA SEQ ID NO: 1081 Probe TGACCAGATCCTTCACAGACTTGTCGTSEQ ID NO: 1082 Reverse Primer AGCGCAGTTTCATAAAGCAA SEQ ID NO: 1083HSPE1 NM_002157.1 Forward Primer GCAAGCAACAGTAGTCGCTG SEQ ID NO: 1084Probe TCTCCACCCTTTCCTTTAGAACCCG SEQ ID NO: 1085 Reverse PrimerCCAACTTTCACGCTAACTGGT SEQ ID NO: 1086 HSPG2 NM_005529.2 Forward PrimerGAGTACGTGTGCCGAGTGTT SEQ ID NO: 1087 Probe CAGCTCCGTGCCTCTAGAGGCCT SEQID NO: 1088 Reverse Primer CTCAATGGTGACCAGGACA SEQ ID NO: 1089 ICAM1NM_000201.1 Forward Primer GCAGACAGTGACCATCTACAGCTT SEQ ID NO: 1090Probe CCGGCGCCCAACGTGATTCT SEQ ID NO: 1091 Reverse PrimerCTTCTGAGACCTCTGGCTTCGT SEQ ID NO: 1092 ICAM2 NM_000873.2 Forward PrimerGGTCATCCTGACACTGCAAC SEQ ID NO: 1093 Probe TTGCCCACAGCCACCAAAGTG SEQ IDNO: 1094 Reverse Primer TGCACTCAATGGTGAAGGAC SEQ ID NO: 1095 ID1NM_002165.1 Forward Primer AGAACCGCAAGGTGAGCAA SEQ ID NO: 1096 ProbeTGGAGATTCTCCAGCACGTCATCGAC SEQ ID NO: 1097 Reverse PrimerTCCAACTGAAGGTCCCTGATG SEQ ID NO: 1098 ID2 NM_002166.1 Forward PrimerAACGACTGCTACTCCAAGCTCAA SEQ ID NO: 1099 Probe TGCCCAGCATCCCCCAGAACAA SEQID NO: 1100 Reverse Primer GGATTTCCATCTTGCTCACCTT SEQ ID NO: 1101 ID3NM_002167.2 Forward Primer CTTCACCAAATCCCTTCCTG SEQ ID NO: 1102 ProbeTCACAGTCCTTCGCTCCTGAGCAC SEQ ID NO: 1103 Reverse PrimerCTCTGGCTCTTCAGGCTACA SEQ ID NO: 1104 ID4 NM_001546.2 Forward PrimerTGGCCTGGCTCTTAATTTG SEQ ID NO: 1105 Probe CTTTTGTTTTGCCCAGTATAGACTCGGAAGSEQ ID NO: 1106 Reverse Primer TGCAATCATGCAAGACCAC SEQ ID NO: 1107 IFIT1NM_001548.1 Forward Primer TGACAACCAAGCAAATGTGA SEQ ID NO: 1108 ProbeAAGTTGCCCCAGGTCACCAGACTC SEQ ID NO: 1109 Reverse PrimerCAGTCTGCCCATGTGGTAAT SEQ ID NO: 1110 IGF1 NM_000618.1 Forward PrimerTCCGGAGCTGTGATCTAAGGA SEQ ID NO: 1111 Probe TGTATTGCGCACCCCTCAAGCCTG SEQID NO: 1112 Reverse Primer CGGACAGAGCGAGCTGACTT SEQ ID NO: 1113 IGF1RNM_000875.2 Forward Primer GCATGGTAGCCGAAGATTTCA SEQ ID NO: 1114 ProbeCGCGTCATACCAAAATCTCCGATTTTGA SEQ ID NO: 1115 Reverse PrimerTTTCCGGTAATAGTCTGTCTCATAGATATC SEQ ID NO: 1116 IGF2 NM_000612.2 ForwardPrimer CCGTGCTTCCGGACAACTT SEQ ID NO: 1117 ProbeTACCCCGTGGGCAAGTTCTTCCAA SEQ ID NO: 1118 Reverse PrimerTGGACTGCTTCCAGGTGTCA SEQ ID NO: 1119 IGFBP2 NM_000597.1 Forward PrimerGTGGACAGCACCATGAACA SEQ ID NO: 1120 Probe CTTCCGGCCAGCACTGCCTC SEQ IDNO: 1121 Reverse Primer CCTTCATACCCGACTTGAGG SEQ ID NO: 1122 IGFBP3NM_000598.1 Forward Primer ACGCACCGGGTGTCTGA SEQ ID NO: 1123 ProbeCCCAAGTTCCACCCCCTCCATTCA SEQ ID NO: 1124 Reverse PrimerTGCCCTTTCTTGATGATGATTATC SEQ ID NO: 1125 IGFBP5 NM_000599.1 ForwardPrimer TGGACAAGTACGGGATGAAGCT SEQ ID NO: 1126 ProbeCCCGTCAACGTACTCCATGCCTGG SEQ ID NO: 1127 Reverse PrimerCGAAGGTGTGGCACTGAAAGT SEQ ID NO: 1128 IGFBP6 NM_002178.1 Forward PrimerTGAACCGCAGAGACCAACAG SEQ ID NO: 1129 Probe ATCCAGGCACCTCTACCACGCCCTC SEQID NO: 1130 Reverse Primer GTCTTGGACACCCGCAGAAT SEQ ID NO: 1131 IGFBP7NM_001553 Forward Primer GGGTCACTATGGAGTTCAAAGGA SEQ ID NO: 1132 ProbeCCCGGTCACCAGGCAGGAGTTCT SEQ ID NO: 1133 Reverse PrimerGGGTCTGAATGGCCAGGTT SEQ ID NO: 1134 IHH NM_002181.1 Forward PrimerAAGGACGAGGAGAACACAGG SEQ ID NO: 1135 Probe ATGACCCAGCGCTGCAAGGAC SEQ IDNO: 1136 Reverse Primer AGATAGCCAGCGAGTTCAGG SEQ ID NO: 1137 IL-8NM_000584.2 Forward Primer AAGGAACCATCTCACTGTGTGTAAAC SEQ ID NO: 1138Probe TGACTTCCAAGCTGGCCGTGGC SEQ ID NO: 1139 Reverse PrimerATCAGGAAGGCTGCCAAGAG SEQ ID NO: 1140 IL10 NM_000572.1 Forward PrimerGGCGCTGTCATCGATTTCTT SEQ ID NO: 1141 Probe CTGCTCCACGGCCTTGCTCTTG SEQ IDNO: 1142 Reverse Primer TGGAGCTTATTAAAGGCATTCTTCA SEQ ID NO: 1143 IL1BNM_000576.2 Forward Primer AGCTGAGGAAGATGCTGGTT SEQ ID NO: 1144 ProbeTGCCCACAGACCTTCCAGGAGAAT SEQ ID NO: 1145 Reverse PrimerGGAAAGAAGGTGCTCAGGTC SEQ ID NO: 1146 IL6 NM_000600.1 Forward PrimerCCTGAACCTTCCAAAGATGG SEQ ID NO: 1147 Probe CCAGATTGGAAGCATCCATCTTTTTCASEQ ID NO: 1148 Reverse Primer ACCAGGCAAGTCTCCTCATT SEQ ID NO: 1149IL6ST NM_002184.2 Forward Primer GGCCTAATGTTCCAGATCCT SEQ ID NO: 1150Probe CATATTGCCCAGTGGTCACCTCACA SEQ ID NO: 1151 Reverse PrimerAAAATTGTGCCTTGGAGGAG SEQ ID NO: 1152 ILT-2 NM_006669.1 Forward PrimerAGCCATCACTCTCAGTGCAG SEQ ID NO: 1153 Probe CAGGTCCTATCGTGGCCCCTGA SEQ IDNO: 1154 Reverse Primer ACTGCAGAGTCAGGGTCTCC SEQ ID NO: 1155 IMP-1NM_006546.2 Forward Primer GAAAGTGTTTGCGGAGCAC SEQ ID NO: 1156 ProbeCTCCTACAGCGGCCAGTTCTTGGT SEQ ID NO: 1157 Reverse PrimerGAAGGCGTAGCCGGATTT SEQ ID NO: 1158 IMP2 NM_006548.3 Forward PrimerCAATCTGATCCCAGGGTTGAA SEQ ID NO: 1159 Probe CTCAGCGCACTTGGCATCTTTTCAACASEQ ID NO: 1160 Reverse Primer GGCCCTGCTGGTGGAGATA SEQ ID NO: 1161 ING1LNM_001564.1 Forward Primer TGTTTCCAAGATCCTGCTGA SEQ ID NO: 1162 ProbeCCATCTTTGCTTTATCTGAGGCTCGTTC SEQ ID NO: 1163 Reverse PrimerTCTTTCTGGTTGGCTGGAAT SEQ ID NO: 1164 ING5 NM_032329.4 Forward PrimerCCTACAGCAAGTGCAAGGAA SEQ ID NO: 1165 Probe CCAGCTGCACTTTGTCGTCACTGT SEQID NO: 1166 Reverse Primer CATCTCGTAGGTCTGCATGG SEQ ID NO: 1167 INHANM_002191.2 Forward Primer CCTCCCAGTTTCATCTTCCACTA SEQ ID NO: 1168 ProbeATGTGCAGCCCACAACCACCATGA SEQ ID NO: 1169 Reverse PrimerAGGGACTGGAAGGGACAGGTT SEQ ID NO: 1170 INHBA NM_002192.1 Forward PrimerGTGCCCGAGCCATATAGCA SEQ ID NO: 1171 Probe ACGTCCGGGTCCTCACTGTCCTTCC SEQID NO: 1172 Reverse Primer CGGTAGTGGTTGATGACTGTTGA SEQ ID NO: 1173 INHBBNM_002193.1 Forward Primer AGCCTCCAGGATACCAGCAA SEQ ID NO: 1174 ProbeAGCTAAGCTGCCATTTGTCACCG SEQ ID NO: 1175 Reverse PrimerTCTCCGACTGACAGGCATTTG SEQ ID NO: 1176 IRS1 NM_005544.1 Forward PrimerCCACAGCTCACCTTCTGTCA SEQ ID NO: 1177 Probe TCCATCCCAGCTCCAGCCAG SEQ IDNO: 1178 Reverse Primer CCTCAGTGCCAGTCTCTTCC SEQ ID NO: 1179 ITGA3NM_002204.1 Forward Primer CCATGATCCTCACTCTGCTG SEQ ID NO: 1180 ProbeCACTCCAGACCTCGCTTAGCATGG SEQ ID NO: 1181 Reverse PrimerGAAGCTTTGTAGCCGGTGAT SEQ ID NO: 1182 ITGA4 NM_000885.2 Forward PrimerCAACGCTTCAGTGATCAATCC SEQ ID NO: 1183 Probe CGATCCTGCATCTGTAAATCGCCC SEQID NO: 1184 Reverse Primer GTCTGGCCGGGATTCTTT SEQ ID NO: 1185 ITGA5NM_002205.1 Forward Primer AGGCCAGCCCTACATTATCA SEQ ID NO: 1186 ProbeTCTGAGCCTTGTCCTCTATCCGGC SEQ ID NO: 1187 Reverse PrimerGTCTTCTCCACAGTCCAGCA SEQ ID NO: 1188 ITGA6 NM_000210.1 Forward PrimerCAGTGACAAACAGCCCTTCC SEQ ID NO: 1189 Probe TCGCCATCTTTTGTGGGATTCCTT SEQID NO: 1190 Reverse Primer GTTTAGCCTCATGGGCGTC SEQ ID NO: 1191 ITGA7NM_002206.1 Forward Primer GATATGATTGGTCGCTGCTTTG SEQ ID NO: 1192 ProbeCAGCCAGGACCTGGCCATCCG SEQ ID NO: 1193 Reverse PrimerAGAACTTCCATTCCCCACCAT SEQ ID NO: 1194 ITGAV NM_002210.2 Forward PrimerACTCGGACTGCACAAGCTATT SEQ ID NO: 1195 Probe CCGACAGCCACAGAATAACCCAAA SEQID NO: 1196 Reverse Primer TGCCATCACCATTGAAATCT SEQ ID NO: 1197 ITGB1NM_002211.2 Forward Primer TCAGAATTGGATTTGGCTCA SEQ ID NO: 1198 ProbeTGCTAATGTAAGGCATCACAGTCTTTTCCA SEQ ID NO: 1199 Reverse PrimerCCTGAGCTTAGCTGGTGTTG SEQ ID NO: 1200 ITGB3 NM_000212.1 Forward PrimerACCGGGAGCCCTACATGAC SEQ ID NO: 1201 Probe AAATACCTGCAACCGTTACTGCCGTGACSEQ ID NO: 1202 Reverse Primer CCTTAAGCTCTTTCACTGACTCAATCT SEQ ID NO:1203 ITGB4 NM_000213.2 Forward Primer CAAGGTGCCCTCAGTGGA SEQ ID NO: 1204Probe CACCAACCTGTACCCGTATTGCGA SEQ ID NO: 1205 Reverse PrimerGCGCACACCTTCATCTCAT SEQ ID NO: 1206 ITGB5 NM_002213.3 Forward PrimerTCGTGAAAGATGACCAGGAG SEQ ID NO: 1207 Probe TGCTATGTTTCTACAAAACCGCCAAGGSEQ ID NO: 1208 Reverse Primer GGTGAACATCATGACGCAGT SEQ ID NO: 1209K-ras NM_033360.2 Forward Primer GTCAAAATGGGGAGGGACTA SEQ ID NO: 1210Probe TGTATCTTGTTGAGCTATCCAAACTGCCC SEQ ID NO: 1211 Reverse PrimerCAGGACCACCACAGAGTGAG SEQ ID NO: 1212 KCNH2 iso NM_000238.2 ForwardPrimer GAGCGCAAAGTGGAAATCG SEQ ID NO: 1213 a/b ProbeTAGGAAGCAGCTCCCATCTTTCCGGTA SEQ ID NO: 1214 Reverse PrimerTCTTCACGGGCACCACATC SEQ ID NO: 1215 KCNH2 iso NM_172057.1 Forward PrimerTCCTGCTGCTGGTCATCTAC SEQ ID NO: 1216 a/c Probe TGTCTTCACACCCTACTCGGCTGCSEQ ID NO: 1217 Reverse Primer CCTTCTTCCGTCTCCTTCAG SEQ ID NO: 1218KCNK4 NM_016611.2 Forward Primer CCTATCAGCCGCTGGTGT SEQ ID NO: 1219Probe ATCCTGCTCGGCCTGGCTTACTTC SEQ ID NO: 1220 Reverse PrimerTGGTGGTGAGCACTGAGG SEQ ID NO: 1221 KDR NM_002253.1 Forward PrimerGAGGACGAAGGCCTCTACAC SEQ ID NO: 1222 Probe CAGGCATGCAGTGTTCTTGGCTGT SEQID NO: 1223 Reverse Primer AAAAATGCCTCCACTTTTGC SEQ ID NO: 1224 Ki-67NM_002417.1 Forward Primer CGGACTTTGGGTGCGACTT SEQ ID NO: 1225 ProbeCCACTTGTCGAACCACCGCTCGT SEQ ID NO: 1226 Reverse PrimerTTACAACTCTTCCACTGGGACGAT SEQ ID NO: 1227 KIAA0125 NM_014792.2 ForwardPrimer GTGTCCTGGTCCATGTGGT SEQ ID NO: 1228 ProbeCACGTGTCTCCACCTCCAAGGAGA SEQ ID NO: 1229 Reverse PrimerGGGAGGTGCACACTGAGG SEQ ID NO: 1230 KIF22 NM_007317.1 Forward PrimerCTAAGGCACTTGCTGGAAGG SEQ ID NO: 1231 Probe TCCATAGGCAAGCACACTGGCATT SEQID NO: 1232 Reverse Primer TCTTCCCAGCTCCTGTGG SEQ ID NO: 1233 KIF2CNM_006845.2 Forward Primer AATTCCTGCTCCAAAAGAAAGTCTT SEQ ID NO: 1234Probe AAGCCGCTCCACTCGCATGTCC SEQ ID NO: 1235 Reverse PrimerCGTGATGCGAAGCTCTGAGA SEQ ID NO: 1236 KIFC1 XM_371813.1 Forward PrimerCCACAGGGTTGAAGAACCAG SEQ ID NO: 1237 Probe AGCCAGTTCCTGCTGTTCCTGTCC SEQID NO: 1238 Reverse Primer CACCTGATGTGCCAGACTTC SEQ ID NO: 1239 KitlngNM_000899.1 Forward Primer GTCCCCGGGATGGATGTT SEQ ID NO: 1240 ProbeCATCTCGCTTATCCAACAATGACTTGGCA SEQ ID NO: 1241 Reverse PrimerGATCAGTCAAGCTGTCTGACAATTG SEQ ID NO: 1242 KLF5 NM_001730.3 ForwardPrimer GTGCAACCGCAGCTTCTC SEQ ID NO: 1243 Probe CTCTGACCACCTGGCCCTGCATATSEQ ID NO: 1244 Reverse Primer CGGGCAGTGCTCAGTTCT SEQ ID NO: 1245 KLF6NM_001300.4 Forward Primer CACGAGACCGGCTACTTCTC SEQ ID NO: 1246 ProbeAGTACTCCTCCAGAGACGGCAGCG SEQ ID NO: 1247 Reverse PrimerGCTCTAGGCAGGTCTGTTGC SEQ ID NO: 1248 KLK10 NM_002776.1 Forward PrimerGCCCAGAGGCTCCATCGT SEQ ID NO: 1249 Probe CCTCTTCCTCCCCAGTCGGCTGA SEQ IDNO: 1250 Reverse Primer CAGAGGTTTGAACAGTGCAGACA SEQ ID NO: 1251 KLK6NM_002774.2 Forward Primer GACGTGAGGGTCCTGATTCT SEQ ID NO: 1252 ProbeTTACCCCAGCTCCATCCTTGCATC SEQ ID NO: 1253 Reverse PrimerTCCTCACTCATCACGTCCTC SEQ ID NO: 1254 KLRK1 NM_007360.1 Forward PrimerTGAGAGCCAGGCTTCTTGTA SEQ ID NO: 1255 Probe TGTCTCAAAATGCCAGCCTTCTGAA SEQID NO: 1256 Reverse Primer ATCCTGGTCCTCTTTGCTGT SEQ ID NO: 1257 KNTC2NM_006101.1 Forward Primer ATGTGCCAGTGAGCTTGAGT SEQ ID NO: 1258 ProbeCCTTGGAGAAACACAAGCACCTGC SEQ ID NO: 1259 Reverse PrimerTGAGCCCCTGGTTAACAGTA SEQ ID NO: 1260 KRAS2 NM_004985.3 Forward PrimerGAGACCAAGGTTGCAAGGC SEQ ID NO: 1261 Probe AAGCTCAAAGGTTCACACAGGGCC SEQID NO: 1262 Reverse Primer CAGTCCATGCTGTGAAACTCTC SEQ ID NO: 1263 KRT19NM_002276.1 Forward Primer TGAGCGGCAGAATCAGGAGTA SEQ ID NO: 1264 ProbeCTCATGGACATCAAGTCGCGGCTG SEQ ID NO: 1265 Reverse PrimerTGCGGTAGGTGGCAATCTC SEQ ID NO: 1266 KRT8 NM_002273.1 Forward PrimerGGATGAAGCTTACATGAACAAGGTAGA SEQ ID NO: 1267 Probe CGTCGGTCAGCCCTTCCAGGCSEQ ID NO: 1268 Reverse Primer CATATAGCTGCCTGAGGAAGTTGAT SEQ ID NO: 1269LAMA3 NM_000227.2 Forward Primer CAGATGAGGCACATGGAGAC SEQ ID NO: 1270Probe CTGATTCCTCAGGTCCTTGGCCTG SEQ ID NO: 1271 Reverse PrimerTTGAAATGGCAGAACGGTAG SEQ ID NO: 1272 LAMB3 NM_000228.1 Forward PrimerACTGACCAAGCCTGAGACCT SEQ ID NO: 1273 Probe CCACTCGCCATACTGGGTGCAGT SEQID NO: 1274 Reverse Primer GTCACACTTGCAGCATTTCA SEQ ID NO: 1275 LAMC2NM_005562.1 Forward Primer ACTCAAGCGGAAATTGAAGCA SEQ ID NO: 1276 ProbeAGGTCTTATCAGCACAGTCTCCGCCTCC SEQ ID NO: 1277 Reverse PrimerACTCCCTGAAGCCGAGACACT SEQ ID NO: 1278 LAT NM_014387.2 Forward PrimerGTGAACGTTCCGGAGAGC SEQ ID NO: 1279 Probe ATCCAGAGACGCTTCTGCGCTCTC SEQ IDNO: 1280 Reverse Primer ACATTCACATACTCCCGGCT SEQ ID NO: 1281 LCN2NM_005564.2 Forward Primer CGCTGGGCAACATTAAGAG SEQ ID NO: 1282 ProbeTCACCACTCGGACGAGGTAACTCG SEQ ID NO: 1283 Reverse PrimerAGCATGCTGGTTGTAGTTGGT SEQ ID NO: 1284 LDLRAP1 NM_015627.1 Forward PrimerCAGTGCCTCTCGCCTGTC SEQ ID NO: 1285 Probe ACTGGGACAAGCCTGACAGCAGC SEQ IDNO: 1286 Reverse Primer TGAAGAGGTCATCCTGCTCTG SEQ ID NO: 1287 LEFNM_016269.2 Forward Primer GATGACGGAAAGCATCCAG SEQ ID NO: 1288 ProbeTGGAGGCCTCTACAACAAGGGACC SEQ ID NO: 1289 Reverse PrimerCCCGGAATAACTCGAGTAGGA SEQ ID NO: 1290 LGALS3 NM_002306.1 Forward PrimerAGCGGAAAATGGCAGACAAT SEQ ID NO: 1291 Probe ACCCAGATAACGCATCATGGAGCGA SEQID NO: 1292 Reverse Primer CTTGAGGGTTTGGGTTTCCA SEQ ID NO: 1293 LGMNNM_001008530.1 Forward Primer TTGGTGCCGTTCCTATAGATG SEQ ID NO: 1294Probe CAGTGCTTGCCTCCATCTTCAGGA SEQ ID NO: 1295 Reverse PrimerGAACCTGCCACGATCACC SEQ ID NO: 1296 LILRB3 NM_006864.1 Forward PrimerCACCTGGTCTGGGAAGATACC SEQ ID NO: 1297 Probe ACCGAGACCCCAATCAAAACCTCC SEQID NO: 1298 Reverse Primer AAGAGCAGCAGGACGAAGG SEQ ID NO: 1299 LMNB1NM_005573.1 Forward Primer TGCAAACGCTGGTGTCACA SEQ ID NO: 1300 ProbeCAGCCCCCCAACTGACCTCATC SEQ ID NO: 1301 Reverse PrimerCCCCACGAGTTCTGGTTCTTC SEQ ID NO: 1302 LMYC NM_012421.1 Forward PrimerCCCATCCAGAACACTGATTG SEQ ID NO: 1303 Probe TGACCTCCATCCCTTTCACTTGAATGSEQ ID NO: 1304 Reverse Primer CTGCTTTCTATGCACCCTTTC SEQ ID NO: 1305 LOXNM_002317.3 Forward Primer CCAATGGGAGAACAACGG SEQ ID NO: 1306 ProbeCAGGCTCAGCAAGCTGAACACCTG SEQ ID NO: 1307 Reverse PrimerCGCTGAGGCTGGTACTGTG SEQ ID NO: 1308 LOXL2 NM_002318.1 Forward PrimerTCAGCGGGCTCTTAAACAA SEQ ID NO: 1309 Probe CAGCTGTCCCCGCAGTAAAGAAGC SEQID NO: 1310 Reverse Primer AAGACAGGAGTTGACCACGC SEQ ID NO: 1311 LRP5NM_002335.1 Forward Primer CGACTATGACCCACTGGACA SEQ ID NO: 1312 ProbeCGCCCATCCACCCAGTAGATGAAC SEQ ID NO: 1313 Reverse PrimerCTTGGCTCGCTTGATGTTC SEQ ID NO: 1314 LRP6 NM_002336.1 Forward PrimerGGATGTAGCCATCTCTGCCT SEQ ID NO: 1315 Probe ATAGACCTCAGGGCCTTCGCTGTG SEQID NO: 1316 Reverse Primer AGTTCAAAGCCAATAGGGCA SEQ ID NO: 1317 LY6DNM_003695.2 Forward Primer AATGCTGATGACTTGGAGCAG SEQ ID NO: 1318 ProbeCACAGACCCCACAGAGGATGAAGC SEQ ID NO: 1319 Reverse PrimerCTGCATCCTCTGTGGGGT SEQ ID NO: 1320 MAD NM_002357.1 Forward PrimerTGGTTCTGATTAGGTAACGTATTGGA SEQ ID NO: 1321 ProbeCTGCCCACAACTCCCTTGCACGTAA SEQ ID NO: 1322 Reverse PrimerGGTCAAGGTGGGACACTGAAG SEQ ID NO: 1323 MAD1L1 NM_003550.1 Forward PrimerAGAAGCTGTCCCTGCAAGAG SEQ ID NO: 1324 Probe CATGTTCTTCACAATCGCTGCATCC SEQID NO: 1325 Reverse Primer AGCCGTACCAGCTCAGACTT SEQ ID NO: 1326 MAD2L1NM_002358.2 Forward Primer CCGGGAGCAGGGAATCAC SEQ ID NO: 1327 ProbeCGGCCACGATTTCGGCGCT SEQ ID NO: 1328 Reverse Primer ATGCTGTTGATGCCGAATGASEQ ID NO: 1329 MADH2 NM_005901.2 Forward Primer GCTGCCTTTGGTAAGAACATGTCSEQ ID NO: 1330 Probe TCCATCTTGCCATTCACGCCGC SEQ ID NO: 1331 ReversePrimer ATCCCAGCAGTCTCTTCACAACT SEQ ID NO: 1332 MADH4 NM_005359.3 ForwardPrimer GGACATTACTGGCCTGTTCACA SEQ ID NO: 1333 ProbeTGCATTCCAGCCTCCCATTTCCA SEQ ID NO: 1334 Reverse PrimerACCAATACTCAGGAGCAGGATGA SEQ ID NO: 1335 MADH7 NM_005904.1 Forward PrimerTCCATCAAGGCTTTCGACTA SEQ ID NO: 1336 Probe CTGCAGGCTGTACGCCTTCTCG SEQ IDNO: 1337 Reverse Primer CTGCTGCATAAACTCGTGGT SEQ ID NO: 1338 MAP2NM_031846.1 Forward Primer CGGACCACCAGGTCAGAG SEQ ID NO: 1339 ProbeCCACTCTTCCCTGCTCTGCGAATT SEQ ID NO: 1340 Reverse PrimerCAGGGGTAGTGGGTGTTGAG SEQ ID NO: 1341 MAP2K1 NM_002755.2 Forward PrimerGCCTTTCTTACCCAGAAGCAGAA SEQ ID NO: 1342 ProbeTCTCAAAGTCGTCATCCTTCAGTTCTCCCA SEQ ID NO: 1343 Reverse PrimerCAGCCCCCAGCTCACTGAT SEQ ID NO: 1344 MAP3K1 XM_042066.8 Forward PrimerGGTTGGCATCAAAAGGAACT SEQ ID NO: 1345 Probe AATTGTCCCTGAAACTCTCCTGCACCSEQ ID NO: 1346 Reverse Primer TGCCATAAATGCAATTGTCC SEQ ID NO: 1347MAPK14 NM_139012.1 Forward Primer TGAGTGGAAAAGCCTGACCTATG SEQ ID NO:1348 Probe TGAAGTCATCAGCTTTGTGCCACCACC SEQ ID NO: 1349 Reverse PrimerGGACTCCATCTCTTCTTGGTCAA SEQ ID NO: 1350 Maspin NM_002639.1 ForwardPrimer CAGATGGCCACTTTGAGAACATT SEQ ID NO: 1351 ProbeAGCTGACAACAGTGTGAACGACCAGACC SEQ ID NO: 1352 Reverse PrimerGGCAGCATTAACCACAAGGATT SEQ ID NO: 1353 MAX NM_002382.3 Forward PrimerCAAACGGGCTCATCATAATGC SEQ ID NO: 1354 Probe TGATGTGGTCCCTACGTTTTCGTTCCASEQ ID NO: 1355 Reverse Primer TCCCGCAAACTGTGAAAGCT SEQ ID NO: 1356 MCM2NM_004526.1 Forward Primer GACTTTTGCCCGCTACCTTTC SEQ ID NO: 1357 ProbeACAGCTCATTGTTGTCACGCCGGA SEQ ID NO: 1358 Reverse PrimerGCCACTAACTGCTTCAGTATGAAGAG SEQ ID NO: 1359 MCM3 NM_002388.2 ForwardPrimer GGAGAACAATCCCCTTGAGA SEQ ID NO: 1360 ProbeTGGCCTTTCTGTCTACAAGGATCACCA SEQ ID NO: 1361 Reverse PrimerATCTCCTGGATGGTGATGGT SEQ ID NO: 1362 MCM6 NM_005915.2 Forward PrimerTGATGGTCCTATGTGTCACATTCA SEQ ID NO: 1363 ProbeCAGGTTTCATACCAACACAGGCTTCAGCAC SEQ ID NO: 1364 Reverse PrimerTGGGACAGGAAACACACCAA SEQ ID NO: 1365 MCP1 NM_002982.1 Forward PrimerCGCTCAGCCAGATGCAATC SEQ ID NO: 1366 Probe TGCCCCAGTCACCTGCTGTTA SEQ IDNO: 1367 Reverse Primer GCACTGAGATCTTCCTATTGGTGAA SEQ ID NO: 1368 MDKNM_002391.2 Forward Primer GGAGCCGACTGCAAGTACA SEQ ID NO: 1369 ProbeATCACACGCACCCCAGTTCTCAAA SEQ ID NO: 1370 Reverse PrimerGACTTTGGTGCCTGTGCC SEQ ID NO: 1371 MDM2 NM_002392.1 Forward PrimerCTACAGGGACGCCATCGAA SEQ ID NO: 1372 Probe CTTACACCAGCATCAAGATCCGG SEQ IDNO: 1373 Reverse Primer ATCCAACCAATCACCTGAATGTT SEQ ID NO: 1374 MGAT5NM_002410.2 Forward Primer GGAGTCGAAGGTGGACAATC SEQ ID NO: 1375 ProbeAATGGCACCGGAACAAACTCAACC SEQ ID NO: 1376 Reverse PrimerTGGGAACAGCTGTAGTGGAGT SEQ ID NO: 1377 MGMT NM_002412.1 Forward PrimerGTGAAATGAAACGCACCACA SEQ ID NO: 1378 Probe CAGCCCTTTGGGGAAGCTGG SEQ IDNO: 1379 Reverse Primer GACCCTGCTCACAACCAGAC SEQ ID NO: 1380 mGST1NM_020300.2 Forward Primer ACGGATCTACCACACCATTGC SEQ ID NO: 1381 ProbeTTTGACACCCCTTCCCCAGCCA SEQ ID NO: 1382 Reverse PrimerTCCATATCCAACAAAAAAACTCAAAG SEQ ID NO: 1383 MMP1 NM_002421.2 ForwardPrimer GGGAGATCATCGGGACAACTC SEQ ID NO: 1384 ProbeAGCAAGATTTCCTCCAGGTCCATCAAAAGG SEQ ID NO: 1385 Reverse PrimerGGGCCTGGTTGAAAAGCAT SEQ ID NO: 1386 MMP12 NM_002426.1 Forward PrimerCCAACGCTTGCCAAATCCT SEQ ID NO: 1387 Probe AACCAGCTCTCTGTGACCCCAATT SEQID NO: 1388 Reverse Primer ACGGTAGTGACAGCATCAAAACTC SEQ ID NO: 1389 MMP2NM_004530.1 Forward Primer CCATGATGGAGAGGCAGACA SEQ ID NO: 1390 ProbeCTGGGAGCATGGCGATGGATACCC SEQ ID NO: 1391 Reverse PrimerGGAGTCCGTCCTTACCGTCAA SEQ ID NO: 1392 MMP7 NM_002423.2 Forward PrimerGGATGGTAGCAGTCTAGGGATTAACT SEQ ID NO: 1393 ProbeCCTGTATGCTGCAACTCATGAACTTGGC SEQ ID NO: 1394 Reverse PrimerGGAATGTCCCATACCCAAAGAA SEQ ID NO: 1395 MMP9 NM_004994.1 Forward PrimerGAGAACCAATCTCACCGACA SEQ ID NO: 1396 Probe ACAGGTATTCCTCTGCCAGCTGCC SEQID NO: 1397 Reverse Primer CACCCGAGTGTAACCATAGC SEQ ID NO: 1398 MRP1NM_004996.2 Forward Primer TCATGGTGCCCGTCAATG SEQ ID NO: 1399 ProbeACCTGATACGTCTTGGTCTTCATCGCCAT SEQ ID NO: 1400 Reverse PrimerCGATTGTCTTTGCTCTTCATGTG SEQ ID NO: 1401 MRP2 NM_000392.1 Forward PrimerAGGGGATGACTTGGACACAT SEQ ID NO: 1402 Probe CTGCCATTCGACATGACTGCAATTT SEQID NO: 1403 Reverse Primer AAAACTGCATGGCTTTGTCA SEQ ID NO: 1404 MRP3NM_003786.2 Forward Primer TCATCCTGGCGATCTACTTCCT SEQ ID NO: 1405 ProbeTCTGTCCTGGCTGGAGTCGCTTTCAT SEQ ID NO: 1406 Reverse PrimerCCGTTGAGTGGAATCAGCAA SEQ ID NO: 1407 MRP4 NM_005845.1 Forward PrimerAGCGCCTGGAATCTACAACT SEQ ID NO: 1408 Probe CGGAGTCCAGTGTTTTCCCACTTG SEQID NO: 1409 Reverse Primer AGAGCCCCTGGAGAGAAGAT SEQ ID NO: 1410 MRPL40NM_003776.2 Forward Primer ACTTGCAGGCTGCTATCCTT SEQ ID NO: 1411 ProbeTTCCTACTCTCAGGGGCAGCATGTT SEQ ID NO: 1412 Reverse PrimerAGCAGACTTGAACCCTGGTC SEQ ID NO: 1413 MSH2 NM_000251.1 Forward PrimerGATGCAGAATTGAGGCAGAC SEQ ID NO: 1414 Probe CAAGAAGATTTACTTCGTCGATTCCCAGASEQ ID NO: 1415 Reverse Primer TCTTGGCAAGTCGGTTAAGA SEQ ID NO: 1416 MSH3NM_002439.1 Forward Primer TGATTACCATCATGGCTCAGA SEQ ID NO: 1417 ProbeTCCCAATTGTCGCTTCTTCTGCAG SEQ ID NO: 1418 Reverse PrimerCTTGTGAAAATGCCATCCAC SEQ ID NO: 1419 MSH6 NM_000179.1 Forward PrimerTCTATTGGGGGATTGGTAGG SEQ ID NO: 1420 Probe CCGTTACCAGCTGGAAATTCCTGAGASEQ ID NO: 1421 Reverse Primer CAAATTGCGAGTGGTGAAAT SEQ ID NO: 1422 MT3NM_005954.1 Forward Primer GTGTGAGAAGTGTGCCAAGG SEQ ID NO: 1423 ProbeCTCTCCGCCTTTGCACACACAGT SEQ ID NO: 1424 Reverse PrimerCTGCACTTCTCTGCTTCTGC SEQ ID NO: 1425 MTA1 NM_004689.2 Forward PrimerCCGCCCTCACCTGAAGAGA SEQ ID NO: 1426 Probe CCCAGTGTCCGCCAAGGAGCG SEQ IDNO: 1427 Reverse Primer GGAATAAGTTAGCCGCGCTTCT SEQ ID NO: 1428 MUC1NM_002456.1 Forward Primer GGCCAGGATCTGTGGTGGTA SEQ ID NO: 1429 ProbeCTCTGGCCTTCCGAGAAGGTACC SEQ ID NO: 1430 Reverse PrimerCTCCACGTCGTGGACATTGA SEQ ID NO: 1431 MUC2 NM_002457.1 Forward PrimerCTATGAGCCATGTGGGAACC SEQ ID NO: 1432 Probe AGCTTCGAGACCTGCAGGACCATC SEQID NO: 1433 Reverse Primer ATGTTGGAGTGGATGCCG SEQ ID NO: 1434 MUC5BXM_039877.11 Forward Primer TGCCCTTGCACTGTCCTAA SEQ ID NO: 1435 ProbeTCAGCCATCCTGCACACCTACACC SEQ ID NO: 1436 Reverse PrimerCAGCCACACTCATCCACG SEQ ID NO: 1437 MUTYH NM_012222.1 Forward PrimerGTACGACCAAGAGAAACGGG SEQ ID NO: 1438 Probe TCTGCCCGTCTTCTCCATGGTAGG SEQID NO: 1439 Reverse Primer CCTGTCCAGGTCCATCTCA SEQ ID NO: 1440 MVPNM_017458.1 Forward Primer ACGAGAACGAGGGCATCTATGT SEQ ID NO: 1441 ProbeCGCACCTTTCCGGTCTTGACATCCT SEQ ID NO: 1442 Reverse PrimerGCATGTAGGTGCTTCCAATCAC SEQ ID NO: 1443 MX1 NM_002462.2 Forward PrimerGAAGGAATGGGAATCAGTCATGA SEQ ID NO: 1444 Probe TCACCCTGGAGATCAGCTCCCGASEQ ID NO: 1445 Reverse Primer GTCTATTAGAGTCAGATCCGGGACAT SEQ ID NO:1446 MXD4 NM_006454.2 Forward Primer AGAAACTGGAGGAGCAGGAC SEQ ID NO:1447 Probe TGCAGCTGCTCCTTGATGCTCAGT SEQ ID NO: 1448 Reverse PrimerCTTCAGGAAACGATGCTCCT SEQ ID NO: 1449 MYBL2 NM_002466.1 Forward PrimerGCCGAGATCGCCAAGATG SEQ ID NO: 1450 Probe CAGCATTGTCTGTCCTCCCTGGCA SEQ IDNO: 1451 Reverse Primer CTTTTGATGGTAGAGTTCCAGTGATTC SEQ ID NO: 1452MYH11 NM_002474.1 Forward Primer CGGTACTTCTCAGGGCTAATATATACG SEQ ID NO:1453 Probe CTCTTCTGCGTGGTGGTCAACCCCTA SEQ ID NO: 1454 Reverse PrimerCCGAGTAGATGGGCAGGTGTT SEQ ID NO: 1455 MYLK NM_053025.1 Forward PrimerTGACGGAGCGTGAGTGCAT SEQ ID NO: 1456 Probe CCCTCCGAGATCTGCCGCATGTACT SEQID NO: 1457 Reverse Primer ATGCCCTGCTTGTGGATGTAC SEQ ID NO: 1458 NAT2NM_000015.1 Forward Primer TAACTGACATTCTTGAGCACCAGAT SEQ ID NO: 1459Probe CGGGCTGTTCCCTTTGAGAACCTTAACA SEQ ID NO: 1460 Reverse PrimerATGGCTTGCCCACAATGC SEQ ID NO: 1461 NAV2 NM_182964.3 Forward PrimerCTCTCCCAGCACAGCTTGA SEQ ID NO: 1462 Probe CCTCACTGAGTCAACCAGCCTGGA SEQID NO: 1463 Reverse Primer CACCAGTGTCATCCAGCAAC SEQ ID NO: 1464 NCAM1NM_000615.1 Forward Primer TAGTTCCCAGCTGACCATCA SEQ ID NO: 1465 ProbeCTCAGCCTCGTCGTTCTTATCCACC SEQ ID NO: 1466 Reverse PrimerCAGCCTTGTTCTCAGCAATG SEQ ID NO: 1467 NDE1 NM_017668.1 Forward PrimerCTACTGCGGAAAGTCGGG SEQ ID NO: 1468 Probe CTGGAGTCCAAACTCGCTTCCTGC SEQ IDNO: 1469 Reverse Primer GGACTGATCGTACACGAGGTT SEQ ID NO: 1470 NDRG1NM_006096.2 Forward Primer AGGGCAACATTCCACAGC SEQ ID NO: 1471 ProbeCTGCAAGGACACTCATCACAGCCA SEQ ID NO: 1472 Reverse PrimerCAGTGCTCCTACTCCGGC SEQ ID NO: 1473 NDUFS3 NM_004551.1 Forward PrimerTATCCATCCTGATGGCGTC SEQ ID NO: 1474 Probe CCCAGTGCTGACTTTCCTCAGGGA SEQID NO: 1475 Reverse Primer TTGAACTGTGCATTGGTGTG SEQ ID NO: 1476 NEDD8NM_006156.1 Forward Primer TGCTGGCTACTGGGTGTTAGT SEQ ID NO: 1477 ProbeTGCAGTCCTGTGTGCTTCCCTCTC SEQ ID NO: 1478 Reverse PrimerGACAACCAGGGACACAGTCA SEQ ID NO: 1479 NEK2 NM_002497.1 Forward PrimerGTGAGGCAGCGCGACTCT SEQ ID NO: 1480 Probe TGCCTTCCCGGGCTGAGGACT SEQ IDNO: 1481 Reverse Primer TGCCAATGGTGTACAACACTTCA SEQ ID NO: 1482 NF2NM_000268.2 Forward Primer ACTCCAGAGCTGACCTCCAC SEQ ID NO: 1483 ProbeCTACAATGACTTCCCAGGCTGGGC SEQ ID NO: 1484 Reverse PrimerTCAGGGCTTCAGTGTCTCAC SEQ ID NO: 1485 NFKBp50 NM_003998.1 Forward PrimerCAGACCAAGGAGATGGACCT SEQ ID NO: 1486 Probe AAGCTGTAAACATGAGCCGCACCA SEQID NO: 1487 Reverse Primer AGCTGCCAGTGCTATCCG SEQ ID NO: 1488 NFKBp65NM_021975.1 Forward Primer CTGCCGGGATGGCTTCTAT SEQ ID NO: 1489 ProbeCTGAGCTCTGCCCGGACCGCT SEQ ID NO: 1490 Reverse PrimerCCAGGTTCTGGAAACTGTGGAT SEQ ID NO: 1491 NISCH NM_007184.1 Forward PrimerCCAAGGAATCATGTTCGTTCAG SEQ ID NO: 1492 Probe TGGCCAGCAGCCTCTCGTCCAC SEQID NO: 1493 Reverse Primer TGGTGCTCGGGAGTCAGACT SEQ ID NO: 1494 Nkd-1NM_033119.3 Forward Primer GAGAGAGTGAGCGAACCCTG SEQ ID NO: 1495 ProbeCCAGGCTCCAAGAAGCAGCTGAAG SEQ ID NO: 1496 Reverse PrimerCGTCGCACTGGAGCTCTT SEQ ID NO: 1497 NMB NM_021077.1 Forward PrimerGGCTGCTGGTACAAATACTGC SEQ ID NO: 1498 ProbeTGTCTGCCCCTATTATTGGTGTCATTTCT SEQ ID NO: 1499 Reverse PrimerCAATCTAAGCCACGCTGTTG SEQ ID NO: 1500 NMBR NM_002511.1 Forward PrimerTGATCCATCTCTAGGCCACA SEQ ID NO: 1501 Probe TTGTCACCTTAGTTGCCCGGGTTC SEQID NO: 1502 Reverse Primer GAGCAAATGGGTTGACACAA SEQ ID NO: 1503 NME1NM_000269.1 Forward Primer CCAACCCTGCAGACTCCAA SEQ ID NO: 1504 ProbeCCTGGGACCATCCGTGGAGACTTCT SEQ ID NO: 1505 Reverse PrimerATGTATAATGTTCCTGCCAACTTGTATG SEQ ID NO: 1506 NOS3 NM_000603.2 ForwardPrimer ATCTCCGCCTCGCTCATG SEQ ID NO: 1507 Probe TTCACTCGCTTCGCCATCACCGSEQ ID NO: 1508 Reverse Primer TCGGAGCCATACAGGATTGTC SEQ ID NO: 1509NOTCH1 NM_017617.2 Forward Primer CGGGTCCACCAGTTTGAATG SEQ ID NO: 1510Probe CCGCTCTGCAGCCGGGACA SEQ ID NO: 1511 Reverse PrimerGTTGTATTGGTTCGGCACCAT SEQ ID NO: 1512 NOTCH2 NM_024408.2 Forward PrimerCACTTCCCTGCTGGGATTAT SEQ ID NO: 1513 Probe CCGTGTTGCACAGCTCATCACACT SEQID NO: 1514 Reverse Primer AGTTGTCAAACAGGCACTCG SEQ ID NO: 1515 NPM1NM_002520.2 Forward Primer AATGTTGTCCAGGTTCTATTGC SEQ ID NO: 1516 ProbeAACAGGCATTTTGGACAACACATTCTTG SEQ ID NO: 1517 Reverse PrimerCAAGCAAAGGGTGGAGTTC SEQ ID NO: 1518 NR4A1 NM_002135.2 Forward PrimerCACAGCTTGCTTGTCGATGTC SEQ ID NO: 1519 Probe CCTTCGCCTGCCTCTCTGCCC SEQ IDNO: 1520 Reverse Primer ATGCCGGTCGGTGATGAG SEQ ID NO: 1521 NRG1NM_013957.1 Forward Primer CGAGACTCTCCTCATAGTGAAAGGTAT SEQ ID NO: 1522Probe ATGACCACCCCGGCTCGTATGTCA SEQ ID NO: 1523 Reverse PrimerCTTGGCGTGTGGAAATCTACAG SEQ ID NO: 1524 NRP1 NM_003873.1 Forward PrimerCAGCTCTCTCCACGCGATTC SEQ ID NO: 1525 Probe CAGGATCTACCCCGAGAGAGCCACTCATSEQ ID NO: 1526 Reverse Primer CCCAGCAGCTCCATTCTGA SEQ ID NO: 1527 NRP2NM_003872.1 Forward Primer CTACAGCCTAAACGGCAAGG SEQ ID NO: 1528 ProbeAGGACCCCAGGACCCAGCAG SEQ ID NO: 1529 Reverse Primer GTTCCCTTCGAACAGCTTTGSEQ ID NO: 1530 NTN1 NM_004822.1 Forward Primer AGAAGGACTATGCCGTCCAG SEQID NO: 1531 Probe ATCCACATCCTGAAGGCGGACAAG SEQ ID NO: 1532 ReversePrimer CCGTGAACTTCCACCAGTC SEQ ID NO: 1533 NUFIP1 NM_012345.1 ForwardPrimer GCTTCCACATCGTGGTATTG SEQ ID NO: 1534 ProbeCTTCTGATAGGTTTCCTCGGCATCAGA SEQ ID NO: 1535 Reverse PrimerAACTGCAGGGTTGAAGGACT SEQ ID NO: 1536 ODC1 NM_002539.1 Forward PrimerAGAGATCACCGGCGTAATCAA SEQ ID NO: 1537 Probe CCAGCGTTGGACAAATACTTTCCGTCASEQ ID NO: 1538 Reverse Primer CGGGCTCAGCTATGATTCTCA SEQ ID NO: 1539OPN, NM_000582.1 Forward Primer CAACCGAAGTTTTCACTCCAGTT SEQ ID NO: 1540osteopontin Probe TCCCCACAGTAGACACATATGATGGCCG SEQ ID NO: 1541 ReversePrimer CCTCAGTCCATAAACCACACTATCA SEQ ID NO: 1542 ORC1L NM_004153.2Forward Primer TCCTTGACCATACCGGAGG SEQ ID NO: 1543 ProbeTGCATGTACATCTCCGGTGTCCCT SEQ ID NO: 1544 Reverse PrimerCAGTGGCAGTCTTCCCTGTC SEQ ID NO: 1545 OSM NM_020530.3 Forward PrimerGTTTCTGAAGGGGAGGTCAC SEQ ID NO: 1546 Probe CTGAGCTGGCCTCCTATGCCTCAT SEQID NO: 1547 Reverse Primer AGGTGTCTGGTTTGGGACA SEQ ID NO: 1548 OSMRNM_003999.1 Forward Primer GCTCATCATGGTCATGTGCT SEQ ID NO: 1549 ProbeCAGGTCTCCTTGATCCACTGACTTTTCA SEQ ID NO: 1550 Reverse PrimerTGTAAGGGTCAGGGATGTCA SEQ ID NO: 1551 P14ARF S78535.1 Forward PrimerCCCTCGTGCTGATGCTACT SEQ ID NO: 1552 Probe CTGCCCTAGACGCTGGCTCCTC SEQ IDNO: 1553 Reverse Primer CATCATGACCTGGTCTTCTAGG SEQ ID NO: 1554 p16-INK4L27211.1 Forward Primer GCGGAAGGTCCCTCAGACA SEQ ID NO: 1555 ProbeCTCAGAGCCTCTCTGGTTCTTTCAATCGG SEQ ID NO: 1556 Reverse PrimerTGATGATCTAAGTTTCCCGAGGTT SEQ ID NO: 1557 p21 NM_000389.1 Forward PrimerTGGAGACTCTCAGGGTCGAAA SEQ ID NO: 1558 Probe CGGCGGCAGACCAGCATGAC SEQ IDNO: 1559 Reverse Primer GGCGTTTGGAGTGGTAGAAATC SEQ ID NO: 1560 p27NM_004064.1 Forward Primer CGGTGGACCACGAAGAGTTAA SEQ ID NO: 1561 ProbeCCGGGACTTGGAGAAGCACTGCA SEQ ID NO: 1562 Reverse PrimerGGCTCGCCTCTTCCATGTC SEQ ID NO: 1563 P53 NM_000546.2 Forward PrimerCTTTGAACCCTTGCTTGCAA SEQ ID NO: 1564 Probe AAGTCCTGGGTGCTTCTGACGCACA SEQID NO: 1565 Reverse Primer CCCGGGACAAAGCAAATG SEQ ID NO: 1566 p53R2AB036063.1 Forward Primer CCCAGCTAGTGTTCCTCAGA SEQ ID NO: 1567 ProbeTCGGCCAGCTTTTTCCAATCTTTG SEQ ID NO: 1568 Reverse PrimerCCGTAAGCCCTTCCTCTATG SEQ ID NO: 1569 PADI4 NM_012387.1 Forward PrimerAGCAGTGGCTTGCTTTCTTC SEQ ID NO: 1570 Probe CCTGTGATGTCCCAGTTTCCCACTC SEQID NO: 1571 Reverse Primer TGCTAGGACCATGTTGGGAT SEQ ID NO: 1572 PAI1NM_000602.1 Forward Primer CCGCAACGTGGTTTTCTCA SEQ ID NO: 1573 ProbeCTCGGTGTTGGCCATGCTCCAG SEQ ID NO: 1574 Reverse PrimerTGCTGGGTTTCTCCTCCTGTT SEQ ID NO: 1575 Pak1 NM_002576.3 Forward PrimerGAGCTGTGGGTTGTTATGGA SEQ ID NO: 1576 Probe ACATCTGTCAAGGAGCCTCCAGCC SEQID NO: 1577 Reverse Primer CCATGCAAGTTTCTGTCACC SEQ ID NO: 1578 PARCNM_015089.1 Forward Primer GGAGCTGACCTGCTTCCTAC SEQ ID NO: 1579 ProbeTCCTTATGCATCGAGGCCAGGC SEQ ID NO: 1580 Reverse PrimerAGCAGAGCACCACAGCATAG SEQ ID NO: 1581 PCAF NM_003884.3 Forward PrimerAGGTGGCTGTGTTACTGCAA SEQ ID NO: 1582 Probe TGCCACAGTTCTGCGACAGTCTACC SEQID NO: 1583 Reverse Primer CACCTGTGTGGTTTCGTACC SEQ ID NO: 1584 PCNANM_002592.1 Forward Primer GAAGGTGTTGGAGGCACTCAAG SEQ ID NO: 1585 ProbeATCCCAGCAGGCCTCGTTGATGAG SEQ ID NO: 1586 Reverse PrimerGGTTTACACCGCTGGAGCTAA SEQ ID NO: 1587 PDGFA NM_002607.2 Forward PrimerTTGTTGGTGTGCCCTGGTG SEQ ID NO: 1588 Probe TGGTGGCGGTCACTCCCTCTGC SEQ IDNO: 1589 Reverse Primer TGGGTTCTGTCCAAACACTGG SEQ ID NO: 1590 PDGFBNM_002608.1 Forward Primer ACTGAAGGAGACCCTTGGAG SEQ ID NO: 1591 ProbeTCTCCTGCCGATGCCCCTAGG SEQ ID NO: 1592 Reverse PrimerTAAATAACCCTGCCCACACA SEQ ID NO: 1593 PDGFC NM_016205.1 Forward PrimerAGTTACTAAAAAATACCACGAGGTCCTT SEQ ID NO: 1594 ProbeCCCTGACACCGGTCTTTGGTCTCAACT SEQ ID NO: 1595 Reverse PrimerGTCGGTGAGTGATTTGTGCAA SEQ ID NO: 1596 PDGFD NM_025208.2 Forward PrimerTATCGAGGCAGGTCATACCA SEQ ID NO: 1597 Probe TCCAGGTCAACTTTTGACTTCCGGT SEQID NO: 1598 Reverse Primer TAACGCTTGGCATCATCATT SEQ ID NO: 1599 PDGFRaNM_006206.2 Forward Primer GGGAGTTTCCAAGAGATGGA SEQ ID NO: 1600 ProbeCCCAAGACCCGACCAAGCACTAG SEQ ID NO: 1601 Reverse PrimerCTTCAACCACCTTCCCAAAC SEQ ID NO: 1602 PDGFRb NM_002609.2 Forward PrimerCCAGCTCTCCTTCCAGCTAC SEQ ID NO: 1603 Probe ATCAATGTCCCTGTCCGAGTGCTG SEQID NO: 1604 Reverse Primer GGGTGGCTCTCACTTAGCTC SEQ ID NO: 1605 PFN1NM_005022.2 Forward Primer GGAAAACGTTCGTCAACATC SEQ ID NO: 1606 ProbeCAACCAGGACACCCACCTCAGCT SEQ ID NO: 1607 Reverse PrimerAAAACTTGACCGGTCTTTGC SEQ ID NO: 1608 PFN2 NM_053024.1 Forward PrimerTCTATACGTCGATGGTGACTGC SEQ ID NO: 1609 Probe CTCCCCACCTTGACTCTTTGTCCGSEQ ID NO: 1610 Reverse Primer GCCGACAGCCACATTGTAT SEQ ID NO: 1611 PGK1NM_000291.1 Forward Primer AGAGCCAGTTGCTGTAGAACTCAA SEQ ID NO: 1612Probe TCTCTGCTGGGCAAGGATGTTCTGTTC SEQ ID NO: 1613 Reverse PrimerCTGGGCCTACACAGTCCTTCA SEQ ID NO: 1614 PI3K NM_002646.2 Forward PrimerTGCTACCTGGACAGCCCG SEQ ID NO: 1615 Probe TCCTCCTGAAACGAGCTGTGTCTGACTTSEQ ID NO: 1616 Reverse Primer AGGCCGTCCTTCAGTAACCA SEQ ID NO: 1617PI3KC2A NM_002645.1 Forward Primer ATACCAATCACCGCACAAACC SEQ ID NO: 1618Probe TGCGCTGTGACTGGACTTAACAAATAGCCT SEQ ID NO: 1619 Reverse PrimerCACACTAGCATTTTCTCCGCATA SEQ ID NO: 1620 PIK3CA NM_006218.1 ForwardPrimer GTGATTGAAGAGCATGCCAA SEQ ID NO: 1621 ProbeTCCTGCTTCTCGGGATACAGACCA SEQ ID NO: 1622 Reverse PrimerGTCCTGCGTGGGAATAGC SEQ ID NO: 1623 PIM1 NM_002648.2 Forward PrimerCTGCTCAAGGACACCGTCTA SEQ ID NO: 1624 Probe TACACTCGGGTCCCATCGAAGTCC SEQID NO: 1625 Reverse Primer GGATCCACTCTGGAGGGC SEQ ID NO: 1626 Pin1NM_006221.1 Forward Primer GATCAACGGCTACATCCAGA SEQ ID NO: 1627 ProbeTCAAAGTCCTCCTCTCCCGACTTGA SEQ ID NO: 1628 Reverse PrimerTGAACTGTGAGGCCAGAGAC SEQ ID NO: 1629 PKD1 NM_000296.2 Forward PrimerCAGCACCAGCGATTACGAC SEQ ID NO: 1630 Probe AGCCATTGTGAGGACTCTCCCAGC SEQID NO: 1631 Reverse Primer CTGAATAGGCCCACGTCC SEQ ID NO: 1632 PKR2NM_002654.3 Forward Primer CCGCCTGGACATTGATTCAC SEQ ID NO: 1633 ProbeACCCATCACAGCCCGGAACACTG SEQ ID NO: 1634 Reverse PrimerCTGGGCCAATGGTACAGATGA SEQ ID NO: 1635 PLA2G2A NM_000300.2 Forward PrimerGCATCCCTCACCCATCCTA SEQ ID NO: 1636 Probe AGGCCAGGCAGGAGCCCTTCTATA SEQID NO: 1637 Reverse Primer GCTGGAAATCTGCTGGATGT SEQ ID NO: 1638 PLAURNM_002659.1 Forward Primer CCCATGGATGCTCCTCTGAA SEQ ID NO: 1639 ProbeCATTGACTGCCGAGGCCCCATG SEQ ID NO: 1640 Reverse PrimerCCGGTGGCTACCAGACATTG SEQ ID NO: 1641 PLK NM_005030.2 Forward PrimerAATGAATACAGTATTCCCAAGCACAT SEQ ID NO: 1642 Probe AACCCCGTGGCCGCCTCC SEQID NO: 1643 Reverse Primer TGTCTGAAGCATCTTCTGGATGA SEQ ID NO: 1644 PLK3NM_004073.2 Forward Primer TGAAGGAGACGTACCGCTG SEQ ID NO: 1645 ProbeCAAGCAGGTTCACTACACGCTGCC SEQ ID NO: 1646 Reverse PrimerCAGGCAGTGAGAGGCTGG SEQ ID NO: 1647 PLOD2 NM_000935.2 Forward PrimerCAGGGAGGTGGTTGCAAAT SEQ ID NO: 1648 Probe TCCAGCCTTTTCGTGGTGACTCAA SEQID NO: 1649 Reverse Primer TCTCCCAGGATGCATGAAG SEQ ID NO: 1650 PMS1NM_000534.2 Forward Primer CTTACGGTTTTCGTGGAGAAG SEQ ID NO: 1651 ProbeCCTCAGCTATACAACAAATTGACCCCAAG SEQ ID NO: 1652 Reverse PrimerAGCAGCCGTTCTTGTTGTAA SEQ ID NO: 1653 PMS2 NM_000535.2 Forward PrimerGATGTGGACTGCCATTCAAA SEQ ID NO: 1654 Probe TCGAAATTTACATCCGGTATCTTCCTGGSEQ ID NO: 1655 Reverse Primer TGCGAGATTAGTTGGCTGAG SEQ ID NO: 1656PPARG NM_005037.3 Forward Primer TGACTTTATGGAGCCCAAGTT SEQ ID NO: 1657Probe TTCCAGTGCATTGAACTTCACAGCA SEQ ID NO: 1658 Reverse PrimerGCCAAGTCGCTGTCATCTAA SEQ ID NO: 1659 PPID NM_005038.1 Forward PrimerTCCTCATTTGGATGGGAAAC SEQ ID NO: 1660 Probe TTCCTTTAATTACTTGGCCAAACACCACASEQ ID NO: 1661 Reverse Primer CCAATATCCTTGCCACTCCTA SEQ ID NO: 1662PPM1D NM_003620.1 Forward Primer GCCATCCGCAAAGGCTTT SEQ ID NO: 1663Probe TCGCTTGTCACCTTGCCATGTGG SEQ ID NO: 1664 Reverse PrimerGGCCATTCCGCCAGTTTC SEQ ID NO: 1665 PPP2R4 NM_178001.1 Forward PrimerGGCTCAGAGCATAAGGCTTC SEQ ID NO: 1666 Probe TTGGTCACTTCTCCCAACTTGGGC SEQID NO: 1667 Reverse Primer ACGGGAACTCAGAAAACTGG SEQ ID NO: 1668 PRNM_000926.2 Forward Primer GCATCAGGCTGTCATTATGG SEQ ID NO: 1669 ProbeTGTCCTTACCTGTGGGAGCTGTAAGGTC SEQ ID NO: 1670 Reverse PrimerAGTAGTTGTGCTGCCCTTCC SEQ ID NO: 1671 PRDX2 NM_005809.4 Forward PrimerGGTGTCCTTCGCCAGATCAC SEQ ID NO: 1672 Probe TTAATGATTTGCCTGTGGGACGCTCCSEQ ID NO: 1673 Reverse Primer CAGCCGCAGAGCCTCATC SEQ ID NO: 1674 PRDX3NM_006793.2 Forward Primer TGACCCCAATGGAGTCATCA SEQ ID NO: 1675 ProbeCATTTGAGCGTCAACGATCTCCCAGTG SEQ ID NO: 1676 Reverse PrimerCCAAGCGGAGGGTTTCTTC SEQ ID NO: 1677 PRDX4 NM_006406.1 Forward PrimerTTACCCATTTGGCCTGGATTAA SEQ ID NO: 1678 Probe CCAAGTCCTCCTTGTCTTCGAGGGGTSEQ ID NO: 1679 Reverse Primer CTGAAAGAAGTGGAATCCTTATTGG SEQ ID NO: 1680PRDX6 NM_004905.2 Forward Primer CTGTGAGCCAGAGGATGTCA SEQ ID NO: 1681Probe CTGCCAATTGTGTTTTCCTGCAGC SEQ ID NO: 1682 Reverse PrimerTGTGATGACACCAGGATGTG SEQ ID NO: 1683 PRKCA NM_002737.1 Forward PrimerCAAGCAATGCGTCATCAATGT SEQ ID NO: 1684 Probe CAGCCTCTGCGGAATGGATCACACTSEQ ID NO: 1685 Reverse Primer GTAAATCCGCCCCCTCTTCT SEQ ID NO: 1686PRKCB1 NM_002738.5 Forward Primer GACCCAGCTCCACTCCTG SEQ ID NO: 1687Probe CCAGACCATGGACCGCCTGTACTT SEQ ID NO: 1688 Reverse PrimerCCCATTCACGTACTCCATCA SEQ ID NO: 1689 PRKCD NM_006254.1 Forward PrimerCTGACACTTGCCGCAGAGAA SEQ ID NO: 1690 Probe CCCTTTCTCACCCACCTCATCTGCACSEQ ID NO: 1691 Reverse Primer AGGTGGTCCTTGGTCTGGAA SEQ ID NO: 1692 PRKRNM_002759.1 Forward Primer GCGATACATGAGCCCAGAACA SEQ ID NO: 1693 ProbeAGGTCCACTTCCTTTCCATAGTCTTGCGA SEQ ID NO: 1694 Reverse PrimerTCAGCAAGAATTAGCCCCAAAG SEQ ID NO: 1695 pS2 NM_003225.1 Forward PrimerGCCCTCCCAGTGTGCAAAT SEQ ID NO: 1696 Probe TGCTGTTTCGACGACACCGTTCG SEQ IDNO: 1697 Reverse Primer CGTCGATGGTATTAGGATAGAAGCA SEQ ID NO: 1698 PTCHNM_000264.2 Forward Primer CCACGACAAAGCCGACTAC SEQ ID NO: 1699 ProbeCCTGAAACAAGGCTGAGAATCCCG SEQ ID NO: 1700 Reverse PrimerTACTCGATGGGCTCTGCTG SEQ ID NO: 1701 PTEN NM_000314.1 Forward PrimerTGGCTAAGTGAAGATGACAATCATG SEQ ID NO: 1702 ProbeCCTTTCCAGCTTTACAGTGAATTGCTGCA SEQ ID NO: 1703 Reverse PrimerTGCACATATCATTACACCAGTTCGT SEQ ID NO: 1704 PTGER3 NM_000957.2 ForwardPrimer TAACTGGGGCAACCTTTTCT SEQ ID NO: 1705 Probe CCTTTGCCTTCCTGGGGCTCTTSEQ ID NO: 1706 Reverse Primer TTGCAGGAAAAGGTGACTGT SEQ ID NO: 1707PTHLH NM_002820.1 Forward Primer AGTGACTGGGAGTGGGCTAGAA SEQ ID NO: 1708Probe TGACACCTCCACAACGTCGCTGGA SEQ ID NO: 1709 Reverse PrimerAAGCCTGTTACCGTGAATCGA SEQ ID NO: 1710 PTHR1 NM_000316.1 Forward PrimerCGAGGTACAAGCTGAGATCAAGAA SEQ ID NO: 1711 Probe CCAGTGCCAGTGTCCAGCGGCTSEQ ID NO: 1712 Reverse Primer GCGTGCCTTTCGCTTGAA SEQ ID NO: 1713 PTK2NM_005607.3 Forward Primer GACCGGTCGAATGATAAGGT SEQ ID NO: 1714 ProbeACCAGGCCCGTCACATTCTCGTAC SEQ ID NO: 1715 Reverse PrimerCTGGACATCTCGATGACAGC SEQ ID NO: 1716 PTK2B NM_004103.3 Forward PrimerCAAGCCCAGCCGACCTAAG SEQ ID NO: 1717 Probe CTCCGCAAACCAACCTCCTGGCT SEQ IDNO: 1718 Reverse Primer GAACCTGGAACTGCAGCTTTG SEQ ID NO: 1719 PTP4A3NM_007079.2 Forward Primer CCTGTTCTCGGCACCTTAAA SEQ ID NO: 1720 ProbeACCTGACTGCCCCGGGGTCTAATA SEQ ID NO: 1721 Reverse PrimerTATTGCCTTCGGGTGTCC SEQ ID NO: 1722 PTP4A3 v2 NM_032611.1 Forward PrimerAATATTTGTGCGGGGTATGG SEQ ID NO: 1723 Probe CCAAGAGAAACGAGATTTAAAAACCCACCSEQ ID NO: 1724 Reverse Primer AACGAGATCCCTGTGCTTGT SEQ ID NO: 1725PTPD1 NM_007039.2 Forward Primer CGCTTGCCTAACTCATACTTTCC SEQ ID NO: 1726Probe TCCACGCAGCGTGGCACTG SEQ ID NO: 1727 Reverse PrimerCCATTCAGACTGCGCCACTT SEQ ID NO: 1728 PTPN1 NM_002827.2 Forward PrimerAATGAGGAAGTTTCGGATGG SEQ ID NO: 1729 Probe CTGATCCAGACAGCCGACCAGCT SEQID NO: 1730 Reverse Primer CTTCGATCACAGCCAGGTAG SEQ ID NO: 1731 PTPRFNM_002840.2 Forward Primer TGTTTTAGCTGAGGGACGTG SEQ ID NO: 1732 ProbeCCGACGTCCCCAAACCTAGCTAGG SEQ ID NO: 1733 Reverse PrimerTACCAACCCTGGAATGTTGA SEQ ID NO: 1734 PTPRJ NM_002843.2 Forward PrimerAACTTCCGGTACCTCGTTCGT SEQ ID NO: 1735 ProbeACTACATGAAGCAGAGTCCTCCCGAATCG SEQ ID NO: 1736 Reverse PrimerAGCACTGCAATGCACCAGAA SEQ ID NO: 1737 PTPRO NM_030667.1 Forward PrimerCATGGCCTGATCATGGTGT SEQ ID NO: 1738 Probe CCCACAGCAAATGCTGCAGAAAGT SEQID NO: 1739 Reverse Primer CCATGTGTACAAACTGCAGGA SEQ ID NO: 1740 PTTG1NM_004219.2 Forward Primer GGCTACTCTGATCTATGTTGATAAGGAA SEQ ID NO: 1741Probe CACACGGGTGCCTGGTTCTCCA SEQ ID NO: 1742 Reverse PrimerGCTTCAGCCCATCCTTAGCA SEQ ID NO: 1743 RAB32 NM_006834.2 Forward PrimerCCTGCAGCTGTGGGACAT SEQ ID NO: 1744 Probe CGATTTGGCAACATGACCCGAGTA SEQ IDNO: 1745 Reverse Primer AGCACCAACAGCTTCCTTG SEQ ID NO: 1746 RAB6CNM_032144.1 Forward Primer GCGACAGCTCCTCTAGTTCCA SEQ ID NO: 1747 ProbeTTCCCGAAGTCTCCGCCCG SEQ ID NO: 1748 Reverse PrimerGGAACACCAGCTTGAATTTCCT SEQ ID NO: 1749 RAC1 NM_006908.3 Forward PrimerTGTTGTAAATGTCTCAGCCCC SEQ ID NO: 1750 Probe CGTTCTTGGTCCTGTCCCTTGGA SEQID NO: 1751 Reverse Primer TTGAGCAAAGCGTACAAAGG SEQ ID NO: 1752 RAD51CNM_058216.1 Forward Primer GAACTTCTTGAGCAGGAGCATACC SEQ ID NO: 1753Probe AGGGCTTCATAATCACCTTCTGTTC SEQ ID NO: 1754 Reverse PrimerTCCACCCCCAAGAATATCATCTAGT SEQ ID NO: 1755 RAD54L NM_003579.2 ForwardPrimer AGCTAGCCTCAGTGACACACATG SEQ ID NO: 1756 ProbeACACAACGTCGGCAGTGCAACCTG SEQ ID NO: 1757 Reverse PrimerCCGGATCTGACGGCTGTT SEQ ID NO: 1758 RAF1 NM_002880.1 Forward PrimerCGTCGTATGCGAGAGTCTGT SEQ ID NO: 1759 Probe TCCAGGATGCCTGTTAGTTCTCAGCASEQ ID NO: 1760 Reverse Primer TGAAGGCGTGAGGTGTAGAA SEQ ID NO: 1761RALBP1 NM_006788.2 Forward Primer GGTGTCAGATATAAATGTGCAAATGC SEQ ID NO:1762 Probe TGCTGTCCTGTCGGTCTCAGTACGTTCA SEQ ID NO: 1763 Reverse PrimerTTCGATATTGCCAGCAGCTATAAA SEQ ID NO: 1764 RANBP2 NM_006267.3 ForwardPrimer TCCTTCAGCTTTCACACTGG SEQ ID NO: 1765 ProbeTCCAGAAGAGTCATGCAACTTCATTTCTG SEQ ID NO: 1766 Reverse PrimerAAATCCTGTTCCCACCTGAC SEQ ID NO: 1767 ranBP7 NM_006391.1 Forward PrimerAACATGATTATCCAAGCCGC SEQ ID NO: 1768 Probe AAGCCAATTTTGTCCACAATGGCA SEQID NO: 1769 Reverse Primer GCCAACAAGCACTGTTATCG SEQ ID NO: 1770 RANBP9NM_005493.2 Forward Primer CAAGTCAGTTGAGACGCCAGTT SEQ ID NO: 1771 ProbeTTCTATGGCGGCCTGACTTCCTCCA SEQ ID NO: 1772 Reverse PrimerTGCAGCTCTCGTCCAAAGTG SEQ ID NO: 1773 RAP1GDS1 NM_021159.3 Forward PrimerTGTGGATGCTGGATTGATTT SEQ ID NO: 1774 Probe CCACTGGTGCAGCTGCTAAATAGCA SEQID NO: 1775 Reverse Primer AAGCAGCACTTCCTGGTCTT SEQ ID NO: 1776 RARANM_000964.1 Forward Primer AGTCTGTGAGAAACGACCGAAAC SEQ ID NO: 1777 ProbeTCGGGCTTGGGCACCTCCTTCTT SEQ ID NO: 1778 Reverse PrimerCGGCGTCAGCGTGTAGCT SEQ ID NO: 1779 RARB NM_016152.2 Forward PrimerTGCCTGGACATCCTGATTCT SEQ ID NO: 1780 Probe TGCACCAGGTATACCCCAGAACAAGASEQ ID NO: 1781 Reverse Primer AAGGCCGTCTGAGAAAGTCA SEQ ID NO: 1782RASSF1 NM_007182.3 Forward Primer AGTGGGAGACACCTGACCTT SEQ ID NO: 1783Probe TTGATCTTCTGCTCAATCTCAGCTTGAGA SEQ ID NO: 1784 Reverse PrimerTGATCTGGGCATTGTACTCC SEQ ID NO: 1785 RBM5 NM_005778.1 Forward PrimerCGAGAGGGAGAGCAAGACCAT SEQ ID NO: 1786 Probe CTGCGCGGCCTTCCCATCA SEQ IDNO: 1787 Reverse Primer TCTCGAATATCGCTCTCTGTGATG SEQ ID NO: 1788 RBX1NM_014248.2 Forward Primer GGAACCACATTATGGATCTTTGC SEQ ID NO: 1789 ProbeTAGAATGTCAAGCTAACCAGGCGTCCGC SEQ ID NO: 1790 Reverse PrimerCATGCGACAGTACACTCTTCTGAA SEQ ID NO: 1791 RCC1 NM_001269.2 Forward PrimerGGGCTGGGTGAGAATGTG SEQ ID NO: 1792 Probe ATACCAGGGCCGGCTTCTTCCTCT SEQ IDNO: 1793 Reverse Primer CACAACATCCTCCGGAATG SEQ ID NO: 1794 REG4NM_032044.2 Forward Primer TGCTAACTCCTGCACAGCC SEQ ID NO: 1795 ProbeTCCTCTTCCTTTCTGCTAGCCTGGC SEQ ID NO: 1796 Reverse PrimerTGCTAGGTTTCCCCTCTGAA SEQ ID NO: 1797 RFC NM_003056.1 Forward PrimerTCAAGACCATCATCACTTTCATTGT SEQ ID NO: 1798 Probe CCTCCCGGTCCGCAAGCAGTTSEQ ID NO: 1799 Reverse Primer GGATCAGGAAGTACACGGAGTATAACT SEQ ID NO:1800 RhoB NM_004040.2 Forward Primer AAGCATGAACAGGACTTGACC SEQ ID NO:1801 Probe CTTTCCAACCCCTGGGGAAGACAT SEQ ID NO: 1802 Reverse PrimerCCTCCCCAAGTCAGTTGC SEQ ID NO: 1803 rhoC NM_175744.1 Forward PrimerCCCGTTCGGTCTGAGGAA SEQ ID NO: 1804 Probe TCCGGTTCGCCATGTCCCG SEQ ID NO:1805 Reverse Primer GAGCACTCAAGGTAGCCAAAGG SEQ ID NO: 1806 RIZ1NM_012231.1 Forward Primer CCAGACGAGCGATTAGAAGC SEQ ID NO: 1807 ProbeTGTGAGGTGAATGATTTGGGGGA SEQ ID NO: 1808 Reverse PrimerTCCTCCTCTTCCTCCTCCTC SEQ ID NO: 1809 RNF11 NM_014372.3 Forward PrimerACCCTGGAAGAGATGGATCA SEQ ID NO: 1810 Probe CCATCATACAGATCACACACTCCCGGSEQ ID NO: 1811 Reverse Primer ATTGGGTCCCCATAAACAAA SEQ ID NO: 1812ROCK1 NM_005406.1 Forward Primer TGTGCACATAGGAATGAGCTTC SEQ ID NO: 1813Probe TCACTCTCTTTGCTGGCCAACTGC SEQ ID NO: 1814 Reverse PrimerGTTTAGCACGCAATTGCTCA SEQ ID NO: 1815 ROCK2 NM_004850.3 Forward PrimerGATCCGAGACCCTCGCTC SEQ ID NO: 1816 Probe CCCATCAACGTGGAGAGCTTGCT SEQ IDNO: 1817 Reverse Primer AGGACCAAGGAATTTAAGCCA SEQ ID NO: 1818 RPLPONM_001002.2 Forward Primer CCATTCTATCATCAACGGGTACAA SEQ ID NO: 1819Probe TCTCCACAGACAAGGCCAGGACTCG SEQ ID NO: 1820 Reverse PrimerTCAGCAAGTGGGAAGGTGTAATC SEQ ID NO: 1821 RPS13 NM_001017.2 Forward PrimerCAGTCGGCTTTACCCTATCG SEQ ID NO: 1822 Probe CAACTTCAACCAAGTGGGGACGCT SEQID NO: 1823 Reverse Primer TCTGCTCCTTCACGTCGTC SEQ ID NO: 1824 RRM1NM_001033.1 Forward Primer GGGCTACTGGCAGCTACATT SEQ ID NO: 1825 ProbeCATTGGAATTGCCATTAGTCCCAGC SEQ ID NO: 1826 Reverse PrimerCTCTCAGCATCGGTACAAGG SEQ ID NO: 1827 RRM2 NM_001034.1 Forward PrimerCAGCGGGATTAAACAGTCCT SEQ ID NO: 1828 Probe CCAGCACAGCCAGTTAAAAGATGCA SEQID NO: 1829 Reverse Primer ATCTGCGTTGAAGCAGTGAG SEQ ID NO: 1830 RTN4NM_007008.1 Forward Primer GACTGGAGTGGTGTTTGGTG SEQ ID NO: 1831 ProbeCCAGCCTATTCCTGCTGCTTTCATTG SEQ ID NO: 1832 Reverse PrimerCTGTTACGCTCACAATGCTG SEQ ID NO: 1833 RUNX1 NM_001754.2 Forward PrimerAACAGAGACATTGCCAACCA SEQ ID NO: 1834 Probe TTGGATCTGCTTGCTGTCCAAACC SEQID NO: 1835 Reverse Primer GTGATTTGCCCAGGAAGTTT SEQ ID NO: 1836 RXRANM_002957.3 Forward Primer GCTCTGTTGTGTCCTGTTGC SEQ ID NO: 1837 ProbeTCAGTCACAGGAAGGCCAGAGCC SEQ ID NO: 1838 Reverse PrimerGTACGGAGAAGCCACTTCACA SEQ ID NO: 1839 S100A1 NM_006271.1 Forward PrimerTGGACAAGGTGATGAAGGAG SEQ ID NO: 1840 Probe CCTCCCCGTCTCCATTCTCGTCTA SEQID NO: 1841 Reverse Primer AGCACCACATACTCCTGGAA SEQ ID NO: 1842 S100A2NM_005978.2 Forward Primer TGGCTGTGCTGGTCACTACCT SEQ ID NO: 1843 ProbeCACAAGTACTCCTGCCAAGAGGGCGAC SEQ ID NO: 1844 Reverse PrimerTCCCCCTTACTCAGCTTGAACT SEQ ID NO: 1845 S100A4 NM_002961.2 Forward PrimerGACTGCTGTCATGGCGTG SEQ ID NO: 1846 Probe ATCACATCCAGGGCCTTCTCCAGA SEQ IDNO: 1847 Reverse Primer CGAGTACTTGTGGAAGGTGGAC SEQ ID NO: 1848 S100A8NM_002964.3 Forward Primer ACTCCCTGATAAAGGGGAATTT SEQ ID NO: 1849 ProbeCATGCCGTCTACAGGGATGACCTG SEQ ID NO: 1850 Reverse PrimerTGAGGACACTCGGTCTCTAGC SEQ ID NO: 1851 S100A9 NM_002965.2 Forward PrimerCTTTGGGACAGAGTGCAAGA SEQ ID NO: 1852 Probe CGATGACTTGCAAAATGTCGCAGC SEQID NO: 1853 Reverse Primer TGGTCTCTATGTTGCGTTCC SEQ ID NO: 1854 S100PNM_005980.2 Forward Primer AGACAAGGATGCCGTGGATAA SEQ ID NO: 1855 ProbeTTGCTCAAGGACCTGGACGCCAA SEQ ID NO: 1856 Reverse PrimerGAAGTCCACCTGGGCATCTC SEQ ID NO: 1857 SAT NM_002970.1 Forward PrimerCCTTTTACCACTGCCTGGTT SEQ ID NO: 1858 Probe TCCAGTGCTCTTTCGGCACTTCTG SEQID NO: 1859 Reverse Primer ACAATGCTGTGTCCTTCCG SEQ ID NO: 1860 SBA2NM_018639.3 Forward Primer GGACTCAACGATGGGCAG SEQ ID NO: 1861 ProbeCCCTGTCTGCACCTCCCAGATCTT SEQ ID NO: 1862 Reverse PrimerCGGAAAGATTCAAAAGCAGG SEQ ID NO: 1863 SDC1 NM_002997.1 Forward PrimerGAAATTGACGAGGGGTGTCT SEQ ID NO: 1864 Probe CTCTGAGCGCCTCCATCCAAGG SEQ IDNO: 1865 Reverse Primer AGGAGCTAACGGAGAACCTG SEQ ID NO: 1866 SEMA3BNM_004636.1 Forward Primer GCTCCAGGATGTGTTTCTGTTG SEQ ID NO: 1867 ProbeTCGCGGGACCACCGGACC SEQ ID NO: 1868 Reverse Primer ACGTGGAGAAGACGGCATAGASEQ ID NO: 1869 SEMA3F NM_004186.1 Forward Primer CGCGAGCCCCTCATTATACASEQ ID NO: 1870 Probe CTCCCCACAGCGCATCGAGGAA SEQ ID NO: 1871 ReversePrimer CACTCGCCGTTGACATCCT SEQ ID NO: 1872 SEMA4B NM_020210.1 ForwardPrimer TTCCAGCCCAACACAGTGAA SEQ ID NO: 1873 Probe ACTTTGGCCTGCCCGCTCCTCTSEQ ID NO: 1874 Reverse Primer GAGTCGGGTCGCCAGGTT SEQ ID NO: 1875 SFRP2NM_003013.2 Forward Primer CAAGCTGAACGGTGTGTCC SEQ ID NO: 1876 ProbeCAGCACCGATTTCTTCAGGTCCCT SEQ ID NO: 1877 Reverse PrimerTGCAAGCTGTCTTTGAGCC SEQ ID NO: 1878 SFRP4 NM_003014.2 Forward PrimerTACAGGATGAGGCTGGGC SEQ ID NO: 1879 Probe CCTGGGACAGCCTATGTAAGGCCA SEQ IDNO: 1880 Reverse Primer GTTGTTAGGGCAAGGGGC SEQ ID NO: 1881 SGCBNM_000232.1 Forward Primer CAGTGGAGACCAGTTGGGTAGTG SEQ ID NO: 1882 ProbeCACACATGCAGAGCTTGTAGCGTACCCA SEQ ID NO: 1883 Reverse PrimerCCTTGAAGAGCGTCCCATCA SEQ ID NO: 1884 SHC1 NM_003029.3 Forward PrimerCCAACACCTTCTTGGCTTCT SEQ ID NO: 1885 Probe CCTGTGTTCTTGCTGAGCACCCTC SEQID NO: 1886 Reverse Primer CTGTTATCCCAACCCAAACC SEQ ID NO: 1887 SHHNM_000193.2 Forward Primer GTCCAAGGCACATATCCACTG SEQ ID NO: 1888 ProbeCACCGAGTTCTCTGCTTTCACCGA SEQ ID NO: 1889 Reverse PrimerGAAGCAGCCTCCCGATTT SEQ ID NO: 1890 SI NM_001041.1 Forward PrimerAACGGACTCCCTCAATTTGT SEQ ID NO: 1891 Probe TGTCCATGGTCATGCAAATCTTGC SEQID NO: 1892 Reverse Primer GAAATTGCAGGGTCCAAGAT SEQ ID NO: 1893 Siah-1NM_003031.2 Forward Primer TTGGCATTGGAACTACATTCA SEQ ID NO: 1894 ProbeTCCGCGGTATCCTCGGATTAGTTC SEQ ID NO: 1895 Reverse PrimerGGTATGGAGAAGGGGGTCC SEQ ID NO: 1896 SIAT4A NM_003033.2 Forward PrimerAACCACAGTTGGAGGAGGAC SEQ ID NO: 1897 Probe CAGAGACAGTTTCCCTCCCCGCT SEQID NO: 1898 Reverse Primer CGAAGGAAGGGTGTTGGTAT SEQ ID NO: 1899 SIAT7BNM_006456.1 Forward Primer TCCAGCCCAAATCCTCCT SEQ ID NO: 1900 ProbeTGGCACATCCTACCCCAGATGCTA SEQ ID NO: 1901 Reverse PrimerGGTGTCCTGGAGTCCTTGAA SEQ ID NO: 1902 SIM2 NM_005069.2 Forward PrimerGATGGTAGGAAGGGATGTGC SEQ ID NO: 1903 Probe CGCCTCTCCACGCACTCAGCTAT SEQID NO: 1904 Reverse Primer CACAAGGAGCTGTGAATGAGG SEQ ID NO: 1905 SIN3ANM_015477.1 Forward Primer CCAGAGTCATGCTCATCCAG SEQ ID NO: 1906 ProbeCTGTCCCTGCACTGGTGCAACTG SEQ ID NO: 1907 Reverse PrimerCCACCTTCAGCCTCTGAAAT SEQ ID NO: 1908 SIR2 NM_012238.3 Forward PrimerAGCTGGGGTGTCTGTTTCAT SEQ ID NO: 1909 Probe CCTGACTTCAGGTCAAGGGATGG SEQID NO: 1910 Reverse Primer ACAGCAAGGCGAGCATAAAT SEQ ID NO: 1911 SKP1ANM_006930.2 Forward Primer CCATTGCCTTTGCTTTGTTCAT SEQ ID NO: 1912 ProbeTCCCATGGTTTTTATTCTGCCCTGCTG SEQ ID NO: 1913 Reverse PrimerTTCCGGATTTCCTTTCTTTGC SEQ ID NO: 1914 SKP2 NM_005983.2 Forward PrimerAGTTGCAGAATCTAAGCCTGGAA SEQ ID NO: 1915 Probe CCTGCGGCTTTCGGATCCCA SEQID NO: 1916 Reverse Primer TGAGTTTTTTGCGAGAGTATTGACA SEQ ID NO: 1917SLC25A3 NM_213611.1 Forward Primer TCTGCCAGTGCTGAATTCTT SEQ ID NO: 1918Probe TGCTGACATTGCCCTGGCTCCTAT SEQ ID NO: 1919 Reverse PrimerTTCGAACCTTAGCAGCTTCC SEQ ID NO: 1920 SLC2A1 NM_006516.1 Forward PrimerGCCTGAGTCTCCTGTGCC SEQ ID NO: 1921 Probe ACATCCCAGGCTTCACCCTGAATG SEQ IDNO: 1922 Reverse Primer AGTCTCCACCCTCAGGCAT SEQ ID NO: 1923 SLC31A1NM_001859.2 Forward Primer CCGTTCGAAGAGTCGTGAG SEQ ID NO: 1924 ProbeTCTCCGAATCTTAACCCGTCACCC SEQ ID NO: 1925 Reverse PrimerAGTCCAGCCACTAGCACCTC SEQ ID NO: 1926 SLC5A8 NM_145913.2 Forward PrimerCCTGCTTTCAACCACATTGA SEQ ID NO: 1927 Probe TCCCATTGCTCTTGCCACTCTGAT SEQID NO: 1928 Reverse Primer AGAGCAGCTTCACAAACGAG SEQ ID NO: 1929 SLC7A5NM_003486.4 Forward Primer GCGCAGAGGCCAGTTAAA SEQ ID NO: 1930 ProbeAGATCACCTCCTCGAACCCACTCC SEQ ID NO: 1931 Reverse PrimerAGCTGAGCTGTGGGTTGC SEQ ID NO: 1932 SLPI NM_003064.2 Forward PrimerATGGCCAATGTTTGATGCT SEQ ID NO: 1933 Probe TGGCCATCCATCTCACAGAAATTGG SEQID NO: 1934 Reverse Primer ACACTTCAAGTCACGCTTGC SEQ ID NO: 1935 SMARCA3NM_003071.2 Forward Primer AGGGACTGTCCTGGCACAT SEQ ID NO: 1936 ProbeAGCAAAAGACCCAGGACATCTGCA SEQ ID NO: 1937 Reverse PrimerCAACAAATTTGCCGCAGTC SEQ ID NO: 1938 SNAI1 NM_005985.2 Forward PrimerCCCAATCGGAAGCCTAACTA SEQ ID NO: 1939 Probe TCTGGATTAGAGTCCTGCAGCTCGC SEQID NO: 1940 Reverse Primer GTAGGGCTGCTGGAAGGTAA SEQ ID NO: 1941 SNAI2NM_003068.3 Forward Primer GGCTGGCCAAACATAAGCA SEQ ID NO: 1942 ProbeCTGCACTGCGATGCCCAGTCTAGAAAATC SEQ ID NO: 1943 Reverse PrimerTCCTTGTCACAGTATTTACAGCTGAA SEQ ID NO: 1944 SNRPF NM_003095.1 ForwardPrimer GGCTGGTCGGCAGAGAGTAG SEQ ID NO: 1945 ProbeAAACTCATGTAAACCACGGCCGAATGTTG SEQ ID NO: 1946 Reverse PrimerTGAGGAAAGGTTTGGGATTGA SEQ ID NO: 1947 SOD1 NM_000454.3 Forward PrimerTGAAGAGAGGCATGTTGGAG SEQ ID NO: 1948 Probe TTTGTCAGCAGTCACATTGCCCAA SEQID NO: 1949 Reverse Primer AATAGACACATCGGCCACAC SEQ ID NO: 1950 SOD2NM_000636.1 Forward Primer GCTTGTCCAAATCAGGATCCA SEQ ID NO: 1951 ProbeAACAACAGGCCTTATTCCACTGCTGGG SEQ ID NO: 1952 Reverse PrimerAGCGTGCTCCCACACATCA SEQ ID NO: 1953 SOS1 NM_005633.2 Forward PrimerTCTGCACCAAATTCTCCAAG SEQ ID NO: 1954 Probe AACACCGTTAACACCTCCGCCTG SEQID NO: 1955 Reverse Primer GTGGTACTGGAAGCACCAGA SEQ ID NO: 1956 SOX17NM_022454.2 Forward Primer TCGTGTGCAAGCCTGAGA SEQ ID NO: 1957 ProbeCTCCCCTACCAGGGGCATGACTC SEQ ID NO: 1958 Reverse PrimerCTGTCGGGGAGATTCACAC SEQ ID NO: 1959 SPARC NM_003118.1 Forward PrimerTCTTCCCTGTACACTGGCAGTTC SEQ ID NO: 1960 Probe TGGACCAGCACCCCATTGACGG SEQID NO: 1961 Reverse Primer AGCTCGGTGTGGGAGAGGTA SEQ ID NO: 1962 SPINT2NM_021102.1 Forward Primer AGGAATGCAGCGGATTCCT SEQ ID NO: 1963 ProbeCCCAAGTGCTCCCAGAAGGCAGG SEQ ID NO: 1964 Reverse PrimerTCGCTGGAGTGGTCTTCAGA SEQ ID NO: 1965 SPRY1 AK026960.1 Forward PrimerCAGACCAGTCCCTGGTCATAGG SEQ ID NO: 1966 Probe CTGGGTCCGGATTGCCCTTTCAG SEQID NO: 1967 Reverse Primer CCTTCAAGTCATCCACAATCAGTT SEQ ID NO: 1968SPRY2 NM_005842.1 Forward Primer TGTGGCAAGTGCAAATGTAA SEQ ID NO: 1969Probe CAGAGGCCTTGGGTAGGTGCACTC SEQ ID NO: 1970 Reverse PrimerGTCGCAGATCCAGTCTGATG SEQ ID NO: 1971 SR-A1 NM_021228.1 Forward PrimerAGATGGAAGAAGCCAACCTG SEQ ID NO: 1972 Probe CTGGATCAGCTCCTGGGCCTTC SEQ IDNO: 1973 Reverse Primer CTGTGGCTGAGGATCTGGT SEQ ID NO: 1974 ST14NM_021978.2 Forward Primer TGACTGCACATGGAACATTG SEQ ID NO: 1975 ProbeAGGTGCCCAACAACCAGCATGT SEQ ID NO: 1976 Reverse PrimerAAGAATTTGAAGCGCACCTT SEQ ID NO: 1977 STAT1 NM_007315.1 Forward PrimerGGGCTCAGCTTTCAGAAGTG SEQ ID NO: 1978 Probe TGGCAGTTTTCTTCTGTCACCAAAA SEQID NO: 1979 Reverse Primer ACATGTTCAGCTGGTCCACA SEQ ID NO: 1980 STAT3NM_003150.1 Forward Primer TCACATGCCACTTTGGTGTT SEQ ID NO: 1981 ProbeTCCTGGGAGAGATTGACCAGCA SEQ ID NO: 1982 Reverse PrimerCTTGCAGGAAGCGGCTATAC SEQ ID NO: 1983 STAT5A NM_003152.1 Forward PrimerGAGGCGCTCAACATGAAATTC SEQ ID NO: 1984 Probe CGGTTGCTCTGCACTTCGGCCT SEQID NO: 1985 Reverse Primer GCCAGGAACACGAGGTTCTC SEQ ID NO: 1986 STAT5BNM_012448.1 Forward Primer CCAGTGGTGGTGATCGTTCA SEQ ID NO: 1987 ProbeCAGCCAGGACAACAATGCGACGG SEQ ID NO: 1988 Reverse PrimerGCAAAAGCATTGTCCCAGAGA SEQ ID NO: 1989 STC1 NM_003155.1 Forward PrimerCTCCGAGGTGAGGAGGACT SEQ ID NO: 1990 Probe CACATCAAACGCACATCCCATGAG SEQID NO: 1991 Reverse Primer ACCTCTCCCTGGTTATGCAC SEQ ID NO: 1992 STK11NM_000455.3 Forward Primer GGACTCGGAGACGCTGTG SEQ ID NO: 1993 ProbeTTCTTGAGGATCTTGACGGCCCTC SEQ ID NO: 1994 Reverse PrimerGGGATCCTTCGCAACTTCTT SEQ ID NO: 1995 STK15 NM_003600.1 Forward PrimerCATCTTCCAGGAGGACCACT SEQ ID NO: 1996 Probe CTCTGTGGCACCCTGGACTACCTG SEQID NO: 1997 Reverse Primer TCCGACCTTCAATCATTTCA SEQ ID NO: 1998 STMN1NM_005563.2 Forward Primer AATACCCAACGCACAAATGA SEQ ID NO: 1999 ProbeCACGTTCTCTGCCCCGTTTCTTG SEQ ID NO: 2000 Reverse PrimerGGAGACAATGCAAACCACAC SEQ ID NO: 2001 STMY3 NM_005940.2 Forward PrimerCCTGGAGGCTGCAACATACC SEQ ID NO: 2002 Probe ATCCTCCTGAAGCCCTTTTCGCAGC SEQID NO: 2003 Reverse Primer TACAATGGCTTTGGAGGATAGCA SEQ ID NO: 2004 STSNM_000351.2 Forward Primer GAAGATCCCTTTCCTCCTACTGTTC SEQ ID NO: 2005Probe CTTCGTGGCTCTCGGCTTCCCA SEQ ID NO: 2006 Reverse PrimerGGATGATGTTCGGCCTTGAT SEQ ID NO: 2007 SURV NM_001168.1 Forward PrimerTGTTTTGATTCCCGGGCTTA SEQ ID NO: 2008 Probe TGCCTTCTTCCTCCCTCACTTCTCACCTSEQ ID NO: 2009 Reverse Primer CAAAGCTGTCAGCTCTAGCAAAAG SEQ ID NO: 2010TAGLN NM_003186.2 Forward Primer GATGGAGCAGGTGGCTCAGT SEQ ID NO: 2011Probe CCCAGAGTCCTCAGCCGCCTTCAG SEQ ID NO: 2012 Reverse PrimerAGTCTGGAACATGTCAGTCTTGATG SEQ ID NO: 2013 TBP NM_003194.1 Forward PrimerGCCCGAAACGCCGAATATA SEQ ID NO: 2014 Probe TACCGCAGCAAACCGCTTGGG SEQ IDNO: 2015 Reverse Primer CGTGGCTCTCTTATCCTCATGAT SEQ ID NO: 2016 TCF-1NM_000545.3 Forward Primer GAGGTCCTGAGCACTGCC SEQ ID NO: 2017 ProbeCTGGGTTCACAGGCTCCTTTGTCC SEQ ID NO: 2018 Reverse PrimerGATGTGGGACCATGCTTGT SEQ ID NO: 2019 TCF-7 NM_003202.2 Forward PrimerGCAGCTGCAGTCAACAGTTC SEQ ID NO: 2020 Probe AAGTCATGGCCCAAATCCAGTGTG SEQID NO: 2021 Reverse Primer CTGTGAATGGGGAGGGGT SEQ ID NO: 2022 TCF7L1NM_031283.1 Forward Primer CCGGGACACTTTCCAGAAG SEQ ID NO: 2023 ProbeTCTCACTTCGGCGAAATAGTCCCG SEQ ID NO: 2024 Reverse PrimerAGAACGCGCTGTCCTGAG SEQ ID NO: 2025 TCF7L2 NM_030756.1 Forward PrimerCCAATCACGACAGGAGGATT SEQ ID NO: 2026 Probe AGACACCCCTACCCCACAGCTCTG SEQID NO: 2027 Reverse Primer TGGACACGGAAGCATTGAC SEQ ID NO: 2028 TCFL4NM_170607.2 Forward Primer CTGACTGCTCTGCTTAAAGGTGAA SEQ ID NO: 2029Probe TAGCAGGAACAACAACAAAAGCCAACCAA SEQ ID NO: 2030 Reverse PrimerATGTCTTGCACTGGCTACCTTGT SEQ ID NO: 2031 TEK NM_000459.1 Forward PrimerACTTCGGTGCTACTTAACAACTTACATC SEQ ID NO: 2032 ProbeAGCTCGGACCACGTACTGCTCCCTG SEQ ID NO: 2033 Reverse PrimerCCTGGGCCTTGGTGTTGAC SEQ ID NO: 2034 TERC U86046.1 Forward PrimerAAGAGGAACGGAGCGAGTC SEQ ID NO: 2035 Probe CACGTCCCACAGCTCAGGGAATC SEQ IDNO: 2036 Reverse Primer ATGTGTGAGCCGAGTCCTG SEQ ID NO: 2037 TERTNM_003219.1 Forward Primer GACATGGAGAACAAGCTGTTTGC SEQ ID NO: 2038 ProbeACCAAACGCAGGAGCAGCCCG SEQ ID NO: 2039 Reverse PrimerGAGGTGTCACCAACAAGAAATCAT SEQ ID NO: 2040 TFF3 NM_003226.1 Forward PrimerAGGCACTGTTCATCTCAGTTTTTCT SEQ ID NO: 2041 Probe CAGAAAGCTTGCCGGGAGCAAAGGSEQ ID NO: 2042 Reverse Primer CATCAGGCTCCAGATATGAACTTTC SEQ ID NO: 2043TGFA NM_003236.1 Forward Primer GGTGTGCCACAGACCTTCCT SEQ ID NO: 2044Probe TTGGCCTGTAATCACCTGTGCAGCCTT SEQ ID NO: 2045 Reverse PrimerACGGAGTTCTTGACAGAGTTTTGA SEQ ID NO: 2046 TGFB2 NM_003238.1 ForwardPrimer ACCAGTCCCCCAGAAGACTA SEQ ID NO: 2047 Probe TCCTGAGCCCGAGGAAGTCCCSEQ ID NO: 2048 Reverse Primer CCTGGTGCTGTTGTAGATGG SEQ ID NO: 2049TGFB3 NM_003239.1 Forward Primer GGATCGAGCTCTTCCAGATCCT SEQ ID NO: 2050Probe CGGCCAGATGAGCACATTGCC SEQ ID NO: 2051 Reverse PrimerGCCACCGATATAGCGCTGTT SEQ ID NO: 2052 TGFBI NM_000358.1 Forward PrimerGCTACGAGTGCTGTCCTGG SEQ ID NO: 2053 Probe CCTTCTCCCCAGGGACCTTTTCAT SEQID NO: 2054 Reverse Primer AGTGGTAGGGCTGCTGGAC SEQ ID NO: 2055 TGFBR1NM_004612.1 Forward Primer GTCATCACCTGGCCTTGG SEQ ID NO: 2056 ProbeAGCAATGACAGCTGCCAGTTCCAC SEQ ID NO: 2057 Reverse PrimerGCAGACGAAGCACACTGGT SEQ ID NO: 2058 TGFBR2 NM_003242.2 Forward PrimerAACACCAATGGGTTCCATCT SEQ ID NO: 2059 Probe TTCTGGGCTCCTGATTGCTCAAGC SEQID NO: 2060 Reverse Primer CCTCTTCATCAGGCCAAACT SEQ ID NO: 2061 THBS1NM_003246.1 Forward Primer CATCCGCAAAGTGACTGAAGAG SEQ ID NO: 2062 ProbeCCAATGAGCTGAGGCGGCCTCC SEQ ID NO: 2063 Reverse PrimerGTACTGAACTCCGTTGTGATAGCATAG SEQ ID NO: 2064 THY1 NM_006288.2 ForwardPrimer GGACAAGACCCTCTCAGGCT SEQ ID NO: 2065 ProbeCAAGCTCCCAAGAGCTTCCAGAGC SEQ ID NO: 2066 Reverse PrimerTTGGAGGCTGTGGGTCAG SEQ ID NO: 2067 TIMP1 NM_003254.1 Forward PrimerTCCCTGCGGTCCCAGATAG SEQ ID NO: 2068 Probe ATCCTGCCCGGAGTGGAACTGAAGC SEQID NO: 2069 Reverse Primer GTGGGAACAGGGTGGACACT SEQ ID NO: 2070 TIMP2NM_003255.2 Forward Primer TCACCCTCTGTGACTTCATCGT SEQ ID NO: 2071 ProbeCCCTGGGACACCCTGAGCACCA SEQ ID NO: 2072 Reverse PrimerTGTGGTTCAGGCTCTTCTTCTG SEQ ID NO: 2073 TIMP3 NM_000362.2 Forward PrimerCTACCTGCCTTGCTTTGTGA SEQ ID NO: 2074 Probe CCAAGAACGAGTGTCTCTGGACCG SEQID NO: 2075 Reverse Primer ACCGAAATTGGAGAGCATGT SEQ ID NO: 2076 TJP1NM_003257.1 Forward Primer ACTTTGCTGGGACAAAGGTC SEQ ID NO: 2077 ProbeCTCGGGCCTGCCCACTTCTTC SEQ ID NO: 2078 Reverse PrimerCACATGGACTCCTCAGCATC SEQ ID NO: 2079 TK1 NM_003258.1 Forward PrimerGCCGGGAAGACCGTAATTGT SEQ ID NO: 2080 Probe CAAATGGCTTCCTCTGGAAGGTCCCASEQ ID NO: 2081 Reverse Primer CAGCGGCACCAGGTTCAG SEQ ID NO: 2082 TLN1NM_006289.2 Forward Primer AAGCAGAAGGGAGAGCGTAAGA SEQ ID NO: 2083 ProbeCTTCCAGGCACACAAGAATTGTGGGC SEQ ID NO: 2084 Reverse PrimerCCTTGGCCTCAATCTCACTCA SEQ ID NO: 2085 TMEPAI NM_020182.3 Forward PrimerCAGAAGGATGCCTGTGGC SEQ ID NO: 2086 Probe ATTCCGTTGCCTGACACTGTGCTC SEQ IDNO: 2087 Reverse Primer GTAGACCTGCGGCTCTGG SEQ ID NO: 2088 TMSB10NM_021103.2 Forward Primer GAAATCGCCAGCTTCGATAA SEQ ID NO: 2089 ProbeCGTCTCCGTTTTCTTCAGCTTGGC SEQ ID NO: 2090 Reverse PrimerGTCGGCAGGGTGTTCTTTT SEQ ID NO: 2091 TMSB4X NM_021109.2 Forward PrimerCACATCAAAGAACTACTGACAACGAA SEQ ID NO: 2092 Probe CCGCGCCTGCCTTTCCCA SEQID NO: 2093 Reverse Primer CCTGCCAGCCAGATAGATAGACA SEQ ID NO: 2094 TNCNM_002160.1 Forward Primer AGCTCGGAACCTCACCGT SEQ ID NO: 2095 ProbeCAGCCTTCGGGCTGTGGACATAC SEQ ID NO: 2096 Reverse PrimerGTAGCAGCCTTGAGGCCC SEQ ID NO: 2097 TNF NM_000594.1 Forward PrimerGGAGAAGGGTGACCGACTCA SEQ ID NO: 2098 Probe CGCTGAGATCAATCGGCCCGACTA SEQID NO: 2099 Reverse Primer TGCCCAGACTCGGCAAAG SEQ ID NO: 2100 TNFRSF5NM_001250.3 Forward Primer TCTCACCTCGCTATGGTTCGT SEQ ID NO: 2101 ProbeTGCCTCTGCAGTGCGTCCTCTGG SEQ ID NO: 2102 Reverse PrimerGATGGACAGCGGTCAGCAA SEQ ID NO: 2103 TNFRSF6B NM_003823.2 Forward PrimerCCTCAGCACCAGGGTACCA SEQ ID NO: 2104 Probe TGACGGCACGCTCACACTCCTCAG SEQID NO: 2105 Reverse Primer TGTCCTGGAAAGCCACAAAGT SEQ ID NO: 2106 TNFSF4NM_003326.2 Forward Primer CTTCATCTTCCCTCTACCCAGA SEQ ID NO: 2107 ProbeCAGGGGTTGGACCCTTTCCATCTT SEQ ID NO: 2108 Reverse PrimerGCTGCATTTCCCACATTCTC SEQ ID NO: 2109 TOP2A NM_001067.1 Forward PrimerAATCCAAGGGGGAGAGTGAT SEQ ID NO: 2110 Probe CATATGGACTTTGACTCAGCTGTGGCSEQ ID NO: 2111 Reverse Primer GTACAGATTTTGCCCGAGGA SEQ ID NO: 2112TOP2B NM_001068.1 Forward Primer TGTGGACATCTTCCCCTCAGA SEQ ID NO: 2113Probe TTCCCTACTGAGCCACCTTCTCTG SEQ ID NO: 2114 Reverse PrimerCTAGCCCGACCGGTTCGT SEQ ID NO: 2115 TP NM_001953.2 Forward PrimerCTATATGCAGCCAGAGATGTGACA SEQ ID NO: 2116 Probe ACAGCCTGCCACTCATCACAGCCSEQ ID NO: 2117 Reverse Primer CCACGAGTTTCTTACTGAGAATGG SEQ ID NO: 2118TP53BP1 NM_005657.1 Forward Primer TGCTGTTGCTGAGTCTGTTG SEQ ID NO: 2119Probe CCAGTCCCCAGAAGACCATGTCTG SEQ ID NO: 2120 Reverse PrimerCTTGCCTGGCTTCACAGATA SEQ ID NO: 2121 TP53BP2 NM_005426.1 Forward PrimerGGGCCAAATATTCAGAAGC SEQ ID NO: 2122 Probe CCACCATAGCGGCCATGGAG SEQ IDNO: 2123 Reverse Primer GGATGGGTATGATGGGACAG SEQ ID NO: 2124 TP53I3NM_004881.2 Forward Primer GCGGACTTAATGCAGAGACA SEQ ID NO: 2125 ProbeCAGTATGACCCACCTCCAGGAGCC SEQ ID NO: 2126 Reverse PrimerTCAAGTCCCAAAATGTTGCT SEQ ID NO: 2127 TRAG3 NM_004909.1 Forward PrimerGACGCTGGTCTGGTGAAGATG SEQ ID NO: 2128 Probe CCAGGAAACCACGAGCCTCCAGC SEQID NO: 2129 Reverse Primer TGGGTGGTTGTTGGACAATG SEQ ID NO: 2130 TRAILNM_003810.1 Forward Primer CTTCACAGTGCTCCTGCAGTCT SEQ ID NO: 2131 ProbeAAGTACACGTAAGTTACAGCCACACA SEQ ID NO: 2132 Reverse PrimerCATCTGCTTCAGCTCGTTGGT SEQ ID NO: 2133 TS NM_001071.1 Forward PrimerGCCTCGGTGTGCCTTTCA SEQ ID NO: 2134 Probe CATCGCCAGCTACGCCCTGCTC SEQ IDNO: 2135 Reverse Primer CGTGATGTGCGCAATCATG SEQ ID NO: 2136 TSTNM_003312.4 Forward Primer GGAGCCGGATGCAGTAGGA SEQ ID NO: 2137 ProbeACCACGGATATGGCCCGAGTCCA SEQ ID NO: 2138 Reverse PrimerAAGTCCATGAAAGGCATGTTGA SEQ ID NO: 2139 TUBA1 NM_006000.1 Forward PrimerTGTCACCCCGACTCAACGT SEQ ID NO: 2140 Probe AGACGCACCGCCCGGACTCAC SEQ IDNO: 2141 Reverse Primer ACGTGGACTGAGATGCATTCAC SEQ ID NO: 2142 TUBBNM_001069.1 Forward Primer CGAGGACGAGGCTTAAAAAC SEQ ID NO: 2143 ProbeTCTCAGATCAATCGTGCATCCTTAGTGAA SEQ ID NO: 2144 Reverse PrimerACCATGCTTGAGGACAACAG SEQ ID NO: 2145 TUFM NM_003321.3 Forward PrimerGTATCACCATCAATGCGGC SEQ ID NO: 2146 Probe CATGTGGAGTATAGCACTGCCGCC SEQID NO: 2147 Reverse Primer CAGTCTGTGTGGGCGTAGTG SEQ ID NO: 2148 TULP3NM_003324.2 Forward Primer TGTGTATAGTCCTGCCCCTCAA SEQ ID NO: 2149 ProbeCCGGATTATCCGACATCTTACTGTGA SEQ ID NO: 2150 Reverse PrimerCCCGATCCATTCCCCTTTTA SEQ ID NO: 2151 tusc4 NM_006545.4 Forward PrimerGGAGGAGCTAAATGCCTCAG SEQ ID NO: 2152 Probe ACTCATCAATGGGCAGAGTGCACC SEQID NO: 2153 Reverse Primer CCTTCAAGTGGATGGTGTTG SEQ ID NO: 2154 UBBNM_018955.1 Forward Primer GAGTCGACCCTGCACCTG SEQ ID NO: 2155 ProbeAATTAACAGCCACCCCTCAGGCG SEQ ID NO: 2156 Reverse PrimerGCGAATGCCATGACTGAA SEQ ID NO: 2157 UBC NM_021009.2 Forward PrimerACGCACCCTGTCTGACTACA SEQ ID NO: 2158 Probe CATCCAGAAAGAGTCCACCCTGCA SEQID NO: 2159 Reverse Primer ACCTCTAAGACGGAGCACCA SEQ ID NO: 2160 UBE2CNM_007019.2 Forward Primer TGTCTGGCGATAAAGGGATT SEQ ID NO: 2161 ProbeTCTGCCTTCCCTGAATCAGACAACC SEQ ID NO: 2162 Reverse PrimerATGGTCCCTACCCATTTGAA SEQ ID NO: 2163 UBE2M NM_003969.1 Forward PrimerCTCCATAATTTATGGCCTGCAGTA SEQ ID NO: 2164 Probe TCTTCTTGGAGCCCAACCCCGAGSEQ ID NO: 2165 Reverse Primer TGCGGCCTCCTTGTTCAG SEQ ID NO: 2166 UBL1NM_003352.3 Forward Primer GTGAAGCCACCGTCATCATG SEQ ID NO: 2167 ProbeCTGACCAGGAGGCAAAACCTTCAACTGA SEQ ID NO: 2168 Reverse PrimerCCTTCCTTCTTATCCCCCAAGT SEQ ID NO: 2169 UCP2 NM_003355.2 Forward PrimerACCATGCTCCAGAAGGAGG SEQ ID NO: 2170 Probe CCCCGAGCCTTCTACAAAGGGTTC SEQID NO: 2171 Reverse Primer AACCCAAGCGGAGAAAGG SEQ ID NO: 2172 UGT1A1NM_000463.2 Forward Primer CCATGCAGCCTGGAATTTG SEQ ID NO: 2173 ProbeCTACCCAGTGCCCCAACCCATTCTC SEQ ID NO: 2174 Reverse PrimerGAGAGGCCTGGGCACGTA SEQ ID NO: 2175 UMPS NM_000373.1 Forward PrimerTGCGGAAATGAGCTCCAC SEQ ID NO: 2176 Probe CCCTGGCCACTGGGGACTACACTA SEQ IDNO: 2177 Reverse Primer CCTCAGCCATTCTAACCGC SEQ ID NO: 2178 UNC5AXM_030300.7 Forward Primer GACAGCTGATCCAGGAGCC SEQ ID NO: 2179 ProbeCGGGTCCTGCACTTCAAGGACAGT SEQ ID NO: 2180 Reverse PrimerATGGATAGGCGCAGGTTG SEQ ID NO: 2181 UNC5B NM_170744.2 Forward PrimerAGAACGGAGGCCGTGACT SEQ ID NO: 2182 Probe CGGGACGCTGCTCGACTCTAAGAA SEQ IDNO: 2183 Reverse Primer CATGCACAGCCCATCTGT SEQ ID NO: 2184 UNC5CNM_003728.2 Forward Primer CTGAACACAGTGGAGCTGGT SEQ ID NO: 2185 ProbeACCTGCCGCACACAGAGTTTGC SEQ ID NO: 2186 Reverse PrimerCTGGAAGATCTGCCCTTCTC SEQ ID NO: 2187 upa NM_002658.1 Forward PrimerGTGGATGTGCCCTGAAGGA SEQ ID NO: 2188 Probe AAGCCAGGCGTCTACACGAGAGTCTCACSEQ ID NO: 2189 Reverse Primer CTGCGGATCCAGGGTAAGAA SEQ ID NO: 2190 UPP1NM_003364.2 Forward Primer ACGGGTCCTGCCTCAGTT SEQ ID NO: 2191 ProbeTCAGCTTTCTCTGCATTGGCTCCC SEQ ID NO: 2192 Reverse PrimerCGGGGCAATCATTGTGAC SEQ ID NO: 2193 VCAM1 NM_001078.2 Forward PrimerTGGCTTCAGGAGCTGAATACC SEQ ID NO: 2194 Probe CAGGCACACACAGGTGGGACACAAATSEQ ID NO: 2195 Reverse Primer TGCTGTCGTGATGAGAAAATAGTG SEQ ID NO: 2196VCL NM_003373.2 Forward Primer GATACCACAACTCCCATCAAGCT SEQ ID NO: 2197Probe AGTGGCAGCCACGGCGCC SEQ ID NO: 2198 Reverse PrimerTCCCTGTTAGGCGCATCAG SEQ ID NO: 2199 VCP NM_007126.2 Forward PrimerGGCTTTGGCAGCTTCAGAT SEQ ID NO: 2200 Probe AGCTCCACCCTGGTTCCCTGAAG SEQ IDNO: 2201 Reverse Primer CTCCACTGCCCTGACTGG SEQ ID NO: 2202 VDAC1NM_003374.1 Forward Primer GCTGCGACATGGATTTCGA SEQ ID NO: 2203 ProbeTTGCTGGGCCTTCCATCCGG SEQ ID NO: 2204 Reverse Primer CCAGCCCTCGTAACCTAGCASEQ ID NO: 2205 VDAC2 NM_003375.2 Forward Primer ACCCACGGACAGACTTGC SEQID NO: 2206 Probe CGCGTCCAATGTGTATTCCTCCAT SEQ ID NO: 2207 ReversePrimer AGCTTTGCCAAGGTCAGC SEQ ID NO: 2208 VDR NM_000376.1 Forward PrimerGCCCTGGATTTCAGAAAGAG SEQ ID NO: 2209 Probe CAAGTCTGGATCTGGGACCCTTTCC SEQID NO: 2210 Reverse Primer AGTTACAAGCCAGGGAAGGA SEQ ID NO: 2211 VEGFNM_003376.3 Forward Primer CTGCTGTCTTGGGTGCATTG SEQ ID NO: 2212 ProbeTTGCCTTGCTGCTCTACCTCCACCA SEQ ID NO: 2213 Reverse PrimerGCAGCCTGGGACCACTTG SEQ ID NO: 2214 VEGF_altsplice1 AF486837.1 ForwardPrimer TGTGAATGCAGACCAAAGAAAGA SEQ ID NO: 2215 ProbeAGAGCAAGACAAGAAAATCCCTGTGGGC SEQ ID NO: 2216 Reverse PrimerGCTTTCTCCGCTCTGAGCAA SEQ ID NO: 2217 VEGF_altsplice2 AF214570.1 ForwardPrimer AGCTTCCTACAGCACAACAAAT SEQ ID NO: 2218 ProbeTGTCTTGCTCTATCTTTCTTTGGTCTGCA SEQ ID NO: 2219 Reverse PrimerCTCGGCTTGTCACATTTTTC SEQ ID NO: 2220 VEGFB NM_003377.2 Forward PrimerTGACGATGGCCTGGAGTGT SEQ ID NO: 2221 Probe CTGGGCAGCACCAAGTCCGGA SEQ IDNO: 2222 Reverse Primer GGTACCGGATCATGAGGATCTG SEQ ID NO: 2223 VEGFCNM_005429.2 Forward Primer CCTCAGCAAGACGTTATTTGAAATT SEQ ID NO: 2224Probe CCTCTCTCTCAAGGCCCCAAACCAGT SEQ ID NO: 2225 Reverse PrimerAAGTGTGATTGGCAAAACTGATTG SEQ ID NO: 2226 VIM NM_003380.1 Forward PrimerTGCCCTTAAAGGAACCAATGA SEQ ID NO: 2227 Probe ATTTCACGCATCTGGCGTTCCA SEQID NO: 2228 Reverse Primer GCTTCAACGGCAAAGTTCTCTT SEQ ID NO: 2229 WIFNM_007191.2 Forward Primer TACAAGCTGAGTGCCCAGG SEQ ID NO: 2230 ProbeTACAAAAGCCTCCATTTCGGCACC SEQ ID NO: 2231 Reverse PrimerCACTCGCAGATGCGTCTTT SEQ ID NO: 2232 WISP1 NM_003882.2 Forward PrimerAGAGGCATCCATGAACTTCACA SEQ ID NO: 2233 Probe CGGGCTGCATCAGCACACGC SEQ IDNO: 2234 Reverse Primer CAAACTCCACAGTACTTGGGTTGA SEQ ID NO: 2235 Wnt-3aNM_033131.2 Forward Primer ACAAAGCTACCAGGGAGTCG SEQ ID NO: 2236 ProbeTTTGTCCACGCCATTGCCTCAG SEQ ID NO: 2237 Reverse PrimerTGAGCGTGTCACTGCAAAG SEQ ID NO: 2238 Wnt-5a NM_003392.2 Forward PrimerGTATCAGGACCACATGCAGTACATC SEQ ID NO: 2239 Probe TTGATGCCTGTCTTCGCGCCTTCTSEQ ID NO: 2240 Reverse Primer TGTCGGAATTGATACTGGCATT SEQ ID NO: 2241Wnt-5b NM_032642.2 Forward Primer TGTCTTCAGGGTCTTGTCCA SEQ ID NO: 2242Probe TTCCGTAAGAGGCCTGGTGCTCTC SEQ ID NO: 2243 Reverse PrimerGTGCACGTGGATGAAAGAGT SEQ ID NO: 2244 WNT2 NM_003391.1 Forward PrimerCGGTGGAATCTGGCTCTG SEQ ID NO: 2245 Probe CTCCCTCTGCTCTTGACCTGGCTC SEQ IDNO: 2246 Reverse Primer CCATGAAGAGTTGACCTCGG SEQ ID NO: 2247 WWOXNM_016373.1 Forward Primer ATCGCAGCTGGTGGGTGTA SEQ ID NO: 2248 ProbeCTGCTGTTTACCTTGGCGAGGCCTTT SEQ ID NO: 2249 Reverse PrimerAGCTCCCTGTTGCATGGACTT SEQ ID NO: 2250 XPA NM_000380.2 Forward PrimerGGGTAGAGGGAAAAGGGTTC SEQ ID NO: 2251 Probe CAAAGGCTGAACTGGATTCTTAACCAAGASEQ ID NO: 2252 Reverse Primer TGCACCACCATTGCTATTATT SEQ ID NO: 2253 XPCNM_004628.2 Forward Primer GATACATCGTCTGCGAGGAA SEQ ID NO: 2254 ProbeTTCAAAGACGTGCTCCTGACTGCC SEQ ID NO: 2255 Reverse PrimerCTTTCAATGACTGCCTGCTC SEQ ID NO: 2256 XRCC1 NM_006297.1 Forward PrimerGGAGATGAAGCCCCCAAG SEQ ID NO: 2257 Probe AGAAGCAACCCCAGACCAAAACCA SEQ IDNO: 2258 Reverse Primer GTCCAGCTGCCTGAGTGG SEQ ID NO: 2259 YB-1NM_004559.1 Forward Primer AGACTGTGGAGTTTGATGTTGTTGA SEQ ID NO: 2260Probe TTGCTGCCTCCGCACCCTTTTCT SEQ ID NO: 2261 Reverse PrimerGGAACACCACCAGGACCTGTAA SEQ ID NO: 2262 YWHAH NM_003405.2 Forward PrimerCATGGCCTCCGCTATGAA SEQ ID NO: 2263 Probe AGGTTCATTCAGCTCTGTCACCGC SEQ IDNO: 2264 Reverse Primer GGAGATTTCGATCTTCATTGGA SEQ ID NO: 2265 zbtb7NM_015898.2 Forward Primer CTGCGTTCACACCCCAGT SEQ ID NO: 2266 ProbeTCTCTCCAGAACAGCTCGCCCTGT SEQ ID NO: 2267 Reverse PrimerCTCAGCCACGACAGATGGT SEQ ID NO: 2268 ZG16 NM_152338.1 Forward PrimerTGCTGAGCCTCCTCTCCTT SEQ ID NO: 2269 Probe TACTCCTCATCACAGTGCCCCTGC SEQID NO: 2270 Reverse Primer GGATGGGGGTTAGTGATAAGG SEQ ID NO: 2271

TABLE B Locus Sequence ID Gene Link Sequence Number A-CateninNM_001903.1 CGTTCCGATCCTCTATACTGCATCCCAGGCATGCCTACA SEQ ID NO: 2272GCACCCTGATGTCGCAGCCTATAAGGCCAACAGGGACCT ABCB1 NM_000927.2AAACACCACTGGAGCATTGACTACCAGGCTCGCCAATGATGCTGCTCAA SEQ ID NO: 2273GTTAAAGGGGCTATAGGTTCCAGGCTTG ABCC5 NM_005688.1TGCAGACTGTACCATGCTGACCATTGCCCATCGCCTGCA SEQ ID NO: 2274CACGGTTCTAGGCTCCGATAGGATTATGGTGCTGGCC ABCC6 NM_001171.2GGATGAACCTCGACCTGCTGCAGGAGCACTCGGACGA SEQ ID NO: 2275GGCTATCTGGGCAGCCCTGGAGACGGTGCAGCTC ACP1 NM_004300.2GCTACCAAGTCCGTGCTGTTTGTGTGTCTGGGTAACA SEQ ID NO: 2276TTTGTCGATCACCCATTGCAGAAGCAGTTTTC ADAM10 NM_001110.1CCCATCAACTTGTGCCAGTACAGGGTCTGTGCAGT SEQ ID NO: 2277GGAGTAGGCACTTCAGTGGTCGAACCATCACC ADAM17 NM_003183.3GAAGTGCCAGGAGGCGATTAATGCTACTTGCAAAGGCGTGT SEQ ID NO: 2278CCTACTGCACAGGTAATAGCAGTGAGTGCCCG ADAMTS12 NM_030955.2GGAGAAGGGTGGAGTGCAGCACCCAGATGGATTCTGAC SEQ ID NO: 2279TGTGCGGCCATCCAGAGACCTGACCCTG ADPRT NM_001618.2TTGACAACCTGCTGGACATCGAGGTGGCCTACAGTCTGCTCAG SEQ ID NO: 2280GGGAGGGTCTGATGATAGCAGCAAGGATCCCAT AGXT NM_000030.1CTTTTCCCTCCAGTGGCACCTCCTGGAAACAGTCCACTT SEQ ID NO: 2281GGGCGCAAAACCCAGTGCCTTCCAAAT AKAP12 NM_005100.2TAGAGAGCCCCTGACAATCCTGAGGCTTCATCAGGAGCTAGA SEQ ID NO: 2282GCCATTTAACATTTCCTCTTTCCAAGACCAACC AKT1 NM_005163.1CGCTTCTATGGCGCTGAGATTGTGTCAGCCCTGGACTACCTG SEQ ID NO: 2283CACTCGGAGAAGAACGTGGTGTACCGGGA AKD2 NM_001626.2TCCTGCCACCCTTCAAACCTCAGGTCACGTCCGAGGTCGACACA SEQ ID NO: 2284AGGTACTTCGATGATGAATTTACCGCC AKT3 NM_005465.1TTGTCTGTGCCTTGGACTATCTACATTCCGGAAAGATTGT SEQ ID NO: 2285GTACCGTGATCTCAAGTTGGAGAATCTAATGCTGG AL137428 AL137428.1CAAGAAGAGGCTCTACCCTGGGACTGGGAATTTCCAAGG SEQ ID NO: 2286CCACCTTTGAGGATCGCAGAGCTCATTT ALCAM NM_001627.1GAGGAATATGGAATCCAAGGGGGCCAGTTCCTGCCGT SEQ ID NO: 2287CTGCTCTTCTGCCTCTTGATCTCCGCCAC ALDH1A1 NM_000689.1GAAGGAGATAAGGAGGATGTTGACAAGGCAGTGAAGGCCG SEQ ID NO: 2288CAAGACAGGCTTTTCAGATTGGATCTCCGTGGCG ALDOA NM_000034.2GCCTGTACGTGCCAGCTCCCCGACTGCCAGAGCC SEQ ID NO: 2289TCAACTGTCTCTGCTTCGAGATCAAGCTCCGATGA AMFR NM_001144.2GATGGTTCAGCTCTGCAAGGATCGATTTGAATATCTT SEQ ID NO: 2290TCCTTCTCGCCCACCACGCCGATGAGCAGCCACGGTCGA ANGPD2 NM_001147.1CCGTGAAAGCTGCTCTGTAAAAGCTGACACAGCCCTCCC SEQ ID NO: 2291AAGTGAGCAGGACTGTTCTTCCCACTGCAA ANTXR1 NM_032208.1CTCCAGGTGTACCTCCAACCCTAGCCTTCTCCCACAGCT SEQ ID NO: 2292GCCTACAACAGAGTCTCCCAGCCTTCTC ANXA1 NM_000700.1GCCCCTATCCTACCTTCAATCCATCCTCGGATGTCGCTG SEQ ID NO: 2293CCTTGCATAAGGCCATAATGGTTAAAGG ANXA2 NM_004039.1CAAGACACTAAGGGCGACTACCAGAAAGCGCTGCTGTACC SEQ ID NO: 2294TGTGTGGTGGAGATGACTGAAGCCCGACACG ANXA5 NM_001154.2GCTCAAGCCTGGAAGATGACGTGGTGGGGGACACTTCAGGG SEQ ID NO: 2295TACTACCAGCGGATGTTGGTGGTTCT AP-1 (JUN NM_002228.2GACTGCAAAGATGGAAACGACCTTCTATGACGATGCCC SEQ ID NO: 2296 official)TCAACGCCTCGTTCCTCCCGTCCGAGAGCGGACCTTATGGCTA APC NM_000038.1GGACAGCAGGAATGTGTTTCTCCATACAGGTCACGGGGA SEQ ID NO: 2297GCCAATGGTTCAGAAACAAATCGAGTGGGT APEX-1 NM_001641.2GATGAAGCCTTTCGCAAGTTCCTGAAGGGCCTGGCTTCC SEQ ID NO: 2298CGAAAGCCCCTTGTGCTGTGTGGAGACCT APG-1 NM_014278.2ACCCCGGCCTGTATATCATTGGGATCAAGAACTCGAGCCAT SEQ ID NO: 2299TGGAAATGCAGCAAAGAGCCAGATAG APN (ANPEP NM_001150.1CCACCTTGGACCAAAGTAAAGCGTGGAATCGTTACCGCCTCCCCA SEQ ID NO: 2300 official)ACACGCTGAAACCCGATTCCTACCAGGTGACGCTGAGA APOC1 NM_001645.3GGAAACACACTGGAGGACAAGGCTCGGGAACTCATCAGCCGCA SEQ ID NO: 2301TCAAACAGAGTGAACTTTCTGCCAAGATGCG AREG NM_001657.1TGTGAGTGAAATGCCTTCTAGTAGTGAACCGTCCTCGGGAGC SEQ ID NO: 2302CGACTATGACTACTCAGAAGAGTATGATAACGAACCACAA ARG NM_005158.2CGCAGTGCAGCTGAGTATCTGCTCAGCAGTCTAATCAATGGCAG SEQ ID NO: 2303CTTCCTGGTGCGAGAAAGTGAGAGTAGCCCTGGGCA ARHF NM_019034.2ACTGGCCCACTTAGTCCTCAAGCTCCCAACCTGCTGTCCCTC SEQ ID NO: 2304AAGCCCCGCTTCTACCAGCCTGTGGAGTTCAG ATOH1 NM_005172.1GCAGCCACCTGCAACTTTGCAGGCGAGAGAGCATCCCG SEQ ID NO: 2305TCTACCCGCCTGAGCTGTCCCTCCTGGA ATP5A1 NM_004046.3GATGCTGCCACTCAACAACTTTTGAGTCGTGGCGTGC SEQ ID NO: 2306GTCTAACTGAGTTGCTGAAGCAAGGACA ATP5E NM_006886.2CCGCTTTCGCTACAGCATGGTGGCCTACTGGAGAC SEQ ID NO: 2307AGGCTGGACTCAGCTACATCCGATACTCCCA AURKB NM_004217.1AGCTGCAGAAGAGCTGCACATTTGACGAGCAGCGAACA SEQ ID NO: 2308GCCACGATCATGGAGGAGTTGGCAGATGC Axin 2 NM_004655.2GGCTATGTCTTTGCACCAGCCACCAGCGCCAACGACA SEQ ID NO: 2309GTGAGATATCCAGTGATGCGCTGACGGAT axin1 NM_003502.2CCGTGTGACAGCATCGTTGTGGCGTACTACTTCTGCGG SEQ ID NO: 2310GGAACCCATCCCCTACCGCACCCTGGTGAG B-Catenin NM_001904.1GGCTCTTGTGCGTACTGTCCTTCGGGCTGGTGACAGGGAA SEQ ID NO: 2311GACATCACTGAGCCTGCCATCTGTGCTCTTCGTCATCTGA BAD NM_032989.1GGGTCAGGTGCCTCGAGATCGGGCTTGGGCCCAG SEQ ID NO: 2312AGCATGTTCCAGATCCCAGAGTTTGAGCCGAGTGAGCAG BAG1 NM_004323.2CGTTGTCAGCACTTGGAATACAAGATGGTTGCCGGGTCATGTTA SEQ ID NO: 2313ATTGGGAAAAAGAACAGTCCACAGGAAGAGGTTGAAC BAG2 NM_004282.2CTAGGGGCAAAAAGCATGACTGCTTTTTCCTGTCTGGCATGGAA SEQ ID NO: 2314TCACGCAGTCACCTTGGGCATTTAG BAG3 NM_004281.2GAAAGTAAGCCAGGCCCAGTTGGACCAGAACTCCCTCCTGG SEQ ID NO: 2315ACACATCCCAATTCAAGTGATCCGCAAAGAGGT Bak NM_001188.1CCATTCCCACCATTCTACCTGAGGCCAGGACGTCTGGGG SEQ ID NO: 2316TGTGGGGATTGGTGGGTCTATGTTCCC Bax NM_004324.1CCGCCGTGGACACAGACTCCCCCCGAGAGGTCTTTTTCCG SEQ ID NO: 2317AGTGGCAGCTGACATGTTTTCTGACGGCAA BBC3 NM_014417.1CCTGGAGGGTCCTGTACAATCTCATCATGGGACTCCTGC SEQ ID NO: 2318CCTTACCCAGGGGCCACAGAGCCCCCGAGATGGAGCCCAATTAG BCAS1 NM_003657.1CCCCGAGACAACGGAGATAAGTGCTGTTGCGGATGCCA SEQ ID NO: 2319ACGGAAAGAATCTTGGGAAAGAGGCCAAACCCGAG Bcl2 NM_000633.1CAGATGGACCTAGTACCCACTGAGATTTCCACGCCGAAG SEQ ID NO: 2320GACAGCGATGGGAAAAATGCCCTTAAATCATAGG BCL2L10 NM_020396.2GCTGGGATGGCTTTTGTCACTTCTTCAGGACCCCCT SEQ ID NO: 2321TTCCACTGGCTTTTTGGAGAAAACAGCTGGTCCAGGC BCL2L11 NM_138621.1AATTACCAAGCAGCCGAAGACCACCCACGAATGGTTAT SEQ ID NO: 2322CTTACGACTGTTACGTTACATTGTCCGCCTG BCL2L12 NM_138639.1AACCCACCCCTGTCTTGGAGCTCCGGGTAGCTCTCAAAC SEQ ID NO: 2323TCGAGGCTGCGCACCCCCTTTCCCGTCAGCTGAG Bclx NM_001191.1CTTTTGTGGAACTCTATGGGAACAATGCAGCAGCCGAGAGC SEQ ID NO: 2324CGAAAGGGCCAGGAACGCTTCAACCGCTG BCRP NM_004827.1TGTACTGGCGAAGAATATTTGGTAAAGCAGGGCATCGATCTCT SEQ ID NO: 2325CACCCTGGGGCTTGTGGAAGAATCACGTGGC BFGF NM_007083.1CCAGGAAGAATGCTTAAGATGTGAGTGGATGGATCTCAATGA SEQ ID NO: 2326CCTGGCGAAGACTGAAAATACAACTCCCATCACCA BGN NM_001711.3GAGCTCCGCAAGGATGACTTCAAGGGTCTCCAGCACCTCT SEQ ID NO: 2327ACGCCCTCGTCCTGGTGAACAACAAG BID NM_001196.2GGACTGTGAGGTCAACAACGGTTCCAGCCTCAGGGATGAG SEQ ID NO: 2328TGCATCACAAACCTACTGGTGTTTGGCTTCC BIK NM_001197.3ATTCCTATGGCTCTGCAATTGTCACCGGTTAACTGTGGC SEQ ID NO: 2329CTGTGCCCAGGAAGAGCCATTCACTCCTGCC BIN1 NM_004305.1CCTGCAAAAGGGAACAAGAGCCCTTCGCCTCCAGATGGCTCC SEQ ID NO: 2330CCTGCCGCCACCCCCGAGATCAGAGTCAACCACG BLMH NM_000386.2GGTTGCTGCCTCCATCAAAGATGGAGAGGCTGTGTGGTTTGGCT SEQ ID NO: 2331GTGATGTTGGAAAACACTTCAATAGCAAGCTGG BMP2 NM_001200.1ATGTGGACGCTCTTTCAATGGACGTGTCCCCGCGTGCTTCTTAG SEQ ID NO: 2332ACGGACTGCGGTCTCCTAAAGGTCGACCATGGT BMP4 NM_001202.2GGGCTAGCCATTGAGGTGACTCACCTCCATCAGACTCGGAC SEQ ID NO: 2333CCACCAGGGCCAGCATGTCAGGATTAGC BMP7 NM_001719.1TCGTGGAACATGACAAGGAATTCTTCCACCCACGCTACCACCA SEQ ID NO: 2334TCGAGAGTTCCGGTTTGATCTTTCCA BMPR1A NM_004329.2TTGGTTCAGCGAACTATTGCCAAACAGATTCAGATGG SEQ ID NO: 2335TCCGGCAAGTTGGTAAAGGCCGATATGGAGA BRAF NM_004333.1CCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAA SEQ ID NO: 2336CGAGACCGATCCTCATCAGCTCCCAATGTGCATATAAA BRCA1 NM_007295.1TCAGGGGGCTAGAAATCTGTTGCTATGGGCCCTTCA SEQ ID NO: 2337CCAACATGCCCACAGATCAACTGGAATGG BRCA2 NM_000059.1AGTTCGTGCTTTGCAAGATGGTGCAGAGCTTTATGAAGCA SEQ ID NO: 2338GTGAAGAATGCAGCAGACCCAGCTTACCTT BRK NM_005975.1GTGCAGGAAAGGTTCACAAATGTGGAGTGTCTGCG SEQ ID NO: 2339TCCAATACACGCGTGTGCTCCTCTCCTTACTCCATCGTGTGTGC BTF3 NM_001207.2CAGTGATCCACTTTAACAACCCTAAAGTTCAGGCATCTCTGG SEQ ID NO: 2340CAGCGAACACTTTCACCATTACAGGCCATGCT BTRC NM_033637.2GTTGGGACACAGTTGGTCTGCAGTCGGCCCAGGACG SEQ ID NO: 2341GTCTACTCAGCACAACTGACTGCTTCA BUB1 NM_004336.1CCGAGGTTAATCCAGCACGTATGGGGCCAAGTGTAGGCTC SEQ ID NO: 2342CCAGCAGGAACTGAGAGCGCCATGTCTT BUB1B NM_001211.3TCAACAGAAGGCTGAACCACTAGAAAGACTACAGTCCCAGCA SEQ ID NO: 2343CCGACAATTCCAAGCTCGAGTGTCTCGGCAAACTCTGTTG BUB3 NM_004725.1CTGAAGCAGATGGTTCATCATTTCCTGGGCTGTTAAACAAAGCG SEQ ID NO: 2344AGGTTAAGGTTAGACTCTTGGGAATCAGC c-abl NM_005157.2CCATCTCGCTGAGATACGAAGGGAGGGTGTACCATTACAGGA SEQ ID NO: 2345TCAACACTGCTTCTGATGGCAAGCTCTACGTCT c-kit NM_000222.1GAGGCAACTGCTTATGGCTTAATTAAGTCAGATGCGGCCATGACTG SEQ ID NO: 2346TCGCTGTAAAGATGCTCAAGCCGAGTGCC c-myb (MYB NM_005375.1AACTCAGACTTGGAAATGCCTTCTTTAACTTCCACCCCCCTC SEQ ID NO: 2347 official)ATTGGTCACAAATTGACTGTTACAACACCATTTCATAGAGACCAG c-Src NM_005417.3TGAGGAGTGGTATTTTGGCAAGATCACCAGACGGGAGTCAGA SEQ ID NO: 2348GCGGTTACTGCTCAATGCAGAGAACCCGAGAG C20 orf1 NM_012112.2TCAGCTGTGAGCTGCGGATACCGCCCGGCAAT SEQ ID NO: 2349GGGACCTGCTCTTAACCTCAAACCTAGGACCGT C20ORF126 NM_030815.2CCAGCACTGCTCGTTACTGTCTGCCTTCAGTGGTCTG SEQ ID NO: 2350AGGTCCCAGTATGAACTGCCGTGAAGTCAA C8orf4 NM_020130.2CTACGAGTCAGCCCATCCATCCATGGCTACCACTTCGACA SEQ ID NO: 2351CAGCCTCTCGTAAGAAAGCCGTGGGCA CA9 NM_001216.1ATCCTAGCCCTGGTTTTTGGCCTCCTTTTTGCTGTCACCAGCG SEQ ID NO: 2352TCGCGTTCCTTGTGCAGATGAGAAGGCAG Cad17 NM_004063.2GAAGGCCAAGAACCGAGTCAAATTATATTCCAGTTTAAGGCCAA SEQ ID NO: 2353TCCTCCTGCTGTGACTTTTGAACTAACTGGGGA CALD1 NM_004342.4CACTAAGGTTTGAGACAGTTCCAGAAAGAACCCAAGCTCAA SEQ ID NO: 2354GACGCAGGACGAGCTCAGTTGTAGAGGGCTAATTCGC CAPG NM_001747.1GATTGTCACTGATGGGGAGGAGCCTGCTGAGATGATCCA SEQ ID NO: 2355GGTCCTGGGCCCCAAGCCTGCTCTGAAGG CAPN1 NM_005186.2CAAGAAGCTGTACGAGCTCATCATCACCCGCTACTCGGAGCCCGAC SEQ ID NO: 2356CTGGCGGTCGACTTTGACAATTTCGTTTGCTGC CASP8 NM_033357.1CCTCGGGGATACTGTCTGATCATCAACAATCACAATTTTG SEQ ID NO: 2357CAAAAGCACGGGAGAAAGTGCCCAAACTTC CASP9 NM_001229.2TGAATGCCGTGGATTGCACGTGGCCTCTTGAGCAGTGGCTG SEQ ID NO: 2358GTCCAGGGCTAGTGACTTGTGTCCCATGATCCCTGT CAT NM_001752.1ATCCATTCGATCTCACCAAGGTTTGGCCTCACAAGGACTACCCT SEQ ID NO: 2359CTCATCCCAGTTGGTAAACTGGTCTTAAACCGGA CAV1 NM_001753.3GTGGCTCAACATTGTGTTCCCATTTCAGCTGATCAGTGGGCCTC SEQ ID NO: 2360CAAGGAGGGGCTGTAAAATGGAGGCCATTG CBL NM_005188.1TCATTCACAAACCTGGCAGTTATATCTTCCGGCTGAGCTGTACTC SEQ ID NO: 2361GTCTGGGTCAGTGGGCTATTGGGTATG CCL20 NM_004591.1CCATGTGCTGTACCAAGAGTTTGCTCCTGGCTGCTTTGATGTCA SEQ ID NO: 2362GTGCTGCTACTCCACCTCTGCGGCG CCL3 NM_002983.1AGCAGACAGTGGTCAGTCCTTTCTTGGCTCTGCTGACACTCGAGCCC SEQ ID NO: 2363ACATTCCGTCACCTGCTCAGAATCATGCAG CCNA2 NM_001237.2CCATACCTCAAGTATTTGCCATCAGTTATTGCTGGAGCTGCCTTTCA SEQ ID NO: 2364TTTAGCACTCTACACAGTCACGGGACAAAGCT CCNB1 NM_031966.1TTCAGGTTGTTGCAGGAGACCATGTACATGACTGTCTCCATTATTGA SEQ ID NO: 2365TCGGTTCATGCAGAATAATTGTGTGCCCAAGAAGATG CCNB2 NM_004701.2AGGCTTCTGCAGGAGACTCTGTACATGTGCGTTGGCATTATG SEQ ID NO: 2366GATCGATTTTTACAGGTTCAGCCAGTTTCCC CCND1 NM_001758.1GCATGTTCGTGGCCTCTAAGATGAAGGAGACCATCCCCCTGA SEQ ID NO: 2367CGGCCGAGAAGCTGTGCATCTACACCG CCND3 NM_001760.2CCTCTGTGCTACAGATTATACCTTTGCCATGTACCCGCCATCCATG SEQ ID NO: 2368ATCGCCACGGGCAGCATTGGGGCTGCAGTG CCNE1 NM_001238.1AAAGAAGATGATGACCGGGTTTACCCAAACTCAACGTGCAA SEQ ID NO: 2369GCCTCGGATTATTGCACCATCCAGAGGCTC CCNE2 NM_057749.1ATGCTGTGGCTCCTTCCTAACTGGGGCTTTCTTGACATGTAGGTT SEQ ID NO: 2370GCTTGGTAATAACCTTTTTGTATATCACAATTTGGGT CCNE2 NM_057749var1GGTCACCAAGAAACATCAGTATGAAATTAGGAATTGTTGGCC SEQ ID NO: 2371 variant 1ACCTGTATTATCTGGGGGGATCAGTCCTTGCATTATCATTGAA CCR7 NM_001838.2GGATGACATGCACTCAGCTCTTGGCTCCACTGGGATG SEQ ID NO: 2372GGAGGAGAGGACAAGGGAAATGTCAGG CD105 NM_000118.1GCAGGTGTCAGCAAGTATGATCAGCAATGAGGCGGTGGT SEQ ID NO: 2373CAATATCCTGTCGAGCTCATCACCACAGCGGAAAAA CD134 NM_003327.1GCCCAGTGCGGAGAACAGGTCCAGCTTGATTCTCGTCTCTGC SEQ ID NO: 2374 (TNFRSF4ACTTAAGCTGTTCTCCAGGTGCGTGTGATT official) CD18 NM_000211.1CGTCAGGACCCACCATGTCTGCCCCATCACGCGGCCGAGACATG SEQ ID NO: 2375GCTTGGCCACAGCTCTTGAGGATGTCACCAATTAACC CD24 NM_013230.1TCCAACTAATGCCACCACCAAGGCGGCTGGTGGTGCCCTGCAGTCAA SEQ ID NO: 2376CAGCCAGTCTCTTCGTGGTCTCACTCTCTC CD28 NM_006139.1TGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGA SEQ ID NO: 2377CCTTCTAAGCCCTTTTGGGTGCT CD31 NM_000442.1TGTATTTCAAGACCTCTGTGCACTTATTTATGAACCTGCCCTGCT SEQ ID NO: 2378CCCACAGAACACAGCAATTCCTCAGGCTAA CD34 NM_001773.1CCACTGCACACACCTCAGAGGCTGTTCTTGGGGCCCTAC SEQ ID NO: 2379ACCTTGAGGAGGGGCAGGTAAACTCCTG CD3z NM_000734.1AGATGAAGTGGAAGGCGCTTTTCACCGCGGCCATCC SEQ ID NO: 2380TGCAGGCACAGTTGCCGATTACAGAGGCA CD44E X55150ATCACCGACAGCACAGACAGAATCCCTGCTACCAATATGGACT SEQ ID NO: 2381CCAGTCATAGTACAACGCTTCAGCCTACTGCAAATCCAAACACAGGT CD44s M59040.1GACGAAGACAGTCCCTGGATCACCGACAGCACAGACAGAATCC SEQ ID NO: 2382CTGCTACCAGAGACCAAGACACATTCCACCCCAGT CD44v3 AJ251595v3CACACAAAACAGAACCAGGACTGGACCCAGTGGAAC SEQ ID NO: 2383CCAAGCCATTCAAATCCGGAAGTGCTACTTCAG CD44v6 AJ251595v6CTCATACCAGCCATCCAATGCAAGGAAGGACAACACCAAGCCCAG SEQ ID NO: 2384AGGACAGTTCCTGGACTGATTTCTTCAACCCAA CD68 NM_001251.1TGGTTCCCAGCCCTGTGTCCACCTCCAAGCCCAGA SEQ ID NO: 2385TTCAGATTCGAGTCATGTACACAACCCAGGGTGGAGGAG CD80 NM_005191.2TTCAGTTGCTTTGCAGGAAGTGTCTAGAGGAAT SEQ ID NO: 2386ATGGTGGGCACAGAAGTAGCTCTGGTGACCTTGATCAA CD82 NM_002231.2GTGCAGGCTCAGGTGAAGTGCTGCGGCTGGGTCAGC SEQ ID NO: 2387TTCTACAACTGGACAGACAACGCTGAGCTCATGAATCGCCCTGAGGTC CD8A NM_171827.1AGGGTGAGGTGCTTGAGTCTCCAACGGCAAGG SEQ ID NO: 2388GAACAAGTACTTCTTGATACCTGGGATACTGTGCCC CD9 NM_001769.1GGGCGTGGAACAGTTTATCTCAGACATCTGCCCCAAGA SEQ ID NO: 2389AGGACGTACTCGAAACCTTCACCGTG CDC2 NM_001786.2GAGAGCGACGCGGTTGTTGTAGCTGCCGCTGCGGCCGCC SEQ ID NO: 2390GCGGAATAATAAGCCGGGATCTACCATAC CDC20 NM_001255.1TGGATTGGAGTTCTGGGAATGTACTGGCCGTGGCACTGGACA SEQ ID NO: 2391ACAGTGTGTACCTGTGGAGTGCAAGC cdc25A NM_001789.1TCTTGCTGGCTACGCCTCTTCTGTCCCTGTTAGACGT SEQ ID NO: 2392CCTCCGTCCATATCAGAACTGTGCCACAATGCAG CDC25B NM_021874.1AAACGAGCAGTTTGCCATCAGACGCTTCCAGTCTATGCCGGT SEQ ID NO: 2393GAGGCTGCTGGGCCACAGCCCCGTGCTTCGGAACATCACCAAC CDC25C NM_001790.2GGTGAGCAGAAGTGGCCTATATCGCTCCCCGTCGATG SEQ ID NO: 2394CCAGAGAACTTGAACAGGCCAAGACTGAAG CDC4 NM_018315.2GCAGTCCGCTGTGTTCAATATGATGGCAGGAGGGTTGTTA SEQ ID NO: 2395GTGGAGCATATGATTTTATGGTAAAGGTGTGGGATCC CDC42 NM_001791.2TCCAGAGACTGCTGAAAAGCTGGCCCGTGACCTGAAGGCTG SEQ ID NO: 2396TCAAGTATGTGGAGTGTTCTGCACTTACACA CDC42BPA NM_003607.2GAGCTGAAAGACGCACACTGTCAGAGGAAACTGGCCATGCA SEQ ID NO: 2397GGAATTCATGGAGATCAATGAGCGGC CDC6 NM_001254.2GCAACACTCCCCATTTACCTCCTTGTTCTCCACCAAAG SEQ ID NO: 2398CAAGGCAAGAAAGAGAATGGTCCCCCTCA CDCA7 v2 NM_145810.1AAGACCGTGGATGGCTACATGAATGAAGATGACCTGC SEQ ID NO: 2399CCAGAAGCCGTCGCTCCAGATCATCCGTGACCCT CDH1 NM_004360.2TGAGTGTCCCCCGGTATCTTCCCCGCCCTGCCAATCCCGATGAAAT SEQ ID NO: 2400TGGAAATTTTATTGATGAAAATCTGAAAGCGGCTG CDH11 NM_001797.2GTCGGCAGAAGCAGGACTTGTACCTTCTGCCCATAGTGATCAGCG SEQ ID NO: 2401ATGGCGGCATCCCGCCCATGAGTAG CDH3 NM_001793.3ACCCATGTACCGTCCTCGGCCAGCCAACCCAGATGAAATCGGCAA SEQ ID NO: 2402CTTTATAATTGAGAACCTGAAGGCGG CDK2 NM_001798.2AATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC SEQ ID NO: 2403CTGGCTCACCCTTTCTTCCAGGATGTGACCAA CDX1 NM_001804.1AGCAACACCAGCCTCCTGGCCACCTCCTCTCCAATGCCTGTGAAA SEQ ID NO: 2404GAGGAGTTTCTGCCATAGCCC Cdx2 NM_001265.2GGGCAGGCAAGGTTTACACTGCGGAAGCCAAAGGCAGCTAAG SEQ ID NO: 2405ATAGAAAGCTGGACTGACCAAAGAC CEACAM1 NM_001712.2ACTTGCCTGTTCAGAGCACTCATTCCTTCCCACCCCCAGTCCTGT SEQ ID NO: 2406CCTATCACTCTAATTCGGATTTGCCA CEACAM6 NM_002483.2CACAGCCTCACTTCTAACCTTCTGGAACCCACCCACCACTGCCAAG SEQ ID NO: 2407CTCACTATTGAATCCACGCCATTCAA CEBPB NM_005194.2GCAACCCACGTGTAACTGTCAGCCGGGCCCTGAGTAA SEQ ID NO: 2408TCGCTTAAAGATGTTCCTACGGGCTTGT CEGP1 NM_020974.1TGACAATCAGCACACCTGCATTCACCGCTCGGAAGAGGGCCTGA SEQ ID NO: 2409GCTGCATGAATAAGGATCACGGCTGTAGTCACA CENPA NM_001809.2TAAATTCACTCGTGGTGTGGACTTCAATTGGCAAGC SEQ ID NO: 2410CCAGGCCCTATTGGCCCTACAAGAGGC CENPE NM_001813.1GGATGCTGGTGACCTCTTCTTCCCTCACGTTGCAACAGGAATTAA SEQ ID NO: 2411AGGCTAAAAGAAAACGAAGAGTTACTTGGTGCCTTGGC CENPF NM_016343.2CTCCCGTCAACAGCGTTCTTTCCAAACACTGGACCAGGAGT SEQ ID NO: 2412GCATCCAGATGAAGGCCAGACTCACCC CES2 NM_003869.4ACTTTGCGAGAAATGGGAACCCCAATGGCGAGGGTCTGCC SEQ ID NO: 2413ACACTGGCCGCTGTTCGACCAGGAGGAGCAATACCTG CGA (CHGA NM_001275.2CTGAAGGAGCTCCAAGACCTCGCTCTCCAAGGCGCCAA SEQ ID NO: 2414 official)GGAGAGGGCACATCAGCAGAAGAAACACAGCGGTTTTG CGB NM_000737.2CCACCATAGGCAGAGGCAGGCCTTCCTACACCCTACTCCCTGT SEQ ID NO: 2415GCCTCCAGCCTCGACTAGTCCCTAGCACTCGACGACT CHAF1B NM_005441.1GAGGCCAGTGGTGGAAACAGGTGTGGAGCTGATGAGTCTGC SEQ ID NO: 2416CCTACCGCCTGGTGTTTGCTGTGGCCTCGGA CHD2 NM_001271.1CTCTGTGCGAGGCTGTCAGCCACACTAGGTATCAGGGATC SEQ ID NO: 2417CCGAGATGGGTACCAGCCCACAGTCCTTACC CHFR NM_018223.1AAGGAAGTGGTCCCTCTGTGGCAAGTGATGAAGTCTCC SEQ ID NO: 2418AGCTTTGCCTCAGCTCTCCCAGACAGAAAGACTGCGTC Chk1 NM_001274.1GATAAATTGGTACAAGGGATCAGCTTTTCCCAGCCCACATGTCCT SEQ ID NO: 2419GATCATATGCTTTTGAATAGTCAGTTACTTGGCACCC Chk2 NM_007194.1ATGTGGAACCCCCACCTACTTGGCGCCTGAAGTTCTTGTTTCTGT SEQ ID NO: 2420TGGGACTGCTGGGTATAACCGTGCTGTGGACTG CIAP1 NM_001166.2TGCCTGTGGTGGGAAGCTCAGTAACTGGGAACCAAAGGATGA SEQ ID NO: 2421TGCTATGTCAGAACACCGGAGGCATTTTCC cIAP2 NM_001165.2GGATATTTCCGTGGCTCTTATTCAAACTCTCCATCAAATCCTGTAA SEQ ID NO: 2422ACTCCAGAGCAAATCAAGATTTTTCTGCCTTGATGAGAAG CKS1B NM_001826.1GGTCCCTAAAACCCATCTGATGTCTGAATCTGAATGGAGGAATC SEQ ID NO: 2423TTGGCGTTCAGCAGAGTCAGGGATGGGTCCATTA CKS2 NM_001827.1GGCTGGACGTGGTTTTGTCTGCTGCGCCCGCTCTTCGCGCTC SEQ ID NO: 2424TCGTTTCATTTTCTGCAGCG Claudin 4 NM_001305.2GGCTGCTTTGCTGCAACTGTCCACCCCGCACAGACAAGCCTTA SEQ ID NO: 2425CTCCGCCAAGTATTCTGCTGCCCGCTCTG CLDN1 NM_021101.3TCTGGGAGGTGCCCTACTTTGCTGTTCCTGTCCCCGAAAAACAA SEQ ID NO: 2426CCTCTTACCCAACACCAAGGCCCTATCCA CLDN7 NM_001307.3GGTCTGCCCTAGTCATCCTGGGAGGTGCACTGCTCTCCTGTT SEQ ID NO: 2427CCTGTCCTGGGAATGAGAGCAAGGCTGGGTAC CLIC1 NM_001288.3CGGTACTTGAGCAATGCCTACGCCCGGGAAGAATTCGCTT SEQ ID NO: 2428CCACCTGTCCAGATGATGAGGAGATCGA CLTC NM_004859.1ACCGTATGGACAGCCACAGCCTGGCTTTGGGTACAGCATGT SEQ ID NO: 2429GAGATGAAGCGCTGATCCTGTAGTCA CLU NM_001831.1CCCCAGGATACCTACCACTACCTGCCCTTCAGCCTGCCCCACCG SEQ ID NO: 2430GAGGCCTCACTTCTTCTTTCCCAAGTCCCGCA cMet NM_000245.1GACATTTCCAGTCCTGCAGTCAATGCCTCTCTGCCCCACCCTTT SEQ ID NO: 2431GTTCAGTGTGGCTGGTGCCACGACAAATGTGTGCGATCGGAG cMYC NM_002467.1TCCCTCCACTCGGAAGGACTATCCTGCTGCCAAGAGGGTCAAGTTGG SEQ ID NO: 2432ACAGTGTCAGAGTCCTGAGACAGATCAGCAACAACCG CNN NM_001299.2TCCACCCTCCTGGCTTTGGCCAGCATGGCGAAGACGAAAG SEQ ID NO: 2433GAAACAAGGTGAACGTGGGAGTGA COL1A1 NM_000088.2GTGGCCATCCAGCTGACCTTCCTGCGCCTGATGTCCACC SEQ ID NO: 2434GAGGCCTCCCAGAACATCACCTACCACTG COL1A2 NM_000089.2CAGCCAAGAACTGGTATAGGAGCTCCAAGGACAAGAAACACGTC SEQ ID NO: 2435TGGCTAGGAGAAACTATCAATGCTGGCAGCCAGTTT COPS3 NM_003653.2ATGCCCAGTGTTCCTGACTTCGAAACGCTATTCTCACAGG SEQ ID NO: 2436TTCAGCTCTTCATCAGCACTTGTAATGGGGAG COX2 NM_000963.1TCTGCAGAGTTGGAAGCACTCTATGGTGACATCGATGC SEQ ID NO: 2437TGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGC COX3 MITO_COX3TCGAGTCTCCCTTCACCATTTCCGACGGCATCTACGGCTC SEQ ID NO: 2438AACATTTTTTGTAGCCACAGGCTTCCACGGACTTCACGTC CP NM_000096.1CGTGAGTACACAGATGCCTCCTTCACAAATCGAAAGGA SEQ ID NO: 2439GAGAGGCCCTGAAGAAGAGCATCTTGGCATCCTGG CRBP NM_002899.2TGGTCTGCAAGCAAGTATTCAAGAAGGTGCAGTGAGGCCC SEQ ID NO: 2440AAGCAGACAACCTTGTCCCAACCAATCAGC CREBBP NM_004380.1TGGGAAGCAGCTGTGTACCATTCCTCGCGATGCTGCCTACTAC SEQ ID NO: 2441AGCTATCAGAATAGGTATCATTTCTGTGAGAAGTGTTTC CRIP2 NM_001312.1GTGCTACGCCACCCTGTTCGGACCCAAAGGCGTGA SEQ ID NO: 2442ACATCGGGGGCGCGGGCTCCTACATCTACGAGAAGCCCCTG cripto (TDGF1 NM_003212.1GGGTCTGTGCCCCATGACACCTGGCTGCCCAA SEQ ID NO: 2443 official)GAAGTGTTCCCTGTGTAAATGCTGGCACGGTCA CRK(a) NM_016823.2CTCCCTAACCTCCAGAATGGGCCCATATATGCCAGGGTT SEQ ID NO: 2444ATCCAGAAGCGAGTCCCCAATGCCTACGACAAGACA CRMP1 NM_001313.1AAGGTTTTTGGATTGCAAGGGGTTTCCAGGGGCATGTATGACG SEQ ID NO: 2445GTCCTGTGTACGAGGTACCAGCTACACCC CRYAB NM_001885.1GATGTGATTGAGGTGCATGGAAAACATGAAGAGCGCCAGGATGAA SEQ ID NO: 2446CATGGTTTCATCTCCAGGGAGTTC CSEL1 NM_001316.2TTACGCAGCTCATGCTCTTGAACGGCTCTTTACTATGCGAGGGCC SEQ ID NO: 2447TAACAATGCCACTCTCTTTACAGCTGC CSF1 NM_000757.3TGCAGCGGCTGATTGACAGTCAGATGGAGACCTCGTGCCAAATTAC SEQ ID NO: 2448ATTTGAGTTTGTAGACCAGGAACAGTTG CSK (SRC) NM_004383.1CCTGAACATGAAGGAGCTGAAGCTGCTGCAGACCATCGGGA SEQ ID NO: 2449AGGGGGAGTTCGGAGACGTGATG CTAG1B NM_001327.1GCTCTCCATCAGCTCCTGTCTCCAGCAGCTTTCCCTGTTGATGT SEQ ID NO: 2450GGATCACGCAGTGCTTTCTGCCCGTGTT CTGF NM_001901.1GAGTTCAAGTGCCCTGACGGCGAGGTCATGAAGAAGAACATGATG SEQ ID NO: 2451TTCATCAAGACCTGTGCCTGCCATTACAACT CTHRC1 NM_138455.2GCTCACTTCGGCTAAAATGCAGAAATGCATGCTGTCAGC SEQ ID NO: 2452GTTGGTATTTCACATTCAATGGAGCTGA CTLA4 NM_005214.2CACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAG SEQ ID NO: 2453GTGACTGAAGTCTGTGCGGCAACCTAC CTNNBIP1 NM_020248.2GTTTTCCAGGTCGGAGACGGAAGACCGGAGGCAGTAGCTG SEQ ID NO: 2454CAAAGCCCTTGGAACACCCTGGATGCT CTSB NM_001908.1GGCCGAGATCTACAAAAACGGCCCCGTGGAGGGAGCTT SEQ ID NO: 2455TCTCTGTGTATTCGGACTTCCTGC CTSD NM_001909.1GTACATGATCCCCTGTGAGAAGGTGTCCACCCTGCCCGCGATCACA SEQ ID NO: 2456CTGAAGCTGGGAGGCAAAGGCTACAAGCTGTCCC CTSH NM_004390.1GCAAGTTCCAACCTGGAAAGGCCATCGGCTTTGTCAAGGATGT SEQ ID NO: 2457AGCCAACATCACAATCTATGACGAGGAAGCGATG CTSL NM_001912.1GGGAGGCTTATCTCACTGAGTGAGCAGAATCTGGTAGACTG SEQ ID NO: 2458CTCTGGGCCTCAAGGCAATGAAGGCTGCAATGG CTSL2 NM_001333.2TGTCTCACTGAGCGAGCAGAATCTGGTGGACTGTTCGCGTCCT SEQ ID NO: 2459CAAGGCAATCAGGGCTGCAATGGT CUL1 NM_003592.2ATGCCCTGGTAATGTCTGCATTCAACAATGACGCTGGCTTT SEQ ID NO: 2460GTGGCTGCTCTTGATAAGGCTTGTGGTCGC CUL4A NM_003589.1AAGCATCTTCCTGTTCTTGGACCGCACCTATGTGCTGCAGAAC SEQ ID NO: 2461TCCACGCTGCCCTCCATCTGGGATATGGGATT CXCL12 NM_000609.3GAGCTACAGATGCCCATGCCGATTCTTCGAAAGCCATGTTGC SEQ ID NO: 2462CAGAGCCAACGTCAAGCATCTCAAA CXCR4 NM_003467.1TGACCGCTTCTACCCCAATGACTTGTGGGTGGTTGTGT SEQ ID NO: 2463TCCAGTTTCAGCACATCATGGTTGGCCTTATCCT CYBA NM_000101.1GGTGCCTACTCCATTGTGGCGGGCGTGTTTGTGTGCCTGCTG SEQ ID NO: 2464GAGTACCCCCGGGGGAAGAGGAAGAAGGGCTCCAC CYP1B1 NM_000104.2CCAGCTTTGTGCCTGTCACTATTCCTCATGCCACCACTGC SEQ ID NO: 2465CAACACCTCTGTCTTGGGCTACCACATTCCC CYP2C8 NM_000770.2CCGTGTTCAAGAGGAAGCTCACTGCCTTGTGGAGGAGTTGAGAAA SEQ ID NO: 2466AACCAAGGCTTCACCCTGTGATCCCACT CYP3A4 NM_017460.3AGAACAAGGACAACATAGATCCTTACATAT SEQ ID NO: 2467ACACACCCTTTGGAAGTGGACCCAGAAACTGCATTGGCATGAGGTTTGC CYR61 NM_001554.3TGCTCATTCTTGAGGAGCATTAAGGTATTTCGAAACTGCCAAGGGT SEQ ID NO: 2468GCTGGTGCGGATGGACACTAATGCAGCCAC DAPK1 NM_004938.1CGCTGACATCATGAATGTTCCTCGACCGGCTGGAGGCGAGTTTGG SEQ ID NO: 2469ATATGACAAAGACACATCGTTGCTGAAAGAGA DCC NM_005215.1AAATGTCCTCCTCGACTGCTCCGCGGAGTCCGACCGAGGAGTTCCAG SEQ ID NO: 2470TGATCAAGTGGAAGAAAGATGGCATTCA DCC_exons18-23 X76132_18-23GGTCACCGTTGGTGTCATCACAGTGCTGGTA SEQ ID NO: 2471GTGGTCATCGTGGCTGTGATTTGCACCCGACGCTC DCC_exons6-7 X76132_6-7ATGGAGATGTGGTCATTCCTAG SEQ ID NO: 2472TGATTATTTTCAGATAGTGGGAGGAAGCAACTTACGGATACTTGGGGTGGTG DCK NM_000788.1GCCGCCACAAGACTAAGGAATGGCCACCCCGCCCAAGAGA SEQ ID NO: 2473AGCTGCCCGTCTTTCTCAGCCAGCTCTGAGGGGACCCG CATCAAGAAAATCTCCATCGAAGGGAACATCGDDB1 NM_001923.2 TGCGGATCATCCGGAATGGAATTGGAATCCACGAGCA SEQ ID NO: 2474TGCCAGCATTGACTTACCAGGCATCAAAGGA DET1 NM_017996.2CTTGTGGAGATCACCCAATCAGGTTCTATGCCCGGGACTCGG SEQ ID NO: 2475GCCTGCTCAAGTTTGAGATCCAGGCGGG DHFR NM_000791.2TTGCTATAACTAAGTGCTTCTCCAAGACCCCAACTGAGTCC SEQ ID NO: 2476CCAGCACCTGCTACAGTGAGCTGCCATTCCAC DHPS NM_013407.1GGGAGAACGGGATCAATAGGATCGGAAACCTGCTGGTGCCC SEQ ID NO: 2477AATGAGAATTACTGCAAGTTTGAGGACTGGCTGATGC DIABLO NM_019887.1CACAATGGCGGCTCTGAAGAGTTGGCTGTCGCGCAG SEQ ID NO: 2478CGTAACTTCATTCTTCAGGTACAGACAGTGTTTGTGT DIAPH1 NM_005219.2CAAGCAGTCAAGGAGAACCAGAAGCGGCGGGAGACA SEQ ID NO: 2479GAAGAAAAGATGAGGCGAGCAAAACT DICER1 NM_177438.1TCCAATTCCAGCATCACTGTGGAGAAAAGCTG SEQ ID NO: 2480TTTGTCTCCCCAGCATACTTTATCGCCTTCACTGCC DKK1 NM_012242.1TGACAACTACCAGCCGTACCCGTGCGCAGAGGACGAGGA SEQ ID NO: 2481GTGCGGCACTGATGAGTACTGCGCTAGTCCC DLC1 NM_006094.3GATTCAGACGAGGATGAGCCTTGTGCCATCAGTGGCAAATGG SEQ ID NO: 2482ACTTTCCAAAGGGACAGCAAGAGGTG DPYD NM_000110.2AGGACGCAAGGAGGGTTTGTCACTGGCAGACTCGAGACTGTAGGC SEQ ID NO: 2483ACTGCCATGGCCCCTGTGCTCAGTAAGGACTCGGCGGACATC DR4 NM_003844.1TGCACAGAGGGTGTGGGTTACACCAATGCTTCCAACAATTTGTTT SEQ ID NO: 2484GCTTGCCTCCCATGTACAGCTTGTAAATCAGATGAAGA DR5 NM_003842.2CTCTGAGACAGTGCTTCGATGACTTTGCAGACTTGGTGCCCTTTGA SEQ ID NO: 2485CTCCTGGGAGCCGCTCATGAGGAAGTTGGGCCTCATGG DRG1 NM_004147.3CCTGGATCTCCCAGGTATCATTGAAGGTGCCAAGGATGGG SEQ ID NO: 2486AAAGGTAGAGGTCGTCAAGTCATTGCA DSP NM_004415.1TGGCACTACTGCATGATTGACATAGAGAAGATCAGGGCCATGAC SEQ ID NO: 2487AATCGCCAAGCTGAAAACAATGCGGCAGG DTYMK NM_012145.1AAATCGCTGGGAACAAGTGCCGTTAATTAAGGAAAAGTTGAGC SEQ ID NO: 2488CAGGGCGTGACCCTCGTCGTGGACAGATACGCATT DUSP1 NM_004417.2AGACATCAGCTCCTGGTTCAACGAGGCCATTGACTTCATAGACTCC SEQ ID NO: 2489ATCAAGAATGCTGGAGGAAGGGTGTTTGTC DUSP2 NM_004418.2TATCCCTGTGGAGGACAACCAGATGGTGGAGATCAGTGCCT SEQ ID NO: 2490GGTTCCAGGAGGCCATAGGCTTCATTGACTGGGTG DUT NM_001948.2ACACATGGAGTGCTTCTGGAACTATCAGCCCACTTGACCAC SEQ ID NO: 2491CCAGTTTGTGGAAGCACAGGCAAGAG DYRK1B NM_004714.1AGCATGACACGGAGATGAAGTACTATATAGTACAC SEQ ID NO: 2492CTGAAGCGGCACTTCATGTTCCGGAACCACCTGTGCCTGGTATT E2F1 NM_005225.1ACTCCCTCTACCCTTGAGCAAGGGCAGGGGTCCCTGAG SEQ ID NO: 2493CTGTTCTTCTGCCCCATACTGAAGGAACTGAGGCCTG EDN1 NM_001955.1TGCCACCTGGACATCATTTGGGTCAACACTCCCGAGCACGT SEQ ID NO: 2494 endothelinTGTTCCGTATGGACTTGGAAGCCCTAGGTCCA EFNA1 NM_004428.2TACATCTCCAAACCCATCCACCAGCATGAAGACCGCTGCT SEQ ID NO: 2495TGAGGTTGAAGGTGACTGTCAGTGGCAA EFNA3 NM_004952.3ACTACATCTCCACGCCCACTCACAACCTGCACTGGAAGTGTC SEQ ID NO: 2496TGAGGATGAAGGTGTTCGTCTGCTG EFNB1 NM_004429.3GGAGCCCGTATCCTGGAGCTCCCTCAACCCCAAGTTCCTGAG SEQ ID NO: 2497TGGGAAGGGCTTGGTGATCTATCC EFNB2 NM_004093.2TGACATTATCATCCCGCTAAGGACTGCGGACAGCGTCTTCT SEQ ID NO: 2498GCCCTCACTACGAGAAGGTCAGCGGGGACTAC EFP NM_005082.2TTGAACAGAGCCTGACCAAGAGGGATGAGTTCGAGTTTCTG SEQ ID NO: 2499GAGAAAGCATCAAAACTGCGAGGAATCTCAACA EGFR NM_005228.1TGTCGATGGACTTCCAGAACCACCTGGGCAGCTGCC SEQ ID NO: 2500AAAAGTGTGATCCAAGCTGTCCCAAT EGLN1 NM_022051.1TCAATGGCCGGACGAAAGCCATGGTTGCTTGTTATCCGGGCAAT SEQ ID NO: 2501GGAACGGGTTATGTACGTCATGTTGATAATCCAAA EGLN3 NM_022073.2GCTGGTCCTCTACTGCGGGAGCCGGCTGGGCAAATACTA SEQ ID NO: 2502CGTCAAGGAGAGGTCTAAGGCAATGGTGG EGR1 NM_001964.2GTCCCCGCTGCAGATCTCTGACCCGTTCGGATCCTT SEQ ID NO: 2503TCCTCACTCGCCCACCATGGACAACTACCCTAAGCTGGAG EGR3 NM_004430.2CCATGTGGATGAATGAGGTGTCTCCTTTCCATACCCAGT SEQ ID NO: 2504CTCACCTTCTCCCCACCCTACCTCACCTCTTCTCAGGCA EI24 NM_004879.2AAAGTGGTGAATGCCATTTGGTTTCAGGATATAGCTGACCT SEQ ID NO: 2505GGCATTTGAGGTATCAGGGAGGAAGCCTCAC EIF4E NM_001968.1GATCTAAGATGGCGACTGTCGAACCGGAAACCACCCCTACTCCTAA SEQ ID NO: 2506TCCCCCGACTACAGAAGAGGAGAAAACGGAATCTAA EIF4EL3 NM_004846.1AAGCCGCGGTTGAATGTGCCATGACCCTCTCCCTCTCTGG SEQ ID NO: 2507ATGGCACCATCATTGAAGCTGGCGTCA ELAVL1 NM_001419.2GACAGGAGGCCTCTATCCTGTCCCTCCACCCCACCCTCCACCTC SEQ ID NO: 2508AATCCCCTCCCATCTTCCCCAGACCTACCTCAC EMP1 NM_001423.1GCTAGTACTTTGATGCTCCCTTGATGGGGTCCAGAGAGCCTCCC SEQ ID NO: 2509TGCAGCCACCAGACTTGGCCTCCAGCTGTTC EMR3 NM_032571.2TGGCCTACCTCTTCACCATCATCAACAGCCTCCAAGGCTTCTT SEQ ID NO: 2510CATCTTCTTGGTCTACTGCCTCCTCA EMS1 NM_005231.2GGCAGTGTCACTGAGTCCTTGAAATCCTCCCCTGCCCCGCGG SEQ ID NO: 2511GTCTCTGGATTGGGACGCACAGTGCA ENO1 NM_001428.2CAAGGCCGTGAACGAGAAGTCCTGCAACTGCCTCCTGCT SEQ ID NO: 2512CAAAGTCAACCAGATTGGCTCCGTGACCG EP300 NM_001429.1AGCCCCAGCAACTACAGTCTGGGATGCCAAGGCCAGCCATGATGT SEQ ID NO: 2513CAGTGGCCCAGCATGGTCAACCTTTGAACA EPAS1 NM_001430.3AAGCCTTGGAGGGTTTCATTGCCGTGGTGACCCAAGATGG SEQ ID NO: 2514CGACATGATCTTTCTGTCAGAAAACATCAGCA EpCAM NM_002354.1GGGCCCTCCAGAACAATGATGGGCTTTATGATCCTGACTGCGA SEQ ID NO: 2515TGAGAGCGGGCTCTTTAAGGCCAAGCAGTGCA EPHA2 NM_004431.2CGCCTGTTCACCAAGATTGACACCATTGCGCCCGATGAGATCA SEQ ID NO: 2516CCGTCAGCAGCGACTTCGAGGCACGCCAC EPHB2 NM_004442.4CAACCAGGCAGCTCCATCGGCAGTGTCCATCATGCA SEQ ID NO: 2517TCAGGTGAGCCGCACCGTGGACAGCATTAC EPHB4 NM_004444.3TGAACGGGGTATCCTCCTTAGCCACGGGGCCCGTCCCA SEQ ID NO: 2518TTTGAGCCTGTCAATGTCACCACTGACCGAGAGGTACCT EphB6 NM_004445.1ACTGGTCCTCCATCGGCTCCCCAGGAGCTTTGGTTT SEQ ID NO: 2519GAGGTGCAAGGCTCAGCACTCATGCTACACTGG EPM2A NM_005670.2ACTGTGGCACTTAGGGGAGATGACATTTGCTTTGG SEQ ID NO: 2520GCAGAGGCAGCTAGCCAGGACACATTTCCACT ErbB3 NM_001982.1CGGTTATGTCATGCCAGATACACACCTCAAAGGTACTCCCTCCT SEQ ID NO: 2521CCCGGGAAGGCACCCTTTCTTCAGTGGGTCTCAGTTC ERCC1 NM_001983.1GTCCAGGTGGATGTGAAAGATCCCCAGCAGGCCCTCAG SEQ ID NO: 2522AGGAGCTGGCTAAGATGTGTATCCTGGCC ERCC2 NM_000400.2TGGCCTTCTTCACCAGCTACCAGTACATGGAGAGCACCG SEQ ID NO: 2523TGGCCTCCTGGTATGAGCAGGGGATCCTTG EREG NM_001432.1ATAACAAAGTGTAGCTCTGACATGAATGGCTATTGTTTGCATGGACAG SEQ ID NO: 2524TGCATCTATCTGGTGGACATGAGTCAAAACTACTGCAGGTGTG ERK1 Z11696.1ACGGATCACAGTGGAGGAAGCGCTGGCTCACCCCTACCTG SEQ ID NO: 2525GAGCAGTACTATGACCCGACGGATGAG ERK2 NM_002745.1AGTTCTTGACCCCTGGTCCTGTCTCCAGCCCGTC SEQ ID NO: 2526TTGGCTTATCCACTTTGACTCCTTTGAGCCGTTT ESPL1 NM_012291.1ACCCCCAGACCGGATCAGGCAAGCTGGCCCTCATGTCCCCT SEQ ID NO: 2527TCACGGTGTTTGAGGAAGTCTGCCCTACA EstR1 NM_000125.1CGTGGTGCCCCTCTATGACCTGCTGCTGGAGATGCTGGACGCC SEQ ID NO: 2528CACCGCCTACATGCGCCCACTAGCC ETV4 NM_001986.1TCCAGTGCCTATGACCCCCCCAGACAAATCGCCATCAAGTCC SEQ ID NO: 2529CCTGCCCCTGGTGCCCTTGGACAGT F3 NM_001993.2GTGAAGGATGTGAAGCAGACGTACTTGGCACGGGTCTTCTCC SEQ ID NO: 2530TACCCGGCAGGGAATGTGGAGAGCACCGGTT FABP4 NM_001442.1GCTTTGCCACCAGGAAAGTGGCTGGCATGGCCAAACC SEQ ID NO: 2531TAACATGATCATCAGTGTGAATGGGGATG FAP NM_004460.2CTGACCAGAACCACGGCTTATCCGGCCTGTCCACG SEQ ID NO: 2532AACCACTTATACACCCACATGACCCACTTCC fas NM_000043.1GGATTGCTCAACAACCATGCTGGGCATCTGGACCCTCCTAC SEQ ID NO: 2533CTCTGGTTCTTACGTCTGTTGCTAGATT ATCGTCCAAAAGTGTTAATGCC fasI NM_000639.1GCACTTTGGGATTCTTTCCATTATGATTCTTTGTTACAGGC SEQ ID NO: 2534ACCGAGAATGTTGTATTCAGTGAGGGTCTTCTTACATGC FASN NM_004104.4GCCTCTTCCTGTTCGACGGCTCGCCCACCTACG SEQ ID NO: 2535TACTGGCCTACACCCAGAGCTACCGGGCAAAGC FBXO5 NM_012177.2GGCTATTCCTCATTTTCTCTACAAAGTGGCCTCA SEQ ID NO: 2536GTGAACATGAAGAAGGTAGCCTCCTGGAGGAGAATTTC GGTGACAGTCTACAATCC FBXW7NM_033632.1 CCCCAGTTTCAACGAGACTTCATTTCATTGCTCCCTA SEQ ID NO: 2537AAGAGTTGGCACTCTATGTGCTTTCATTCCTGGAAC FDXR NM_004110.2GAGATGATTCAGTTACCGGGAGCCCGGCCCATTTT SEQ ID NO: 2538GGATCCTGTGGATTTCTTGGGTCTCCAGGACAAGAT FES NM_002005.2CTCTGCAGGCCTAGGTGCAGCTCCTCAGCGGCTCCA SEQ ID NO: 2539GCTCATATGCTGACAGCTCTTCACAGTCCTGG FGF18 NM_003862.1CGGTAGTCAAGTCCGGATCAAGGGCAAGGAGACGG SEQ ID NO: 2540AATTCTACCTGTGCATGAACCGCAAAGGCAAGC FGF2 NM_002006.2AGATGCAGGAGAGAGGAAGCCTTGCAAACCTGCAGAC SEQ ID NO: 2541TGCTTTTTGCCCAATATAGATTGGGTAAGGCTGCAAAAC FGFR1 NM_023109.1CACGGGACATTCACCACATCGACTACTATAAAAAGA SEQ ID NO: 2542CAACCAACGGCCGACTGCCTGTGAAGTGGATGGCACCC FGFR2 NM_000141.2GAGGGACTGTTGGCATGCAGTGCCCTCCCAGAGACCA SEQ ID NO: 2543 isoform 1ACGTTCAAGCAGTTGGTAGAAGACTTGGATCGAATTCTCACTC FHIT NM_002012.1CCAGTGGAGCGCTTCCATGACCTGCGTCCTG SEQ ID NO: 2544ATGAAGTGGCCGATTTGTTTCAGACGACCCAGAGAG FIGF NM_004469.2GGTTCCAGCTTTCTGTAGCTGTAAGCATTG SEQ ID NO: 2545GTGGCCACACCACCTCCTTACAAAGCAACTAGAACCTGCGGC FLJ12455 NM_022078.1CCACCAGCATGAAGTTTCGGACAGACATG SEQ ID NO: 2546GCCTTTGTGAGGGGTTCCAGTTGTGCTTCAGACAGCC FLJ20712 AK000719.1GCCACACAAACATGCTCCTGCTCCTGGCGGAGGCAGAGC SEQ ID NO: 2547TGCTGGGAAAGACATTTCGGAAGTTTCCTGTGGC FLT1 NM_002019.1GGCTCCCGAATCTATCTTTGACAAAATCTACAGCACCAAGA SEQ ID NO: 2548GCGACGTGTGGTCTTACGGAGTATTGCTGTGGGA FLT4 NM_002020.1ACCAAGAAGCTGAGGACCTGTGGCTGAGCCCGCTGACCATG SEQ ID NO: 2549GAAGATCTTGTCTGCTACAGCTTCCAGG FOS NM_005252.2CGAGCCCTTTGATGACTTCCTGTTCCCAGCATC SEQ ID NO: 2550ATCCAGGCCCAGTGGCTCTGAGACAGCCCGCTCC FOXO3A NM_001455.1TGAAGTCCAGGACGATGATGCGCCTCTCTCGCCCATGCTCTACAGC SEQ ID NO: 2551AGCTCAGCCAGCCTGTCACCTTCAGTAAGCAAGCCGT FPGS NM_004957.3CAGCCCTGCCAGTTTGACTATGCCGTCTTCTGCCCTA SEQ ID NO: 2552ACCTGACAGAGGTGTCATCCACAGGCAAC FRP1 NM_003012.2TTGGTACCTGTGGGTTAGCATCAAGTTCTCCCCAGGGTAGA SEQ ID NO: 2553ATTCAATCAGAGCTCCAGTTTGCATTTGGATGTG FST NM_006350.2GTAAGTCGGATGAGCCTGTCTGTGCCAGTGACAATGCCACT SEQ ID NO: 2554TATGCCAGCGAGTGTGCCATGAAGGAAGCTG Furin NM_002569.1AAGTCCTCGATACGCACTATAGCACCGAGAATGACGTGGAGACCAT SEQ ID NO: 2555CCGGGCCAGCGTCTGCGCCCCCTGCCACGCCTCATGTGCCACATGCCAG FUS NM_004960.1GGATAATTCAGACAACAACACCATCTTTGTGCAA SEQ ID NO: 2556GGCCTGGGTGAGAATGTTACAATTGAGTCTGTGGCTGATTACTTCA FUT1 NM_000148.1CCGTGCTCATTGCTAACCACTGTCTGTCCCT SEQ ID NO: 2557GAACTCCCAGAACCACTACATCTGGCTTTGGGCAG FUT3 NM_000149.1CAGTTCGGTCCAACAGAGAAAGCAGGCAACCA SEQ ID NO: 2558CCATGTCATTTGAAAACAGTTTCATCGGGATATAATTCGCA FUT6 NM_000150.1CGTGTGTCTCAAGACGATCCCACTGTGTACCCTAAT SEQ ID NO: 2559GGGTCCCGCTTCCCAGACAGCACAGGGACC FXYD5 NM_014164.4AGAGCACCAAAGCAGCTCATCCCACTGATGACAC SEQ ID NO: 2560CACGACGCTCTCTGAGAGACCATCCCCAAGCAC FYN NM_002037.3GAAGCGCAGATCATGAAGAAGCTGAAGCACGACAAG SEQ ID NO: 2561CTGGTCCAGCTCTATGCAGTGGTGTCTGAGGAG FZD1 NM_003505.1GGTGCACCAGTTCTACCCTCTAGTGAAAGTGCAGTGTTCC SEQ ID NO: 2562GCTGAGCTCAAGTTCTTCCTGTGCTCCATGTACGC FZD2 NM_001466.2TGGATCCTCACCTGGTCGGTGCTGTGCTGCGCTTCCACCTTCTT SEQ ID NO: 2563CACTGTCACCACGTACTTGGTAGACATGCAGCGC FZD6 NM_003506.2AATGAGAGAGGTGAAAGCGGACGGAGCTAGCACC SEQ ID NO: 2564CCCAGGTTAAGAGAACAGGACTGTGGTGAACCT G-Catenin NM_002230.1TCAGCAGCAAGGGCATCATGGAGGAGGATGAG SEQ ID NO: 2565GCCTGCGGGCGCCAGTACACGCTCAAGAAAACCACC G1P2 NM_005101.1CAACGAATTCCAGGTGTCCCTGAGCAGCTCCATGTC SEQ ID NO: 2566GGTGTCAGAGCTGAAGGCGCAGATC GADD45 NM_001924.2GTGCTGGTGACGAATCCACATTCATCTCAATGGAAGGATCC SEQ ID NO: 2567TGCCTTAAGTCAACTTATTTGTTTTTGCCGGG GADD45B NM_015675.1ACCCTCGACAAGACCACACTTTGGGACTTGGGAGCTG SEQ ID NO: 2568GGGCTGAAGTTGCTCTGTACCCATGAACTCCCA GADD45G NM_006705.2CGCGCTGCAGATCCATTTTACGCTGATCCAGGCTTTC SEQ ID NO: 2569TGCTGCGAGAACGACATCGACATAGTGCG GAGE4 NM_001474.1GGAACAGGGTCACCCACAGACTGGGTGTGAGTGTGAAGA SEQ ID NO: 2570TGGTCCTGATGGGCAGGAGATGGACCCGCCAAATC GBP1 NM_002053.1TTGGGAAATATTTGGGCATTGGTCTGGCCAAGTCTACAAT SEQ ID NO: 2571GTCCCAATATCAAGGACAACCACCCTAGCTTCT GBP2 NM_004120.2GCATGGGAACCATCAACCAGCAGGCCATGGACCAACTTCACTA SEQ ID NO: 2572TGTGACAGAGCTGACAGATCGAATCAAGGCAAACTCCTCA GCLC NM_001498.1CTGTTGCAGGAAGGCATTGATCATCTCCTGGCCC SEQ ID NO: 2573AGCATGTTGCTCATCTCTTTATTAGAGACCCACTGAC GCLM NM_002061.1TGTAGAATCAAACTCTTCATCATCAACTAGAAGTGCAGTTGACA SEQ ID NO: 2574TGGCCTGTTCAGTCCTTGGAGTTGCACAGCTGGATTCTGTG GCNT1 NM_001490.3TGGTGCTTGGAGCATAGAAGACTGCCCTTCACAAAG SEQ ID NO: 2575GAAATCCCTGATTATTGTTTGAAATGCTGAGGACGTTGC GDF15 NM_004864.1CGCTCCAGACCTATGATGACTTGTTAGCCAA SEQ ID NO: 2576AGACTGCCACTGCATATGAGCAGTCCTGGTCCTTCCACTGT GIT1 NM_014030.2GTGTATGACGAGGTGGATCGAAGAGAAAAT SEQ ID NO: 2577GATGCAGTGTGGCTGGCTACCCAAAACCACAGCACTCTGGT GJA1 NM_000165.2GTTCACTGGGGGTGTATGGGGTAGATGGG SEQ ID NO: 2578TGGAGAGGGAGGGGATAAGAGAGGTGCATGTTGGTATTT GJB2 NM_004004.3TGTCATGTACGACGGCTTCTCCATGCAGC SEQ ID NO: 2579GGCTGGTGAAGTGCAACGCCTGGCCTTGTCCCAACACTGTGGACT GPX1 NM_000581.2GCTTATGACCGACCCCAAGCTCATCACC SEQ ID NO: 2580TGGTCTCCGGTGTGTCGCAACGATGTTGCCTGGAACTTT GPX2 NM_002083.1CACACAGATCTCCTACTCCATCCAGTCCTGAGGAGCC SEQ ID NO: 2581TTAGGATGCAGCATGCCTTCAGGAGACACTGCTGGACC Grb10 NM_005311.2CTTCGCCTTTGCTGATTGCCTCTCC SEQ ID NO: 2582AAACGCCTGCCTGACGACTGCCTTGGAGCATGTGCGTTATGG GRB14 NM_004490.1TCCCACTGAAGCCCTTTCAGTTGCGGTTGAAGAAGG SEQ ID NO: 2583ACTCGCTTGGAGGAAAAAAGGATGTTTACGCCTGGGCACT GRB2 NM_002086.2GTCCATCAGTGCATGACGTTTAAGGCCACGTATAGTCC SEQ ID NO: 2584TAGCTGACGCCAATAATAAAAAACAAGAAACCAAGTGGGCT GRB7 NM_005310.1CCATCTGCATCCATCTTGTTTGGGCTCCCCA SEQ ID NO: 2585CCCTTGAGAAGTGCCTCAGATAATACCCTGGTGGCC GRIK1 NM_000830.2GTTGGGTGCATCTCTCGGGCGTCCGGCAGCGGCTGTATC SEQ ID NO: 2586TCGGCATGAATTAAGAAGCTAGGAAGATGGAGCACG GRO1 NM_001511.1CGAAAAGATGCTGAACAGTGACAAATCCAACTGACCAGA SEQ ID NO: 2587AGGGAGGAGGAAGCTCACTGGTGGCTGTTCCTGA GRP NM_002091.1CTGGGTCTCATAGAAGCAAAGGAGAACAGAAACCACCAGCCACCTC SEQ ID NO: 2588AACCCAAGGCCTTGGGCAATCAGCAGCCTTCGTGG GRPR NM_005314.1ATGCTGCTGGCCATTCCAGAGGCCGTGTTTTCTGACCTC SEQ ID NO: 2589CATCCCTTCCATGAGGAAAGCACCAACCAGACCT GSK3B NM_002093.2GACAAGGACGGCAGCAAGGTGACAACAGTGGTGGCA SEQ ID NO: 2590ACTCCTGGGCAGGGTCCAGACAGGCCACAA GSTA3 NM_000847.3TCTCCAACTTCCCTCTGCTGAAGGCCCTGAAAACCAGA SEQ ID NO: 2591ATCAGCAACCTGCCCACGGTGAAGAAGT GSTM1 NM_000561.1AAGCTATGAGGAAAAGAAGTACACGATGGGGGACGCTCCTGATTATGACAG SEQ ID NO: 2592AAGCCAGTGGCTGAATGAAAAATTCAAGCTGGGCC GSTM3 NM_000849.3CAATGCCATCTTGCGCTACATCGCTCGCAAGCACAACAT SEQ ID NO: 2593GTGTGGTGAGACTGAAGAAGAAAAGATTCGAGTGGAC GSTp NM_000852.2GAGACCCTGCTGTCCCAGAACCAGGGAGGCAAGACCTTCATTGTGGGAGA SEQ ID NO: 2594CCAGATCTCCTTCGCTGACTACAACC GSTT1 NM_000853.1CACCATCCCCACCCTGTCTTCCACAGCCGCCTGAAAGCC SEQ ID NO: 2595ACAATGAGAATGATGCACACTGAGGCC H2AFZ NM_002106.2CCGGAAAGGCCAAGACAAAGGCGGTTTCCCGCTCGCAGA SEQ ID NO: 2596GAGCCGGCTTGCAGTTCCCAGTGGGCCGTATT HB-EGF NM_001945.1GACTCCTTCGTCCCCAGTTGCCGTCTAGGATTGGGCCTCCCATAATT SEQ ID NO: 2597GCTTTGCCAAAATACCAGAGCCTTCAAGTGCCA hCRA a U78556.1TGACACCCTTACCTTCCTGAGAAATACCCCCTGGGAGCGCGGAAAGCAGAGCG SEQ ID NO: 2598GACAGGTCAGTGACTTCTATTTTTGACTCGTGTTTTT HDAC1 NM_004964.2CAAGTACCACAGCGATGACTACATTAAATTCTTGCGCTCC SEQ ID NO: 2599ATCCGTCCAGATAACATGTCGGAGTACAGCAAGC HDAC2 NM_001527.1GGTGGCTACACAATCCGTAATGTTGCTCGATGTTGGACA SEQ ID NO: 2600TATGAGACTGCAGTTGCCCTTGATTGTGAGATTCCCA HDGF NM_004494.1TCCTAGGCATTCTGGACCTCTGGGTTGGGATCAGGGG SEQ ID NO: 2601TAGGAATGGAAGGATGGAGCATCAACAGC hENT1 NM_004955.1AGCCGTGACTGTTGAGGTCAAGTCCAGCATCGCAG SEQ ID NO: 2602GCAGCAGCACCTGGGAACGTTACTT Hepsin NM_002151.1AGGCTGCTGGAGGTCATCTCCGTGTGTGATTGCCCCAGAGGCCGT SEQ ID NO: 2603TTCTTGGCCGCCATCTGCCAAGACTGTGGCCGCAGGAAG HER2 NM_004448.1CGGTGTGAGAAGTGCAGCAAGCCCTGTGCCCGAGTGTGCT SEQ ID NO: 2604ATGGTCTGGGCATGGAGCACTTGCGAGAGG Herstatin AF177761.2CACCCTGTCCTATCCTTCCTCAGACCCTCTTGGGACCTAGTC SEQ ID NO: 2605TCTGCCTTCTACTCTCTACCCCTGGCC HES6 NM_018645.3TTAGGGACCCTGCAGCTCTGGAGTGGGTGGAGGGAG SEQ ID NO: 2606GGAGCTACGGGCAGGAGGAAGAATTTTGTAG HGF M29145.1CCGAAATCCAGATGATGATGCTCATGGACCCTGGT SEQ ID NO: 2607GCTACACGGGAAATCCACTCATTCCTTGGG HIF1A NM_001530.1TGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACA SEQ ID NO: 2608GGCCACATTCACGTATATGATACCAACAGTAACCAACCTCA HK1 NM_000188.1TACGCACAGAGGCAAGCAGCTAAGAGTCCGGGATCCCC SEQ ID NO: 2609AGCCTACTGCCTCTCCAGCACTTCTCTC HLA-DPB1 NM_002121.4TCCATGATGGTTCTGCAGGTTTCTGCGGCCCCCCGGACAGTGGCT SEQ ID NO: 2610CTGACGGCGTTACTGATGGTGCTGCTCA HLA-DRA NM_019111.3GACGATTTGCCAGCTTTGAGGCTCAAGGTGCATTGGCC SEQ ID NO: 2611AACATAGCTGTGGACAAAGCCAACCTGGA HLA-DRB1 NM_002124.1GCTTTCTCAGGACCTGGTTGCTACTGGTTCGG SEQ ID NO: 2612CAACTGCAGAAAATGTCCTCCCTTGTGGCTTCCT HLA-G NM_002127.2CCTGCGCGGCTACTACAACCAGAGCGAGGCCAGTTC SEQ ID NO: 2613TCACACCCTCCAGTGGATGATTGGCTGCGACCTG HMGB1 NM_002128.3TGGCCTGTCCATTGGTGATGTTGCGAAGAAACTGGG SEQ ID NO: 2614AGAGATGTGGAATAACACTGCTGCAGATGACAAGC hMLH NM_000249.2CTACTTCCAGCAACCCCAGAAAGAGACATCGGGAAGATTCTG SEQ ID NO: 2615ATGTGGAAATGGTGGAAGATGATTCCCGAAAG HNRPAB NM_004499.2CAAGGGAGCGACCAACTGATCGCACACATGCTTTGTTTGGAT SEQ ID NO: 2616ATGGAGTGAACACAATTATGTACCAAATTTAACTTGGCAAAC HNRPD NM_031370.2GCCAGTAAGAACGAGGAGGATGAAGGCCATTCAAACTCC SEQ ID NO: 2617TCCCCACGACACTCTGAAGCAGCGACG HoxA1 NM_005522.3AGTGACAGATGGACAATGCAAGAATGAACTCCTTCCTG SEQ ID NO: 2618GAATACCCCATACTTAGCAGTGGCGACTCGG HoxA5 NM_019102.2TCCCTTGTGTTCCTTCTGTGAAGAAGCCCTGTTCTCGTT SEQ ID NO: 2619GCCCTAATTCATCTTTTAATCATGAGCCTGTTTATTGCC HOXB13 NM_006361.2CGTGCCTTATGGTTACTTTGGAGGCGGGTACTACTCC SEQ ID NO: 2620TGCCGAGTGTCCCGGAGCTCGCTGAAACCCTGTG HOXB7 NM_004502.2CAGCCTCAAGTTCGGTTTTCGCTACCGGAGCCTT SEQ ID NO: 2621CCCAGAACAAACTTCTTGTGCGTTTGCTTCCAAC HRAS NM_005343.2GGACGAATACGACCCCACTATAGAGGATTCCTACCG SEQ ID NO: 2622GAAGCAGGTGGTCATTGATGGGGAGACGTGC HSBP1 NM_001537.1GGAGATGGCCGAGACTGACCCCAAGACCGTGCAGG SEQ ID NO: 2623ACCTCACCTCGGTGGTGCAGACACTCCTGCAG HSD17B1 NM_000413.1CTGGACCGCACGGACATCCACACCTTCCACCGCTTCTACCA SEQ ID NO: 2624ATACCTCGCCCACAGCAAGCAAGTCTTTCGCGAGGCG HSD17B2 NM_002153.1GCTTTCCAAGTGGGGAATTAAAGTTGCTTCCATCCA SEQ ID NO: 2625ACCTGGAGGCTTCCTAACAAATATCGCAGGCA HSPA1A NM_005345.4CTGCTGCGACAGTCCACTACCTTTTTCGAGAGTGACTCCCGTT SEQ ID NO: 2626GTCCCAAGGCTTCCCAGAGCGAACCTG HSPA1B NM_005346.3GGTCCGCTTCGTCTTTCGAGAGTGACTCCCGCGGTC SEQ ID NO: 2627CCAAGGCTTTCCAGAGCGAACCTGTGC HSPA4 NM_002154.3TTCAGTGTGTCCAGTGCATCTTTAGTGGAGGTTCACAAG SEQ ID NO: 2628TCTGAGGAAAATGAGGAGCCAATGGAAACAGAT HSPA5 NM_005347.2GGCTAGTAGAACTGGATCCCAACACCAAACTCTTAATTAGACCT SEQ ID NO: 2629AGGCCTCAGCTGCACTGCCCGAAAAGCATTTGGGCAGACC HSPA8 NM_006597.3CCTCCCTCTGGTGGTGCTTCCTCAGGGCCCACCATTGA SEQ ID NO: 2630AGAGGTTGATTAAGCCAACCAAGTGTAGATGTAGC HSPB1 NM_001540.2CCGACTGGAGGAGCATAAAAGCGCAGCCGAGCCCAGCGCCC SEQ ID NO: 2631CGCACTTTTCTGAGCAGACGTCCAGAGCAGAGTCAGCCAGCAT HSPCA NM_005348.2CAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAG SEQ ID NO: 2632GATCTGGTCATCTTGCTTTATGAAACTGCGCT HSPE1 NM_002157.1GCAAGCAACAGTAGTCGCTGTTGGATCGGGTTCTAAAGGAA SEQ ID NO: 2633AGGGTGGAGAGATTCAACCAGTTAGCGTGAAAGTTGG HSPG2 NM_005529.2GAGTACGTGTGCCGAGTGTTGGGCAGCTCCGTGCCT SEQ ID NO: 2634CTAGAGGCCTCTGTCCTGGTCACCATTGAG ICAM1 NM_000201.1GCAGACAGTGACCATCTACAGCTTTCCGGCGCCCAACGTGAT SEQ ID NO: 2635TCTGACGAAGCCAGAGGTCTCAGAAG ICAM2 NM_000873.2GGTCATCCTGACACTGCAACCCACTTTGGTGGCTGT SEQ ID NO: 2636GGGCAAGTCCTTCACCATTGAGTGCA ID1 NM_002165.1AGAACCGCAAGGTGAGCAAGGTGGAGATTCTCCAGCAC SEQ ID NO: 2637GTCATCGACTACATCAGGGACCTTCAGTTGGA ID2 NM_002166.1AACGACTGCTACTCCAAGCTCAAGGAGCTGGTGCC SEQ ID NO: 2638CAGCATCCCCCAGAACAAGAAGGTGAGCAAGATGGAAATCC ID3 NM_002167.2CTTCACCAAATCCCTTCCTGGAGACTAAACCTGGTGCTCAGGA SEQ ID NO: 2639GCGAAGGACTGTGAACTTGTAGCCTGAAGAGCCAGAG ID4 NM_001546.2TGGCCTGGCTCTTAATTTGCTTTTGTTTTGCCCAGTATAGACTCGGA SEQ ID NO: 2640AGTAAGAGTTATAGCTAGTGGTCTTGCATGATTGCA IFIT1 NM_001548.1TGACAACCAAGCAAATGTGAGGAGTCTGGTGACCTGGGGCAAC SEQ ID NO: 2641TTTGCCTGGATGTATTACCACATGGGCAGACTG IGF1 NM_000618.1TCCGGAGCTGTGATCTAAGGAGGCTGGAGATGTATTGCGC SEQ ID NO: 2642ACCCCTCAAGCCTGCCAAGTCAGCTCGCTCTGTCCG IGF1R NM_000875.2GCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTA SEQ ID NO: 2643TGACGCGAGATATCTATGAGACAGACTATTACCGGAAA IGF2 NM_000612.2CCGTGCTTCCGGACAACTTCCCCAGATACCCCGTGGGCAAGT SEQ ID NO: 2644TCTTCCAATATGACACCTGGAAGCAGTCCA IGFBP2 NM_000597.1GTGGACAGCACCATGAACATGTTGGGCGGGGGAGGCAGTG SEQ ID NO: 2645CTGGCCGGAAGCCCCTCAAGTCGGGTATGAAGG IGFBP3 NM_000598.1ACGCACCGGGTGTCTGATCCCAAGTTCCACCCCCTC SEQ ID NO: 2646CATTCAAAGATAATCATCATCAAGAAAGGGCA IGFBP5 NM_000599.1TGGACAAGTACGGGATGAAGCTGCCAGGCATGGAGTA SEQ ID NO: 2647CGTTGACGGGGACTTTCAGTGCCACACCTTCG IGFBP6 NM_002178.1TGAACCGCAGAGACCAACAGAGGAATCCAGGCACCTCTAC SEQ ID NO: 2648CACGCCCTCCCAGCCCAATTCTGCGGGTGTCCAAGAC IGFBP7 NM_001553GGGTCACTATGGAGTTCAAAGGACAGAACTCCTGCCTGG SEQ ID NO: 2649TGACCGGGACAACCTGGCCATTCAGACCC IHH NM_002181.1AAGGACGAGGAGAACACAGGCGCCGACCGCCTCATGAC SEQ ID NO: 2650CCAGCGCTGCAAGGACCGCCTGAACTCGCTGGCTATCT IL-8 NM_000584.2AAGGAACCATCTCACTGTGTGTAAACATGACTTCCAAG SEQ ID NO: 2651CTGGCCGTGGCTCTCTTGGCAGCCTTCCTGAT IL10 NM_000572.1GGCGCTGTCATCGATTTCTTCCCTGTGAAAACAAGAGCAAGGCC SEQ ID NO: 2652GTGGAGCAGGTGAAGAATGCCTTTAATAAGCTCCA IL1B NM_000576.2AGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCT SEQ ID NO: 2653TCCAGGAGAATGACCTGAGCACCTTCTTTCC IL6 NM_000600.1CCTGAACCTTCCAAAGATGGCTGAAAAAGATGGATG SEQ ID NO: 2654CTTCCAATCTGGATTCAATGAGGAGACTTGCCTGGT IL6ST NM_002184.2GGCCTAATGTTCCAGATCCTTCAAAGAGTCATATTGCCCAGTGGTC SEQ ID NO: 2655ACCTCACACTCCTCCAAGGCACAATTTT ILT-2 NM_006669.1AGCCATCACTCTCAGTGCAGCCAGGTCCTATCGTGGC SEQ ID NO: 2656CCCTGAGGAGACCCTGACTCTGCAGT IMP-1 NM_006546.2GAAAGTGTTTGCGGAGCACAAGATCTCCTACAGCGGCCA SEQ ID NO: 2657GTTCTTGGTCAAATCCGGCTACGCCTTC IMP2 NM_006548.3CAATCTGATCCCAGGGTTGAACCTCAGCGCACTTGGCATCTTTT SEQ ID NO: 2658CAACAGGACTGTCCGTGCTATCTCCACCAGCAGGGCC ING1L NM_001564.1TGTTTCCAAGATCCTGCTGAAAGTGAACGAGCCTCAGA SEQ ID NO: 2659TAAAGCAAAGATGGATTCCAGCCAACCAGAAAGA ING5 NM_032329.4CCTACAGCAAGTGCAAGGAATACAGTGACGACAAAGTG SEQ ID NO: 2660CAGCTGGCCATGCAGACCTACGAGATG INHA NM_002191.2CCTCCCAGTTTCATCTTCCACTACTGTCATGGTGGTTGTGG SEQ ID NO: 2661GCTGCAGATCCCACCAAACCTGTCCCTTCCAGTCCCT INHBA NM_002192.1GTGCCCGAGCCATATAGCAGGCACGTCCGGGTCCTC SEQ ID NO: 2662ACTGTCCTTCCACTCAACAGTCATCAACCACTACCG INHBB NM_002193.1AGCCTCCAGGATACCAGCAAATGGATGCGGTGACAAATGGCA SEQ ID NO: 2663GCTTAGCTACAAATGCCTGTCAGTCGGAGA IRS1 NM_005544.1CCACAGCTCACCTTCTGTCAGGTGTCCATCCCAGCTCCAGC SEQ ID NO: 2664CAGCTCCCAGAGAGGAAGAGACTGGCACTGAGG ITGA3 NM_002204.1CCATGATCCTCACTCTGCTGGTGGACTATACACTCCA SEQ ID NO: 2665GACCTCGCTTAGCATGGTAAATCACCGGCTACAAAGCTTC ITGA4 NM_000885.2CAACGCTTCAGTGATCAATCCCGGGGCGATTTACAGATG SEQ ID NO: 2666CAGGATCGGAAAGAATCCCGGCCAGAC ITGA5 NM_002205.1AGGCCAGCCCTACATTATCAGAGCAAGAGCCGGATAGAGG SEQ ID NO: 2667ACAAGGCTCAGATCTTGCTGGACTGTGGAGAAGAC ITGA6 NM_000210.1CAGTGACAAACAGCCCTTCCAACCCAAGGAATCCCACA SEQ ID NO: 2668AAAGATGGCGATGACGCCCATGAGGCTAAAC ITGA7 NM_002206.1GATATGATTGGTCGCTGCTTTGTGCTCAGCCAGGACCTGGCCA SEQ ID NO: 2669TCCGGGATGAGTTGGATGGTGGGGAATGGAAGTTCT ITGAV NM_002210.2ACTCGGACTGCACAAGCTATTTTTGATGACAGCTAT SEQ ID NO: 2670TTGGGTTATTCTGTGGCTGTCGGAGATTTCAATGGTGATGGCA ITGB1 NM_002211.2TCAGAATTGGATTTGGCTCATTTGTGGAAAAGACTGTGAT SEQ ID NO: 2671GCCTTACATTAGCACAACACCAGCTAAGCTCAGG ITGB3 NM_000212.1ACCGGGAGCCCTACATGACCGAAAATACCTGCAACCGTTACT SEQ ID NO: 2672GCCGTGACGAGATTGAGTCAGTGAAAGAGCTTAAGG ITGB4 NM_000213.2CAAGGTGCCCTCAGTGGAGCTCACCAACCTGTAC SEQ ID NO: 2673CCGTATTGCGACTATGAGATGAAGGTGTGCGC ITGB5 NM_002213.3TCGTGAAAGATGACCAGGAGGCTGTGCTATGTTTCTACAAAA SEQ ID NO: 2674CCGCCAAGGACTGCGTCATGATGTTCACC K-ras NM_033360.2GTCAAAATGGGGAGGGACTAGGGCAGTTTGGATAGCTCAA SEQ ID NO: 2675CAAGATACAATCTCACTCTGTGGTGGTCCTG KCNH2 iso NM_000238.2GAGCGCAAAGTGGAAATCGCCTTCTACCGGAAAGATGGGAG SEQ ID NO: 2676 a/bCTGCTTCCTATGTCTGGTGGATGTGGTGCCCGTGAAGA KCNH2 iso NM_172057.1TCCTGCTGCTGGTCATCTACACGGCTGTCTTCACACCCTACTCG SEQ ID NO: 2677 a/cGCTGCCTTCCTGCTGAAGGAGACGGAAGAAGG KCNK4 NM_016611.2CCTATCAGCCGCTGGTGTGGTTCTGGATCCTGCTCG SEQ ID NO: 2678GCCTGGCTTACTTCGCCTCAGTGCTCACCACCA KDR NM_002253.1GAGGACGAAGGCCTCTACACCTGCCAGGCATGCAGT SEQ ID NO: 2679GTTCTTGGCTGTGCAAAAGTGGAGGCATTTTT Ki-67 NM_002417.1CGGACTTTGGGTGCGACTTGACGAGCGGTGGTTCGACAAGTGGCC SEQ ID NO: 2680TTGCGGGCCGGATCGTCCCAGTGGAAGAGTTGTAA KIAA0125 NM_014792.2GTGTCCTGGTCCATGTGGTGCACGTGTCTCCACC SEQ ID NO: 2681TCCAAGGAGAGGCTCCTCAGTGTGCACCTCCC KIF22 NM_007317.1CTAAGGCACTTGCTGGAAGGGCAGAATGCCAGT SEQ ID NO: 2682GTGCTTGCCTATGGACCCACAGGAGCTGGGAAGA KIF2C NM_006845.2AATTCCTGCTCCAAAAGAAAGTCTTCGAAGCCGCTCCA SEQ ID NO: 2683CTCGCATGTCCACTGTCTCAGAGCTTCGCATCACG KIFC1 XM_371813.1CCACAGGGTTGAAGAACCAGAAGCCAGTTCCTGCTGT SEQ ID NO: 2684TCCTGTCCAGAAGTCTGGCACATCAGGTG Kitlng NM_000899.1GTCCCCGGGATGGATGTTTTGCCAAGTCATTGTTGGATAAGC SEQ ID NO: 2685GAGATGGTAGTACAATTGTCAGACAGCTTGACTGATC KLF5 NM_001730.3GTGCAACCGCAGCTTCTCGCGCTCTGACCACCTGGCCCTGCAT SEQ ID NO: 2686ATGAAGAGGCACCAGAACTGAGCACTGCCCG KLF6 NM_001300.4CACGAGACCGGCTACTTCTCGGCGCTGCCGTCTCT SEQ ID NO: 2687GGAGGAGTACTGGCAACAGACCTGCCTAGAGC KLK10 NM_002776.1GCCCAGAGGCTCCATCGTCCATCCTCTTCCTCCCCAGTCGGCTGAA SEQ ID NO: 2688CTCTCCCCTTGTCTGCACTGTTCAAACCTCTG KLK6 NM_002774.2GACGTGAGGGTCCTGATTCTCCCTGGTTTTACCCCAGCTCCAT SEQ ID NO: 2689CCTTGCATCACTGGGGAGGACGTGATGAGTGAGGA KLRK1 NM_007360.1TGAGAGCCAGGCTTCTTGTATGTCTCAAAATGCCA SEQ ID NO: 2690GCCTTCTGAAAGTATACAGCAAAGAGGACCAGGAT KNTC2 NM_006101.1ATGTGCCAGTGAGCTTGAGTCCTTGGAGAAACACAA SEQ ID NO: 2691GCACCTGCTAGAAAGTACTGTTAACCAGGGGCTCA KRAS2 NM_004985.3GAGACCAAGGTTGCAAGGCCAGGCCCTGTGTGAA SEQ ID NO: 2692CCTTTGAGCTTTCATAGAGAGTTTCACAGCATGGACTG KRT19 NM_002276.1TGAGCGGCAGAATCAGGAGTACCAGCGGCTCATG SEQ ID NO: 2693GACATCAAGTCGCGGCTGGAGCAGGAGATTGCCACCTACCGCA KRT8 NM_002273.1GGATGAAGCTTACATGAACAAGGTAGAGCTGGAGTCTCGCCTGGA SEQ ID NO: 2694AGGGCTGACCGACGAGATCAACTTCCTCAGGCAGCTATATG LAMA3 NM_000227.2CAGATGAGGCACATGGAGACCCAGGCCAAGGACCTGAGG SEQ ID NO: 2695AATCAGTTGCTCAACTACCGTTCTGCCATTTCAA LAMB3 NM_000228.1ACTGACCAAGCCTGAGACCTACTGCACCCAGTATGGCGA SEQ ID NO: 2696GTGGCAGATGAAATGCTGCAAGTGTGAC LAMC2 NM_005562.1ACTCAAGCGGAAATTGAAGCAGATAGGTCTTATCAGCACAGTCTCC SEQ ID NO: 2697GCCTCCTGGATTCAGTGTCTCGGCTTCAGGGAGT LAT NM_014387.2GTGAACGTTCCGGAGAGCGGGGAGAGCGCAGAAGCG SEQ ID NO: 2698TCTCTGGATGGCAGCCGGGAGTATGTGAATGT LCN2 NM_005564.2CGCTGGGCAACATTAAGAGTTACCCTGGATTAACGAGTTACCTCGTCC SEQ ID NO: 2699GAGTGGTGAGCACCAACTACAACCAGCATGCT LDLRAP1 NM_015627.1CAGTGCCTCTCGCCTGTCGACTGGGACAAGCCTGACA SEQ ID NO: 2700GCAGCGGCACAGAGCAGGATGACCTCTTCA LEF NM_016269.2GATGACGGAAAGCATCCAGATGGAGGCCTCTACAACA SEQ ID NO: 2701AGGGACCCTCCTACTCGAGTTATTCCGGG LGALS3 NM_002306.1AGCGGAAAATGGCAGACAATTTTTCGCTCCATGAT SEQ ID NO: 2702GCGTTATCTGGGTCTGGAAACCCAAACCCTCAAG LGMN NM_001008530.1TTGGTGCCGTTCCTATAGATGATCCTGAAGATGGAGGCAAG SEQ ID NO: 2703CACTGGGTGGTGATCGTGGCAGGTTC LILRB3 NM_006864.1CACCTGGTCTGGGAAGATACCTGGAGGTTTTGATT SEQ ID NO: 2704GGGGTCTCGGTGGCCTTCGTCCTGCTGCTCTT LMNB1 NM_005573.1TGCAAACGCTGGTGTCACAGCCAGCCCCCCAA SEQ ID NO: 2705CTGACCTCATCTGGAAGAACCAGAACTCGTGGGG LMYC NM_012421.1CCCATCCAGAACACTGATTGCTGTCATTCAAGTGAAAGGG SEQ ID NO: 2706ATGGAGGTCAGAAAGGGTGCATAGAAAGCAG LOX NM_002317.3CCAATGGGAGAACAACGGGCAGGTGTTCAGCTTG SEQ ID NO: 2707CTGAGCCTGGGCTCACAGTACCAGCCTCAGCG LOXL2 NM_002318.1TCAGCGGGCTCTTAAACAACCAGCTGTCCCCGCAGTA SEQ ID NO: 2708AAGAAGCCTGCGTGGTCAACTCCTGTCTT LRP5 NM_002335.1CGACTATGACCCACTGGACAAGTTCATCTACTGGGTGGATGG SEQ ID NO: 2709GCGCCAGAACATCAAGCGAGCCAAG LRP6 NM_002336.1GGATGTAGCCATCTCTGCCTCTATAGACCTCAGGGCCTTCG SEQ ID NO: 2710CTGTGCTTGCCCTATTGGCTTTGAACT LY6D NM_003695.2AATGCTGATGACTTGGAGCAGGCCCCACAGACCCCACAGAGG SEQ ID NO: 2711ATGAAGCCACCCCACAGAGGATGCAG MAD NM_002357.1TGGTTCTGATTAGGTAACGTATTGGACCTGCCCACAACT SEQ ID NO: 2712CCCTTGCACGTAAACTTCAGTGTCCCACCTTGACC MAD1L1 NM_003550.1AGAAGCTGTCCCTGCAAGAGCAGGATGCAGCGATTGT SEQ ID NO: 2713GAAGAACATGAAGTCTGAGCTGGTACGGCT MAD2L1 NM_002358.2CCGGGAGCAGGGAATCACCCTGCGCGGGAGCGCCGAAATCGT SEQ ID NO: 2714GGCCGAGTTCTTCTCATTCGGCATCAACAGCAT MADH2 NM_005901.2GCTGCCTTTGGTAAGAACATGTCGTCCATCTTGCCAT SEQ ID NO: 2715TCACGCCGCCAGTTGTGAAGAGACTGCTGGGAT MADH4 NM_005359.3GGACATTACTGGCCTGTTCACAATGAGCTTGCATTCCAGCCTCCC SEQ ID NO: 2716ATTTCCAATCATCCTGCTCCTGAGTATTGGT MADH7 NM_005904.1TCCATCAAGGCTTTCGACTACGAGAAGGCGTACAGCCTGCAGCGGC SEQ ID NO: 2717CCAATGACCACGAGTTTATGCAGCAG MAP2 NM_031846.1CGGACCACCAGGTCAGAGCCAATTCGCAGAGCAGGGAAGAG SEQ ID NO: 2718TGGTACCTCAACACCCACTACCCCTG MAP2K1 NM_002755.2GCCTTTCTTACCCAGAAGCAGAAGGTGGGAGAACTGAAGGATGACG SEQ ID NO: 2719ACTTTGAGAAGATCAGTGAGCTGGGGGCTG MAP3K1 XM_042066.8GGTTGGCATCAAAAGGAACTGGTGCAGGAGAGTTTCAGG SEQ ID NO: 2720GACAATTACTGGGGACAATTGCATTTATGGCA MAPK14 NM_139012.1TGAGTGGAAAAGCCTGACCTATGATGAAGTCATCAGCTTTGTGCC SEQ ID NO: 2721ACCACCCCTTGACCAAGAAGAGATGGAGTCC Maspin NM_002639.1CAGATGGCCACTTTGAGAACATTTTAGCTGACAACAGTGTGA SEQ ID NO: 2722ACGACCAGACCAAAATCCTTGTGGTTAATGCTGCC MAX NM_002382.3CAAACGGGCTCATCATAATGCACTGGAACGAAAACGTAGG SEQ ID NO: 2723GACCACATCAAAGACAGCTTTCACAGTTTGCGGGA MCM2 NM_004526.1GACTTTTGCCCGCTACCTTTCATTCCGGCGTGACAACAATGA SEQ ID NO: 2724GCTGTTGCTCTTCATACTGAAGCAGTTAGTGGC MCM3 NM_002388.2GGAGAACAATCCCCTTGAGACAGAATATGGCCTTTCTGTCTA SEQ ID NO: 2725CAAGGATCACCAGACCATCACCATCCAGGAGAT MCM6 NM_005915.2TGATGGTCCTATGTGTCACATTCATCACAGGTTTCATACCAAC SEQ ID NO: 2726ACAGGCTTCAGCACTTCCTTTGGTGTGTTTCCTGTCCCA MCP1 NM_002982.1CGCTCAGCCAGATGCAATCAATGCCCCAGTCACCTGCTGT SEQ ID NO: 2727TATAACTTCACCAATAGGAAGATCTCAGTGC MDK NM_002391.2GGAGCCGACTGCAAGTACAAGTTTGAGAACTGG SEQ ID NO: 2728GGTGCGTGTGATGGGGGCACAGGCACCAAAGTC MDM2 NM_002392.1CTACAGGGACGCCATCGAATCCGGATCTTGATGCTGG SEQ ID NO: 2729TGTAAGTGAACATTCAGGTGATTGGTTGGAT MGAT5 NM_002410.2GGAGTCGAAGGTGGACAATCTTGTTGTCAATGGCACCGGAA SEQ ID NO: 2730CAAACTCAACCAACTCCACTACAGCTGTTCCCA MGMT NM_002412.1GTGAAATGAAACGCACCACACTGGACAGCCCTTTGGGG SEQ ID NO: 2731AAGCTGGAGCTGTCTGGTTGTGAGCAGGGTC mGST1 NM_020300.2ACGGATCTACCACACCATTGCATATTTGACACCCCTTCCCC SEQ ID NO: 2732AGCCAAATAGAGCTTTGAGTTTTTTTGTTGGATATGGA MMP1 NM_002421.2GGGAGATCATCGGGACAACTCTCCTTTTGATGGACCTGGAGG SEQ ID NO: 2733AAATCTTGCTCATGCTTTTCAACCAGGCCC MMP12 NM_002426.1CCAACGCTTGCCAAATCCTGACAATTCAGAACCAGCT SEQ ID NO: 2734CTCTGTGACCCCAATTTGAGTTTTGATGCTGTCACTACCGT MMP2 NM_004530.1CCATGATGGAGAGGCAGACATCATGATCAACTTTGG SEQ ID NO: 2735CCGCTGGGAGCATGGCGATGGATACCCCTTTGACGGTAAGGACGGACTCC MMP7 NM_002423.2GGATGGTAGCAGTCTAGGGATTAACTTCCTGTATGC SEQ ID NO: 2736TGCAACTCATGAACTTGGCCATTCTTTGGGTATGGGACATTCC MMP9 NM_004994.1GAGAACCAATCTCACCGACAGGCAGCTGGCAGAGGAA SEQ ID NO: 2737TACCTGTACCGCTATGGTTACACTCGGGTG MRP1 NM_004996.2TCATGGTGCCCGTCAATGCTGTGATGGCGATGAAGACCA SEQ ID NO: 2738AGACGTATCAGGTGGCCCACATGAAGAGCAAAGACAATCG MRP2 NM_000392.1AGGGGATGACTTGGACACATCTGCCATTCGACATG SEQ ID NO: 2739ACTGCAATTTTGACAAAGCCATGCAGTTTT MRP3 NM_003786.2TCATCCTGGCGATCTACTTCCTCTGGCAGAACCTAGGTCCCTCTGTC SEQ ID NO: 2740CTGGCTGGAGTCGCTTTCATGGTCTTGCTGATTCCACTCAACGG MRP4 NM_005845.1AGCGCCTGGAATCTACAACTCGGAGTCCAGTGTTT SEQ ID NO: 2741TCCCACTTGTCATCTTCTCTCCAGGGGCTCT MRPL40 NM_003776.2ACTTGCAGGCTGCTATCCTTAACATGCTGCCCCTGAG SEQ ID NO: 2742AGTAGGAATGACCAGGGTTCAAGTCTGCT MSH2 NM_000251.1GATGCAGAATTGAGGCAGACTTTACAAGAAGATTTACT SEQ ID NO: 2743TCGTCGATTCCCAGATCTTAACCGACTTGCCAAGA MSH3 NM_002439.1TGATTACCATCATGGCTCAGATTGGCTCCTATGTTCC SEQ ID NO: 2744TGCAGAAGAAGCGACAATTGGGATTGTGGATGGCATTTTCACAAG MSH6 NM_000179.1TCTATTGGGGGATTGGTAGGAACCGTTACCAGCTG SEQ ID NO: 2745GAAATTCCTGAGAATTTCACCACTCGCAATTTG MT3 NM_005954.1GTGTGAGAAGTGTGCCAAGGACTGTGTGTGCAAA SEQ ID NO: 2746GGCGGAGAGGCAGCTGAGGCAGAAGCAGAGAAGTGCAG MTA1 NM_004689.2CCGCCCTCACCTGAAGAGAAACGCGCTCCTTGGCGGAC SEQ ID NO: 2747ACTGGGGGAGGAGAGGAAGAAGCGCGGCTAACTTATTCC MUC1 NM_002456.1GGCCAGGATCTGTGGTGGTACAATTGACTCTGGC SEQ ID NO: 2748CTTCCGAGAAGGTACCATCAATGTCCACGACGTGGAG MUC2 NM_002457.1CTATGAGCCATGTGGGAACCGGAGCTTCGAGACCTGC SEQ ID NO: 2749AGGACCATCAACGGCATCCACTCCAACAT MUC5B XM_039877.11TGCCCTTGCACTGTCCTAACGGCTCAGCCATCCT SEQ ID NO: 2750GCACACCTACACCCACGTGGATGAGTGTGGCTG MUTYH NM_012222.1GTACGACCAAGAGAAACGGGACCTACCATGGAGAAGA SEQ ID NO: 2751CGGGCAGAAGATGAGATGGACCTGGACAGG MVP NM_017458.1ACGAGAACGAGGGCATCTATGTGCAGGATGTCAAGACCGGAAA SEQ ID NO: 2752GGTGCGCGCTGTGATTGGAAGCACCTACATGC MX1 NM_002462.2GAAGGAATGGGAATCAGTCATGAGCTAATCACCCTGGAGAT SEQ ID NO: 2753CAGCTCCCGAGATGTCCCGGATCTGACTCTAATAGAC MXD4 NM_006454.2AGAAACTGGAGGAGCAGGACCGCCGGGCACTGAGCATCA SEQ ID NO: 2754AGGAGCAGCTGCAGCAGGAGCATCGTTTCCTGAAG MYBL2 NM_002466.1GCCGAGATCGCCAAGATGTTGCCAGGGAGGACAGACAA SEQ ID NO: 2755TGCTGTGAAGAATCACTGGAACTCTACCATCAAAAG MYH11 NM_002474.1CGGTACTTCTGAGGGCTAATATATACGTACTCTGGCCTCT SEQ ID NO: 2756TCTGCGTGGTGGTCAACCCCTATAAACACCTGCCCATCTACTCGG MYLK NM_053025.1TGACGGAGCGTGAGTGCATCAAGTACATGCGGCAGATC SEQ ID NO: 2757TCGGAGGGAGTGGAGTACATCCACAAGCAGGGCAT NAD2 NM_000015.1TAACTGACATTCTTGAGCACCAGATCCGGGCTGTTCCCTTTG SEQ ID NO: 2758AGAACCTTAACATGCATTGTGGGCAAGCCAT NAV2 NM_182964.3CTCTCCCAGCACAGCTTGAACCTCACTGAGTCAACCA SEQ ID NO: 2759GCCTGGACATGTTGCTGGATGACACTGGTG NCAM1 NM_000615.1TAGTTCCCAGCTGACCATCAAAAAGGTGGATAAGAACGACGAG SEQ ID NO: 2760GCTGAGTACATCTGCATTGCTGAGAACAAGGCTG NDE1 NM_017668.1CTACTGCGGAAAGTCGGGGCACTGGAGTCCAAACTCGCT SEQ ID NO: 2761TCCTGCCGGAACCTCGTGTACGATCAGTCC NDRG1 NM_006096.2AGGGCAACATTCCACAGCTGCCCTGGCTGTGATGAGTG SEQ ID NO: 2762TCCTTGCAGGGGCCGGAGTAGGAGCACTG NDUFS3 NM_004551.1TATCCATCCTGATGGCGTCATCCCAGTGCTGACTTTCCTCAG SEQ ID NO: 2763GGATCACACCAATGCACAGTTCAA NEDD8 NM_006156.1TGCTGGCTACTGGGTGTTAGTTTGCAGTCCTGTGTG SEQ ID NO: 2764CTTCCCTCTCTTATGACTGTGTCCCTGGTTGTC NEK2 NM_002497.1GTGAGGCAGCGCGACTCTGGCGACTGGCCGGCCATGCCTTCCC SEQ ID NO: 2765GGGCTGAGGACTATGAAGTGTTGTACACCATTGGCA NF2 NM_000268.2ACTCCAGAGCTGACCTCCACCGCCCAGCCTGGGAAG SEQ ID NO: 2766TCATTGTAGGGAGTGAGACACTGAAGCCCTGA NFKBp50 NM_003998.1CAGACCAAGGAGATGGACCTCAGCGTGGTGCGGCTCATGTT SEQ ID NO: 2767TACAGCTTTTCTTCCGGATAGCACTGGCAGCT NFKBp65 NM_021975.1CTGCCGGGATGGCTTCTATGAGGCTGAGCTCTGC SEQ ID NO: 2768CCGGACCGCTGCATCCACAGTTTCCAGAACCTGG NISCH NM_007184.1CCAAGGAATCATGTTCGTTCAGGAGGAGGCCCTGGCCA SEQ ID NO: 2769GCAGCCTCTCGTCCACTGACAGTCTGACTCCCGAGCACCA Nkd-1 NM_033119.3GAGAGAGTGAGCGAACCCTGCCCAGGCTCCAAGAAGC SEQ ID NO: 2770AGCTGAAGTTTGAAGAGCTCCAGTGCGACG NMB NM_021077.1GGCTGCTGGTACAAATACTGCAGAAATGACACCAA SEQ ID NO: 2771TAATAGGGGCAGACACAACAGCGTGGCTTAGATTG NMBR NM_002511.1TGATCCATCTCTAGGCCACATGATTGTCACCTTAGTTGCCCGGG SEQ ID NO: 2772TTCTCAGTTTTGGCAATTCTTGTGTCAACCCATTTGCTC NME1 NM_000269.1CCAACCCTGCAGACTCCAAGCCTGGGACCATCCGTGG SEQ ID NO: 2773AGACTTCTGCATACAAGTTGGCAGGAACATTATACAT NOS3 NM_000603.2ATCTCCGCCTCGCTCATGGGCACGGTGATGGCGAAGC SEQ ID NO: 2774GAGTGAAGGCGACAATCCTGTATGGCTCCGA NOTCH1 NM_017617.2CGGGTCCACCAGTTTGAATGGTCAATGCGAGTGGCTGT SEQ ID NO: 2775CCCGGCTGCAGAGCGGCATGGTGCCGAACCAATACAAC NOTCH2 NM_024408.2CACTTCCCTGCTGGGATTATATCAACAACCAGTG SEQ ID NO: 2776TGATGAGCTGTGCAACACGGTCGAGTGCCTGTTTGACAACT NPM1 NM_002520.2AATGTTGTCCAGGTTCTATTGCCAAGAATGTGTTGTCCAAA SEQ ID NO: 2777ATGCCTGTTTAGTTTTTAAAGATGGAACTCCACCCTTTGCTTG NR4A1 NM_002135.2CACAGCTTGCTTGTCGATGTCCCTGCCTTCGCCTG SEQ ID NO: 2778CCTCTCTGCCCTTGTCCTCATCACCGACCGGCAT NRG1 NM_013957.1CGAGACTCTCCTCATAGTGAAAGGTATGTGTCAGCCATGACCAC SEQ ID NO: 2779CCCGGCTCGTATGTCACCTGTAGATTTCCACACGCCAAG NRP1 NM_003873.1CAGCTCTCTCCACGCGATTCATCAGGATCTACCCCGAGAGAGCCACT SEQ ID NO: 2780CATGGCGGACTGGGGCTCAGAATGGAGCTGCTGGG NRP2 NM_003872.1CTACAGCCTAAACGGCAAGGACTGGGAATACATTCA SEQ ID NO: 2781GGACCCCAGGACCCAGCAGCCAAAGCTGTTCGAAGGGAAC NTN1 NM_004822.1AGAAGGACTATGCCGTCCAGATCCACATCCTGAAGG SEQ ID NO: 2782CGGACAAGGCGGGGGACTGGTGGAAGTTCACGG NUFIP1 NM_012345.1GCTTCCACATCGTGGTATTGGAGACAGTCTTCTGATAGGTTTCCT SEQ ID NO: 2783CGGCATCAGAAGTCCTTCAACCCTGCAGTT ODC1 NM_002539.1AGAGATCACCGGCGTAATCAACCCAGCGTTGGACAAATACTTTC SEQ ID NO: 2784CGTCAGACTCTGGAGTGAGAATCATAGCTGAGCCCG OPN, NM_000582.1CAACCGAAGTTTTCACTCCAGTTGTCCCCACAGTAGACACAT SEQ ID NO: 2785 osteopontinATGATGGCCGAGGTGATAGTGTGGTTTATGGACTGAGG ORC1L NM_004153.2TCCTTGACCATACCGGAGGGTGCATGTACATCTCCGG SEQ ID NO: 2786TGTCCCTGGGACAGGGAAGACTGCCACTG OSM NM_020530.3GTTTCTGAAGGGGAGGTCACAGCCTGAGCTGGC SEQ ID NO: 2787CTCCTATGCCTCATCATGTCCCAAACCAGACACCT OSMR NM_003999.1GCTCATCATGGTCATGTGCTACTTGAAAAGTCAGTGGATCAA SEQ ID NO: 2788GGAGACCTGTTATCCTGACATCCCTGACCCTTACA P14ARF S78535.1CCCTCGTGCTGATGCTACTGAGGAGCCAGCGTCTAGGGCAGCAG SEQ ID NO: 2789CCGCTTCCTAGAAGACCAGGTCATGATG p16-INK4 L27211.1GCGGAAGGTCCCTCAGACATCCCCGATTGAAAGAACCAGAGA SEQ ID NO: 2790GGCTCTGAGAAACCTCGGGAAACTTAGATCATCA p21 NM_000389.1TGGAGACTCTCAGGGTCGAAAACGGCGGCAGA SEQ ID NO: 2791CCAGCATGACAGATTTCTACCACTCCAAACGCC p27 NM_004064.1CGGTGGACCACGAAGAGTTAACCCGGGACTT SEQ ID NO: 2792GGAGAAGCACTGCAGAGACATGGAAGAGGCGAGCC P53 NM_000546.2CTTTGAACCCTTGCTTGCAATAGGTGTGCGTC SEQ ID NO: 2793AGAAGCACCCAGGACTTCCATTTGCTTTGTCCCGGG p53R2 AB036063.1CCCAGCTAGTGTTCCTCAGAACAAAGATTGGAAAAAGCTGGCCGAG SEQ ID NO: 2794AACCATTTATACATAGAGGAAGGGCTTACGG PADI4 NM_012387.1AGCAGTGGCTTGCTTTCTTCTCCTGTGATGTCCCA SEQ ID NO: 2795GTTTCCCACTCTGAAGATCCCAACATGGTCCTAGCA PAI1 NM_000602.1CCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCG SEQ ID NO: 2796GTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCA Pak1 NM_002576.3GAGCTGTGGGTTGTTATGGAATACTTGGCTGGAGGCT SEQ ID NO: 2797CCTTGACAGATGTGGTGACAGAAACTTGCATGG PARC NM_015089.1GGAGCTGACCTGCTTCCTACATCGCCTGGCC SEQ ID NO: 2798TCGATGCATAAGGACTATGCTGTGGTGCTCTGCT PCAF NM_003884.3AGGTGGCTGTGTTACTGCAACGTGCCACAGTTCTGC SEQ ID NO: 2799GACAGTCTACCTCGGTACGAAACCACACAGGTG PCNA NM_002592.1GAAGGTGTTGGAGGCACTCAAGGACCTCATCAACAGGCCT SEQ ID NO: 2800GCTGGGATATTAGCTCCAGCGGTGTAAACC PDGFA NM_002607.2TTGTTGGTGTGCCCTGGTGCCGTGGTGGCGGTCACT SEQ ID NO: 2801CCCTCTGCTGCCAGTGTTTGGACAGAACCCA PDGFB NM_002608.1ACTGAAGGAGACCCTTGGAGCCTAGGGGCATC SEQ ID NO: 2802GGCAGGAGAGTGTGTGGGCAGGGTTATTTA PDGFC NM_016205.1AGTTACTAAAAAATACCACGAGGTCCTTCAGTTGAGACCAAAGA SEQ ID NO: 2803CCGGTGTCAGGGGATTGCACAAATCACTCACCGAC PDGFD NM_025208.2TATCGAGGCAGGTCATACCATGACCGGAAGTCAAAAGTTG SEQ ID NO: 2804ACCTGGATAGGCTCAATGATGATGCCAAGCGTTA PDGFRa NM_006206.2GGGAGTTTCCAAGAGATGGACTAGTGCTTGGTC SEQ ID NO: 2805GGGTCTTGGGGTCTGGAGCGTTTGGGAAGGTGGTTGAAG PDGFRb NM_002609.2CCAGCTCTCCTTCCAGCTACAGATCAATGTCC SEQ ID NO: 2806CTGTCCGAGTGCTGGAGCTAAGTGAGAGCCACCC PFN1 NM_005022.2GGAAAACGTTCGTCAACATCACGCCAGCTGAGGTG SEQ ID NO: 2807GGTGTCCTGGTTGGCAAAGACCGGTCAAGTTTT PFN2 NM_053024.1TCTATACGTCGATGGTGACTGCACAATGGACATCCGGACAAAG SEQ ID NO: 2808AGTCAAGGTGGGGAGCCAACATACAATGTGGCTGTCGGC PGK1 NM_000291.1AGAGCCAGTTGCTGTAGAACTCAAATCTCTGCTGGGC SEQ ID NO: 2809AAGGATGTTCTGTTCTTGAAGGACTGTGTAGGCCCAG PI3K NM_002646.2TGCTACCTGGACAGCCCGTTGGTGCGCTTCCTCCTGAAACGAGCT SEQ ID NO: 2810GTGTCTGACTTGAGAGTGACTCACTACTTCTTCTGGTTACTGAAGGACGGCCT PI3KC2ANM_002645.1 ATACCAATCACCGCACAAACCCAGGCTATTTGTTAAG SEQ ID NO: 2811TCCAGTCACAGCGCAAAGAAACATATGCGGAGAAAATGCTAGTGTG PIK3CA NM_006218.1GTGATTGAAGAGCATGCCAATTGGTCT SEQ ID NO: 2812GTATCCCGAGAAGCAGGATTTAGCTATTCCCACGCAGGAC PIM1 NM_002648.2CTGCTCAAGGACACCGTCTACACGGACTT SEQ ID NO: 2813CGATGGGACCCGAGTGTATAGCCCTCCAGAGTGGATCC Pin1 NM_006221.1GATCAACGGCTACATCCAGAAGATCAAGT SEQ ID NO: 2814CGGGAGAGGAGGACTTTGAGTCTCTGGCCTCACAGTTCA PKD1 NM_000296.2CAGCACCAGCGATTACGACGTTGGCTGGG SEQ ID NO: 2815AGAGTCCTCACAATGGCTCGGGGACGTGGGCCTATTCAG PKR2 NM_002654.3CCGCCTGGACATTGATTCACCACCCATCAC SEQ ID NO: 2816AGCCCGGAACACTGGCATCATCTGTACCATTGGCCCAG PLA2G2A NM_000300.2GCATCCCTCACCCATCCTAGAGGCCAGGCAGG SEQ ID NO: 2817AGCCCTTCTATACCCACCCAGAATGAGACATCCAGCAGATTTCCAGC PLAUR NM_002659.1CCCATGGATGCTCCTCTGAAGAGACTTTCCTCATTG SEQ ID NO: 2818ACTGCCGAGGCCCCATGAATCAATGTCTGGTAGCCACCGG PLK NM_005030.2AATGAATACAGTATTCCCAAGCACATC SEQ ID NO: 2819AACCCCGTGGCCGCCTCCCTCATCCAGAAGATGCTTCAGACA PLK3 NM_004073.2TGAAGGAGACGTACCGCTGCATCAAGC SEQ ID NO: 2820AGGTTCACTACACGCTGCCTGCCAGCCTCTCACTGCCTG PLOD2 NM_000935.2CAGGGAGGTGGTTGCAAATTTCTAAGGTACAATT SEQ ID NO: 2821GCTCTATTGAGTCACCACGAAAAGGCTGGAGCTTCATGCATCCTGGGAGA PMS1 NM_000534.2CTTACGGTTTTCGTGGAGAAGCCTTGGGGTCAATTT SEQ ID NO: 2822GTTGTATAGCTGAGGTTTTAATTACAACAAGAACGGCTGCT PMS2 NM_000535.2GATGTGGACTGCCATTCAAACCAGGAAGATACCGGATGT SEQ ID NO: 2823AAATTTCGAGTTTTGCCTCAGCCAACTAATCTCGCA PPARG NM_005037.3TGACTTTATGGAGCCCAAGTTTGAGTTTG SEQ ID NO: 2824CTGTGAAGTTCAATGCACTGGAATTAGATGACAGCGACTTGGC PPID NM_005038.1TCCTCATTTGGATGGGAAACATGTGGTGT SEQ ID NO: 2825TTGGCCAAGTAATTAAAGGAATAGGAGTGGCAAGGATATTGG PPM1D NM_003620.1GCCATCCGCAAAGGCTTTCTCGCTT SEQ ID NO: 2826GTCACCTTGCCATGTGGAAGAAACTGGCGGAATGGCC PPP2R4 NM_178001.1GGCTCAGAGCATAAGGCTTCAGGGCCCAAGTTGGG SEQ ID NO: 2827AGAAGTGACCAAAGTGTAGCCAGTTTTCTGAGTTCCCGT PR NM_000926.2GCATCAGGCTGTCATTATGGTGTCCTTACCTGTGGGAGC SEQ ID NO: 2828TGTAAGGTCTTCTTTAAGAGGGCAATGGAAGGGCAGCACAACTACT PRDX2 NM_005809.4GGTGTCCTTCGCCAGATCACTGTTAAT SEQ ID NO: 2829GATTTGCCTGTGGGACGCTCCGTGGATGAGGCTCTGCGGCTG PRDX3 NM_006793.2TGACCCCAATGGAGTCATCAAGCATTTGAGCGTCAACGAT SEQ ID NO: 2830CTCCCAGTGGGCCGAAGCGTGGAAGAAACCCTCCGCTTGG PRDX4 NM_006406.1TTACCCATTTGGCCTGGATTAATACCCCTCGAAGAC SEQ ID NO: 2831AAGGAGGACTTGGGCCAATAAGGATTCCACTTCTTTCAG PRDX6 NM_004905.2CTGTGAGCCAGAGGATGTCAGCTGCCAATTGTGT SEQ ID NO: 2832TTTCCTGCAGCAATTCCATAAACACATCCTGGTGTCATCACA PRKCA NM_002737.1CAAGCAATGCGTCATCAATGTCCCC SEQ ID NO: 2833AGCCTCTGCGGAATGGATCACACTGAGAAGAGGGGGCGGATTTAC PRKCB1 NM_002738.5GACCCAGCTCCACTCCTGCTTCC SEQ ID NO: 2834AGACCATGGACCGCCTGTACTTTGTGATGGAGTACGTGAATGGG PRKCD NM_006254.1CTGACACTTGCCGCAGAGAATCCC SEQ ID NO: 2835TTTCTCACCCACCTCATCTGCACCTTCCAGACCAAGGACCACCT PRKR NM_002759.1GCGATACATGAGCCCAGAACAGATTTCTTCGCAAGA SEQ ID NO: 2836CTATGGAAAGGAAGTGGACCTCTACGCTTTGGGGCTAATTCTTGCTGA pS2 NM_003225.1GCCCTCCCAGTGTGCAAATAAGGGCTGCTGTTTCGACGACA SEQ ID NO: 2837CCGTTCGTGGGGTCCCCTGGTGCTTCTATCCTAATACCATCGACG PTCH NM_000264.2CCACGACAAAGCCGACTACATGCCTGAAA SEQ ID NO: 2838CAAGGCTGAGAATCCCGGCAGCAGAGCCCATCGAGTA PTEN NM_000314.1TGGCTAAGTGAAGATGACAATCATGTTGCAGCAATTCA SEQ ID NO: 2839CTGTAAAGCTGGAAAGGGACGAACTGGTGTAATGATATGTGCA PTGER3 NM_000957.2TAACTGGGGCAACCTTTTCTTCGCCTCTGCCTTTGCCTT SEQ ID NO: 2840CCTGGGGCTCTTGGCGCTGACAGTCACCTTTTCCTGCAA PTHLH NM_002820.1AGTGACTGGGAGTGGGCTAGAAGGGGACCACCTGTCTGAC SEQ ID NO: 2841ACCTCCACAACGTCGCTGGAGCTCGATTCACGGTAACAGGCTT PTHR1 NM_000316.1CGAGGTACAAGCTGAGATCAAGAAATCTTGGAGCCGCTG SEQ ID NO: 2842GACACTGGCACTGGACTTCAAGCGAAAGGCACGC PTK2 NM_005607.3GACCGGTCGAATGATAAGGTGTACGAGAATGTGA SEQ ID NO: 2843CGGGCCTGGTGAAAGCTGTCATCGAGATGTCCAG PTK2B NM_004103.3CAAGCCCAGCCGACCTAAGTACAGACCCCCTCCGC SEQ ID NO: 2844AAACCAACCTCCTGGCTCCAAAGCTGCAGTTCCAGGTTC PTP4A3 NM_007079.2AATATTTGTGCGGGGTATGGGGGTGGGTTTTT SEQ ID NO: 2845AAATCTCGTTTCTCTTGGACAAGCACAGGGATCTCGTT PTP4A3 v2 NM_032611.1CCTGTTCTCGGCACCTTAAATTATT SEQ ID NO: 2846AGACCCCGGGGCAGTCAGGTGCTCCGGACACCCGAAGGCAATA PTPD1 NM_007039.2CGCTTGCCTAACTCATACTTTCCCGTTGACACTTGATCCACG SEQ ID NO: 2847CAGCGTGGCACTGGGACGTAAGTGGCGCAGTCTGAATGG PTPN1 NM_002827.2AATGAGGAAGTTTCGGATGGGGCTGATCCAGACAGCCGACC SEQ ID NO: 2848AGCTGCGCTTCTCCTACCTGGCTGTGATCGAAG PTPRF NM_002840.2TGTTTTAGCTGAGGGACGTGGTGCCGACGTCCCCA SEQ ID NO: 2849AACCTAGCTAGGCTAAGTCAAGATCAACATTCCAGGGTTGGTA PTPRJ NM_002843.2AACTTCCGGTACCTCGTTCGTGACTACATGAAGCAGA SEQ ID NO: 2850GTCCTCCCGAATCGCCGATTCTGGTGCATTGCAGTGCT PTPRO NM_030667.1CATGGCCTGATCATGGTGTGCCCACAGC SEQ ID NO: 2851AAATGCTGCAGAAAGTATCCTGCAGTTTGTACACATGG PTTG1 NM_004219.2GGCTACTCTGATCTATGTTGATAAGGAAAATGGAG SEQ ID NO: 2852AACCAGGCACCCGTGTGGTTGCTAAGGATGGGCTGAAGC RAB32 NM_006834.2CCTGCAGCTGTGGGACATCGCGGGGCAGGAGCGATTTGGC SEQ ID NO: 2853AACATGACCCGAGTATACTACAAGGAAGCTGTTGGTGCT RAB6C NM_032144.1GCGACAGCTCCTCTAGTTCCACCATGTCCGCGGGCGGAGACTT SEQ ID NO: 2854CGGGAATCCGCTGAGGAAATTCAAGCTGGTGTTCC RAC1 NM_006908.3TGTTGTAAATGTCTCAGCCCCTCGTTCTTGGTCCTG SEQ ID NO: 2855TCCCTTGGAACCTTTGTACGCTTTGCTCAA RAD51C NM_058216.1GAACTTCTTGAGCAGGAGCATACCCAGGGCTTCATAATCA SEQ ID NO: 2856CCTTCTGTTCAGCACTAGATGATATTCTTGGGGGTGGA RAD54L NM_003579.2AGCTAGCCTCAGTGACACACATGACAGGTTGCACT SEQ ID NO: 2857GCCGACGTTGTGTCAACAGCCGTCAGATCCGG RAF1 NM_002880.1CGTCGTATGCGAGAGTCTGTTTCCAGGATGCCTGTTAG SEQ ID NO: 2858TTCTCAGCACAGATATTCTACACCTCACGCCTTCA RALBP1 NM_006788.2GGTGTCAGATATAAATGTGCAAATGCCTTCTTGCTGTCCTGTCGGT SEQ ID NO: 2859CTCAGTACGTTCACTTTATAGCTGCTGGCAATATCGAA RANBP2 NM_006267.3TCCTTCAGCTTTCACACTGGGCTCAGAAATGAAGTTG SEQ ID NO: 2860CATGACTCTTCTGGAAGTCAGGTGGGAACAGGATTT ranBP7 NM_006391.1AACATGATTATCCAAGCCGCTGGACTGCCATTGTGGACAAAATTGGCTTTTA SEQ ID NO: 2861TCTTCAGTCCGATAACAGTGCTTGTTGGC RANBP9 NM_005493.2CAAGTCAGTTGAGACGCCAGTTGTGTGGAGGAAGTC SEQ ID NO: 2862AGGCCGCCATAGAAAGAATGATCCACTTTGGACGAGAGCTGCA RAP1GDS1 NM_021159.3TGTGGATGCTGGATTGATTTCACCACTGGTGCAGC SEQ ID NO: 2863TGCTAAATAGCAAAGACCAGGAAGTGCTGCTT RARA NM_000964.1AGTCTGTGAGAAACGACCGAAACAAGAAGAAGAAGGAGGTGCC SEQ ID NO: 2864CAAGCCCGAGTGCTCTGAGAGCTACACGCTGACGCCG RARB NM_016152.2TGCCTGGACATCCTGATTCTTAGAATTTGCACCAGGTATACC SEQ ID NO: 2865CCAGAACAAGACACCATGACTTTCTCAGACGGCCTT RASSF1 NM_007182.3AGTGGGAGACACCTGACCTTTCTCAAGCTGAGATTG SEQ ID NO: 2866AGCAGAAGATCAAGGAGTACAATGCCCAGATCA RBM5 NM_005778.1CGAGAGGGAGAGCAAGACCATCATGCTGCGCGGCCTT SEQ ID NO: 2867CCCATCACCATCACAGAGAGCGATATTCGAGA RBX1 NM_014248.2GGAACCACATTATGGATCTTTGCATAGAATGTCAAGCTAACCA SEQ ID NO: 2868GGCGTCCGCTACTTCAGAAGAGTGTACTGTCGCATG RCC1 NM_001269.2GGGCTGGGTGAGAATGTGATGGAGAGGAAGAAGCCG SEQ ID NO: 2869GCCCTGGTATCCATTCCGGAGGATGTTGTG REG4 NM_032044.2TGCTAACTCCTGCACAGCCCCGTCCTCTTCCTTTCTGCTAGCCTGGC SEQ ID NO: 2870TAAATCTGCTCATTATTTCAGAGGGGAAACCTAGCA RFC NM_003056.1TCAAGACCATCATCACTTTCATTGTCTCGGA SEQ ID NO: 2871CGTGCGGGGCCTGGGCCTCCCGGTCCGCA AGCAGTTCCAGTTATACTCCGTGTACTTCCTGATCC RhoBNM_004040.2 AAGCATGAACAGGACTTGACCATCTTTCCAACCCC SEQ ID NO: 2872TGGGGAAGACATTTGCAACTGACTTGGGGAGG rhoC NM_175744.1CCCGTTCGGTCTGAGGAAGGCCGGGACATGGCGAAC SEQ ID NO: 2873CGGATCAGTGCCTTTGGCTACCTTGAGTGCTC RIZ1 NM_012231.1CCAGACGAGCGATTAGAAGCGGCAGCTTGTGAGGTGAAT SEQ ID NO: 2874GATTTGGGGGAAGAGGAGGAGGAGGAAGAGGAGGA RNF11 NM_014372.3ACCCTGGAAGAGATGGATCAGAAAAAAAGATCCGGGAGTGTGTGAT SEQ ID NO: 2875CTGTATGATGGACTTTGTTTATGGGGACCCAAT ROCK1 NM_005406.1TGTGCACATAGGAATGAGCTTCAGATGCAGTTGGCCAGCAAA SEQ ID NO: 2876GAGAGTGATATTGAGCAATTGCGTGCTAAAC ROCK2 NM_004850.3GATCCGAGACCCTCGCTCCCCCATCAACGTGGAG SEQ ID NO: 2877AGCTTGCTGGATGGCTTAAATTCCTTGGTCCT RPLPO NM_001002.2CCATTCTATCATCAACGGGTACAAACGAGTCCTGGCCTTGTCTG SEQ ID NO: 2878TGGAGACGGATTACACCTTCCCACTTGCTGA RPS13 NM_001017.2CAGTCGGCTTTACCCTATCGACGCAGCGTCCC SEQ ID NO: 2879CACTTGGTTGAAGTTGACATCTGACGACGTGAAGGAGCAGA RRM1 NM_001033.1GGGCTACTGGCAGCTACATTGCTGGGACTAATGGCA SEQ ID NO: 2880ATTCCAATGGCCTTGTACCGATGCTGAGAG RRM2 NM_001034.1CAGCGGGATTAAACAGTCCTTTAACCAGCACAGC SEQ ID NO: 2881CAGTTAAAAGATGCAGCCTCACTGCTTCAACGCAGAT RTN4 NM_007008.1GACTGGAGTGGTGTTTGGTGCCAGCCTATTCCTGCTGC SEQ ID NO: 2882TTTCATTGACAGTATTCAGCATTGTGAGCGTAACAG RUNX1 NM_001754.2AACAGAGACATTGCCAACCATATTGGATCTGCTTGC SEQ ID NO: 2883TGTCCAAACCAGCAAACTTCCTGGGCAAATCAC RXRA NM_002957.3GCTCTGTTGTGTCCTGTTGCCGGCTCTGGCCTTC SEQ ID NO: 2884CTGTGACTGACTGTGAAGTGGCTTCTCCGTAC S100A1 NM_006271.1TGGACAAGGTGATGAAGGAGCTAGACGAGAATGGAGAC SEQ ID NO: 2885GGGGAGGTGGACTTCCAGGAGTATGTGGTGCT S100A2 NM_005978.2TGGCTGTGCTGGTCACTACCTTCCACAAGTACTCCTGCCAAGA SEQ ID NO: 2886GGGCGACAAGTTCAAGCTGAGTAAGGGGGA S100A4 NM_002961.2GACTGCTGTCATGGCGTGCCCTCTGGAGAAGGCC SEQ ID NO: 2887CTGGATGTGATGGTGTCCACCTTCCACAAGTACTCG S100A8 NM_002964.3ACTCCCTGATAAAGGGGAATTTCCATGCCGTCTA SEQ ID NO: 2888CAGGGATGACCTGAAGAAATTGCTAGAGACCGAGTGTCCTCA S100A9 NM_002965.2CTTTGGGACAGAGTGCAAGACGATGACTTGC SEQ ID NO: 2889AAAATGTCGCAGCTGGAACGCAACATAGAGACCA S100P NM_005980.2AGACAAGGATGCCGTGGATAAATTGCTCAAGGACCT SEQ ID NO: 2890GGACGCCAATGGAGATGCCCAGGTGGACTTC SAT NM_002970.1CCTTTTACCACTGCCTGGTTGCAGAAGTGCCGAAAG SEQ ID NO: 2891AGCACTGGACTCCGGAAGGACACAGCATTGT SBA2 NM_018639.3GGACTCAACGATGGGCAGATCAAGATCTGGGA SEQ ID NO: 2892GGTGCAGACAGGGCTCCTGCTTTTGAATCTTTCCG SDC1 NM_002997.1GAAATTGACGAGGGGTGTCTTGGGCAGAGCTGGCTCTGAGCGCCT SEQ ID NO: 2893CCATCCAAGGCCAGGTTCTCCGTTAGCTCCT SEMA3B NM_004636.1GCTCCAGGATGTGTTTCTGTTGTCCTCGCGGGAC SEQ ID NO: 2894CACCGGACCCCGCTGCTCTATGCCGTCTTCTCCACGT SEMA3F NM_004186.1CGCGAGCCCCTCATTATACACTGGGCAGCCTCCCCACAG SEQ ID NO: 2895CGCATCGAGGAATGCGTGCTCTCAGGCAAGGATGTCAACGGCGAGTG SEMA4B NM_020210.1TTCCAGCCCAACACAGTGAACACT SEQ ID NO: 2896TTGGCCTGCCCGCTCCTCTCCAACCTGGCGACCCGACTC SFRP2 NM_003013.2CAAGCTGAACGGTGTGTCCGAAAGGGACC SEQ ID NO: 2897TGAAGAAATCGGTGCTGTGGCTCAAAGACAGCTTGCA SFRP4 NM_003014.2TACAGGATGAGGCTGGGCATTGCCTGGGACA SEQ ID NO: 2898GCCTATGTAAGGCCATGTGCCCCTTGCCCTAACAAC SGCB NM_000232.1CAGTGGAGACCAGTTGGGTAGTGGTGACTGGGTA SEQ ID NO: 2899CGCTACAAGCTCTGCATGTGTGCTGATGGGACGCTCTTCAAGG SHC1 NM_003029.3CCAACACCTTCTTGGCTTCTGGGACCTG SEQ ID NO: 2900TGTTCTTGCTGAGCACCCTCTCCGGTTTGGGTTGGGATAACAG SHH NM_000193.2GTCCAAGGCACATATCCACTGCTCGGTGAAA SEQ ID NO: 2901GCAGAGAACTCGGTGGCGGCCAAATCGGGAGGCTGCTTC SI NM_001041.1AACGGACTCCCTCAATTTGTGCAAGATTTGCATGACCA SEQ ID NO: 2902TGGACAGAAATATGTCATCATCTTGGACCCTGCAATTTC Siah-1 NM_003031.2TTGGCATTGGAACTACATTCAATCCGCGGTATCC SEQ ID NO: 2903TCGGATTAGTTCTAGGACCCCCTTCTCCATACC SIAT4A NM_003033.2AACCACAGTTGGAGGAGGACGGCAGAGACA SEQ ID NO: 2904GTTTCCCTCCCCGCTATACCAACACCCTTCCTTCG SIAT7B NM_006456.1TCCAGCCCAAATCCTCCTGGTGGCACATCCTACCCC SEQ ID NO: 2905AGATGCTAAAGTGATTCAAGGACTCCAGGACACC SIM2 NM_005069.2GATGGTAGGAAGGGATGTGCCCGCCTCTCCACG SEQ ID NO: 2906CACTCAGCTATACCTCATTCACAGCTCCTTGTG SIN3A NM_015477.1CCAGAGTCATGCTCATCCAGCCCCACCAGTTGCACC SEQ ID NO: 2907AGTGCAGGGACAGCAGCAATTTCAGAGGCTGAAGGTGG SIR2 NM_012238.3AGCTGGGGTGTCTGTTTCATGTGGAATACCTGACTT SEQ ID NO: 2908CAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGT SKP1A NM_006930.2CCATTGCCTTTGCTTTGTTCATAATTTCAGC SEQ ID NO: 2909AGGGCAGAATAAAAACCATGGGAGGCAAAGAAAGGAAATCCGGAA SKP2 NM_005983.2AGTTGCAGAATCTAAGCCTGGAAGGCCTGC SEQ ID NO: 2910GGCTTTCGGATCCCATTGTCAATACTCTCGCAAAAAACTCA SLC25A3 NM_213611.1TCTGCCAGTGCTGAATTCTTTGCTGACATTGCCCTGG SEQ ID NO: 2911CTCCTATGGAAGCTGCTAAGGTTCGAA SLC2A1 NM_006516.1GCCTGAGTCTCCTGTGCCCACATCCCAGGCTTCA SEQ ID NO: 2912CCCTGAATGGTTCCATGCCTGAGGGTGGAGACT SLC31A1 NM_001859.2CCGTTCGAAGAGTCGTGAGGGGGTGACGGGTTAAG SEQ ID NO: 2913ATTCGGAGAGAGAGGTGCTAGTGGCTGGACT SLC5A8 NM_145913.2CCTGCTTTCAACCACATTGAATTGAACTCAGA SEQ ID NO: 2914TCAGAGTGGCAAGAGCAATGGGACTCGTTTGTGAAGCTGCTCT SLC7A5 NM_003486.4GCGCAGAGGCCAGTTAAAGTAGATCACCTCCTCG SEQ ID NO: 2915AACCCACTCCGGTTCCCCGCAACCCACAGCTCAGCT SLPI NM_003064.2ATGGCCAATGTTTGATGCTTAACCCCCCCAATTTCTGTG SEQ ID NO: 2916AGATGGATGGCCAGTGCAAGCGTGACTTGAAGTGT SMARCA3 NM_003071.2AGGGACTGTCCTGGCACATTATGCAGATGTCC SEQ ID NO: 2917TGGGTCTTTTGCTTAGACTGCGGCAAATTTGTTG SNAI1 NM_005985.2CCCAATCGGAAGCCTAACTACAGCGAGCTGCAGGA SEQ ID NO: 2918CTCTAATCCAGAGTTTACCTTCCAGCAGCCCTAC SNAI2 NM_003068.3GGCTGGCCAAACATAAGCAGCTGCACTGCGATGCCCAG SEQ ID NO: 2919TCTAGAAAATCTTTCAGCTGTAAATACTGTGACAAGGA SNRPF NM_003095.1GGCTGGTCGGCAGAGAGTAGCCTGCAACATTCGGCCGT SEQ ID NO: 2920GGTTTACATGAGTTTACCCCTCAATCCCAAACCTTTCCTCA SOD1 NM_000454.3TGAAGAGAGGCATGTTGGAGACTTGGGCAATGTG SEQ ID NO: 2921ACTGCTGACAAAGATGGTGTGGCCGATGTGTCTATT SOD2 NM_000636.1GCTTGTCCAAATCAGGATCCACTGCAAGGAACAACA SEQ ID NO: 2922GGCCTTATTCCACTGCTGGGGATTGATGTGTGGGAGCACGCT SOS1 NM_005633.2TCTGCACCAAATTCTCCAAGAACACCGTTAAC SEQ ID NO: 2923ACCTCCGCCTGCTTCTGGTGCTTCCAGTACCAC SOX17 NM_022454.2TCGTGTGCAAGCCTGAGATGGGCCTCCCCTAC SEQ ID NO: 2924CAGGGGCATGACTCCGGTGTGAATCTCCCCGACAG SPARC NM_003118.1TCTTCCCTGTACACTGGCAGTTCGGCCAGCTGGACCAGC SEQ ID NO: 2925ACCCCATTGACGGGTACCTCTCCCACACCGAGCT SPIND2 NM_021102.1AGGAATGCAGCGGATTCCTCTGTCCCAAGTGC SEQ ID NO: 2926TCCCAGAAGGCAGGATTCTGAAGACCACTCCAGCGA SPRY1 AK026960.1CAGACCAGTCCCTGGTCATAGGTCTGAAAGGGCAATCCGGACCC SEQ ID NO: 2927AGCCCAAGCAACTGATTGTGGATGACTTGAAGG SPRY2 NM_005842.1TGTGGCAAGTGCAAATGTAAGGAGTGC SEQ ID NO: 2928ACCTACCCAAGGCCTCTGCCATCAGACTGGATCTGCGAC SR-A1 NM_021228.1AGATGGAAGAAGCCAACCTGGCGAGCCGAGCGAAGGCC SEQ ID NO: 2929CAGGAGCTGATCCAGGCCACCAACCAGATCCTCAGCCACAG ST14 NM_021978.2TGACTGCACATGGAACATTGAGGTGCCCAACAA SEQ ID NO: 2930CCAGCATGTGAAGGTGCGCTTCAAATTCTT STAT1 NM_007315.1GGGCTCAGCTTTCAGAAGTGCTGAGTTGGCAGTTTT SEQ ID NO: 2931CTTCTGTCACCAAAAGAGGTCTCAATGTGGACCAGCTGAACATGT STAT3 NM_003150.1TCACATGCCACTTTGGTGTTTCATAATC SEQ ID NO: 2932TCCTGGGAGAGATTGACCAGCAGTATAGCCGCTTCCTGCAAG STAT5A NM_003152.1GAGGCGCTCAACATGAAATTCAAGGCCGAAGTGCAGAGCAACCG SEQ ID NO: 2933GGGCCTGACCAAGGAGAACCTCGTGTTCCTGGC STAT5B NM_012448.1CCAGTGGTGGTGATCGTTCATGGCA SEQ ID NO: 2934GCCAGGACAACAATGCGACGGCCACTGTTCTCTGGGACAATGCTTTTGC STC1 NM_003155.1CTCCGAGGTGAGGAGGACTCTCCCTCCCACATCAA SEQ ID NO: 2935ACGCACATCCCATGAGAGTGCATAACCAGGGAGAGGT STK11 NM_000455.3GGACTCGGAGACGCTGTGCAGGAGGGC SEQ ID NO: 2936CGTCAAGATCCTCAAGAAGAAGAAGTTGCGAAGGATCCC STK15 NM_003600.1CATCTTCCAGGAGGACCACTCTCTGTGGC SEQ ID NO: 2937ACCCTGGACTACCTGCCCCCTGAAATGATTGAAGGTCGGA STMN1 NM_005563.2AATACCCAACGCACAAATGACCGCACGTTCTCTGCC SEQ ID NO: 2938CCGTTTCTTGCCCCAGTGTGGTTTGCATTGTCTCC STMY3 NM_005940.2CCTGGAGGCTGCAACATACCTCAATCCTGTCCCAGGCCGGATCCTCCT SEQ ID NO: 2939GAAGCCCTTTTCGCAGCACTGCTATCCTCCAAAGCCATTGTA STS NM_000351.2GAAGATCCCTTTCCTCCTACTGTTCTTTCTGTG SEQ ID NO: 2940GGAAGCCGAGAGCCACGAAGCATCAAGGCCGAACATCATCC SURV NM_001168.1TGTTTTGATTCCCGGGCTTACCAGGTGAGAAGTGAGGGAG SEQ ID NO: 2941GAAGAAGGCAGTGTCCCTTTTGCTAGAGCTGACAGCTTTG TAGLN NM_003186.2GATGGAGCAGGTGGCTCAGTTCCTGAAGGCGGCTGAGG SEQ ID NO: 2942ACTCTGGGGTCATCAAGACTGACATGTTCCAGACT TBP NM_003194.1GCCCGAAACGCCGAATATAATCCCAAGCGGTTTGC SEQ ID NO: 2943TGCGGTAATCATGAGGATAAGAGAGCCACG TCF-1 NM_000545.3GAGGTCCTGAGCACTGCCAGGAGGGACAAAGGAGCCT SEQ ID NO: 2944GTGAACCCAGGACAAGCATGGTCCCACATC TCF-7 NM_003202.2GCAGCTGCAGTCAACAGTTCAAAGAAGTCA SEQ ID NO: 2945TGGCCCAAATCCAGTGTGCACCCCTCCCCATTCACAG TCF7L1 NM_031283.1CCGGGACACTTTCCAGAAGCCGCGGGACTA SEQ ID NO: 2946TTTCGCCGAAGTGAGAAGGCCTCAGGACAGCGCGTTCT TCF7L2 NM_030756.1CCAATCACGACAGGAGGATTCAGACACCCCT SEQ ID NO: 2947ACCCCACAGCTCTGACCGTCAATGCTTCCGTGTCCA TCFL4 NM_170607.2CTGACTGCTCTGCTTAAAGGTGAAAGTAGCAGGAACAACAAC SEQ ID NO: 2948AAAAGCCAACCAAAAACAAGGTAGCCAGTGCAAGACAT TEK NM_000459.1ACTTCGGTGCTACTTAACAACTTACATCCCAGGGA SEQ ID NO: 2949GCAGTACGTGGTCCGAGCTAGAGTCAACACCAAGGCCCAGG TERC U86046.1AAGAGGAACGGAGCGAGTCCCCGCGCGCGGCGCGATTCCC SEQ ID NO: 2950TGAGCTGTGGGACGTGCACCCAGGACTCGGCTCACACAT TERT NM_003219.1GACATGGAGAACAAGCTGTTTGCGGGGATTCGGCGGGAC SEQ ID NO: 2951GGGCTGCTCCTGCGTTTGGTGGATGATTTCTTGTTGGTGACACCTC TFF3 NM_003226.1AGGCACTGTTCATCTCAGTTTTTCTGTCCCTTTG SEQ ID NO: 2952CTCCCGGCAAGCTTTCTGCTGAAAGTTCATATCTGGAGCCTGATG TGFA NM_003236.1GGTGTGCCACAGACCTTCCTACTTGGCCTGTAATCACCTGTGC SEQ ID NO: 2953AGCCTTTTGTGGGCCTTCAAAACTCTGTCAAGAACTCCGT TGFB2 NM_003238.1ACCAGTCCCCCAGAAGACTATCCTGAGCCCGAGGAAG SEQ ID NO: 2954TCCCCCCGGAGGTGATTTCCATCTACAACAGCACCAGG TGFB3 NM_003239.1GGATCGAGCTCTTCCAGATCCTTCGGCCAGATG SEQ ID NO: 2955AGCACATTGCCAAACAGCGCTATATCGGTGGC TGFBI NM_000358.1GCTACGAGTGCTGTCCTGGATATGAAAAGGTCCCTG SEQ ID NO: 2956GGGAGAAGGGCTGTCCAGCAGCCCTACCACT TGFBR1 NM_004612.1GTCATCACCTGGCCTTGGTCCTGTGGAACTGGC SEQ ID NO: 2957AGCTGTCATTGCTGGACCAGTGTGCTTCGTCTGC TGFBR2 NM_003242.2AACACCAATGGGTTCCATCTTTCTGGGCTCC SEQ ID NO: 2958TGATTGCTCAAGCACAGTTTGGCCTGATGAAGAGG THBS1 NM_003246.1CATCCGCAAAGTGACTGAAGAGAACAAAGAGTTGGCCAATGA SEQ ID NO: 2959GCTGAGGCGGCCTCCCCTATGCTATCACAACGGAGTTCAGTAC THY1 NM_006288.2GGACAAGACCCTCTCAGGCTGTCCCAAGCTCCC SEQ ID NO: 2960AAGAGCTTCCAGAGCTCTGACCCACAGCCTCCAA TIMP1 NM_003254.1TCCCTGCGGTCCCAGATAGCCTGAATCCTGCCCGGAGTGGAAC SEQ ID NO: 2961TGAAGCCTGCACAGTGTCCACCCTGTTCCCAC TIMP2 NM_003255.2TCACCCTCTGTGACTTCATCGTGCCCTGGGACACCC SEQ ID NO: 2962TGAGCACCACCCAGAAGAAGAGCCTGAACCACA TIMP3 NM_000362.2CTACCTGCCTTGCTTTGTGACTTCCAAGAACG SEQ ID NO: 2963AGTGTCTCTGGACCGACATGCTCTCCAATTTCGGT TJP1 NM_003257.1ACTTTGCTGGGACAAAGGTCAACTGAAGAAGTGGGCAGGCC SEQ ID NO: 2964CGAGGCAGGAGAGATGCTGAGGAGTCCATGTG TK1 NM_003258.1GCCGGGAAGACCGTAATTGTGGCTGCACTGGATGGGACCT SEQ ID NO: 2965TCCAGAGGAAGCCATTTGGGGCCATCCTGAACCTGGTGCCGCTG TLN1 NM_006289.2AAGCAGAAGGGAGAGCGTAAGATCTTCCAGGCACACAA SEQ ID NO: 2966GAATTGTGGGCAGATGAGTGAGATTGAGGCCAAGG TMEPAI NM_020182.3CAGAAGGATGCCTGTGGCCCTCGGAGAGCACAGT SEQ ID NO: 2967GTCAGGCAACGGAATCCCAGAGCCGCAGGTCTAC TMSB10 NM_021103.2GAAATCGCCAGCTTCGATAAGGCCAAGCTGAA SEQ ID NO: 2968GAAAACGGAGACGCAGGAAAAGAACACCCTGCCGAC TMSB4X NM_021109.2CACATCAAAGAACTACTGACAACGAAGGC SEQ ID NO: 2969CGCGCCTGCCTTTCCCATCTGTCTATCTATCTGGCTGGCAGG TNC NM_002160.1AGCTCGGAACCTCACCGTGCCTGGCAGCCTTC SEQ ID NO: 2970GGGCTGTGGACATACCGGGCCTCAAGGCTGCTAC TNF NM_000594.1GGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCG SEQ ID NO: 2971GCCCGACTATCTCGACTTTGCCGAGTCTGGGCA TNFRSF5 NM_001250.3TCTCACCTCGCTATGGTTCGTCTGCCTCTGCAGTGCGTCC SEQ ID NO: 2972TCTGGGGCTGCTTGCTGACCGCTGTCCATC TNFRSF6B NM_003823.2CCTCAGCACCAGGGTACCAGGAGCTGAGGAGTG SEQ ID NO: 2973TGAGCGTGCCGTCATCGACTTTGTGGCTTTCCAGGACA TNFSF4 NM_003326.2CTTCATCTTCCCTCTACCCAGATTGTGAAGATGGAAAGGGT SEQ ID NO: 2974CCAACCCCTGGAAGAGAATGTGGGAAATGCAGC TOP2A NM_001067.1AATCCAAGGGGGAGAGTGATGACTTCCATATGGACTTTGA SEQ ID NO: 2975CTCAGCTGTGGCTCCTCGGGCAAAATCTGTAC TOP2B NM_001068.1TGTGGACATCTTCCCCTCAGACTTCCCTACTGAGC SEQ ID NO: 2976CACCTTCTCTGCCACGAACCGGTCGGGCTAG TP NM_001953.2CTATATGCAGCCAGAGATGTGACAGCCACCGTGGACAGCCTGCCACTC SEQ ID NO: 2977ATCACAGCCTCCATTCTCAGTAAGAAACTCGTGG TP53BP1 NM_005657.1TGCTGTTGCTGAGTCTGTTGCCAGTCCCCAGAA SEQ ID NO: 2978GACCATGTCTGTGTTGAGCTGTATCTGTGAAGCCAGGCAAG TP53BP2 NM_005426.1GGGCCAAATATTCAGAAGCTTTTATATCAGAGGACCACCA SEQ ID NO: 2979TAGCGGCCATGGAGACCATCTCTGTCCCATCATACCCATCC TP53I3 NM_004881.2GCGGACTTAATGCAGAGACAAGGCCAGTATGAC SEQ ID NO: 2980CCACCTCCAGGAGCCAGCAACATTTTGGGACTTGA TRAG3 NM_004909.1GACGCTGGTCTGGTGAAGATGTCCAGGAAACCA SEQ ID NO: 2981CGAGCCTCCAGCCCATTGTCCAACAACCACCCA TRAIL NM_003810.1CTTCACAGTGCTCCTGCAGTCTCTCTGTGTGGCTGTAACTTA SEQ ID NO: 2982CGTGTACTTTACCAACGAGCTGAAGCAGATG TS NM_001071.1GCCTCGGTGTGCCTTTCAACATCGCCAGCTACGCC SEQ ID NO: 2983CTGCTCACGTACATGATTGCGCACATCACG TST NM_003312.4GGAGCCGGATGCAGTAGGACTGGACTCGGGCCA SEQ ID NO: 2984TATCCGTGGTGCCGTCAACATGCCTTTCATGGACTT TUBA1 NM_006000.1TGTCACCCCGACTCAACGTGAGACGCACCGCCC SEQ ID NO: 2985GGACTCACCATGCGTGAATGCATCTCAGTCCACGT TUBB NM_001069.1CGAGGACGAGGCTTAAAAACTTCTCAGATCAATCGT SEQ ID NO: 2986GCATCCTTAGTGAACTTCTGTTGTCCTCAAGCATGGT TUFM NM_003321.3GTATCACCATCAATGCGGCTCATGTGGAGTATAGCACT SEQ ID NO: 2987GCCGCCCGCCACTACGCCCACACAGACTG TULP3 NM_003324.2TGTGTATAGTCCTGCCCCTCAAGGTGTCACAGT SEQ ID NO: 2988AAGATGTCGGATAATCCGGGATAAAAGGGGAATGGATCGGG tusc4 NM_006545.4GGAGGAGCTAAATGCCTCAGGCCGGTGCACTCT SEQ ID NO: 2989GCCCATTGATGAGTCCAACACCATCCACTTGAAGG UBB NM_018955.1GAGTCGACCCTGCACCTGGTCCTGCGTCTGA SEQ ID NO: 2990GAGGTGGTATGCAGATCTTCGTGAAGACCCTGACCGGCAAGACCATCACCCTGGAAGTGGAGCCCAGTGACACCAT CGAAAATGTGAAGGCCAAGATCCAGGATAAAGAAGGCATCCCTCCCGACCAGCAGAGGCTCATCTTTGC AGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAACATCCAGAAGGAGTCGACCCTGCACCTGG TCCTGCGTCTGAGAGGTGGTATGCAGATCTTCGTGAAGACCCTGACCGGCAAGACCATCACTCTGGAAGTG GAGCCCAGTGACACCATCGAAAATGTGAAGGCCAAGATCCAAGATAAAGAAGGCATCCCTCCCGACCAG CAGAGGCTCATCTTTGCAGGCAAGCAGCTGGAAGATGGCCGCACTCTTTCTGACTACAACATCCAGAAGGAGT CGACCCTGCACCTGGTCCTGCGCCTGAGGGGTGGCTGTTAATTCTTCAGTCATGGCATTCGC UBC NM_021009.2ACGCACCCTGTCTGACTACAACATCCAGAAAGA SEQ ID NO: 2991GTCCACCCTGCACCTGGTGCTCCGTCTTAGAGGT UBE2C NM_007019.2TGTCTGGCGATAAAGGGATTTCTGCCTTCCC SEQ ID NO: 2992TGAATCAGACAACCTTTTCAAATGGGTAGGGACCAT UBE2M NM_003969.1CTCCATAATTTATGGCCTGCAGTATCTCTTCTTGGAGCC SEQ ID NO: 2993CAACCCCGAGGACCCACTGAACAAGGAGGCCGCA UBL1 NM_003352.3GTGAAGCCACCGTCATCATGTCTGACCAGGAGGCAAA SEQ ID NO: 2994ACCTTCAACTGAGGACTTGGGGGATAAGAAGGAAGG UCP2 NM_003355.2ACCATGCTCCAGAAGGAGGGGCCCCGAGC SEQ ID NO: 2995CTTCTACAAAGGGTTCATGCCCTCCTTTCTCCGCTTGGGTT UGT1A1 NM_000463.2CCATGCAGCCTGGAATTTGAGGCTACCCAG SEQ ID NO: 2996TGCCCCAACCCATTCTCCTACGTGCCCAGGCCTCTC UMPS NM_000373.1TGCGGAAATGAGCTCCACCGGCTCCCTGGCCACTGG SEQ ID NO: 2997GGACTACACTAGAGCAGCGGTTAGAATGGCTGAGG UNC5A XM_030300.7GACAGCTGATCCAGGAGCCACGGGTCCTGCACTTCAAG SEQ ID NO: 2998GACAGTTACCACAACCTGCGCCTATCCAT UNC5B NM_170744.2AGAACGGAGGCCGTGACTGCAGCGGGACGCTG SEQ ID NO: 2999CTCGACTCTAAGAACTGCACAGATGGGCTGTGCATG UNC5C NM_003728.2CTGAACACAGTGGAGCTGGTTTGCAAACTCTGTGTG SEQ ID NO: 3000CGGCAGGTGGAAGGAGAAGGGCAGATCTTCCAG upa NM_002658.1GTGGATGTGCCCTGAAGGACAAGCCAGGCGTCTACA SEQ ID NO: 3001CGAGAGTCTCACACTTCTTACCCTGGATCCGCAG UPP1 NM_003364.2ACGGGTCCTGCCTCAGTTGGCGGAATGGCGGCCACGGGA SEQ ID NO: 3002GCCAATGCAGAGAAAGCTGAAAGTCACAATGATTGCCCCG VCAM1 NM_001078.2TGGCTTCAGGAGCTGAATACCCTCCCAGGCACACAC SEQ ID NO: 3003AGGTGGGACACAAATAAGGGTTTTGGAACCACTATTTTCTCATCACGACAGCA VCL NM_003373.2GATACCACAACTCCCATCAAGCTGTTGGC SEQ ID NO: 3004AGTGGCAGCCACGGCGCCTCCTGATGCGCCTAACAGGGA VCP NM_007126.2GGCTTTGGCAGCTTCAGATTCCCTTCAGGGAACCAGG SEQ ID NO: 3005GTGGAGCTGGCCCCAGTCAGGGCAGTGGAG VDAC1 NM_003374.1GCTGCGACATGGATTTCGACATTGCTGGGCCTTCCATCCGG SEQ ID NO: 3006GGTGCTCTGGTGCTAGGTTACGAGGGCTGG VDAC2 NM_003375.2ACCCACGGACAGACTTGCGCGCGTCCAATG SEQ ID NO: 3007TGTATTCCTCCATCATATGCTGACCTTGGCAAAGCT VDR NM_000376.1GCCCTGGATTTCAGAAAGAGCCAAGTCTGGATCT SEQ ID NO: 3008GGGACCCTTTCCTTCCTTCCCTGGCTTGTAACT VEGF NM_003376.3CTGCTGTCTTGGGTGCATTGGAGCCTTGCCTTGCT SEQ ID NO: 3009GCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGC VEGF_altsplice1 AF486837.1TGTGAATGCAGACCAAAGAAAGATAGAG SEQ ID NO: 3010CAAGACAAGAAAATCCCTGTGGGCCTTGCTCAGAGCGGAGAAAGC VEGF_altsplice2 AF214570.1AGCTTCCTACAGCACAACAAATGTGAATGCAGACCAA SEQ ID NO: 3011AGAAAGATAGAGCAAGACAAGAAAAATGTGACAAGCCGAG VEGFB NM_003377.2TGACGATGGCCTGGAGTGTGTGCCCACTGGGCA SEQ ID NO: 3012GCACCAAGTCCGGATGCAGATCCTCATGATCCGGTACC VEGFC NM_005429.2CCTCAGCAAGACGTTATTTGAAATTACAGTGCCTCTCTCTCAAGGCC SEQ ID NO: 3013CCAAACCAGTAACAATCAGTTTTGCCAATCACACTT VIM NM_003380.1TGCCCTTAAAGGAACCAATGAGTCCCTGGAACGCCAG SEQ ID NO: 3014ATGCGTGAAATGGAAGAGAACTTTGCCGTTGAAGC WIF NM_007191.2TACAAGCTGAGTGCCCAGGCGGGTGCCGAAATGGA SEQ ID NO: 3015GGCTTTTGTAATGAAAGACGCATCTGCGAGTG WISP1 NM_003882.2AGAGGCATCCATGAACTTCACACTTGCGGGC SEQ ID NO: 3016TGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTG Wnt-3a NM_033131.2ACAAAGCTACCAGGGAGTCGGCCTTTGTCCACGCCA SEQ ID NO: 3017TTGCCTCAGCCGGTGTGGCCTTTGCAGTGACACGCTCA Wnt-5a NM_003392.2GTATCAGGACCACATGCAGTACATCGGAGAAG SEQ ID NO: 3018GCGCGAAGACAGGCATCAAAGAATGCCAGTATCAATTCCGACA Wnt-5b NM_032642.2TGTCTTCAGGGTCTTGTCCAGAATGTAGATGGGTTC SEQ ID NO: 3019CGTAAGAGGCCTGGTGCTCTCTTACTCTTTCATCCACGTGCAC WND2 NM_003391.1CGGTGGAATCTGGCTCTGGCTCCCTCTGC SEQ ID NO: 3020TCTTGACCTGGCTCACCCCCGAGGTCAACTCTTCATGG WWOX NM_016373.1ATCGCAGCTGGTGGGTGTACACACTGCTGTTT SEQ ID NO: 3021ACCTTGGCGAGGCCTTTCACCAAGTCCATGCAACAGGGAGCT XPA NM_000380.2GGGTAGAGGGAAAAGGGTTCAACAAAGGCTGAACTG SEQ ID NO: 3022GATTCTTAACCAAGAAACAAATAATAGCAATGGTGGTGCA XPC NM_004628.2GATACATCGTCTGCGAGGAATTCAAAGACGTGCTCC SEQ ID NO: 3023TGACTGCCTGGGAAAATGAGCAGGCAGTCATTGAAAG XRCC1 NM_006297.1GGAGATGAAGCCCCCAAGCTTCCTCAGA SEQ ID NO: 3024AGCAACGCCAGACCAAAACCAAGCCCACTCAGGCAGCTGGAC YB-1 NM_004559.1AGACTGTGGAGTTTGATGTTGTTGAAGGAGA SEQ ID NO: 3025AAAGGGTGCGGAGGCAGCAAATGTTACAGGTCCTGGTGGTGTTCC YWHAH NM_003405.2CATGGCCTCCGCTATGAAGGCGGTGACAGAG SEQ ID NO: 3026CTGAATGAACCTCTCTCCAATGAAGATCGAAATCTCC zbtb7 NM_015898.2CTGCGTTCACACCCCAGTGTCACAGGGCGA SEQ ID NO: 3027GCTGTTCTGGAGAGAAAACCATCTGTCGTGGCTGAG ZG16 NM_152338.1TGCTGAGCCTCCTCTCCTTGGCAGGGGCACTGTGATGA SEQ ID NO: 3028GGAGTAAGAACTCCCTTATCACTAACCCCCATCC

1. A method of predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining evidence of the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 2A, 3A, 4A and/or 5A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 2. The method of claim 1 wherein said subject is a human patient.
 3. The method of claim 2 wherein evidence of said expression level is obtained by a method of gene expression profiling.
 4. The method of claim 3 wherein said method is a PCR-based method.
 5. The method of claim 4 wherein said expression levels are normalized relative to the expression levels of one or more reference genes, or their expression products.
 6. The method of claim 2 wherein said clinical outcome is expressed in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).
 7. The method of claim 2 wherein said cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer.
 8. The method of claim 7 wherein said cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.
 9. The method of claim 2 comprising determining evidence of the expression levels of at least two of said genes, or their expression products.
 10. The method of claim 2 comprising determining evidence of the expression levels of at least three of said genes, or their expression products.
 11. The method of claim 2 comprising determining evidence of the expression levels of at least four of said genes, or their expression products.
 12. The method of claim 2 comprising determining evidence of the expression levels of at least five of said genes, or their expression products.
 13. The method of claim 2 further comprising the step of creating a report summarizing said prediction.
 14. A method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1A and 1B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A or 5A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1B or 5B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
 15. The method of claim 14 wherein said subject is a human patient.
 16. The method of claim 15 wherein evidence of said expression level is obtained by a method of gene expression profiling.
 17. The method of claim 16 wherein said method is a PCR-based method.
 18. The method of claim 17 wherein, if said RFI is predicted to be shorter, said patient is subjected to further therapy following said surgical removal.
 19. The method of claim 18 wherein said further therapy is chemotherapy and/or radiation therapy.
 20. The method of claim 15 further comprising the step of creating a report summarizing said prediction.
 21. The method of claim 15 comprising determining evidence of the expression levels of at least two of said genes, or their expression products.
 22. The method of claim 15 comprising determining evidence of the expression levels of at least three of said genes, or their expression products.
 23. The method of claim 15 comprising determining evidence of the expression levels of at least four of said genes, or their expression products.
 24. The method of claim 15 comprising determining evidence of the expression levels of at least five of said genes, or their expression products.
 25. A method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2A and 2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
 26. A method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3A and 3B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 3A, or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
 27. A method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4A and 4B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 4A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
 28. A method of predicting clinical outcome in a subject diagnosed with Dukes B (stage II) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome.
 29. A method of predicting clinical outcome in a subject diagnosed with Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, and SIR2, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome.
 30. A method of predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining evidence of the expression level of one or more predictive RNA transcripts listed in Tables 1.2A-B, 2.2A-B, 3.2A-B, 4.2A-B, 5.2A-B, 6.2 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 31. A method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1.2A, 1.2B, 5.2A and 5.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A or 5.2A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B or 5.2B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
 32. A method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2.2A and 2.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 2.2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2.2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
 33. A method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3.2A and 3.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 3.2A, or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3.2B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
 34. A method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4.2A and 4.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 4.2A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4.2B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
 35. A method of predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising determining evidence of the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 1.2A-B, 2A-B, 2.2A-B, 3A-B, 3.2A-B, 4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 2A, 2.2A, 3A, 3.2A, 4A, 4.2A, 5A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 2B, 2.2B, 3B, 3.2B, 4B, 4.2B, 5B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 36. A method of predicting the duration of Recurrence-Free Interval (RFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 1A, 1.2A, 1B, 1.2B, 5A, 5.2A, 5B and 5.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 5A or 5.2A, or the corresponding expression product, indicates that said RFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 5B or 5.2B, or the corresponding expression product, indicates that said RFI is predicted to be longer.
 37. A method of predicting Overall Survival (OS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 2A, 2.2A, 2B and 2.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 2A or 2.2A, or the corresponding expression product, indicates that said OS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 2B or 2.2B, or the corresponding expression product, indicates that said OS is predicted to be longer.
 38. A method of predicting Disease-Free Survival (DFS) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 3A, 3.2A, 3B and 3.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 3A or 3.2A, or the corresponding expression product, indicates that said DFS is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 3B or 3.2B, or the corresponding expression product, indicates that said DFS is predicted to be longer.
 39. A method of predicting the duration of Distant Recurrence-Free Interval (DRFI) in a subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colon cancer following surgical resection of said cancer, comprising determining the expression level of one or more predictive RNA transcripts listed in Tables 4A, 4.2A, 4B and 4.2B, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 4A or 4.2A, or the corresponding expression product, indicates that said DRFI is predicted to be shorter; and (b) evidence of increased expression of one or more of the genes listed in Table 4B or 4.2B, or the corresponding expression product, indicates that said DRFI is predicted to be longer.
 40. A report predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 2A-B, 3A-B, 4A-B, 5A-B, 6 and/or 7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 2A, 3A, 4A and/or 5A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 2B, 3B, 4B and/or 5B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 41. A report predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1.2A-B, 2.2A-B, 3.2A-B, 4.2A-B, 5.2A-B, 6.2 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1.2A, 2.2A, 3.2A, 4.2A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1.2B, 2.2B, 3.2B, 4.2B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 42. A report predicting clinical outcome for a subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts listed in Tables 1A-B, 1.2A-B, 2A-B, 2.2A-B, 3A-B, 3.2A-B, 4A-B, 4.2A-B, 5A-B, 5.2A-B, 6, 6.2, 7 and/or 7.2, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes listed in Table 1A, 1.2A, 2A, 2.2A, 3A, 3.2A, 4A, 4.2A, 5A and/or 5.2A, or the corresponding expression product, indicates a decreased likelihood of a positive clinical outcome; and (b) evidence of increased expression of one or more of the genes listed in Table 1B, 1.2B, 2B, 2.2B, 3B, 3.2B, 4B, 4.2B, 5B and/or 5.2B, or the corresponding expression product, indicates an increased likelihood of a positive clinical outcome.
 43. A report predicting clinical outcome in a subject diagnosed with Dukes B (stage II) colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, WIF, CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDH11, CENPE, CLTC, CYR61, EMR3, ICAM2, LOX, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SIR2, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CDC20, CKS1B, DKK1, HSD17B2, and MMP7, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome.
 44. A report predicting clinical outcome in a subject diagnosed with Dukes C (stage III) colorectal cancer following surgical resection of said cancer, comprising a prediction of clinical outcome based on information comprising the expression level of one or more predictive RNA transcripts selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, SIR2, ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or their expression products, in a biological sample comprising cancer cells obtained from said subject, wherein (a) evidence of increased expression of one or more of the genes selected from the group consisting of CAPG, CD28, CKS1B, CYR61, DKK1, HSD17B2, LOX, MMP7, and SIR2, or the corresponding expression product, indicates a decreased likelihood of positive clinical outcome; and (b) evidence of increased expression of one or more of the genes selected from the group consisting of ALCAM, CD24, CDC20, CDH11, CENPE, CLTC, EMR3, ICAM2, MADH2, MGAT5, MT3, NUFIP1, PRDX6, SOS1, STAT5B, TFF3, TMSB4X, TP53BP1, and WIF, or the corresponding expression product, indicates an increased likelihood of positive clinical outcome. 